Effect of polyphenol-rich dark chocolate on anthropometric, nutritional, biochemical and physiological markers in normal weight and overweight adults by Farhat, Grace
  
EFFECT OF POLYPHENOL-RICH DARK 
CHOCOLATE ON ANTHROPOMETRIC, 
NUTRITIONAL, BIOCHEMICAL AND 
PHYSIOLOGICAL MARKERS IN NORMAL 
WEIGHT AND OVERWEIGHT ADULTS 
 
 
 
 
 
GRACE FARHAT 
 
 
 
 
A thesis submitted in partial fulfilment 
of the requirements for the degree of  
Doctor of Philosophy 
 
 
QUEEN MARGARET UNIVERSITTY 
 
2014 
ii 
 
Table of Contents 
 
Abstract .................................................................................................................................. v 
Acknowledgments ................................................................................................................ vi 
List of figures ...................................................................................................................... vii 
List of tables ......................................................................................................................... ix 
List of abbreviations ............................................................................................................. xi 
Publications ........................................................................................................................ xiv 
 
CHAPTER 1: GENERAL INTRODUCTION ...................................................................... 1 
1.1 Obesity, type 2 Diabetes and Cardiovascular diseases: The major prevailing 
public health challenges ..................................................................................................... 1 
1.1.1 Introduction ..................................................................................................... 1 
1.1.2 Overweight and Obesity .................................................................................. 1 
1.1.3 Atherosclerosis and Cardiovascular diseases ................................................ 11 
1.1.4 Type 2 Diabetes and Insulin Resistance ........................................................ 18 
1.1.5 Role of cortisol in obesity-related complications .......................................... 27 
1.1.6 Importance of prevention............................................................................... 29 
1.2 Polyphenols: Overview ......................................................................................... 29 
1.2.1 Definition and properties ............................................................................... 29 
1.2.2 Types of polyphenols, chemical structure and food sources ......................... 31 
1.2.3 Factors affecting polyphenol content in foods .............................................. 36 
1.2.4 Metabolism of polyphenols: from absorption to elimination ........................ 38 
1.2.5 Bioavailability of polyphenols in the human body ........................................ 40 
1.2.6 Toxicity of polyphenols ................................................................................. 43 
1.3 Cocoa / Dark chocolate ......................................................................................... 44 
1.3.1 History ........................................................................................................... 44 
1.3.2 Cocoa and dark chocolate composition ......................................................... 46 
1.3.3 Cocoa and chocolate production.................................................................... 48 
1.3.4 Effect of processing on polyphenol content .................................................. 51 
iii 
 
1.3.5 Bioavailability of cocoa polyphenols in the human body ............................. 53 
1.3.6 Benefits of cocoa/dark chocolate ................................................................... 55 
1.3.7 Difference between cocoa and dark chocolate .............................................. 56 
1.4 Effects of cocoa/dark chocolate on inflammation and antioxidant capacity ........ 59 
1.5 Effects of cocoa/dark chocolate on insulin and glucose metabolism ................... 68 
1.6 Effects of cocoa/dark chocolate on lipid profile ................................................... 79 
1.7 Effects of cocoa/dark chocolate on blood pressure............................................... 82 
1.8 Effects of cocoa/dark chocolate on glucocorticoid metabolism ........................... 88 
1.9 Effects of cocoa/dark chocolate on fat metabolism, body weight and obesity ..... 89 
1.10 Proposed investigations ...................................................................................... 100 
1.10.1 Study I: Effect of polyphenol-rich dark chocolate on insulin sensitivity in 
normal weight and overweight adults ........................................................................ 100 
1.10.2 Study 2: Effect of polyphenol-rich dark chocolate on body weight in 
overweight and obese adults ...................................................................................... 103 
CHAPTER 2: GENERAL MATERIALS AND METHODS ........................................... 109 
2.1 Ethical approval .................................................................................................. 109 
2.2 Nutritional and chemical composition of the experimental dark chocolate ....... 109 
2.3 STUDY I ............................................................................................................. 112 
2.3.1 Study population .......................................................................................... 112 
2.3.2 Determination of sample size ...................................................................... 113 
2.3.3 Study design ................................................................................................ 114 
2.3.4 Justification for the chosen methods ........................................................... 117 
2.3.5 Data collection and processing .................................................................... 119 
2.3.6 Compliance and diet diaries collection ........................................................ 134 
2.3.7 Statistical analysis ....................................................................................... 136 
2.4 Study II ............................................................................................................... 136 
2.4.1 Study population .......................................................................................... 136 
2.4.2 Determination of sample size for the small scale study .............................. 137 
2.4.3 Estimation of sample size for a larger study based on Study II results ....... 137 
2.4.4 Study design ................................................................................................ 138 
2.4.5 Justification for the chosen methods ........................................................... 140 
iv 
 
2.4.6 Data collection and processing .................................................................... 142 
2.4.7 Compliance and diet diaries collection ........................................................ 151 
2.4.8 Statistical analysis ....................................................................................... 152 
CHAPTER 3: INTRA-OBSERVER RELIABILITY OF WAIST CIRCUMFERENCE 
MEASUREMENT ............................................................................................................. 153 
3.1 Rationale for the intra-observer reliability study ................................................ 154 
3.2 Objective ............................................................................................................. 154 
3.3 Materials and methods ........................................................................................ 155 
3.4 Statistical analysis ............................................................................................... 157 
3.5 Results ................................................................................................................. 157 
3.6 Discussion ........................................................................................................... 158 
CHAPTER 4: RESULTS AND DISCUSSION ................................................................ 160 
4.1 Study I ................................................................................................................. 160 
4.1.1 Results ......................................................................................................... 160 
4.1.2 Discussion .................................................................................................... 178 
4.2 Study II ............................................................................................................... 197 
4.2.1 Results ......................................................................................................... 197 
4.2.2 Discussion .................................................................................................... 211 
CHAPTER 5: GENERAL DISCUSSION AND CONCLUSION .................................... 227 
5.1.1 Limitations ................................................................................................... 230 
5.1.2 Directions for future research ...................................................................... 235 
5.1.3 General Conclusion ..................................................................................... 237 
CHAPTER 6: REFERENCES ........................................................................................... 241 
CHAPTER 7: APPENDICES ............................................................................................ 302 
 
 
 
 
 
 
v 
 
 Abstract 
 
Polyphenols are phytochemicals widely available in plants. Dark chocolate (DC) is a high 
source of polyphenols, particularly flavanols. Studies previously reported a beneficial 
effect of polyphenol-rich dark chocolate (PRDC) on insulin sensitivity and oxidative 
stress, while its effects on blood pressure, serum lipid levels and inflammation remain 
unclear. In addition, a research area regarding the effect of PRDC on body weight control 
emerged recently. Two investigations were carried out. Study I (61 participants) looked at 
the effect of PRDC on insulin sensitivity in normal weight and overweight adults, while 
Study II (14 participants) investigated the effect of PRDC on body weight in overweight 
individuals. Volunteers received 20g of either PRDC (500mg of polyphenols) or placebo 
DC (low in polyphenols) daily for 4 weeks (Study I) or 12 weeks (Study II). 
Anthropometric measures and blood, saliva and urine samples were taken. Results showed 
that 4 weeks of PRDC supplementation decreased insulin levels (p<0.001) and HOMA-IR 
(p=0.003), and increased QUICKI (p<0.001), but had no significant impact on glucose 
levels (p=0.16). However, participants administered placebo DC showed an increase in 
insulin (p=0.014), HOMA-IR (p=0.003), TG (p= 0.008), glucose (p=0.041) and BMI 
(p=0.007) levels and a decrease in QUICKI (p=0.013). No significant changes in blood 
pressure, other serum lipid levels or glucocorticoid hormones were noted in both groups. 
In study II, there was an increase in BMI in the whole study population (p=0.046) with no 
significant difference between groups. 
Results indicate a potential implication of PRDC in the prevention of risk factors for 
cardiovascular diseases. Findings also highlight the detrimental effects of placebo DC, and 
propose the analysis of polyphenol content of different DC brands in the market.  The 
increase in BMI and other markers only in the placebo group after four weeks, suggests 
that PRDC may counteract the adverse effects of fat and energy in the diet. However, the 
increase in BMI in both groups after 12 weeks implies further investigations to test the 
counteracting effect of PRDC over the long term.  
  
Keywords: Polyphenol-rich dark chocolate, placebo DC, insulin sensitivity, HOMA-IR, 
QUICKI, LDL oxidation, glucose, TG, BMI. 
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 CHAPTER 1: GENERAL INTRODUCTION 
1.1 Obesity, type 2 Diabetes and Cardiovascular diseases: The major 
prevailing public health challenges  
1.1.1 Introduction 
Obesity, type 2 diabetes and cardiovascular diseases (CVD) currently constitute the 
major causes of death and disability. These chronic conditions have caused a 
dramatic increase in health care costs and a decline in the quality of life (Anderson 
2004). It is established that a lack of physical activity and a poor nutrition are the 
major contributors for the considerable increase in the prevalence of obesity and its 
related complications, with lifestyle modification being the major preventive factor 
(CDC 2009a). In view of these diseases burden and the diet implication, promoting 
dietary strategies that aim to improve health are becoming crucial. 
Section 1.1 provides a background of the current status of obesity and chronic 
diseases worldwide, and presents an overview of the pathophysiology of obesity-
related complications. This will help in understanding the mechanisms of action of 
polyphenols, and their potential role in preventing its associated diseases. 
1.1.2 Overweight and Obesity 
1.1.2.1 Definition 
Overweight and obesity are terms used to define weight ranges that are considered 
above to what is regarded as healthy for a given height (CDC 2012). Body mass 
index (BMI) is the most useful and common tool for the determination of weight 
status of individuals, and it is adapted to both genders and all ages in adults. BMI 
provides a rough estimate of body fat percentage for most people, with few 
exceptions as in the case of athletes (it overestimates fat mass), and older people (it 
underestimates fat mass) (Snijder et al. 2006). The WHO (World Health 
Organization) defines a BMI greater than or equal to 30 Kg/m
2
 as obesity, and a BMI 
between 25 - 29.9 Kg/m
2
 as overweight (WHO 2013a). These cut-offs are based on 
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epidemiological studies which assessed the link between BMI and high mortality 
risk (PSC et al. 2009). 
Waist circumference (WC) is an important tool for assessing adiposity, since it is 
correlated with total body fat percentage as well as with abdominal fat (Han et al. 
1997). WC is considered a surrogate indicator of central fat mass. Central body fat 
distribution has been regarded as an important contributor to chronic disorders such 
as CVD and type 2 diabetes (Snijder et al. 2006). WC is considered a better predictor 
of the risk of diseases than BMI (IDF 2005). Yet, because of the lack of a uniform 
protocol for the measurement of WC, the latter has not been extensively adopted 
(Mason and Katzmarzyk 2009), and BMI is still the most widely used tool for 
assessing weight status. On the other hand, BMI has been shown to be strongly 
associated with WC (Vazquez et al. 2007). The cut-off points for WC are presented 
in Table 1.1.  
 
        Table 1.1: Cut-offs for waist circumference in adults 
 
       (Adapted from Lean 2002)      
      M: Male, F: Female 
       Waist circumference is measured as the midway between the lowest rib and the iliac      
       crest. Classification is based on Scottish Intercollegiate Guidelines Network (1996) and 
      the National Institutes of Health, National Heart, Lung and Blood Institute (1998). 
  
          
1.1.2.2 Prevalence 
The rates of overweight and obesity have dramatically increased over the past two 
decades, and reached epidemic rates in several regions in the world (WHO 2013a) 
(View Figure 1.1 on the prevalence of obesity in adults by region). More than one-
third (35.7%) of the US adult population is currently obese, with no difference in the 
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prevalence between men and women (Ogden et al. 2012). The UK seems to have the 
fastest increasing obesity rate in the developed world, and one of the highest 
overweight and obesity rates in Europe (Figure 1.2). Around two-thirds of UK men 
and women are currently either overweight or obese (Diabetes UK 2005).  It is 
estimated that half of the US and UK adult population will be obese by the year 2030 
(MRC 2007). 
 
 
Figure 1.1: Prevalence of obesity in adults between 1980-2008                      
(WHO 2012) 
Prevalence by region. AFR: Africa, AMR: America, SEAR: South-East Asia Region, EUR: 
Europe, EMR:  Eastern Mediterranean Region, WPR: Western Pacific Region. 
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Figure 1.2: Prevalence of obesity in adults in Europe 
(OECD 2012) 
The prevalence is in 2010 or nearest year 
EU27: European Union member states (27 countries) 
1.1.2.3 The adipose tissue as an active metabolic organ 
It is now agreed that the adipose tissue is no longer recognized as a site merely for 
fat storage (Trayhurn and Beattie 2001; Mariman and Wang 2010), as traditionally 
known, but an endocrine organ and a secretor of biologically active substances 
which play a significant role in the occurrence of diseases (Adamczak and Wiecek 
2013). In addition to adipocytes, adipose tissue contains macrophages and 
fibroblasts, which constitute about half of the total number of adipose tissue cells 
(Hausman 1985). 
The adipose tissue secretes inflammatory factors including adipokines (leptin, 
resistin, adiponectin) and cytokines (like TNF-α (tumor necrosis factor-α) and IL-6 
(Interleukin-6)) (Fantuzzi 2005). These factors are implicated in atherosclerosis, 
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diabetes mellitus, inflammation, endothelial dysfunction and kidney problems 
(Adamczak and Wiecek 2013). Notably, leptin has been reported to inhibit food 
intake by halting the appetite stimulator neuropeptide Y (NPY) (Stephens et al. 
1995), and to increase energy expenditure (Myers et al. 2008). Leptin rises 
proportionally to the adipose tissue expansion; however, it becomes dysfunctional in 
the event of excess fat or obesity. In fact, obese people exhibit higher levels of leptin 
compared to normal weight people. Yet, this hormone is unable to counter the effects 
of obesity due to a state called “leptin resistance”, caused by many factors such as a 
defect in the transport of leptin through the blood brain barrier in obese individuals 
(Myers et al. 2008). Adiponectin has been inversely associated with insulin 
resistance and inflammation, and its levels decrease with obesity (Kershaw and Flier 
2004). As for cytokines, IL-6 levels increase with increasing adiposity (particularly 
visceral adiposity), and exert a prodiabetic and proatherogenic role by reducing 
insulin sensitivity, and increasing the coagulation of platelets. Elevated levels of IL-6 
have been correlated with low HDL levels and high blood pressure levels (Yudkin et 
al. 1999). Also, TNF-α, which levels rise in obesity, play a particularly important 
role in inflammation. TNF-α levels have been shown to increase lipolysis in 
adipocytes, leading to an increase in circulating free fatty acids (FFA) (Green et al. 
2004), and to exert a similar role to IL-6 on insulin sensitivity and platelets (Berry 
2008) (The role of FFA in obesity related complications is discussed in section 
1.1.4.4). The adipose tissue is also the location of secretion of plasma activator 
inhibitor-1 (PAI-1), which levels increase in obesity. PAI-1 is upregulated by several 
factors such as TNF- α, hyperinsulinemia and hypertriglyceridemia, the latter being 
consequences of obesity and insulin resistance (Lau et al. 2005). 
In addition, the white adipose tissue expresses several proteins involved in the Renin 
Angiotensin system, the latter being responsible for blood pressure homeostasis 
(View Figure 1.3 on the overview of Renin Angiotensin system). The adipose tissue 
secretes angiotensinogen (Trayhurn and Beattie 2001), angiotensin I and II, as well 
as the enzyme ACE (angiotensin converting enzyme). ACE leads to an increase in 
the antiudiuretic hormone (leading to sodium and water retention), and to an 
inhibition of the vasodilators bradykinin and kallidin (Shearer et al. 2013). The 
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expression of angiotensinogen and ACE is higher in visceral adipose tissue 
compared to subcutaneous adipose tissue (Engeli et al. 2003).  
The adipose tissue is also a metabolic regulator involved in glucose haomeostasis 
(Trayhurn and Beattie 2001), and plays a role in cortisol metabolism due to its 
implication in the conversion of the hormone cortisone to cortisol through the 
enzyme 11-hydroxysteroid dehydrogenase type 1 (11 β-HSD 1) existent in this tissue 
(Chudek et al. 2006).  
Lastly, the adipose tissue expresses a variety of hormones and receptors that 
communicate with the central nervous system, and control numerous biological 
processes including immune function, energy expenditure and neuroendocrine 
function. Examples comprise glucagon and insulin receptors, vitamin D receptors 
and androgen receptors (Kershaw and Flier 2004). 
In view of these functions, excess adipose tissue may possibly lead to conditions 
such as hypertension, hyperglycemia, dyslipidemia, as well as prothrombotic and 
proinflammatory states (Grundy 2004).  
 
 
 
 
 
 
       
 
 
 
 
  Figure 1.3: Overview of the Renin Angiotensin system  
  (Adapted from Shearer et al. 2013) 
 ACE: Angiotensin converting enzyme. The Renin angiotensin system is responsible for 
blood pressure regulation. Renin converts Angiotensinogen to Angiotensin I. Subsequently, 
ACE converts Angiotensin I into Angiotensin II (a vasoconstrictor). This stimulates 
aldosterone release, resulting in an increase in sodium and water retention. 
 
 
Angiotensin II 
Aldosterone  
Renal sodium/fluid retention 
Angiotensinogen 
Angiotensin I 
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The Brown adipose tissue 
 
In addition to the white adipose tissue, the brown adipose tissue (BAT) has lately 
received attention for its potential role in obesity and the regulation of energy 
metabolism. Animal studies have shown that BAT contains a large number of 
mitochondria, which include a unique protein called uncoupling protein 1 (UCP1). 
One of the main roles of UCP1 is to dissipate energy in the form of heat. In fact, 
upon exposure to cold, norepinephrine activates β-adrenergic signalling pathways in 
BAT, leading to the induction of thermogenesis and the activation of lipolysis. 
Lipolysis leads to the formation of FFA, the main substrate for the production of 
heat. FFA stimulate UCP1 which is responsible of uncoupling oxidative 
phosphorylation and producing energy (Lidell et al. 2014). In addition, 
thermogenesis leads to the increase in energy expenditure (Virtanen et al. 2009). The 
mechanism of action of UCP1 involves the peroxisome proliferator-activated 
receptors (PPARs) (Ali et al. 2014), which are nuclear receptors that act as 
transcription factors, and are involved in decreasing insulin resistance and 
dyslipidemia, as well as in attenuating inflammatory response. PPARs consist of 
PPAR-α, PPAR-β/δ and PPAR-γ, which are expressed in adipose tissue as well as in 
other organs such as heart and liver (Stienstra et al. 2014). In brown adipose tissue, 
UCP1 is stimulated by PPAR-γ, the latter being activated by the transcription factor 
PGC-1α (peroxisome proliferator-activated receptor-γ coactivator-1) and involved in 
mitochondrial biogenesis and oxidative phosphorylation (Lidell et al. 2014).  
Animal studies have also shown that in addition to the brown adipocytes, some 
brown-like adipocytes exist within the white adipose tissue. The latter, called 
inducible brown adipocytes or beige adipocytes have been shown to express UCP1 
and PGC-1α genes, and are therefore implicated in thermogenesis (Lidell et al. 
2014).  
Furthermore, the enzyme AMPK (Adenosine monophosphate-activated protein 
kinase), which is expressed in BAT but also in white adipose tissue, is thought to 
play a crucial role in energy metabolism and obesity regulation (Mulligan et al. 
2007). This enzyme consists of α, β, and γ subunits (α1, α2, β1, β2, γ1, γ2, γ3), 
which effects on the function of AMPK remains unclear.  In response to fasting 
and/or exercise, AMPK is stimulated by leptin and adiponectin, and leads to an 
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increase in fatty acid oxidation in the adipose tissue. AMPK has been suggested to 
induce thermogenesis in brown adipose tissue via stimulating UCP1 (Ahmadian et 
al. 2011). AMPK is also expressed in several organs like skeletal muscle and liver, in 
which functions involve the increase of glycolysis and glucose transport in skeletal 
muscle, the decrease of gluconeogenesis, the increase in mitochondrial biogenesis, 
and the decrease in cholesterol synthesis (Daval et al. 2006; Viollet et al. 2007). 
Therefore, AMPK plays a protective role against obesity and its related 
complications. AMPK signalling has been reported to be defective in obesity and 
related diseases (Hardie 2008).  
 
In humans, BAT has been recognized to be abundant in newborns and to decrease 
with age. It has been suggested that the effect of BAT on energy homeostasis in 
adults is negligible due to its small proportion (around 700g in a man) (Astrup et al. 
1985), and the activity of UCP1 is not physiologically relevant in humans (Cypess et 
al. 2009). However, in the last few years, it has been reported that adult humans may 
have significant amounts of BAT which can be implicated in energy balance (Seale 
and Lazar 2009). An inverse association between BMI and BAT mass has been 
reported in a study including 1972 patients (Cypess et al. 2009). However, the effect 
of BAT on adiposity and energy expenditure has been proposed to be temperature-
dependent. An exposure to the cold for 2 hours at 19
o
C resulted in the activation of 
BAT mass in 56 volunteers, while this was not the case when the exposure was at 
higher temperature (27 
o
 C ) (Saito et al. 2000). Also, the increase of BAT volume by 
10.5 ± 11.1% (p<0.001) and energy expenditure by 5.3 ± 5.9% (p < 0.001) has been 
documented upon an overnight exposure to a temperature of 19
o
 C (Chen et al. 
2013). Furthermore, exposure to 17°C (2 hours per day) for 6 weeks has been shown 
to increase the activity of BAT (p< 0.0001), and to cause a decrease in body fat        
(–5.2% ± 1.9%, P < 0.05). Yet, no significant changes in BAT and body fat have 
resulted from an exposure to 27 °C (Yoneshiro et al. 2013). In view of this, inter-
individual differences in BAT resulting from differences in cold exposure can be 
large between humans. These findings, although preliminary, provide a line of 
evidence that BAT induced via cold temperature can constitute a target for managing 
obesity and related diseases in humans (Chen et al. 2013). Further studies looking at 
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the relevance of BAT in humans and its implications in body weight control are then 
needed. 
 
1.1.2.4 Health Outcomes 
Obesity constitutes a major socio-economic challenge due to its impact on the work 
productivity and the quality of life (MRC 2007), and its burden on the health care 
system (DH 2013). Unhealthy diets and sedentary lifestyles have notably contributed 
to the epidemic increase in obesity worldwide (Diabetes UK 2005). Obesity results 
in multiple consequences including physical (e.g. back pain), social (e.g. isolation), 
psychological (e.g. low self esteem) and most importantly medical consequences 
(Ogden et al. 2006; NHS 2011a). The disease risks notably start at the overweight 
stage and rise with the increase in BMI (NHLBI 2012a). Studies have shown that the 
prevalence of CVD in the Scottish population is 37% in obese adults (BMI >30 
Kg/m
2
), and 21% in overweight adults (BMI between 25 and 30 Kg/m
2
), whereas it 
is around 10% in subjects with BMI<25 Kg/m
2
. In addition, excess body fat has been 
linked to an acceleration of atheroma and to an increased risk of thrombosis, stroke 
and myocardial infarction (Lean 2000). Furthermore, a BMI over 30 Kg/m
2 
increases 
by 10 times the risk of type 2 diabetes, whereas a BMI over 35 Kg/m
2
 increases the 
risk by 80 times over 10 years (Williams and Pickup 2004). Obesity also raises the 
risk of death: Morbidly obese individuals have 8-10 years lower life expectancy than 
normal weight individuals, and it has been stated that each 15 kilograms in excess of 
normal range raises the risk of premature death by 30 % (OECD 2012). Moreover, 
obesity has been reported to affect mental health (Chapman et al. 2005), and to 
interfere with muscle function and strength, possibly leading to impaired physical 
movement (Hilton et al. 2008) and musculoskeletal disorders (CDC 2013).    
On the other hand, it is worth mentioning that normal weight individuals (BMI<25 
Kg/m
2
) might be candidates of a syndrome called normal weight obese (NWO) 
syndrome, which is characterized by a normal BMI but a high body fat percentage 
(more than 33.3% in women and more than 23.1% in men) when the latter was 
assessed by bioelectrical impedance (Romero-Corral et al. 2010).The NWO is 
clinically important as it is strongly correlated with disease risk. NWO has been 
shown to raise cardiovascular mortality by 2.2 in women, and to increase 
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cardiovascular risk factors in men. Increased levels of proinflammatory cytokines 
like TNF-α have also been noted in individuals with NWO syndrome. Interestingly, 
there was a positive association between WC and body fat percentage in this study 
(Romero-Corral et al. 2010). 
This highlights one of the drawbacks of BMI in identifying a range of individuals 
with cardiovascular risk, and emphasizes the need to assess body fat percentage 
and/or WC in order to recognize individuals at risk, and implement appropriate 
prevention strategies. 
1.1.2.5 Obesity as a “disease” 
Despite the fact that the majority of the literature stills consider obesity as a risk 
factor for cardiovascular diseases rather than a disease by itself (Lean 2000), the 
serious outcomes of this condition on morbidity and mortality has led to the 
reconsideration of the definition of obesity. Kopelman (2000) stated that obesity is 
now perceived as a disease rather than a cosmetic issue. Moreover, in a recent 
position statement of the American society of endocrinologists, obesity has been 
recognized as a disease, rather than a result of an adopted lifestyle, as it fulfils the 
three disease criteria including: 
a. Morbidity: mainly due to central obesity which modulates appetite and 
energy balance, and may lead to insulin resistance, high blood pressure, 
dyslipidemia, infertility, and non alcoholic fatty liver disease (Mechanick et 
al. 2012) (The role of central obesity in the occurrence of metabolic 
syndrome is discussed in section 1.1.4.4). This position is reinforced by the 
secretory and endocrine properties of adipose tissue, which secretes 
substances that are linked to the occurrence of diseases (Adamczak and 
Wiecek 2013), as previously stated. 
b. Specific signs and symptoms: Obesity is physically identifiable by the 
increase in body fat to which manifestations like joint pain and low self 
esteem are related.  
c. Alteration in body functioning: obesity may lead to conditions like 
osteoarthritis, decrease in body motion and sleep apnea.  
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Although subject to criticism (due to reasons such as the use of BMI which presents 
drawbacks in estimating weight status), this new perspective is thought to be 
beneficial in bringing the attention of health care providers, scientists and the 
government to the necessity of implementing and improving strategies that aim to 
prevent and treat obesity, and reduce its financial and social burdens (Mechanick et 
al. 2012). 
 
1.1.3 Atherosclerosis and Cardiovascular diseases 
1.1.3.1  Overview 
CVD define a cluster of conditions of the heart and blood vessels, including coronary 
heart disease, peripheral artery disease and stroke. CVD are the leading cause of 
death in the world (17.3 million people per year). It is expected that by the year 
2030, the number will reach 23 million (WHO 2013b). In 2009, CVD were 
responsible for one third of the deaths in the UK, mainly caused by coronary artery 
diseases and stroke (BHF 2013; WHO 2013b). CVD are a major consequence of 
obesity, and constitute a serious burden on the health care system (WHO 2013b).  
 
CVD may be the result of atherosclerosis or “hardening of the arteries”, a condition 
characterized by the accumulation of lipids in the arteries, particularly cholesterol. 
This leads to the formation of plaque which narrows the artery, and consequently 
causes ischemia (restriction of blood flow) (Figure 1.4). The rupture of the plaque 
causes the release of thromobogenic factors in the circulation, and is responsible for 
blocking blood supply either to the heart, causing myocardial infarction, or to the 
brain, resulting in stroke (Zebrack and Anderson 2002; NHS 2013).  
 
CVD are viewed as an inflammatory progression because of the involvement of 
inflammation in the pathogenesis of the atherosclerotic plaque (Shah and Prediman 
2009). In fact, due to environmental and/or genetic factors (which cause endothelial 
injury), there is a release of the nuclear factor-kappa B (NF-KB) (a transcription 
factor expressed in many cell types including adipose tissue, liver and central 
nervous system, and a chief regulator of inflammation). NF-KB activates chemokines 
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(small cytokines) and adhesion molecules (Baker et al. 2011). Chemokines such as 
MCP-1 (monocyte chemoattractant protein-1) attract monocytes from the circulation, 
and adhesion molecules allow the monocytes to cross the endothelial wall to be 
converted to macrophages, constituting a key step in atherosclerosis (Zebrack and 
Anderson 2002). Macrophages are then responsible for the secretion of cytokines 
(TNF-α, IL-6 and IL-1) and metalloproteinases (have a role in the migration of 
vascular smooth muscle cells (Lee et al. 2008)) in the vessel walls, leading to the 
initiation of the inflammatory cascade. LDL (Low density lipoproteins) cholesterol, 
which have been oxidised in the artery walls, are then taken by macrophages. This 
results in the formation of foam cells and eventually, the atherosclerotic plaque. At 
this stage, some inflammatory factors help in plaque growth and destabilization, and 
might result in its rupture (Zebrack and Anderson 2002). Furthermore, 
proinflammatory enzymes like NADPH (nicotinamide-adenine dinucleotide 
phosphate) oxidase and xanthine oxidase are implicated in endothelial dysfunction 
(Maytin et al. 1999). NADPH oxidase leads to vascular dysfunction through the 
formation of reactive oxygen species (ROS) (Steffen et al. 2006). Xanthine oxidase 
binds to endothelial cells, and generates oxygen and hydrogen peroxide (H2O2) 
species when reacting with xanthine or hypoxanthine (White et al. 1996). 
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     Figure 1.4: Development of plaque in atherosclerosis  
(NHLBI 2011) 
The accumulation of LDL particles and their oxidation in the artery walls result in 
their scavenging by macrophages and the formation of foam cells. This leads to the 
formation of atherosclerotic plaque which restricts normal blood flow.   
 
1.1.3.2 Nitric oxide, endothelial dysfunction and oxidative stress 
Nitric oxide (NO) is a biologically active free radical implicated in several reactions 
in the body, and is the most important endothelium-derived vasodilator (eNOS) 
(Dobutovic et al. 2011). NO is responsible for the proliferation of smooth muscle 
cells, as well as the inhibition of platelet aggregation and thrombosis. NO has been 
also involved in the haemostasis of blood pressure through mechanisms involving 
vasodilatation (Napoli and Ignarro 2009).  
NO is produced by a series of NO synthase (NOS) enzymes, the main ones being: 
neuronal NOS, endothelial NOS and inducible NOS (iNOS) (Liu and Hang 2008).  
The mechanisms of action of NOS enzymes involve catalysing the oxidation of       
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L-arginine to NO and citrulline (Stuehr et al. 2004). NO then binds to guanylyl 
cyclase and results in increased levels of cGMP (cyclic guanosine monophosphate), 
resulting in the increase in vasodilatation, the relaxation of smooth muscle cells 
(Napoli and Ignarro 2001; Napoli and Ignarro 2006) and the decrease in platelet 
aggregation (Jerca et al. 2002) (Figure 1.5). 
 
Endothelial dysfunction refers to a state during which the endothelium loses its 
vasodilatory and anti-aggregation properties (Avogaro et al. 2011), leading to an 
increase in the risk of thrombosis, diabetes mellitus, hypertension and cardiovascular 
and cerebrovascular diseases (Napoli and Ignarro 2001). The reduction in NO levels 
has been suggested to be responsible for the development of vascular problems; 
however, it is not clear yet whether this reduction is a cause or a consequence of 
endothelial dysfunction. Nevertheless, it is known that synthesis and bioavailability 
of NO are crucial for maintaining a healthy endothelium. Decreased levels of NO 
could be due to several factors such as a decrease in NOS enzyme levels, or a 
decrease in the bioavailability of NO (Napoli and Ignarro 2009). Studies have shown 
that mice lacking certain forms of NOS are hypertensive, have endothelial 
dysfunction, and demonstrated a more severe response to a high cholesterol diet-
induced atherogenesis. This can also be applicable to humans, since the similarity in 
the isoforms of NOS between mice and humans ranges between 80-96% (Liu and 
Huang 2008). It has also been stated that some risk factors for coronary heart 
diseases like hypertension, diabetes and hypercholesterolemia can reduce the levels 
of L-arginine, leading to a reduction in NO bioavailability (Böger and Ron 2005).  
 
Oxidative stress, a contributor to endothelial dysfunction, is described as an 
imbalance between pro-oxidants (ROS) and antioxidants (supposed to repair the 
damage), resulting in an alteration of the redox signalling (Jones 2006). Oxidative 
stress is of particular importance, as it may contribute to several chronic diseases 
such as CVD, cancer and hypertension (Urquiaga and Leighton 2000). Oxidative 
stress results in the formation of ROS, which act as scavengers for NO, and cause 
endothelial dysfunction (Steffen et al. 2006). In particular, oxidised LDL can reduce 
the uptake of L-arginine by uncoupling NOS enzymes, giving rise to ROS (Napoli 
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and Ignarro 2009). Moreover, in the presence of oxidants like superoxide (which can 
originate through several pathways like xanthine oxidase, NADPH oxidase, and 
endothelial NOS), NO gives peroxynitrite (an oxidant implicated in cellular 
dysfunction). Peroxynitrite reduces the bioavailability of NO and leads to an increase 
in inflammation and oxidative damage (Radi 2004). Consequently, atherosclerosis 
may be caused by the disruption of the balance between the bioactivity of NO and 
oxidative stress (Napoli and Ignarro 2001). 
 
 
 
Figure 1.5: Synthesis and mechanism of action of nitric oxide  
(Adapted from Jerca et al. 2002) 
SMC: Smooth muscle cells, cGMP: Cyclic guanosine monophosphate, NO: Nitric oxide 
NO synthase catalyses the oxidation of L-arginine to NO. NO results in the increase in 
cGMP levels leading to vasodilatation of smooth muscle cells, and to inhibition of platelet 
aggregation. 
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1.1.3.3 Risk Factors   
        a. High blood pressure or Hypertension 
 
Hypertension is known as the “silent killer” (NHS 2012a), as it might be undetected 
for years until a cardiovascular event like a stroke or a heart attack occurs (Cataldo 
2002). It is estimated that around one in 3 adults in the US is hypertensive (NHLBI 
2012b). However, approximately one third of these individuals are undiagnosed 
(Cataldo 2002). 
A high blood pressure is defined as an elevated systolic blood pressure (SBP) and/or 
diastolic blood pressure (DBP) above the normal levels (NHLBI 2012b) (view Table 
1.2 on the classification of blood pressure in adults). Prehypertension should be 
carefully considered since it can contribute to hypertension, and to an increased risk 
of heart diseases. In fact, the Framingham Heart study showed that men with 
prehypertension have 3.5 times more risk of having heart attacks than normotensive 
men (Qureshi et al. 2005). Hypertension leads to or worsens atherosclerosis by 
damaging the walls of the arteries, and increasing the risk of developing plaques and 
clots. This results in the occurrence of stroke and other heart conditions (Cataldo 
2002).  Hypertension is responsible for 37% of deaths in the western population 
(Martiniuk et al. 2007), and for 54% of strokes and 47% of ischemic heart diseases 
globally (Lawes et al. 2008). The risk rises proportionally to blood pressure 
(Lewington et al. 2002). 
 
          b. Dyslipidemia and oxidised LDL 
 
Dyslipidemia is a disorder of the metabolism of lipoproteins, expressed by high total 
serum cholesterol, high LDL cholesterol (the small and dense LDL are considered 
the most atherogenic), low HDL cholesterol and/or elevated triglycerides (TG) levels 
(Toth 2008). Dyslipidemia is considered an increasing problem and one of the major 
risk factors for CVD. The condition may be caused by many factors, such as an 
unhealthy diet (high in trans-fatty acids, saturated fatty acids and cholesterol and low 
in fiber), low levels of physical activity, overweight and obesity (mainly abdominal 
obesity), smoking and high alcohol consumption. High TG and low HDL levels play 
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an important role in the development of atherosclerosis (Talayero and Marks 2011), 
and are implicated in atherogenic dyslipidemia, the latter being described as a triad 
of high levels of TG and small and dense LDL, and low levels of HDL.  
LDL oxidation is one of the most important factors in the development of 
atherosclerosis, and results from the oxidation of LDL particles in the artery walls 
leading to these particles being scavenged by the monocytes, and resulting in the 
formation of fibrous plaque (Sorace et al. 2006), as previously discussed. Oxidised 
LDL is more crucial in atherosclerosis than LDL, and is a main contributor to 
endothelial dysfunction and to an increase in arterial thickness (Li and Mehta 2000). 
Oxidised LDL exerts its pro-oxidant and pro-inflammatory effects by stimulating the 
release of factors involved in the pathogenesis of atherosclerosis such as cytokines 
(TNF-α and IL-1), and chemokines like interleukin-8 (a chemokine with angiogenic 
properties) (Claise et al. 1996). Higher levels of oxidised LDL have been reported in 
subjects with hyperlipidemia compared to normolipemic subjects (Liu et al. 2004).  
Oxidised LDL has been suggested to be inversely correlated to HDL levels, as an 
increase in the latter cause an inhibition of LDL oxidation (Holvoet et al. 1998). The 
mechanisms involve a role of HDL in reversing cholesterol transport through the 
lecithin-cholesterol acyltransferase (LCAT) enzyme, which is activated by Apo A-1 
(apolipoprotein A-1), the major protein of HDL. This results in the transfer of 
cholesterol from peripheral tissues to the liver (Itabe et al. 1999). Also, HDL has 
been shown to inhibit the stimulatory effect of LDL oxidation on monocyte 
infiltration. This happens through the action of HDL associated enzymes, such as 
paraoxonase which inhibits the oxidation of PAF-AH (Platelet-activating factor 
acetyl hydrolase) enzyme. The latter enzyme suppresses PAF (Platelet-activating 
factor) which contributes to atherosclerosis by stimulating the formation of 
superoxide anions by macrophages. PAF-AH has been reported to increase the 
degradation of oxidised lipids in the artey walls. PAF-AH is secreted by 
macrophages and platelets, and circulates in association with HDL. Therefore, HDL 
has been suggested as an antagonist to oxidised LDL in the event of CVD risk 
(Mertens and Holvoet 2001).  However, a weak or no correlation between LDL 
oxidation and plasma LDL cholesterol has been noted (Holvoet et al. 1998; Baba et 
al. 2007b). 
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c. Other risk factors 
Factors such as overweight and obesity, smoking, high alcohol consumption, family 
history of premature cardiovascular diseases (defined by the occurrence of CVD at 
an age less than 55 years in males and 65 years in females) and age (men≥45 years, 
women ≥55 years) may all contribute to an increase in cardiovascular risk (Lee and 
Nieman 2010; WHO 2013b).  
 
Table 1.2: Classification of blood pressure in adults 
Blood Pressure 
classification 
SBP 
(mmHg) 
DBP 
(mmHg) 
Normal < 140 and <90 
Stage 1 Hypertension ≥140 or ≥ 90 
Stage 2 Hypertension ≥ 160 or ≥ 100 
Severe Hypertension ≥ 180 or ≥ 110 
(Adapted from the National Institute for Health and Care Excellence (NICE) 2011) 
SBP: Systolic blood pressure, DBP: Diastolic blood pressure. 
 
            
1.1.4 Type 2 Diabetes and Insulin Resistance 
1.1.4.1 Definitions 
Type 2 diabetes is a globally common complex disease characterized by insulin 
resistance (IR) and a gradual destruction of pancreatic beta cells, and ultimately 
leading to an increase in glucose levels (Deckert et al. 1992) (Figure 1.6). IR is the 
state when the body is producing insulin but unable to use it effectively. IR is a 
leading factor for the occurrence of type 2 diabetes (NIDDK 2013), and may precede 
the development of the disease by more than 10 years (Zimmet et al. 1992). 
1.1.4.2 Prevalence 
Type 2 Diabetes is now considered one of the biggest health challenges worldwide. 
In the UK, the prevalence of diabetics has dramatically increased over the past 2 
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decades, and reached more than 2.6 million. It is also suggested that the undiagnosed 
cases account for an additional half a million of diabetics. It is estimated that by the 
year 2025, the number will rise to four millions. In the US, type 2 diabetes has 
reached epidemic levels, and around 26 million individuals currently suffer from 
type 2 diabetes (NDEP 2013). Type 2 diabetes is mainly associated with obesity 
(Diabetes UK 2012), and its diagnosis at an early stage is extremely important, as 
50% of the cases of type 2 diabetes can be avoided if prevention strategies are 
implemented (Diabetes UK 2012). Type 2 diabetes is a major risk factor for CVD 
(Bartels et al. 2007). CVD and type 2 diabetes account together for 75% of the 
deaths worldwide (WHO 2003). 
 
 
            Figure 1.6: Progression of type 2 diabetes  
(Adapted from Bergenstal and Bailey 2000)   
Insulin resistance causes an increase in insulin secretion and a gradual destruction 
of β-cells. This eventually leads to a decrease in insulin secretion and an increase in 
glucose levels. 
 
1.1.4.3  Risk factors 
Diabetes type 2 is considered to be the result of an interaction between genetic and 
environmental factors (Diabetes UK 2005). Overweight and obesity, particularly 
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central obesity, remain the most important contributors for type 2 diabetes. IR is very 
common in overweight individuals, as 80% of individuals diagnosed with type 2 
diabetes are overweight (Astrup and Finer 2000). Ethnicity and age may also exert 
an influence. Age increases the risk, and some ethnic groups like Hispanic have a 
higher risk of type 2 diabetes than others (Oldroyd et al. 2005). 
1.1.4.4 The metabolic Syndrome 
The metabolic syndrome (MS) is defined as a clustering of risk factors for type 2 
diabetes and CVD, resulting from obesity (particularly visceral obesity) and IR. MS 
consists of several risk factors such as abdominal obesity, dyslipidemia, high blood 
pressure and glucose intolerance. The National cholesterol education program adult 
treatment panel III defines MS as the presence of 3 of the five following criteria: 
high waist circumference (≥102 cm in men and ≥ 88cm in women), high TG levels 
(≥ 1.7 mmol/l), low HDL levels (< 1 mmol/l in men and < 1.3 mmol/l in women), 
elevated fasting glucose levels (≥ 5.5 mmol/l) and high blood pressure (≥ 135/80 
mmHg or hypertension medication). Knowing that there has been some confusion 
over the purpose and definition of this syndrome (Blaha and Elasy 2006), the main 
purpose of discussing MS is to demonstrate how obesity and its resultant IR might 
lead to a series of abnormalities, and subsequently to the development of chronic 
diseases.   
One approach considers obesity, particularly visceral obesity, an essential 
contributor to the syndrome, which can lead to IR and consequently to an increased 
risk of type 2 diabetes, CVD and other diseases (Grundy et al. 2004) (Figure 1.7). 
Another approach considers IR as located in the heart of pathophysiological 
mechanisms that originate this syndrome, and that obesity is thought to exacerbate 
IR, but is not an essential contributor to its occurrence (Reaven 1988). The latter 
approach is, in fact, the theory of the founder of this syndrome. IR results in 
conditions like type 2 diabetes, CVD, polycystic ovarian syndrome and nonalcoholic 
fatty liver disease (Reaven 1988). However, it has been subsequently widely proven 
that obesity is strongly associated with the development of insulin resistance (Kahn 
et al. 2006; Qatanani and Lazar 2007), rendering body fat a crucial factor in the 
occurrence of MS.  
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FFAs play a central role in the pathophysiology of MS and in the occurrence of type 
2 diabetes (Reaven et al. 1988). The increase in body fat, particularly visceral fat, 
causes an increase in FFA in the circulation, and results in a set of pathological 
consequences (Snijder et al. 2006). The pathophysiology of the metabolic syndrome 
and the role of obesity are illustrated in Figure 1.8. 
 
Figure 1.7: Consequences of central obesity and its implications in the 
metabolic syndrome 
(Adapted from Dixon 2010) 
ER: Endoplasmic reticulum  
 
a. Obesity and insulin and glucose metabolism 
The increase of FFA in the circulation, mainly due to abdominal obesity, leads to a 
decrease in the uptake and oxidation of glucose by muscles and other organs.  The 
pancreas will then offset the decline in the uptake of glucose by increasing insulin 
secretion, resulting in hyperinsulinemia (Jensen et al. 2006; Snijder et al. 2006), and 
eventually leading to IR. IR is due to many factors such as the downregulation of 
insulin receptors caused by chronic hyperinsulinemia (Gavin et al. 1974). In 
addition, FFA accumulate in some organs (mainly liver and muscle but also 
pancreas), and cause lipotoxicity or “ectopic fat storage” (Kahn and Flier 2000). This 
will affect the functioning of pancreatic β cells. In the liver, the excess of FFA 
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causes an increase in gluconeogenesis and a decrease in the clearance of insulin from 
the liver (caused by the inhibition of the binding of insulin molecules to their 
receptors due to excess FFA). This contributes to or worsens hyperinsulinemia 
(Svedberg et al. 1992). Furthermore, the adipose tissue secretions (section 1.1.2.3) 
play a pivotal role in the manifestation of MS (Hermans and Amoussou-Guenou 
2005).  
            b. Obesity, insulin resistance and dyslipidemia 
Insulin plays a significant role in the metabolism of lipids. Dyslipidemia is 
recognized as a common feature in IR (Lamarche and Mauger 2005). Under normal 
conditions, insulin inhibits gluconeogenesis and lipolysis, induces lipogenesis 
(Saltiel and Khan 2001), and increases the activity of LPL (lipoprotein lipase) in the 
postprandial state (resulting in the uptake of fat by the adipose tissue) (Panarotto et 
al. 2002). However, in the event of IR, there is an abnormality in lipid metabolism: 
the insulin-mediated suppression of lipolysis and the stimulation of lipogenesis are 
defective. The reasons are mainly due to the fact that insulin resistant subjects have a 
decrease in insulin-stimulated glucose transporter (precursor of TG synthesis) (Kahn 
and Flier 2000), which affects the rate-limiting step in the synthesis of Triglycerides 
(Farese et al. 2000). Moreover, a problem in the regulation of LPL has been noted in 
obese and insulin resistant individuals (Yost et al. 1995). This results in the increase 
in the accumulation of FFA levels (Kahn and Flier 2000). 
In the liver, the excess of FFA resulting from obesity is secreted in form of VLDL 
(Very low density lipoproteins) particles rich in TG and Apo B 100 (the protein 
transporter of VLDL and LDL) (Bjorntorp 1990), resulting in hypertriglyceridemia, 
and in most of the lipid abnormalities associated with MS. Also, collisions between 
VLDL and HDL particles through to the cholesteryl-ester transfer protein (CETP) 
enzyme lead to a transfer of TG to HDL, in exchange of cholesteryl esters. HDL 
molecules rich in TG become substrate for the hepatic lipase and LPL, which 
hydrolyse their TG. Reduced HDL molecules partially lose their cortex, and are then 
eliminated by the kidneys. As a result, smaller and denser HDL (HDL3) will be 
abundant at the expense of larger, less dense and more cardioprotective particles 
(HDL2). Furthermore, LDL particles enriched in TG become substrates for the 
hepatic lipase and LPL, which hydrolyse their TG. Thus, these LDL particles 
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become small and dense. The metabolic syndrome is thus characterized by the 
presence of small and dense LDL, high TG and low HDL levels, albeit serum LDL 
levels are not necessarily increased (Goff et al. 2005; Hermans and Amoussou-
Guenou 2005). 
 
     c. Obesity, insulin resistance and hypertension  
It has been acknowledged that obesity is responsible for 65-75% of essential 
hypertension (Hall et al. 2001). Although not clearly elucidated, proposed 
mechanisms involve a high salt intake accompanying a high calorie diet (Carroll et 
al. 1997), and an increase in renal sodium tubular absorption. This increase in 
sodium reabsorption has been explained by the activation of the renin-angiotensin 
system (Atlas 2007) and the increase in renal sympathetic activity; the latter has been 
documented to be elevated in obese adults (Esler 2000). Indeed, a high blood 
pressure has been noticed in dogs fed a high fat diet, who exhibit hyperinsulinemia, 
sodium retention and hypertension similarly to obese humans (Hall et al. 1993).  
Furthermore, under normal conditions, insulin is known to exert a vasodilatory effect 
on the kidneys, and this effect is mediated by nitric oxide (Hayashi et al. 1997).  
However, in the case of IR, the insulin-dependent vasodilatory role is impaired due 
to a defect in insulin signalling mechanisms (Li et al. 2010), resulting in an increase 
in hypertension risk. 
 
Overall, inflammation and alterations in FFA metabolism play a pivotal role in the 
occurrence of MS. Excess FFA released from the adipose tissue can increase hepatic 
glucose production and suppress the ability of insulin to increase cellular glucose 
uptake, leading to IR (Snijder et al. 2006). Furthermore, oxidised LDL (which levels 
increase with the increase in adipose tissue) can contribute to IR by impairing insulin 
signalling, decreasing adiponectin and causing pancreatic β-cell death. Oxidised 
LDL is thought to be an initiator of the MS (Holveot et al. 2008). IR can be also 
induced or exacerbated by inflammatory cytokines secreted by the adipose tissue. In 
fact, the increase of lipid deposition in adipose tissue can activate NF-KB which 
stimulates intracellular pathways that cause IR. However, the mechanisms involved 
in the effect of FFA on NF-KB remain unclear. Furthermore, TNF-α decreases 
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insulin signalling (Shoelson et al. 2006). IL-6 can stimulate inflammation directly or 
by inducing the secretion of CRP in the liver (Park et al. 2004), and can contribute to 
IR. Moreover, MCP-1, which is highly expressed in visceral adipose tissue of obese 
individuals, participates in the recruitment of monocytes into the arterial wall and in 
the activation of macrophages in the atherosclerotic plaque. This will result in 
oxidised LDL being incorporated into macrophages. IL-8 plays a similar role to 
MCP-1 and attracts monocytes into the arterial wall (Trøseid et al. 2004). MCP-1 has 
been shown to induce IR in rats (Panee 2012). Oxidised LDL has also been involved 
in increasing the infiltration of monocytes (Holveot et al. 2008). As for lipid levels, 
the excess of FFA can cause dyslipidemia by increasing VLDL production and TG 
levels, and decreasing HDL levels (Hermans and Amoussou-Cuenou 2005). 
Oxidised LDL stimulates LPL which leads to an increase inTG levels (Holveot et al. 
2008). IR can also contribute to dyslipidemia due to impairment in insulin-mediated 
suppression of lipolysis, which increases FFA release from adipose tissue (Kahn and 
Flier 2000). In addition, IR can lead to increased blood pressure due to the impaired 
role of insulin as a vasodilator (Hayashi et al. 1997). Inflammation can be an 
additional risk factor for hypertension due to the inhibitory effect of CRP on NO 
production (Ghanem and Movahed 2007) (Figure 1.8). 
In view of the inter –related abnormalities, there is a need for effective intervention 
strategies that target different components of the MS including inflammation, 
oxidative stress, IR, dyslipidemia, blood pressure and weight management in order to 
reduce the incidence of type 2 diabetes and CVD. 
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Figure 1.8: Pathophysiology and consequences of the metabolic syndrome 
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d. Insulin signalling downstream pathways in obesity and insulin resistance 
Insulin is the central regulator of the metabolism of glucose and fat in the body. In 
addition to its role in inhibiting gluconeogenesis, lipolysis, and glycogenolysis, 
insulin induces proteogenesis, lipogenesis and glycogenesis (Figure 1.9). 
Furthermore, insulin increases the uptake of glucose by skeletal muscle through the 
increase in the translocation of the glucose transporter (GLUT4). Insulin also plays a 
significant role in cell growth and proliferation (Saltiel and Khan 2001). 
Insulin receptor is a member of the family of tyrosine kinase receptors, and has 
numerous properties including secretion of insulin growth factor-1 (IGF-1), which is 
activated by insulin, and plays a role in regulating glucose homeostasis and insulin 
sensitivity (Clemmons 2004). The binding of insulin to insulin receptor leads to 
tyrosine phosphorylation of the insulin receptor substrate (IRS) proteins (comprises 
six types of IRS labelled from IRS-1 to IRS-6), which stimulate the activation of 
insulin downstream signalling pathways like Ras-mitogen-activated protein kinase 
(MAPK) and the phosphatidylinositol 3-kinase (PI3K)–AKT/protein kinase B 
(PKB). These pathway cascades are responsible for most of insulin actions (Saltiel 
and Khan 2001), such as the increase in the translocation of GLUT4 (Wang et al. 
1999). Obesity and IR have been reported to cause an alteration in the insulin 
signalling pathways. This has explained one of the mechanisms by which glucose 
metabolism is altered in obese individuals. A significant reduction in insulin-
stimulated PI3K pathway has been noted in the muscle tissues of obese humans, 
while MAPK pathways have been shown to be normal (Cusi et al. 2000). It has been 
suggested that FFA lead to a reduction in PI3K activity (Saltiel and Khan 2001). In 
addition, in insulin resistant humans, it has been shown an impairment of AKT 
phosphorylation, suggesting a correlation between AKT and insulin sensitivity 
(Tonks et al. 2013). 
Because of the major role of insulin in brain function, disruption of insulin-signalling 
pathways has been proposed to contribute to brain dysfunction. This may be due to a 
decrease in insulin uptake, leading to vascular damage caused by oxidative stress 
(Desideri et al. 2012). 
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Figure 1.9: Role of insulin in metabolic regulation  
(Saltiel and Khan 2001) 
FFA: Free fatty acids 
Insulin is involved in the synthesis of carbohydrates, lipids and proteins and their storage. 
This hormone leads to an increase in the uptake of glucose, amino acids and fatty acids 
while inhibiting enzymes involved in the degradation of glycogen, protein and lipids. Insulin 
receptor is a mediator of these reactions (Saltiel and Khan 2001). 
 
1.1.5 Role of cortisol in obesity-related complications   
Cortisol is a glucocorticoid counter-regulatory hormone secreted by the adrenal 
cortex in response to several stimuli such as stress and inflammation (Newton 2000).  
The role of this hormone involves the reduction of the insulin-dependent uptake of 
glucose, the decrease in insulin secretion by β-cells, as well as the increase in 
lipolysis and gluconeogenesis. Thus, cortisol acts as an antagonist for insulin (Rizza 
et al. 1982; Stulnig and Waldhausl 2004).  
Stress caused by factors like smoking and alcohol may result in an increase in HPA 
(hypothalamic-pituitary-adrenal) axis activity, and a subsequent increase in cortisol 
levels (Andrews et al. 1999).  However, stress can be induced by visceral obesity 
through the secretion of cytokines proportionally to abdominal fat. This results in the 
stimulation of HPA axis activity (Drapeau et al. 2003). 
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Cortisol is implicated in the pathology of insulin resistance through several 
mechanisms: Firstly, it increases hepatic glucose production and induces 
gluconeogenesis (Stulnig and Waldhausl 2004). In fact, glucocorticoids increase the 
hepatic gene expression of phosphoenolpyruvate carboxykinase (PEPCK), an 
enzyme that catalyses the rate-limiting step in gluconeogenesis (Stulnig and 
Waldhausl 2004). Also, glucocorticoids inhibit GLUT4, resulting in the inhibition of 
cellular glucose uptake (Dimitriadis et al. 1997). Secondly, cortisol stimulates the 
secretion of the protein “resistin” by the adipose tissue (Qi and Rodrigues 2007), 
which may exacerbate IR (Pi-Sunyer 2007). Moreover, the elevated cortisol and 
HPA axis activity in abdominal obesity increase the mobilization of FFA, and lead to 
or exacerbate insulin resistance (Qi and Rodrigues 2007). 
Glucocorticoid metabolism is mainly regulated by the enzyme 11β-HSD (11 beta 
hydroxysteroid dehydrogenase) which has two isoforms: 11β-HSD type 1            
(11β-HSD 1), an enzyme that converts cortisone to cortisol using NADPH, and is 
highly expressed in the liver, central nervous system and adipose tissue; 11β-HSD 
type 2 (11β-HSD 2) an enzyme that oxidises cortisol to cortisone, and is essential to 
avoid the mineralocorticoid activity of cortisol. The enzyme 11 B-HSD2 is present in 
aldosterone-selective tissues such as kidneys (Van Uum et al. 1998; Agarwal et al. 
1999). 
As adipose tissue is the site of action of 11β-HSD1, the expansion of abdominal fat 
mass increases the enzyme activity, leading to an elevation in cortisol production 
(Stulnig and Waldhausl, 2004). The activity of this enzyme is particularly important 
in obesity, as it can be overexpressed in adipose tissue along with normal plasma 
cortisol levels (Engeli et al. 2004). Finally, the increased activity of 11β-HSD1 may 
inhibit the secretion of insulin from β cells, and cause a defect in the insulin-
dependent uptake of glucose (Stulnig and Waldhausl 2004). Therefore, 11β-HSD1 
plays a significant role in insulin resistance and glucose intolerance (Masuzaki et al. 
2001), and may have a potential implication in the prevention/treatment of the 
metabolic syndrome. 
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1.1.6 Importance of prevention 
There has recently been a large emphasis on the importance of prevention of chronic 
diseases before they occur, and its impact on reducing the burden on the health care 
system, and improving the nation’s health and productivity. In fact, out of every two 
adults in the US, one person has a chronic disease, which is mostly preventable 
(CDC 2011a). Studies have shown that even a modest reduction in risk factors for 
chronic diseases may have a significant impact on decreasing their occurrence and/or 
their complications. Regarding obesity, a modest loss in body weight (5-10%) is 
associated with a significant decrease in risk factors for type 2 diabetes and CVD 
(Resnick et al. 2000; Wing et al. 2011). In addition, reducing IR preserves β-cell 
function, and prevents or delays the occurrence of type 2 diabetes (Chiasson and 
Rabasa-Lhoret 2004). As for blood pressure, studies have demonstrated that a slight 
decrease (5 mm Hg) in systolic and/or diastolic blood pressure is effective in 
decreasing cardiovascular risk by 20% (Glynn et al. 2002), the risk of stroke by 20% 
(Mclnnes et al. 2005), and mortality risk by 7% (Whelton et al. 2002). Finally, 
elevated lipid levels or dyslipidemia have been shown to be strong contributors to 
cardiovascular risk, and a small reduction of these levels may reduce the risk: A 
reduction of 1% in LDL cholesterol can decrease the risk of cardiovascular diseases 
by 2 % (Jia et al. 2010). Furthermore, according to the Framingham study, an 
increase in HDL levels by only 10 mg/dl leads to a reduction in cardiovascular risk 
by 2-3% (Ali et al. 2012). Therefore, any intervention that might have a slight 
significant impact on the above mentioned parameters can possibly improve the 
general health, and help in decreasing the occurrence of chronic diseases. 
 
1.2 Polyphenols: Overview 
1.2.1 Definition and properties 
Polyphenols (PPs) constitute a class of phytochemicals widely available in plants 
(Stevenson and Hurst 2007), in which they are known to exhibit numerous functions 
including protection from solar UV radiation and free radicals generated during 
photosynthesis, prevention of insect feeding, as well as anti-microbial and anti-
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fungal functions. PPs also play a role in the determination of the colour of the leaves, 
fruits and flowers (Gould and Lister 2006).  PPs are not essential nutrients, therefore 
are not required for growth and reproduction. PPs have been frequently described as 
non nutrients (Martin and Appel 2010). 
Polyphenols are largely abundant in the human diet, and their average daily intake is 
estimated to be around 1 g/day (Scalbert and Williamson 2000). The studies of diet 
diaries in the UK showed that the mean intake of total polyphenols ranges between 
780 mg/day for females and 1058 mg/day for males, with flavonoids consisting of 
20-25% of the polyphenol intake (Stevenson and Hurst 2007). However, individual 
preferences might influence this intake (Manach et al. 2004). PPs are extensive in 
chocolate, tea, coffee, wine, olive, dry legumes, and some vegetables (like lettuce 
and cabbage) and fruits (like apples and berries) (Manach et al. 2004; D’archivio et 
al. 2007). 
 
Polyphenols have gained a particular interest over the past two decades as positive 
contributors to human health, mainly because of their antioxidant properties and their 
possible implication in the prevention of several diseases such as CVD, cancer, and 
neurodegenerative diseases, all known to be related to oxidative stress (Manach et al. 
2004; D’archivio et al. 2007). The antioxidant properties of polyphenols rely in their 
potential reducing capacity, and their ability to bind to free radicals and neutralize 
them (Scalbert and Williamson 2000), resulting in the reduction in the development 
of atheromatous lesions (D’archivio et al. 2007).  Polyphenols have been suggested 
to improve insulin sensitivity (De Bock et al. 2013), to function as vasodilators (Kim 
2007) and to exert positive effects on the metabolism of lipids (by increasing fat 
oxidation) (Dulloo et al. 1999) and carbohydrates (by inhibiting digestive enzymes 
(Ishikawa et al. 2007), and decreasing glucose absorption (Johnston et al. 2005)). 
PPs have been also implicated in several biological functions such as protecting the 
skin (Nichols and Katiyar 2010), improving the immune system (Safonova et al. 
2001; Baeza et al. 2010), decreasing platelet aggregation (Murphy et al. 2003) and 
reducing inflammation by inhibiting cyclooxygenase 2 (COX-2)  (O’Leary et al. 
2004), and lipoxygenase (Sadik et al. 2003) enzymes. The latter enzymes are 
implicated in inflammation through the secretion of prostanglandins.  
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Despite their high intake in the diet, the maximum plasma concentration of 
polyphenols is usually in the micromolar and nanomolar ranges. This is due to the 
low bioavailability of PPs, which is dependent on their chemical structure. In fact, 
the structure is a better determinant of the bioavailability of polyphenols than their 
concentration (D’archivio et al. 2007). Consequently, not all pps can be attributed 
beneficial properties (Scalbert and Williamson 2000).  Recognizing the different 
types and structures of pps and their bioavailability will help to determine the PPs 
that are more likely to exert a favourable effect on human health. This will provide a 
background for understanding the mechanism of action of cocoa polyphenols, which 
are the ones of interest in this thesis. 
 
1.2.2 Types of polyphenols, chemical structure and food sources 
PPs are vastly diverse with a complex chemical structure (D’archivio et al. 2007). 
Around 8000 structures of PPs have been already identified (Martin and Appel 
2010). PPs are characterized by having at least one six-carbon aromatic ring and not 
less than two phenolic hydroxyl groups (Stevenson and Hurst 2007), and are 
classified according to their chemical structure (such as the number of phenol rings, 
the ways of binding between aromatic rings) into four groups: Flavonoids, Lignans, 
Stilbenes and Phenolic acids (Manach et al. 2004) (Figure 1.10) 
 
1.2.2.1 Flavonoids 
Flavonoids are the most abundant type of PPs in foods (Salbert and Williamson 
2000), and more than 4000 flavonoids have been recognized in plants (D’archivio et 
al. 2007). Flavonoids consist of 2 aromatic rings bound by a three carbon chain 
which form an oxygenated heterocycle, and are subdivided into 6 classes according 
to the degree of oxidation of the oxygen heterocycle into flavonols, flavones, 
isoflavones, flavanones, anthocyanidins and flavanols (Manach et al. 2004) (Figure 
1.11).   
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a. Flavonols 
Flavonols consist of a double bond between Carbon 2 and Carbon 3, and a hydroxyl 
group in the Carbon 3 position (D’archivio et al. 2007). Flavonoids are stimulated by 
light, hence the flavonol content of plants depends on sunlight exposure (Manach et 
al. 2004), which results in differences in the concentration of fruits on the same tree 
and even between different parts of the same fruit (D’archivio et al. 2007). Flavonols 
consist of quercetin, kaempferol, myricetin and isorhamnetin, and are widely present 
in onions, kale, red wine, teas, and blueberries (Manach el al. 2004; D’archivio et al. 
2007). 
b. Flavones 
Flavones are less common than other flavonoids. They have a double bond between 
Carbon 2 and Carbon 3 (D’archivio at al. 2007), and consist of apigenin and luteolin. 
Flavones are available in parsley, thyme, celery, hot peppers, cereals (Manach el al. 
2004), and the skin of citrus fruits (Shahidi and Naczk 1995).  
 
c. Isoflavones 
Isoflavones are flavonoids that have a structural similarity with estrogen. They are 
classified as non steroids, and are able to bind to estrogen receptors. They consist of 
daidzen, genistein and glycitein, which are mainly present in soya and its derived 
products. Due to their estrogenic properties, isoflavones have been implicated in the 
prevention of breast cancer and osteoporosis (Adlercreutz and Mazur 1997). These 
polyphenols are sensitive to heat and are often hydrolysed to glycosides during 
industrial processing and storage, such as during the production of soy milk 
(D’archivio at al. 2007). 
 
d. Flavanones 
Flavanones are characterized by a saturated three-carbon chain and an oxygen atom 
in the Carbon 4 (D’archivio at al. 2007). They are usually glycosylated by a 
disaccharide, and are widely available in citrus fruits like oranges, lemons and 
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grapefruit (Manach et al. 2004). The main aglycones are naringenin in grapefruit, 
hesperetin in oranges, and eriodictyol in lemons. The flavonone content is 
particularly high in the solid part of citrus fruits, especially in the white spongy 
portion and the membranes that separate the segment (D’archivio at al. 2007). 
e. Anthocyanidins 
Anthocyanins are pigments mostly abundant in fruits, and are responsible for the 
pink, red, blue, and purple colour of berries (Clifford 2000). They are characterized 
by a positive charge on the heterocyclic ring (Alkema and Spencer 1982). 
Also called anthocyanidins, anthocyanins are mostly available in berries, cherries, 
blackcurrant and grapes, but also in vegetables such as cabbage, onions and 
aubergines. Anthocyanins are mainly found in the skin of fruits, except for some red 
fruits (cherries and strawberries), in which they are found in the flesh. Red wine is 
also an important source of anthocyanins. Food content of anthocyanidins is 
correlated with the colour intensity and the degree of ripeness of fruits. (D’archivio 
et al. 2007). Anthocyanidins consist of cyanidin (the most common food source of 
anthocyanidins), delphindin, malvidin, pelargonidin, peomidin and petunidin 
(Manach et al. 2004; Jakobek et al. 2007).  
 
f. Flavanols 
Flavanols are one of the most abundant types of flavonoids in the diet (Scalbert and 
Williamson 2000).  They contain a saturated three-carbon chain with a hydroxyl 
group in the Carbon 3 (hence the nomination flavan-3-ols). They are available as 
monomers (catechins), dimers (theaflavins) and polymers (thearubigins and 
proanthocyanidins). The dimers and polypmers are building blocks of monomers 
(Cooper et al. 2008). Catechins consist of catechin, epicatechin, epicatechin gallate 
and epigallocatechin gallate, which are widely available in teas, especially green and 
white tea (Scalbert and Williamson 2000; Higdon 2005). Epicatechin is abundant in 
cocoa and chocolate, as well as in berries, grapes and apples, but to a lesser extent 
(Manach et al. 2004). Theaflavins and thearubigins are particularly present in black 
and oolong teas. As for proanthocyanidins (also known as procyanidins or condensed 
tannins), they are abundant in chocolate, red wine, apples, berries and red grapes, 
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and give the astringency to fruits and beverages, and the bitterness to chocolate. 
Proanthocyanidins usually occur along with catechins in foods (Santos-Buelga and 
Scalbert 2000). Unlike other types of flavonoids, flavanols are not glycosylated in 
foods (Zhu et al. 1997). 
Catechin and epicatechin have two chiral centers each: (+)- catechin, (-)-catechin, 
(+)-epicatechin and (-)-epicatechin, respectively (Figure 1.12). The enantiomers     
(+) – catechin and (-)-epicatechin are predominant in foods, while the two other 
epimers rarely occur in nature (Kofink et al. 2007). Proanthocyanidins occur as 
oligomers (with degree of polymerization between 2-10) and polymers (degree of 
polymerization > 10) in plants (Glinski et al. 2012) (View Figure 1.13 on the 
chemical structure of the most common procyanidins). 
 
1.2.2.2 Lignans 
Are only found in significant amounts in flaxseed and flaxseed oil, and are mostly 
present in nature in their free form. Linseed is the most abundant dietary source of 
lignans (D’archivio et al. 2007). Lignans are also present in oleaginous seeds, and 
some vegetables (like garlic and carrots), and fruits (like pears and prunes) 
(Thompson et al. 1991). Lignans are mainly known for their estrogenic properties 
(Scalbert and Williamson 2000), and their use in cancer chemotherapy and some 
medications (Saleem et al. 2005).  
 
1.2.2.3 Stilbenes 
Human diets provide low quantities of stilbenes. The most common type is 
resveratrol which has been reported to have anticarcinogenic properties. Resveratrol 
is found particularly in the skin of red grapes, and consequently in red wine and 
grape juice (Manach et al. 2004; D’archivio et al. 2007). 
 
1.2.2.4 Phenolic acids 
Are divided into two classes: hydroxybenzoic acids and hydroxycinammic acids 
(D’archivio et al. 2007) 
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a. Hydroxybenzoic acids 
Are divided into gallic acid and components of tannins (gallotannins and 
ellagitannins), which are rare in the edible parts of plants, except for some red fruits, 
onions and black raddish (Shahidi and Naczk 2005). Tea contains a considerable 
amount of gallic acid (Tomás‐Barberán and Clifford 2000). Due to their limited 
occurrence in plants, limited research has been carried out on these acids. 
 
b. Hydroxycinnamic acids 
Are more common than hydroxybenzoic acids, and have 4 subclasses: p-coumaric, 
caffeic, (the most abundant phenolic acid), ferulic, and sinapic acids. Caffeic acid is 
usually combined to quinic acid to form chlorogenic acid, which is abundant in 
coffee (Clifford 2000). These phenolic acids are also present in fruits such as 
blueberries, apples and cherries (Macheix et al. 1990). 
 
 
      Figure 1.10: Chemical structure of polyphenols  
      (Pandey and Rizvi 2009) 
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         Figure 1.11: Chemical structure of flavonoids  
         (Pandey and Rizvi 2009) 
 
1.2.3 Factors affecting polyphenol content in foods 
Several factors may affect the polyphenol content in foods. Different varieties of the 
same fruit contain various amounts of polyphenols (Manach et al. 2004). Hence, the 
amount or percentage of PPs in foods is usually estimated. In addition, 
environmental factors such as climate (like degree of sun exposure and rain), 
agronomy (like type of culture, yield of fruit per tree and degree of ripeness) and 
sunlight exposure exert an important influence on the polyphenol content of fruits 
and vegetables (Macheix et al. 1990; Van der Sluis 2001). For instance, the degree of 
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ripeness may decrease the proportion of some PPs like phenolic acids, but increase 
the concentration of anthocyanins (Shahidi et al. 1997). Storage at room temperature 
may also lower polyphenol content in foods due to the fact that PPs can be readily 
oxidised (Manach et al. 2004), whereas this is not the case during cold storage 
(Burda et al. 1990). Furthermore, the polyphenol content is influenced by the method 
of culinary preparation. Cooking and peeling of vegetables and fruits may cause a 
substantial loss of polyphenols in foods (Crozier et al. 1997; Manach et al. 2004). 
Lastly, industrial food processing may result in a decrease in polyphenol content as 
during the production of tomato products (Takeoka et al. 2001), or an increase in this 
content as during the production of beer (due to ethanol which increases the 
extraction of polyphenols) (Leitao et al. 2011). 
 
 
 
Figure 1.12: Chemical structure of catechin and epicatechin enantiomers 
(Adapted from Kofink et al. 2007) 
S stands for left and R stands for right 
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Figure 1.13: Chemical structure of common procyanidins 
(Adapted from De Freitas and Mateus 2001) 
epi: epicatechin, cat: catechin. Figure represents procyanidins dimers (B1-B8) and trimer 
C1. The latter is an epicatechin trimer. 
 
1.2.4 Metabolism of polyphenols: from absorption to elimination 
Because they are extremely diverse, the metabolism of PPs differs with types and 
within subtypes and is not yet fully elucidated in the human body. About 5-10% of 
polyphenols are absorbed in the small intestine (the aglycones), and the rest 
(occurring in the glycosylated form) escape the intestinal absorption and pass into 
the colon where they are broken down by the colonic micro-flora, and transformed 
into metabolites. A small fraction of these metabolites is then absorbed (Clifford 
2005).  
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Most of flavonoids (with the exception of flavanols) occur in the glycosylated form 
(D’archivio et al. 2007), which pass through the intestine (Manach and Donovan 
2005) and are then transported into the colon where they are hydrolysed by the 
colonic flora into derivatives of benzoic acids (D’archivio et al. 2007).  The 
concentration of polyphenol metabolites can reach hundreds of micromoles/liter in 
the colon (Manach et al. 2004). It could be therefore suggested that many of the 
biological effects of polyphenols are due to their metabolites produced in the colon. 
These metabolites have been involved in the protection from oxidative stress 
(Manach et al. 2004), and in the inhibition of platelet aggregation (Rechner and 
Kroner 2005).  Polyphenol metabolites in the colon have been also reported to 
increase the number of gut microbiota; thus they can exert a beneficial role in the gut 
(Parkar et al. 2008). For instance, administration of red wine polyphenols to rats 
increased the faecal bacterial composition of Lactobacillus and Bifidobacterium spp, 
which resulted in a decrease in inflammation and oxidative stress (Dolara et al. 
2005). Also, in humans, the administration of cocoa (494 mg of flavanols) for 4 
weeks increased bifidobacteria and lactobacilli counts in the fecal samples at the end 
of the intervention. Lactobacilli counts were inversely proportional to CRP levels in 
this study (Tzounis et al. 2011). Moreover, an increase in bifidobacteria was noted 
after blueberry drink supplementation daily for 2 weeks (Vendrame et al. 2011). 
These examples highlight the potential role of polyphenols in increasing specific 
bacteria counts in the colon, and might provide an explanation for their potential 
lowering effects on inflammation and oxidative stress, despite their low 
concentrations in the blood. 
 
After absorption, PPs undergo series of conjugation reactions, including methylation 
glucuronidation and/or sulfation in the liver, resulting in metabolites that are 
different from the ones originally present in foods (D’archivio et al. 2007). 
Conjugation is mainly carried out as a detoxication process in order to facilitate the 
elimination of polyphenols and limit their toxic effects. This results in small 
concentrations of polyphenols reaching the plasma (Manach et al. 2004). Polyphenol 
metabolites circulate in the blood bind to proteins, mainly albumin. Hence, it is 
likely that the cellular uptake of metabolites depends on the amount of PPs bound to 
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albumin (D’archivio et al. 2007). PPs are then taken by tissues, and subsequently 
eliminated in addition to their metabolites in the urine and bile. This elimination is 
dependent on the level of conjugation, so that highly conjugated metabolites are 
eliminated in the bile (like genistein and epigallocatechin gallate), and less 
conjugated ones are eliminated in the urine (like flavanones and isoflavones) 
(Manach et al. 2004; D’archivio et al. 2007). A simplified explanation of the 
metabolism of polyphenols in the human body is presented in Figure 1.14. 
 
                                 
Figure 1.14: Possible pathways of polyphenols in the human body  
(Scalbert and Williamson 2000) 
 
1.2.5 Bioavailability of polyphenols in the human body  
Recognizing the bioavailability of polyphenols is highly important, as some types of 
PPs are abundant in the diet, but are poorly bioavailable because of their reduced 
intestinal absorption or their rapid elimination which makes them less likely to 
accumulate in the plasma (Manach et al. 2005). Another issue in estimating the 
bioavailability of PPs remains in the fact that some polyphenol metabolites are still 
unknown, which renders it more difficult to evaluate the biological activity of PPs in 
the body (D’archivio et al. 2007). These metabolites might actually be the true active 
components rather than the native polyphenols (Kroon et al. 2004).  
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The bioavailability of polyphenols, apart from being dependent on the chemical 
structure, is also subject to intra-individual variety. This is probably due to the 
different composition of the colonic microflora, which may result in differences in 
the metabolism of PPs between individuals (D’archivio et al. 2007). Other factors, 
such as food matrix, efficiency of binding to albumin and extent of excretion in urine 
and bile may also affect bioavailability (Ali et al. 2014). It has been estimated that 
the bioavailability of PPs range between 2 - 20% (Hu 2007).  
Data collected from 97 bioavailability studies provided valuable information 
regarding polyphenol bioavailability (Manach et al. 2005). Among flavonoids, 
anthocyanins have a poor bioavailability despite their high intake in certain diets, 
mainly because of their low absorption rate and their rapid elimination. In addition, 
the bioavailability of flavonols is usually limited in the diet, and its bioavailability is 
dependent on the food source (for instance, onions contain more bioavailable 
quercetin than apples). As for flavanols, catechins are highly abundant in the diet and 
are generally well absorbed (except for galloylated tea catechins). While 
proanthocyanidins are poorly absorbed, data on flavanone bioavailability is limited. 
Finally, isoflavones have been shown to be the best bioavailable among polyphenols, 
yet their intake in the human diet is limited to citrus fruits and soja (Manach et al. 
2005). An example of the bioavailability of various types of flavonoids or foods 
containing flavonoids based on human studies is presented in Table 1.3. 
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Table 1.3: Bioavailability of different types of flavonoids 
Polyphenols Source Quantity of 
polyphenols 
(mg) 
Maximum 
concentration  
(µM) 
Anthocyanins 
Cyanidine 3-glucoside 
Malvidin 3-glucoside 
 
Orange juice (1 L) 
Red wine (500 ml) 
 
71 
68 
 
0.002 
0.001 
Flavanols 
Epigallocatechin gallate 
Catechin 
Epicatechin 
Catechin 
Epigallocatechin gallate 
Epigallocatechin gallate 
Epicatechins 
Procyanidin B1 
 
Green tea infusion(5g) 
Red wine (120 ml) 
Chocolate (80g) 
Pure compound 
Pure compound 
Green tea extract 
Black tea 
Grapeseed extract 
 
 
105 
34 
137 
0.36 mg/kg/bw 
50-1600 
110-328 
140 
18 
 
0.13 - 0.31 
0.072 
0.26 
0.14 - 0.29 
0.28 - 7.4 
0.26 – 0.7 
0.34 
0.011 
Flavanones 
Hesperidin 
Hesperidin 
Naringenin 
 
Orange juice 
Pure compound 
Grapefruit juice 
 
61 
135 
199 
 
0.48 
2.7 
5.99 
Flavonols 
Quercetin 
Quercetin 
 
Apples 
Onions 
 
107 
100 
 
0.3 
7.6 
Isoflavones 
Genistein 
Genistein 
Daidzen 
Daidzen 
 
Soy milk 
Pure compound 
Pure compound 
Soy nuts 
 
108 
50 
50 
9.8 – 39.2 
 
0.47 
0.76 
1.26 
0.59 – 2.21 
 
(Adapted from D’archivio et al. 2007) 
Bw: body weight. Data based on human studies. 
 43 | P a g e  
 
1.2.6 Toxicity of polyphenols 
Despite their beneficial role in human health, high intakes of polyphenols have been 
suspected to have pro-oxidant effects. Because of their low bioavailability which 
plays a regulatory role, PPs are unlikely to cause side effects when consumed in 
foods, and are expected to exhibit antioxidant properties. It is mainly the 
pharmacological doses that may cause adverse effects. Also, supplementing foods 
with polyphenols can be problematic (Martin and Appel 2007). Dietary supplements 
of polyphenols usually contain high levels ranging from 1 g of flavonoids, 20 mg 
resveratrol and 300 mg of quercetin per capsule, and the recommendations 
commonly range from 1- 6 capsules per day. This leads to intakes that are 100 times 
higher than the usual western polyphenol intake (Mennen at al. 2005).   
 
Animal studies have related high doses of green tea polyphenols to several side 
effects like severe kidney and liver damage, haemorrhagic lesions in stomach and 
intestine, and multi-organ toxicity (Bonkovsky 2006). In addition, some human case 
studies showed hepatotoxicity related to tea dietary supplements enriched in 
polyphenols, and an increase in liver enzymes and in serum bilirubin levels which 
went back to normal after discontinuation of the supplement (Martin and Appel 
2010). Furthermore, isoflavones such as genistein and daidzen, have been potentially 
involved in the occurrence of breast cancer due to their estrogenic like effects and 
their role in tumour growth (Messina and Loprinzi 2001).  
High doses of flavonoids have been reported to cause clastogenicity and 
chromosome translocation in human cell line studies, due to the fact that flavonoids 
act as inhibitors of topoisomerase II (an enzyme that plays an essential role in 
cellular DNA transcription and replication) (Constantinou et al. 1995). Polyphenols 
may also affect nutritional status; the most eminent example is the inhibitory effect 
of tea polyphenols on heme iron absorption (Nelson and Poutler 2004).   
 
Data are still lacking regarding the doses of polyphenols supposed to cause toxicity 
effects. Hence, further research particularly in animal toxicology testing, is needed. 
In view of these studies, more attention should be given to the dose of PPs used in 
supplements or in polyphenol-enriched foods. 
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1.3 Cocoa / Dark chocolate 
Chocolate, a product of cocoa, is a largely consumed food in the western society. It 
is estimated that the consumption of chocolate is around 10 Kg per person per year 
in the UK (CAOBISCO 2013). Chocolate constitutes the snack of choice for 40% of 
women in the US (Rozin et al. 1991). Chocolate is also a highly craved food: It has 
been reported that it constitutes 59 % and 91 % of the food cravings in American 
university males and females, respectively (Osman et al. 2006). Yet, chocolate does 
not qualify for addiction, due to the lack of evidence of physical dependency towards 
any of the chocolate components (Rogers and Smit 1999). The popularity of 
chocolate and its frequent consumption made it the target of many research studies, 
due its favourable effects, and to the significant role it may exert on improving the 
population’s health. Therefore, studies that elucidate these effects are/were needed to 
guide the consumers’ choice.  
 
1.3.1 History  
Cocoa and chocolate are derived form cacao beans, the fruit seeds of “Theobroma 
cacao” tree, which stands for “the food of the Gods” (Lima et al. 2011; Lima et al. 
2012). The tree is originally a tropical tree from the rain forest of Amazon, but was 
brought by the human activity to the rest of the world (Kris-Etherton and Keen 
2002). The term “cacao” originated from the Olmec peoples, and was named 
“Cacahuatl” by the Mayans who considered it to be a divine food (Dillinger et al. 
2000; Lippi et al. 2009).  
The cultivation of cocoa and the tradition of drinking chocolate might have first 
originated in the Maya Lowlands in Mesoamerica as early as 600 years BC. The 
Mayans and the Aztecs used to froth liquid chocolate to produce foam, which was 
the most appealing part of the drink (Hurst et al. 2002; Lippi et al. 2009). Another 
research suggested that solid and liquid chocolate foods were consumed by the 
inhabitants of the North of Honduras by 1200-1100 BC. However, more recent data 
indicate that chocolate was consumed by the pre-Olmec and the Mokaya peoples as 
early as 1750 BC and 1900 BC, pushing back the use and cultivation of cacao by 
around 700 years (Powis et al. 2007).  
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Cocoa was claimed to be aphrodisiac. It was rumoured that Montezuma, the Aztec 
emperor, used to have a cocoa drink before visiting his wives (Dillinger et al. 2000). 
Cocoa was also claimed to make people happy and strong (Steinberg et al. 2003), 
and was restricted to high social classes (Lippi et al. 2009). 
The Spanish brought cocoa to Europe after the conquest of South and North America 
during the 16
th
 century (Bearden et al. 2000). The conquistador Hernando Cortes 
wrote a letter to the Spanish crown describing cocoa as having miraculous 
properties, claiming that one cup allows a soldier to have enough strength to march 
for a whole day (Lippi et al. 2009). Cocoa was traditionally consumed as a cold 
drink, without any sugar added, and often mixed with starch and spices. Sugar was 
subsequently added to it (Lippi et al. 2009). 
Europeans tended to consider chocolate sinful, the same way was every black, spicy 
and hot food. Due to its euphoric effects, the church considered drinking chocolate 
as a breaking of the fast, and its use was only restricted to medical reasons (Lippi et 
al. 2009). 
The production of cocoa powder only started in the 18
th
 century, followed by the 
production of solid chocolate then milk chocolate. These products were then 
consumed by all society classes (Borchers et al. 2000). From the sixteenth till the 
early twentieth century, more than 100 medicinal uses were attributed to cocoa and 
chocolate, such as treating anemia, fever, tuberculosis, gout, kidney stones, and 
curing some tumours. Furthermore, chocolate was used in the conditions of 
haemorrhoids, hypochondria, poor breast milk production and fatigue (Dillinger et 
al. 2000; Lippi et al. 2009). It was believed that cocoa relieves heart pain, 
strengthens the heart, comforts the liver, helps in digestion and induces sleep 
(Steinberg et al. 2003; Lippi et al. 2009). Chocolate was also used to help wasted 
patients to gain weight (Dillinger et al. 2000).  
Chocolate is considered more than a snack or beverage: it is a connection from 3000 
years ago to the present, and is an important part of the history. The current society 
has a high demand for cocoa products, and sees chocolate as a luxury (McShea et al. 
2008), energizing, healthy but sometimes fattening and unhealthy food (Dillinger et 
al. 2000). 
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1.3.2 Cocoa and dark chocolate composition 
Dark chocolate (DC) contains high amounts of cocoa which usually range between 
50-85%, while white chocolate contains 20-30% of cocoa (Ried et al. 2012). DC 
contains over 500 different components (Powis et al. 2007), including theobromine 
(significant concentrations), caffeine (small amounts), amino acids, sour tasting 
compounds (like acetic acid), sweet tasting compounds (like sucrose which is 
naturally occurring but also added to increase palatability) and polyphenols. Cocoa is 
also a source of fibre (mainly insoluble), which remains from the processed bran 
(contains initially a high amount of fibre) (Cooper et al. 2008). DC consists of cocoa 
liquor (not less than 35% by weight (FDA 2013)) and cocoa butter (makes about 50 
– 57 % of the dry weight of cacao beans) (Hannum and Erdman 2000). The cocoa 
liquor consists of the non fat cocoa solids, and comprises polyphenols (as well as 
vitamins, minerals and fibre), whereas cocoa butter contains no polyphenols (Cooper 
et al. 2008).  Cocoa butter contains 33% of stearic acid, 33% of oleic acid and 25% 
of palmitic acid (USDA 2011a). Although a saturated fatty acid, stearic acid is 
considered neutral on cholesterol and has been therefore considered nonatherogenic 
(Bracco 1994).  
 
As for polyphenols, cocoa beans contain 6-8% of polyphenols by dry weight (Bravo 
et al. 1998). Cocoa products are considered, along with tea, the major contributors to 
polyphenol intake in the western diet (Taubert et al. 2007). Cocoa polyphenols 
mainly consist of flavanols (including epicatechin, catechin and procyanidins) and 
quercetin (flavonol). Other polyphenols such as anthocyanins, phenolic acids and 
stilbenes have also been reported to be present in small amounts (Hurst et al. 2008). 
Flavanols are responsible in addition to theobromine and caffeine of the astringent 
taste of chocolate (Stark et al. 2006; McShea et al. 2008). Flavanols are highly 
available in DC (Chaitman et al. 2004). It is estimated that commercial DC contains 
5 times more flavanols that milk chocolate (Miller et al. 2008). The amount of 
epicatechin and catechin in DC is approximately 20 times higher than that of tea, and 
four times higher than milk chocolate (Chaitman et al. 2004). Flavanols monomers 
consist of (+)catechin  and –(-)epicatechin (Porter et al. 1991). The isomer   –(-) 
epicatechin is the main flavanol, and constitutes up to 35% of the polyphenol content 
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of cocoa (Cooper et al. 2008). Procyanidins are usually present as dimers (B1, B2, 
B3, B4, B5), trimers (C1) and tetramers (Cinnamtannin A2) in chocolate, and are 
linked by 46 or 48 bounds (Porter et al. 1991; Natsume et al. 2000). 
Procyanidins dimers type B2 are the most available (Galleano et al. 2009), and it has 
been reported that other procyanidins polymers exist in unfermented cocoa beans 
(Kelm et al. 2006). As for quercetin, limited studies have quantified its content in 
cocoa/chocolate, due to its low concentration compared to flavanols. Several forms 
of quercetin have been identified in cocoa, such as quercetin aglycone (quercetin) 
and the glycosides quercetin-3-O-glucoside (isoquercitrin), quercetin-3-O-
glucuronide and quercetin-3-O-arabinoside. The latter two forms have been shown to 
be the most prevalent in cocoa (Andres-Lacueva et al. 2008) (Figure 1.15). 
This high amount of PPs provides cocoa/DC a high antioxidant activity, which 
together with the high concentration of lipids, extends the shelf-life of these products 
(McShea et al. 2008). Interestingly, PPs and flavanols can be stable for over a year in 
commercial cocoa products, and it has been shown that pure cocoa powder retains a 
high level of antioxidant capacity for almost 80 years (Hurst et al. 2009). 
 
Nonetheless, the amount of polyphenols in cocoa/DC, and consequently the 
antioxidant activity, depends on the variety and ripeness of cacao beans (Ried et al. 
2012), as well as the origin, agricultural practices, and handling following the 
harvesting of cacao beans (Chaitman et al. 2004). However, the method of 
processing is the major determinant of the final polyphenol content. Hence, it is very 
likely that the amount of flavanols in two different types of chocolate with equal 
cocoa concentrations markedly differ from one chocolate to another in the market 
depending on the level of processing (McShea et al. 2008; Ried et al. 2012).  
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Figure 1.15: Chemical structure of the major forms of quercetin in 
cocoa/chocolate 
(Adapted from Andres-Lacueva et al. 2008) 
Glc: glucoside, arb: arabinoside, gluc: glucuronic acid 
R1, R2 and R3 represent the monovalent groups 
1.3.3 Cocoa and chocolate production 
The three main varieties of theobroma cacao are: Criollo, Forastero, and Trinitario 
(the most common). Cocoa has a significant genetic diversity, and more than 14000 
varieties of cocoa have been suggested. However, the distinction between one type to 
another is minimal, as cocoa products contain a mixture of these varieties (Turnbull 
et al. 2004).   
Chocolate production has always remained undisclosed, and little has been said 
about the details of its manufacturing. The process results in rendering the cacao 
bean more palatable, and in producing different flavours by altering the physical and 
chemical properties of cacao beans (McShea et al. 2008). The processing of 
chocolate is also related to national preferences (Egan et al. 2010).  
Since processing is a crucial stage in the determination of the final polyphenol 
content in cocoa/chocolate, it is therefore important to understand the different steps 
involved in the production of these cocoa products, and to identify the phases that 
mostly affect the polyphenol content of the end product. The processing of cocoa and 
dark chocolate is presented in Figure 1.16. 
The process starts by fermentation of the dried beans (for up to 7 days), resulting in 
the breakdown of the seed. This step is followed by drying, cleaning and 
subsequently roasting; the latter process permits the loss of the shell, and the 
development of different flavours through several reactions like Maillard and 
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caramelisation of sugars. The roasted beans next undergo winnowing; a subsequent 
step that removes the husk of the cacao bean, and breaks the latter into small 
particles called cocoa nibs, which constitute the first palatable produce of chocolate 
processing. Cocoa nibs then undergo milling in order to develop more flavours and 
to yield the chocolate liquor (McShea et al. 2008). 
Depending on the end product, several ingredients (sugar, milk powder and some 
additives) are then added to the liquor, and the quantities vary considerably. For 
instance, in milk chocolate, there is an addition of a significant amount of milk 
powder and sugar, whereas in the manufacture of dark chocolate, there is only 
addition of sugar and cocoa butter and additives at this stage (Minifie and Chem 
1989). This step is followed by further refining and mixing to ensure the particle 
sizes are homogenously distributed inside the product. Subsequently, a heating step 
called “conching”, aims to improve the flavours and reduce the amount of volatile 
substances that negatively influence the flavour (MsShea et al. 2008). An alternative 
step to conching is “dutching” or “alkalinisation”, a popular method that processes 
cocoa with alkali. This method aims to improve flavours and taste by reducing 
bitterness, and imparts darkness to the cocoa ingredients (Miller et al. 2008). As for 
cocoa, a method following alkalinisation called “fat pressing” aims to separate cocoa 
butter from cocoa solids, resulting in a defatted cacao product (Sivasankar 2002). 
Chocolate is then moulded into different shapes constituting the final product 
(McShea et al. 2008).  
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1.3.4 Effect of processing on polyphenol content 
Processing of cocoa beans causes a considerable loss of polyphenols, and varies 
depending on the degree of processing. It has been postulated that a high temperature 
and an elevated pH lead to a significant loss in flavanols, particularly the monomeric 
ones (epicatechin and catechin). Initially, the method of drying slightly affects 
flavanol concentration (freeze-dried beans contain 3% more epicatechin than sun-
dried beans) (Payne et al. 2010). However, fermentation, a step used in most of the 
processing industries, causes a significant loss of flavanols so that marginally 
fermented cocoa contains more antioxidants (Counet et al. 2004). The amount of 
flavanols decreases with the increase of the duration of fermentation, which could 
vary between 2-7 days. Highly fermented cocoa beans can lose up to 86% of their 
epicatechin content (Payne et al. 2010). 
Roasting causes a significant loss of polyphenols depending on the temperature used. 
Losses begin to be considerable after 70
o
C, and maximum losses are reached at 
120
o
C (losses up to 82% of epicatechin) (Payne et al. 2010). However, a study 
indicated that the loss of polyphenols, and consequently the reduction in the 
antioxidant capacity, may be restored during heat treatment by the generation of 
compounds during Maillard reaction such as 3-deoxyhexosuloses; the latter have 
been suggested to have a potential antioxidant capacity (Oliviero et al. 2008).  
Dutching also causes a considerable loss of flavanols, and depends on the level of 
dutching. For instance, heavy dutching results in a loss of 81% of procyanidins and 
78% of total flavanols (Miller et al. 2008), so that highly alkalized chocolates may 
only retain 2-18% of their epicatechin levels (Payne et al. 2010). In addition, 
dutching causes a significant decrease in quercetin and its glycosides (losses range 
between 58 – 86%) (Andres-Lacueva et al. 2008).  
Furthermore, it has been stated that exposing the cocoa beans to high temperatures 
(as in roasting and alkalinization) may result in the modification of the chirality 
properties of catechin monomers. In fact, the abundance of (+)- catechin and –(-) 
epicatechin will be reduced due to the formation of –(-) catechin resulting from the 
epimerization of -(-) epicatechin (Kofink et al. 2007). The latter epicatechin is 
known to have a lower bioavailability than -(-) epicatechin (Donovan et al. 2006) 
(Table 1.4).  
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Thus, the change in the amount and properties of these flavonoids due to processing 
will affect the bioavailability, and consequently the potential benefits of these 
components (Donovan et al. 2006).  
As a result, highlighting polyphenol losses at each step is vital to develop methods 
that aim to minimize losses and increase chocolate health benefits in the market. For 
instance, a recently developed processing method called “Patented Acticoa process” 
has been used in a large worldwide chocolate brand factory (Bisson et al. 2008). This 
method naturally preserves the flavanols in a way that every step of the 
manufacturing chain from bean to chocolate has been optimized for this purpose. For 
example, this method checks the ways of harvesting and treating cocoa beans (Barry 
Callebaut 2010), and uses non-roasted beans (Bisson et al. 2008). However, little has 
been said about the ways of preserving flavanols during the subsequent steps of the 
manufacturing process.  
It is worth mentioning that there is no association between the darkness of the 
chocolate and the flavanol content, as it is the manufacturing of the chocolate that 
mainly determines its polyphenol content (Hollenberg and Ficher 2007). For 
instance, a highly alkalized cocoa is manufactured to a very dark chocolate that 
contains low levels of flavanols. Thus, a chocolate with 100% of cocoa solids may 
contain less flavonoid than a chocolate with 63% of cocoa solids (Langer et al. 
2011). 
Consequently, the amount of polyphenols largely depends on the methods of 
processing, and therefore the benefits of DC cannot be attributed to all the types of 
DC in the market. 
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Table 1.4: Changes in the ratios of (-)-catechin (-)-epicatechin following roasting 
and alkalinisation in different cocoa samples  
     *Undetectable levels of –(-) catechin 
    **Grade of alkalization not known     
       (Kofink et al. 2007) 
 
1.3.5 Bioavailability of cocoa polyphenols in the human body 
Because of their complexity, the bioavailability of cocoa polyphenols is not 
completely understood. This has affected the understanding of the health benefits of 
these components. As they are stable in an acidic environment, cocoa flavanols 
escape the digestion in the stomach, and reach the small intestine intact. In the small 
intestine, flavanols rapidly undergo glucuronidation and methylation in order to be 
absorbed. The fact that plasma concentrations of cocoa polyphenols are in the 
micromolar and nanomolar range following ingestion may have several explanations, 
such as the conversion of these polyphenols into metabolites and the rapid 
metabolism and elimination of polyphenols. This makes it difficult to detect these 
metabolites in the blood (Ali et al. 2014).  
 -(-)Epicatechin and (+)-catechin are considered highly bioavailable due to their 
chirality properties (Cooper et al. 2008), and are extensively metabolized and readily 
adsorbed into the bloodstream, with epicatechin having the highest bioavailability 
(McShea et al. 2008). However, as previously stated, due to cocoa processing, some 
of the –(-)epicatechin portion may be epimerized to –(-catechin) (Kofenk et al. 
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2007), which has been reported to have a poor bioavailability and a lower intestinal 
absorption than –(-) epicatechin (Donovan et al. 2006). This will most likely affect 
the beneficial properties of cocoa containing products. The metabolites (such as 3’-
O-methylepicatechin) and the non methylated epicatechins (such as epicatechin-7-
sulfate) reach the blood an hour after ingestion, in the micromolar range and in a 
dose dependent manner. The peak plasma concentration of metabolites occurs 2.5 
hours after flavanol-rich foods consumption and reaches baseline levels after 
approximately 8 hours (Hackman et al. 2008). Regarding procyanidins, a small part 
of procyanidin dimers is metabolized and absorbed in the small intestine (Rios et al. 
2003) (the same way as catechin and epicatechin), and then undergo conjugation, 
sulfation and glucuronidation in the liver (keen et al. 2005). Procyanidin dimer B2 
has been detected in human plasma following the consumption of a cocoa drink 
(Holt et al. 2002). However, procyanidins with a higher degree of polymerization are 
not absorbed in the small intestine (absorption of procyanidins with a degree of 
polymerization > 5 is estimated to be 1%), and are then fermented by the colonic 
microflora, leading to phenols with low molecular weight (Holt et al. 2002; Manach 
et al. 2005) such as vanillic acid and ferulic acid (Rios et al. 2003). Although it was 
reported in studies with rats that a small fraction of epicatechin in plasma can result 
from the breakdown of cocoa procyanidins (Baba et al. 2002), another study suggests 
that the degradation of procyanidins is not possible in humans. This was explained 
by the need for a higher degree of acidity to hydrolyse procyanidins in the human 
stomach (Rios et al. 2002). Consequently, the poor intestinal absorption of 
procyanidins may suggest that they exert their effects locally in the gastrointestinal 
tract, or through phenolic acids generated during their degradation in the colonic 
microflora (Manach et al. 2004).   
As for quercetin, its bioavailability in cocoa has not been extensively studied, and 
the exact metabolites known to reach the plasma following cocoa consumption have 
not been clearly elucidated. Yet, it has been documented that quercetin glucosides 
(the most prevalent forms of quercetin in cocoa) are absorbed via the small intestine, 
and some quercetin metabolites have been identified in the colon (Manach et al. 
2005). Further studies looking at the bioavalibility of quercetin in human plasma 
following cocoa/DC consumption are then needed. Interestingly, a study showed that 
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epicatechin and quercetin can even cross the blood brain barrier through unclear 
mechanisms (Abd el Mohsen et al. 2002), which might explain the possible 
implication of cocoa/DC in neurodegenerative disorders.  
Furthermore, other factors may affect the bioavailability of cocoa polyphenols: A 
meal high in carbohydrates (bread or sugar) could increase the absorption of 
flavanols in a sugar free cocoa-rich flavanols by 140 % compared to consuming 
sugar free cocoa-rich flavanols alone. However, lipids and proteins seem to 
minimally affect the absorption of these flavanols. Many explanations have been 
provided regarding this effect. Carbohydrates may influence the physiology of the 
gastrointestinal tract including motility and secretion, which enhances the uptake of 
flavanols. An implication of carbohydrate-flavanol transporter that enhances flavanol 
absorption has also been suggested. Yet, this transporter has not been yet identified 
(Schramm et al. 2003). In addition, the consumption of milk with cocoa product has 
been controversial: while a study noted an impact of milk on decreasing the 
bioavailability of cocoa polyphenols (Serafini et al. 2003), other studies have not 
showed such influence (Keogh et al. 2007; Roura et al. 2007). 
 
1.3.6 Benefits of cocoa/dark chocolate  
In the last decade, many studies have highlighted the effects of cocoa/chocolate on 
health. However, the conflicting results and the huge amount of marketing and 
scientific information rendered the consumer undetermined whether the chocolate is 
beneficial or detrimental to health (McShea et al. 2008). In a recent statement of the 
European food safety authority (EFSA), a relationship between cocoa flavanols and 
the maintenance of a healthy endothelium has been claimed. This suggests a 
beneficial effect of these flavanols on the prevention CVD in the general population 
(EFSA 2012). 
Studies on cocoa/dark chocolate have primarily investigated their effects on risk 
factors for type 2 diabetes and CVD, including lipid profile, antioxidant capacity, 
insulin resistance, blood pressure and inflammation, suggesting a possible 
implication of cocoa/DC in tackling the metabolic syndrome (These effects will be 
discussed in detail in sections 1.4 - 1.10).  
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Cocoa has been proposed to have beneficial effects on visual functions and cognitive 
performance (which are explained by the increased cerebral blood flow observed 
following cocoa flavanol consumption) (Field et al. 2011), and immune system (due 
to the effect of cocoa on increasing the percentage of B-cells (Ramiro-puig et al. 
2009). Additionally, cocoa has been claimed to have anti-cancer properties (due its 
antioxidant properties) (Carnésecchi et al. 2002), skin protection properties against 
oxidative damage (because of its ability to increase dermal flow) (Neukam et al. 
2007), as well as a neuroprotection role against inflammation and neurodegradation, 
by preventing death of neurons (Joseph et al. 1999). This may confer a source of 
protection against neuroinflammatory diseases like Parkinson and Alzheimer 
diseases (Francis et al. 2006). However, most of these studies have been carried out 
on animals or in vitro, highlighting the need for human studies to evidence these 
effects.  
 
Nonetheless, despite all the favourable effects of dark chocolate on health, there has 
been some discrepancy over the consumption of dark chocolate, suggesting that the 
beneficial effects of cocoa may be limited to its raw consumption, the way it was 
previously consumed by the primary civilizations. Additionally, DC may contain a 
high amount of saturated fat, sugar and added vegetable oils (McShea et al. 2011), 
which increase energy intake in unbalanced diets, and can lead to weight gain 
(Rimbach et al. 2011). Moreover, cocoa and chocolate were associated with 
significantly higher pulse rates in older adults. However, this has been attributed to 
the methylxantine content of DC (theobromine and caffeine), known to exert a 
stimulant effect (Crews et al. 2008).  
Given the potential adverse outcomes and the reported beneficial effects of chocolate 
on human health in a large number of research studies, it is important to weigh the 
benefits of chocolate against the unhealthy components, and consume it in moderate 
amounts (McShea et al. 2011) to avoid its potential undesirable effects. 
 
1.3.7 Difference between cocoa and dark chocolate  
Although the terms “cocoa” and “dark chocolate” often overlap in the literature, 
these two products differ by polyphenol and fat composition. Generally, cocoa 
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powder contains a higher amount of total polyphenols compared to DC (Miller et al. 
2004), as well as a higher amount of catechin and epicatechin (Natsume et al. 2000), 
and consequently a higher antioxidant capacity (Miller et al. 2006).  Furthermore, 
due to fat pressing (Figure 1.16), cocoa contains less cocoa butter and consequently a 
lesser amount of fat than DC (Sivasankar 2002) (Table 1.5 provides examples of 
polyphenol and fat contents of commercial cocoa and DC brands). These differences 
in fat and polyphenol content could make the comparison between cocoa and DC 
inaccurate, particularly when studying their effect on body weight and lipid 
metabolism. This has led to the suggestion that the recent beneficial effects of cocoa 
polyphenols on reducing obesity cannot be attributed to ordinary chocolate products 
(Ali et al. 2014). Ideally, studies on cocoa should only provide a background for 
carrying out human investigations looking at the effects of DC. However, since the 
quantity of polyphenols was controlled by the companies that provided cocoa or 
chocolate to research studies, the polyphenol amount was not necessarily higher in 
cocoa compared to chocolate. Furthermore, despite the difference in fat ratio, the 
energy content of the daily dose of DC was not commonly greater than the energy 
provided by cocoa in many research studies that investigated the effect of cocoa/DC 
on cardiovascular health (view Table 1.6 on examples of the fat and polyphenol 
content of cocoa/DC used in research studies). In addition, studies have previously 
shown that the total energy of a diet is more effective than its fat content in reducing 
weight, suggesting that calorie counts more than fat. This was demonstrated in 
weight loss studies, where a low calorie diet and a low fat/low calorie diet were 
equally effective in reducing weight (Harvey-Berino 1999; Djuric et al. 2002). 
Moreover, it seems there are no significant differences in the plasma or urine 
concentrations of flavanols after the consumption of the same amount of flavanols 
from chocolate or dry cocoa (Baba et al. 2000). Consequently, acknowledging the 
energy content and the amount of polyphenols of cocoa and dark chocolate in 
research studies will provide a better way of comparison between the two cocoa tree 
derivatives.  
Nevertheless, a problem remains in extrapolating the results of cocoa studies to 
chocolate, and making recommendations to the general population through 
commercial cocoa and chocolate products. The difference in the amounts of 
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polyphenols and energy between the two products may possibly affect the properties 
of DC. 
Table 1.5: Polyphenol and fat content of selected commercial cocoa and dark 
chocolate products 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from Miller et al. 2009)                                                                                      
*Polyphenol content is expressed as mg of gallic acid equivalents (GAE) 
DC: Dark chocolate 
 
Table 1.6: Examples of studies showing the difference in energy and polyphenol 
contents between cocoa and dark chocolate 
Study Cacao derivative 
used/ daily amount 
Amount of 
polyphenols 
(mg/g) 
Amount of Fat 
(g) 
Total Energy 
(Kcal) 
Allen et al. 
(2008) 
DC/ 22g 360 12 200 
Al Moosawi et 
al. (2012) 
DC/20g 500 7.34 108 
Baba et al. 
(2007b) 
Cocoa /26g 234 2.99 122 
Monagas et al. 
(2009) 
Cocoa/40g 495.2 2.1 136 
DC: Dark chocolate. Amounts of cocoa/DC represent the daily doses used in research 
studies. 
 
 
Product Fat percentage 
% 
*Total 
polyphenol 
content (mg/g) 
Epicatechin 
+catechin content 
(mg/g) 
Cocoa powder 1 12.4 60.2 3.723 
Cocoa powder 2 21.7 45.3 1.610 
Cocoa powder 11 51.7 1.963 
DC-1 33.4 11.7 0.478 
DC-2 40.7 14.9 0.149 
DC-3 30 12.3 0.605 
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1.4 Effects of cocoa/dark chocolate on inflammation and antioxidant 
capacity 
As mentioned in section 1.1, oxidative stress and chronic inflammation are both 
considered playing a pivotal role in the occurrence of CVD (Urquiaga and Leighton 
2000; Shah 2009). In fact, a NO-dependent link has been suggested between 
oxidative stress, inflammation and cardiovascular risk (Rein et al. 2000) (Figure 
1.17). Additionally, oxidative stress can possibly lead to the activation of NF-KB 
which stimulates the inflammatory cascade, and may result in the production of the 
inflammatory C-reactive protein (CRP) (Wanner and Metzger 2002).  
 
Several epidemiological studies have found an inverse association between regular 
chocolate consumption and CVD (Djousse et al. 2001; Buijsse et al. 2010; 
Mostofsky et al. 2010). In a meta-analysis of cross-sectional and cohort studies, 
highest levels of chocolate consumption have been linked to a lower risk of CVD (by 
37%), and a lower risk of stroke (by 29%) (Buitrago-Lopez et al. 2011). Several 
mechanisms have been suggested, yet there has been no agreement on the role of 
cocoa polyphenols in CVD. The preventive effect of cocoa/DC on CVD has been 
postulated to be due to four main properties of flavonoids: anti-inflammatory, anti-
oxidant, anti-platelet aggregation and vasodilative properties (Pucciarelli 2013). This 
section will mainly focus on the antioxidant and anti-inflammatory functions of 
cocoa polyphenols. 
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Figure 1.17: Nitric oxide-dependent association between oxidative stress, 
inflammation and cardiovascular risks 
(Cooper et al. 2008) 
NO: Nitric oxide, eNOS: Endothelial nitric oxide synthase. NO exerts an inhibitory effect on 
inflammation, oxidation and endothelial dysfunction, which can increase cardiovascular 
risk. 
 
 
The antioxidant properties of flavonoids in cocoa/DC have been mainly related to 
their chemical structure (Galleano et al. 2009). The aromatic ring (specifically the 
catechol group on the B ring (Sekher Pannala et al. 2001)) allows flavonoids to act as 
scavengers for ROS. Flavonoids also participate in the chelation of metals that 
enhance ROS (Cotelle 2001), and in the inhibition of enzymes like xanthine oxidase 
and NADPH-oxidase (and consequently the inhibition of the reaction between O2 
generated by these enzymes and NO). This leads to an increase in NO and to the 
protection of the endothelium (Engler and Engler 2006) (Figure 1.18). The increase 
in NO production by flavanoids has been also suggested to be due to a mechanism 
involving the decrease in the activity of vascular arginase, which competes with the 
enzyme iNOS for L-arginine (Schnorr et al. 2008). Also, cocoa flavanols interact 
with the NF-Kb pathway, resulting in a decrease in its activation (Mackenzie et al. 
2002). Furthermore, the hydrophobic and hydrophilic ends in flavonoids allow the 
latter to interact with the phospholipids on the membrane surfaces of lipids, proteins 
and nucleic acids, and modify their membrane properties (Oteiza et al. 2005), 
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leading to their protection from oxidative damage (Rein et al. 2000). Enzymes like 
lipoxygenase and COX-2 can also be inhibited by cocoa flavanols (Galleano et al. 
2010). Lastly, the antioxidant capacity of polyphenols has been explained by the fact 
that PPs increase the gene and protein expression of antioxidant enzymes like 
superoxide dismutase (SOD) and glutathione oxidase (Rahman et al. 2006). 
 
Several markers of oxidation have been studied. In human studies lasting 2 - 4 
weeks, cocoa/DC supplementation has been effective in increasing flow mediated 
dilation (FMD) (an indicator of endothelial dysfunction) (Hooper et al. 2008), 
ascorbic acid (Murphy et al. 2003), TBARs (Thiobarbituric acid reactive substances) 
(Wan et al. 2000), oxygen radical absorbance capacity (ORAC) (Al Moosawi et al. 
2012), F2-isoprostanes (Lettieri-Barbato et al. 2012), and decrease vascular 
constriction of the brachial artery (West et al. 2014). Cocoa polyphenol extract has 
been recently shown to reduce peroxynitrite, along with an increase in NO levels in 
men and women (Nanetti et al. 2013).  
Regarding LDL oxidation, which has been shown to be a better predictor of coronary 
artery diseases than lipid levels (TG, HDL and LDL) (Ehara et al. 2001), results have 
been promising. Previous research showed that in vitro, cocoa and cocoa flavonoids 
prevent the oxidation of LDL (Salah et al. 1995; Kondo et al. 1996) in a greater 
extent than red wine polyphenols (Waterhouse et al. 1996). Cocoa polyphenols have 
also inhibited LDL oxidation in rabbits with hypercholesterolemia (Kurosawa et al. 
2005), and in rats fed a high fat diet (Osakabe and Shibata 2012). These findings 
have been supported by several human studies. A crossover study demonstrated that 
LDL oxidation is decreased after 4 weeks of consuming a diet enriched in cocoa and 
dark chocolate (containing 466 mg of procyanidins) by 23 healthy individuals. This 
was evidenced by a longer lag time (an indicator of oxidative status, and is defined 
as the time required for the consumption of an antioxidant) which increased by 8% 
(p= 0.03) in this group. However, there was no significant change in LDL oxidation 
following the consumption of an American diet free of DC and cocoa. This decrease 
in LDL oxidation was accompanied by an increase in HDL (p= 0.02) (Wan el al. 
2001), suggesting an inverse association between the two parameters. Baba et al. 
(2007b) demonstrated that cocoa consumption (containing 174 mg of flavanols) 
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decreased LDL oxidation in 25 healthy subjects, indicated by a 9.4% increase in lag 
time after 12 weeks (p<0.001). A significant decrease in lag time (19.8%, p< 0.001) 
was noted in participants in the control group. LDL oxidation levels were also 
decreased after 4 weeks of the consumption of cocoa high in polyphenols (140-281 
mg) in normocholesterolemic and hypercholesterolemic participants (p<0.05) (Baba 
et al. 2007a). Moreover, a study performed on 15 volunteers showed that the 
consumption of cocoa powder rich in polyphenols for 2 weeks (2610 mg) decreased 
LDL oxidation susceptibility by increasing the lag time of LDL oxidation (Osakabe 
et al. 2001). An increase in lag time of LDL oxidation by 9.8%  (p< 0.05) was also 
noted after 6 weeks of the daily consumption of cocoa and dark chocolate rich in 
polyphenols (651 mg) (Mathur et al. 2002). Lastly, the consumption of ready-to-eat 
meals supplemented with cocoa extract (containing 645 mg of polyphenols) within a 
hypocaloric diet resulted in a greater reduction in plasma oxidised LDL (p= 0.03) 
compared to a hypocaloric control diet with no cocoa extract (Ibero-Baraibar et al. 
2014). Although a study conducted on 21 healthy adults failed to show a significant 
change in LDL oxidation susceptibility when participants were assigned either a high 
flavonoid dark chocolate (259 mg of flavonoids) or a low flavonoid chocolate for 2 
weeks (Engler et al. 2004), most of the studies in the literature support a beneficial 
effect of DC or cocoa on LDL oxidation. This effect has been mainly explained by 
the binding of flavonoids to the surface of LDL particles, leading to an increase in 
the resistance of LDL to oxidation, by either chelating metals or scavenging oxygen 
radicals (Terao 1999). 
 
The antioxidant effect of cocoa polyphenols has been mainly attributed to the 
monomeric fraction of flavanols. A meta-analysis of seventy human studies on cocoa 
showed that epicatechin increases NO synthesis via inhibition of NADPH oxidase 
and arginase (Ellam and Williamson 2013), and protects against oxidative stress 
induced by oxidised LDL (Schewe et al. 2008). Epicatechin was effective in 
protecting LDL and VLDL from oxidation when the latter particles were isolated 
from the plasma of normocholesterolemic individuals. This was demonstrated by a 
longer lag time in cells administered epicatechin (Vinson et al. 1995). The 
enantiomer –(-)epicatechin and its metabolite epicatechin-7-O-glucuronide seemed 
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to exert the most prominent role on the increase in the synthesis of NO (Schroeter et 
al. 2006). 
Procyanidins were also implicated in increasing the lag time of LDL oxidation 
(Pearson et al. 2001), lowering DNA oxidative damage (Ottaviani et al. 2002), and 
attenuating the transcription of NF-kB (Mackenzie et al. 2004). Cocoa procyanidins 
also inhibited LDL oxidation in vitro (Mazur et al. 1999). Moreover, quercetin was 
demonstrated to have an inhibitory role on LDL oxidation in vitro via the modulation 
of pathways involved in oxidative damage (Choi et al. 2009). Yet, it is not clear 
whether the cocoa content of quercetin is sufficient to induce such effect. These 
findings lead to the conclusion that the different fractions of cocoa polyphenols may 
exert a combined effect on antioxidant capacity. Further human studies are needed to 
elucidate this effect.   
 
However, there have been some doubts regarding the antioxidant capacity of cocoa 
polyphenols. This is mainly due to the low plasma polyphenol concentration 
achieved after the consumption of foods rich in flavonoids (estimated to be in the 
micromolar and nanomolar range) (Spencer et al. 2001; Holt et al. 2002), mainly due 
to the low bioavailability of polyphenols in humans (Lotito and Frei 2006). In fact, 
the administration of a single dose of radiolabeled flavonoids to rats showed that 
these polyphenols were mainly traced in stomach, intestine and liver with very low 
concentrations reaching the bloodstream (Mullen et al. 2002). This raises questions 
over the ability of these flavonoids (and mainly flavanols) to exert free radical 
scavenging properties, particularly when present in the blood simultaneously with 
other antioxidant compounds like tocopherols with much higher concentrations (Holt 
et al. 2002).  In addition, the accumulation of polyphenols in tissues is not well 
elucidated (Manach et al. 2004).  Hence, the antioxidant capacity of cocoa flavanols 
may be restricted to the blood and gastrointestinal tract, which are exposed to 
flavanol doses right after consumption (Fraga 2007). Further research using 
radiolabelled flavanols is needed to identify their mechanism of action as 
antioxidants in humans. 
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In view of this, it is possible that polyphenols metabolites that are generated by the 
colonic microflora (which most of them are still unknown and their concentration 
can reach hundreds of micromoles/liter in the colon) are responsible for exerting 
most of the polyphenols benefits, including antioxidant properties. For example, the 
administration of radiolabelled quercetin ([2-14C]quercetin- 4’-O-glucoside) showed 
that the biggest fraction of quercetin reached the colon and was degraded into 
benzoic acid and 3-hydroxyphenylacetic acid, while there was no accumulation of 
this flavonoid in tissues (Mullen et al. 2002). Benzoic acid has been previously 
regarded to have a potential antioxidant capacity (Manach et al. 2004). Rios et al. 
(2003) showed that after cocoa consumption, the colonic metabolites 3-(3’-
hydroxyphenyl) propionic acid, 3’hydroxyphenyl acetic acid, 3-hydroxybenzoic acid 
and ferulic acid were present in the urine. Other colonic metabolites such as 5-(3’,4’-
methoxy-4’-hydroxyphenyl)- γ-valerolactone  and 5-(3’,4’-dihydroxyphenyl)- γ-
valerolactone were found in the urine after administration of cocoa powder (Urpi-
Sarda et al. 2009). In particular, the 5-(3’,4’-dihydroxyphenyl)- γ-valerolactone  
metabolite produced from the hydrolysis of +(-) catechin in the colon was shown to 
have a higher antioxidant capacity compared to  +(-) catechin. This metabolite was 
also shown to inhibit metalloproteinases and therefore decrease inflammation 
(Monagas et al. 2010).  Furthermore, the metabolite 3,4-dihydroxytoluene (a 
metabolite of quercetin) derived from gut microbiota was demonstrated to inhibit 
lipid peroxidation in the hepatocytes of rats (Glässer et al. 2002). Research is still 
limited regarding the role and the mechanisms of action of polyphenol metabolites 
produced in the colonic microflora on health.  
 
 An indirect mechanism on antioxidant capacity via the upregulation of antioxidant 
enzymes (such as SOD) by cocoa polyphenols has been suggested in humans 
(Rahman et al. 2006). Further research looking at the mechanism involved in the 
antioxidant role of cocoa polyphenols in humans is needed to support these effects. 
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Figure 1.18: Mechanisms by which flavanols can possibly reduce oxidative 
damage 
(Galleano et al. 2009) 
NO: Nitric oxide, eNOS: endothelium nitric oxide synthase, O2
-
: Superoxide, NADPH: 
Nicotinamide adenine dinucleotide phosphate hydrogenase, ONOO
-
: peroxynitrite, H2O2: 
hydrogen peroxide. Flavanols (indicated by circles) inhibit NADPH oxidase (which 
generates O2
- 
and leads to the production of Reactive oxygen species) and increase NO 
production through the activation of eNOS. Flavanols can act by modifying membrane 
properties leading to an increase in NO and superoxide production. NO will attain smooth 
muscle cells and lead to vascular relaxation.  
 
Regarding the effects of cocoa/DC on inflammatory markers, results are still 
controversial. Most of the favourable effects on inflammation have been reported by 
“in vitro” studies. Cocoa flavonoids have been shown to decrease the production of 
COX-2, as well as pro-inflammatory cytokines (like Interleukin 2 (IL-2) and 
prostaglandins (Selmi et al. 2006). Cocoa polyphenols decreased inflammation by 
modulating the activity of eicosanoids (vasoconstrictor), through the decrease of 
leukotrienes and the increase of prostacyclin (a vasodilator) (Schramm et al. 2001), 
and the inhibition of the synthesis and gene expression of cytokines (Middleton et al. 
2000). The potential effect of cocoa polyphenols on inflammation has been attributed 
to flavanols (particularly epicatechin) which inhibit ROS (Corti et al. 2009), and 
interfere with the NF-KB pathway. Furthermore, in vitro studies showed that cocoa 
procyanidins inhibited metalloproteinase in human aortic cells (Lee et al. 2008). 
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Among inflammatory markers, CRP has a particular importance, as apart from being 
a biomarker of chronic inflammation as well as a marker of CVD (Chun et al. 2008), 
it is also a contributor to endothelial dysfunction (Pasceri et al. 2000). Indeed, CRP 
may participate in the uptake of LDL by macrophages and the formation of foam 
cells, thus helping in the initiation of the atherosclerotic plaque (Zwaka et al. 2001). 
CRP may also increase tissue damage in the event of plaque rupture (Zebrack and 
Anderson 2002). 
 
High-sensitivity CRP (hs-CRP) has been shown to be a stronger predictor of 
coronary artery diseases than CRP (Jousilahti et al. 2001): A high hs-CRP has been 
correlated with 3-4 fold higher risk of myocardial infarction in men (Ridker et al. 
1997). Hs-CRP is considered the test of choice when assessing inflammation in 
individuals with no history of CVD. The reason is due to the inaccuracy of CRP test 
in detecting low CRP levels in healthy individuals (Zebrack and Anderson 2002). 
Hs-CRP can be helpful in the primary prevention of CVD, as it helps to detect early 
signs of coronary risk (Ridker 2001). Hs-CRP is principally stimulated by IL-6, a 
predictor of coronary diseases. Levels of hs-CRP have been reported to be higher 
with increasing BMI, suggesting a low grade inflammation state in the obese 
category (Visser et al. 1999). 
 
Studies investigating the effect of cocoa polyphenols on CRP and hs-CRP have led 
to confounding results: Epidemiological studies have mainly documented positive 
findings. Data from NHANES (National Health and Nutrition Examination Survey) 
1999-2002 have been used for a cross-sectional study, and showed that dietary 
flavonoids are inversely correlated with serum CRP levels (p<0.05) in 8335 adults 
(Chun et al. 2008). In addition, a cohort study showed that after adjustment of many 
confounding factors such as age, sex, social status, BMI and energy intake, regular 
dark chocolate eaters have lower hs-CRP levels (p= 0.038) than subjects who do not 
regularly eat chocolate. Interestingly, hs-CRP levels were lower in moderate 
consumers (20g of DC every 3 days) than higher consumers (20g of DC/day) 
(Gisueppe et al. 2008), suggesting that a moderate amount of chocolate is more 
beneficial on cardiovascular risk than higher amounts. 
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On the other hand, intervention studies have been less likely to show a favourable 
effect of cocoa/DC on hs-CRP/CRP levels. Hamed et al. (2008) reported a decrease 
in hs-CRP only in women (from 1.8± 2.1 mg/l to 1.4±1.7 mg/l, p< 0.04) after one 
week of daily DC supplementation (providing 700 mg of flavonoids), and Stote et el. 
(2012) indicated a decrease in CRP levels following 5 days of cocoa drink 
supplementation (containing doses of PPs ranging from 30-900mg) in a dose 
dependent manner (p = 0.01) (by 0.7 mg/l with the highest polyphenol dose). 
However, the decrease in hs-CRP/CRP levels was small in the latter two studies, 
thus it is unlikely that these changes are clinically relevant.  Most of other studies 
failed to demonstrate this. Grassi et al. (2008) showed no significant effect on CRP 
levels after 2 weeks of flavonoid-rich chocolate (500 mg) supplementation in 
hypertensives. Similar results were noted in healthy individuals. Mathur et al. (2002) 
did not note a significant effect of 6 weeks of cocoa supplementation (651mg of 
procyanidins) on the markers of inflammation including hs-CRP, IL-1, IL-6 and 
TNF-α. This outcome was explained by the short biological half-life of flavonoids in 
cocoa products, resulting in a decrease in their plasma levels shortly after 
supplementation, and making flavonoids less likely to exert an effect on 
inflammation (Mathur et al. 2002). In addition, a recent study showed no effect on 
the inflammatory markers TNF-α, IL-1 α, IL-1β, IL-6 and hs-CRP after 7 days of 
DC supplementation (with 2000 mg of polyphenols) (Di Renzo et al. 2013). Also, 
hs-CRP levels were not significantly changed after the intake of DC rich in 
polyphenols (180 mg) for 4 weeks (Allen et al. 2008), and Nogueira et al. (2012) 
showed no significant changes in hs-CRP levels after four weeks of high polyphenol 
chocolate consumption (2135 mg).  
Furthermore, a meta-analysis of 5 studies found no significant impact of flavonoid 
rich chocolate on circulating CRP levels, a finding that remained constant after 
subgroup analysis based on baseline health status (Shrime et al. 2011). These results 
were consistent with another meta-analysis of 10 studies, which did not show a 
significant effect of cocoa/DC on CRP levels (Hooper et al. 2012).  
These controversial results may suggest an adaptation effect to the quantity of 
flavonoids, which explained the positive results observed in some of the short-term 
studies (Hamed et al. 2008; Stote et al. 2012). Further studies are needed to clarify 
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the discrepancy between epidemiological and intervention studies when studying the 
effect of cocoa/DC on inflammation. However, as epidemiological studies do not 
show cause and effect (CDC 2004), only associations have been made. In addition, 
this discrepancy may be due to other confounding factors that have not been 
controlled in epidemiological studies. A prominent example is the proportion of 
saturated fatty acids in the diet. The latter factor is known to increase inflammation 
(Chait and Kim 2010), and may have confounded the relationship between frequent 
chocolate eaters and CRP. 
 
1.5 Effects of cocoa/dark chocolate on insulin and glucose metabolism  
There has been a considerable amount of research on polyphenols and their effect on 
biomarkers of glucose metabolism. For instance, IR and glucose levels have been 
reported to decrease following the administration of resveratrol in mice (Chen et al. 
2012) and EGCG in rodents (Bose et al. 2008). Flavonoid-rich berries extracts have 
decreased intestinal uptake of glucose in human intestinal cells (Alzaid et al. 2011). 
These findings provide a growing body of evidence that polyphenols may be 
effective in improving glucose and insulin metabolism in humans, and helping in the 
management/prevention of diabetes. Nevertheless, human data on cocoa polyphenols 
and insulin and glucose metabolism remain relatively limited. This is mainly due to 
the limited animal studies and the lack of knowledge of the mechanisms of action of 
cocoa flavanols (Dorenkott et al. 2014). In fact, although few studies have proposed 
a preventive effect of cocoa polyphenols on IR and glucose levels, the mechanisms 
responsible for these effects remain unclear. Additionally, these mechanisms have 
been mostly suggested through research on animal and in vitro (View Figure 1.19 on 
the mechanisms of action of cocoa polyphenols) and have not been yet evidenced by 
studies on humans. 
 
Cocoa phenolic extracts have been documented to inhibit alpha-amylase (Quesada et 
al. 1996), to reduce the postprandial elevation of glucose in rats (Tanaka et al. 2004), 
and to decrease hyperglycemia in diabetic rats (Song et al. 2002). Furthermore, the 
effect of cocoa polyphenols on insulin sensitivity has been proposed to be due to the 
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link between insulin sensitivity and NO bioavailability in endothelial cells 
(Konopatskaya et al. 2003; Faridi et al. 2008). IR has been reported to be a cause or a 
consequence of endothelial dysfunction (Sydow et al. 2005). In fact, by increasing 
the bioavailability of NO, cocoa flavanols enhance vasodilatation, and result in 
improving insulin-stimulated blood flow, which increases the supply of insulin to 
target tissues like skeletal muscle and liver (Sydow et al. 2005). In humans, this was 
supported by the decrease in IR along with an improvement of endothelial function 
(Grassi et al. 2005; Kim et al. 2006), and the simultaneous decrease in blood 
pressure and IR in the 2 studies conducted by Grassi et al. (2005; 2008), suggesting a 
link between insulin sensitivity, blood pressure and endothelial dysfunction. NO has 
been also suggested to stimulate GLUT4 leading to an increase in cellular glucose 
uptake (Etgen et al. 1997). 
 
As for the fraction of polyphenols involved in the beneficial effect on insulin 
responses and glucose metabolism, epicatechin has been previously regarded as the 
main agent responsible for such effects. Epicatechin increases pancreatic β-cell 
insulin secretion (Chakravarthy et al. 1982; Hii et al. 1985), possibly via modulation 
of Ca
2+
 metabolism (Ca
2+ 
is the key regulator in the secretion of β-cells (Xuelin et al. 
2001)), and its promotion of the release of insulin (Rutter 2001). This has explained 
one of the mechanisms by which epicatechin may prevent the occurrence of type 1 
diabetes in mice (Fu et al. 2013). Results were reinforced by a human study which 
showed that epicatechin decreases postprandial hyperglycemia in 20 adults 
(Gutiérrez-Salmeán et al. 2014). Procyanidins from phenolic extracts have also 
contributed to the improvement in glucose metabolism through to the inhibition of 
the activity of α-glucosidase, as well as salivary and pancreatic α-amylases in vitro 
(McDougall et al. 2005). Procyanidins have been also implicated in the decrease of 
the degradation of GLP-1 (Glucagon-like peptide 1), a hormone that stimulates 
insulin β-cell secretion and inhibits gastric emptying (Drucker 2002). Furthermore, 
procyanidins have been proposed to inhibit endotoxemia. Endotoxin, known as an 
important mediator of low-grade inflammation, and a component of the membrane of 
bacteria in the colon, has been related to obesity and IR. Endotoxin induces the Toll-
like receptors (TLR), which activate NF-kb and stimulate inflammation leading to an 
 70 | P a g e  
 
impairment of insulin signalling in skeletal muscle. Procyanidins have been effective 
in inhibiting TLR4 (Sung et al. 2013), constituting one of the mechanisms by which 
procyanidins may lower IR. These findings suggest that procyanidins exert their 
main function in the gut, since they have a low bioavailability and are mainly 
unabsorbed (Dorenkott et al. 2014). This was further demonstrated by the ability of 
procyanidins to improve glucose tolerance only when given orally, but not when 
injected into the peritoneum (Gonzalez-Abuin 2012). Lastly, in addition to its 
functions in the gut, procyandins have been proposed to ameliorate pancreatic β-cell 
function, thus playing an additional role in glucose metabolism. Yet, it is not clear 
whether this role is exerted via metabolites generated in the colonic flora, or by 
direct effect of procyanidins (Dorenkott et al. 2014). Additionally, a cell study 
showed that epicatechin and cocoa polyphenolic extracts are equally effective in 
improving insulin sensitivity in human hepatic cells (HepG2) treated with high 
glucose. This was demonstrated by the ability of both fractions to improve tyrosine 
phosphorylation and insulin receptors (including IRS-1 and IRS-2) and to activate 
PI3K/AKT pathway in hepatic cells. Furthermore, epicatechin and CPE (cocoa 
polyphenol extract) have been documented to attenuate the increase in PEPCK levels 
(which play a role in gluconeogenesis) (Cordero-Herrera et al. 2013). 
Moreover, the flavonol quercetin has been reported to decrease hyperinsulinemia (Li 
et al. 2013), and to improve glucose absorption and transport through the inhibition 
of the glucose transporter GLUT2 (which facilitates intestinal glucose absorption) 
(Song et al. 2002; Chen et al. 2007), and the digestive enzymes α-amylase and        
α-glucosidase (both implicated in the digestion of carbohydrates) (Tadera et al. 
2006) in vitro. Quercetin has also been shown to interact with the sodium-dependent 
glucose transporter (SGLT1) in the intestinal mucosa in vesicles of porcine jejunum, 
resulting in its inhibition, and to decrease in glucose uptake (Cermak et al. 2004). 
Again, it is not clear whether the dose of quercetin supposed to exert such effects is 
sufficient in chocolate. 
In addition, the implication of the colonic microflora in improving insulin sensitivity 
and glucose metabolism following polyphenol administration can also be suggested. 
In fact, undigested carbohydrates (resulting from the inhibitory effect of PPs on 
digestive enzymes) enter the colon. They are then converted into short-chain fatty 
 71 | P a g e  
 
acids (SCFA) (such as propionic and butyric acids) which are subsequently 
absorbed. Studies demonstrated a potential role of SCFA in improving insulin 
sensitivity by stimulating GLP-1 secretion; the latter has been shown to increase      
β-cell proliferation, to improve glucose-dependent insulin secretion and to inhibit 
gastric emptying (which results in the decrease in glycemic excursion following 
meal consumption by slowing the rate of nutrient passage into the small intestine) 
(Drucker 2002). However, the mechanisms linking SCFA and GLP-1 secretion 
remain poorly understood. Also, by reducing inflammation (through decreasing the 
secretion of proinflammatory cytokines), SCFA can reduce IR and decrease serum 
glucose levels (Puddu et al. 2014) (The role of inflammation in the occurrence of IR 
is discussed in section 1.1.4.4). Lastly, SCFA have been implicated in increasing 
satiety and decreasing food intake through several mechanisms such as the inhibition 
of gastric emptying via the increase of GLP-1 (Drucker 2002). Importantly, the 
administration of GLP-1 to rodents reduced short term and long term food intake 
(Szayna et al. 2000). This suggests a potential role of GLP-1 in long term weight 
management in humans (mainly by reducing food intake and improving insulin 
sensitivity). Another proposed mechanism for the effect of SCFA on inducing satiety 
is through the stimulation of secretion of PYY in rodents (Psichas et al. 2014). This 
might be relevant to obese humans since it was demonstrated that levels of PYY are 
low in obese individuals. Also, PYY levels have been inversely correlated to changes 
in body weight (Guo et al. 2006). Therefore, PYY might present an important 
strategy to help decreasing obesity over the long term. PYY has been also shown to 
be implicated in improving insulin sensitivity through the increase of glucose uptake 
in muscle (Den Besten et al. 2013), proposing another implication of this hormone in 
body weight control. It is then important to elucidate the effects of SCFA on PYY 
and GLP-1 in humans as well as the mechanisms involved. 
 
In addition to the nature and concentration of cocoa flavanols in cocoa/dark 
chocolate, the degree of polymerization of flavanols (and hence the size) has been 
suggested to affect the bioactivity of these components, and consequently influence 
their outcomes on insulin and glucose metabolism. For instance, cinnamtannin A2 (a 
procyanidin oligomer) has been shown to cause a greater activation of insulin 
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signalling compared to epicatechin and other procyanidins, and to inhibit GLP-1 in 
mice (Yamashita et al. 2013). Additionally, a long term study investigating the 
effects of different types of flavanols (based on the degree of polymerization) in 
mice fed a high fat diet for 12 weeks, showed that mice administered oligomeric 
cocoa procyanidins have prevented IR and impaired glucose tolerance to a greater 
extent  than monomeric and polymeric cocoa procyanidins (Dorenkott et al. 2014). A 
point worth of note is that the bioavailability of procyanidins has been shown to be 
inversely proportional to procyanidin size, and consequently to the degree of 
polymerization (Pinent et al. 2012). This could provide an explanation for the inverse 
association between the degree of polymerization and the inhibition of digestive 
enzymes (Gu et al. 2011). 
In view of these findings, epicatechin, procyanidins as well as quercetin have been 
deemed to exert beneficial effects on insulin resistance and glucose levels; however 
the contribution of each of these fractions to the favourable effect remains unclear. 
Ideally, a study comparing the effects of isolated epicatechin against different 
polymers of procyanidins and cocoa liquor/dark chocolate might be helpful in 
identifying the impact of each fraction on the beneficial effect on insulin and glucose 
metabolism. This will help in making future recommendations based on the 
fraction/amount of flavonoids in chocolate. 
In addition to the polyphenol/flavonoid implication, the insulinogenic effect of cocoa 
might be attributed to other compounds, as suggested by an experimental study 
which included 11 healthy men and women. Participants were provided six pairs of 
foods, each pair containing the same type of food, but one was flavoured with 
chocolate and the other was not. There was no difference in the glycemic index or in 
the macronutrient content of foods in each pair. Results showed that chocolate 
elicited a higher postprandial insulin secretion than other flavourings (p<0.05) 
(Brand-Miller et al. 2003). This higher insulin secretion was explained by the 
presence of arginine and other mixtures of amino acids in cocoa, which have been 
known to stimulate the secretion of insulin when consumed with carbohydrates (Van 
Haeften et al. 1989). Other reasons might also be the palatability of chocolate which 
may stimulate a pavlovian response, and therefore trigger insulin secretion, 
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particularly in people who have a preference for chocolate (Brand-Miller et al. 
2003).   
  
Studies on diabetic or glucose intolerant animals and humans with cardiovascular 
risk are still conflicting regarding the association between the consumption of 
cocoa/dark chocolate and IR and/or glucose levels. Cocoa extracts have been shown 
to decrease blood glucose levels in diabetic rats (Ruzaidi et al. 2005) and mice 
(Tomaru et al. 2007) in a dose dependent manner, and to decrease glucose and 
insulin levels in rats (Jalil et al. 2008). In addition, cocoa supplementation has been 
effective in counteracting the effects of induced obesity on IR in rats (Gu et al. 
2013).  In humans with CVD or type 2 diabetes, a crossover study documented that 
two weeks of DC supplementation rich in polyphenols (1080 mg) to 19 participants 
with essential hypertension and impaired glucose tolerance, decreases HOMA-IR 
(Homeostasis modelling assessment-IR) (p<0.05), and increases QUICKI 
(quantitative insulin sensitivity check index) (p = 0.001) (both being indicators of 
insulin sensitivity). However, no changes in these parameters were noticed after the 
consumption of white chocolate free of flavanols. The improvement of IR was 
accompanied by a decrease in SBP and DBP (Grassi et al. 2008).  Also, Curtis et al. 
(2012) included 93 diabetic men and women in a parallel study, for whom he 
administered 27 g of either a placebo DC (with no flavonoids) or a flavonoid-rich 
DC (containing 850 mg of total flavan-3-ols and 100mg of isoflavones) daily for a 
period of one year, and noted a decrease in HOMA-IR (p=0.004), and an increase in 
QUICKI (p=0.04) in the group administered DC enriched in flavonoids. In addition, 
Desideri et al. (2012) included 90 elderly individuals for whom he administered 
doses of cocoa flavanols ranging from 45 mg to 990 mg for 8 weeks, and 
demonstrated a significant decrease in IR following the intervention (p < 0.0001). 
However, a crossover study undertaken on hypertensives treated with cocoa drink 
rich in flavanols (containing 900 mg of flavanols) for 2 weeks, did not show an 
improvement in insulin resistance (assessed by QUICKI)  (p=0.54) or glucose levels 
(p=0.11). There was only an increase in insulin-stimulated vasodilatation of the 
brachial artery (p<0.04) (Muniyappa et al. 2008). Also, Balzer et al. (2008) showed 
that in diabetic patients, blood glucose levels were not affected by 30 days of daily 
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flavanol-rich cocoa supplementation (321 mg, p = 0.44), but HbA1C was reduced at 
the end of the intervention (p= 0.0038). Moreover, a crossover study including 42 
volunteers at high risk of cardiovascular diseases (having diabetes and/or 
hypertension, high cholesterol levels, obesity and family history of premature CHD), 
who were assigned to consume a skimmed milk drink with or without cocoa powder 
(containing 495.2 mg of polyphenols) for period of 4 weeks (and separated by 2 
weeks of washout period), showed no significant decrease in glucose levels 
following the consumption of cocoa and skimmed milk (p= 0.18)  (Monagas et al. 
2009). Lastly, Taubert et al. (2007) failed to show favourable effects on insulin 
sensitivity or glucose levels in prehypertensive patients following the consumption 
of 6.3g of DC (containing 30mg of polyphenols) for 18 months (p=0.82) (Taubert et 
al. 2007). A similar outcome was noticed by the study of Mellor et al. (2010) (after 8 
weeks of daily chocolate consumption (45g) containing 16.6 mg of epicatechin) 
undertaken on diabetics. 
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Figure 1.19: Possible mechanisms by which cocoa polyphenols exert a beneficial effect on 
insulin and glucose metabolism 
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To our knowledge, only five studies have investigated the effect of daily polyphenol-
rich dark chocolate on insulin sensitivity in adults with no history of hypertension, 
diabetes and CVD. A description of these studies is presented in Table 1.7. A 
crossover trial included 15 healthy adults who were assigned to receive either dark 
chocolate or white chocolate for a period of fifteen days each, showed a significant 
decrease in insulin levels, HOMA-IR as well as an increase in QUICKI only after the 
consumption of DC (Grassi et al. 2005). In addition, another crossover study 
including 42 female volunteers recruited according to BMI (BMI<25 Kg/m
2
 and 
BMI≥25 Kg/m2), showed that 20g of dark chocolate containing 500 mg of 
polyphenols decreased HOMA-IR and an increase in QUICKI only in overweight 
females after 4 weeks. Interestingly, there was an increase in HOMA-IR (p= 0.03), 
glucose levels (p=0.002), and a decrease in QUICKI (p= 0.033) in overweight 
females when assigned the placebo dark chocolate (with negligible amount of 
polyphenols) at the end of the intervention. It has been suggested that overweight 
individuals might be more affected by the unfavourable effects of DC deficient in 
polyphenols compared to normal weight individuals (Al Moosawi et al. 2012). 
Moreover, a study carried out on 49 overweight and obese adults showed a decrease 
in insulin resistance (assessed by HOMA-IR) after 12 weeks of high flavanol cocoa 
consumption (Davison et al. 2008). However, a recent study did not show an 
improvement in HOMA-IR after 7 days of DC supplementation in normal weight 
women (Di Renzo et al. 2013). Furthermore, no significant effect on insulin levels 
and HOMA-IR was noticed by a short-term study (5 days) in which twenty 
overweight and obese participants were assigned to consume cocoa beverages 
(containing 30 – 900 mg of flavanols). The latter two studies suggest that the short 
intake of cocoa flavanols may not exert positive effects on insulin and glucose levels 
(Stote et al. 2012).   
Importantly, there was no influence of the type of cacao product used (cocoa or DC) 
on the results. Both products have been shown to exert beneficial effects on insulin 
metabolism, while other studies showed no significant effect of cocoa and DC on IR 
(Table 1.7). Yet, the limited studies suggest the need for further investigations to 
identify any potential difference in the response based on the use of cocoa or DC. 
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Regarding glucose levels, the supplementation of DC containing 500 mg of 
polyphenols significantly decreased glucose levels after 2 weeks (from 4.42 ± 0.7 
mmol/l to 3.97 ± 0.54 mmol/l) (Al Moosawi et al. 2010) and 4 weeks (by 0.58 ± 0.68 
mmol/l) (Al Moosawi et al. 2012). The latter study noted a decrease in glucose levels 
only in individuals with BMI>25 Kg/m
2
, but not in normal weight individuals. In the 
latter two studies, the decrease in glucose levels was small, which raises questions 
about the clinical relevance of these outcomes.  Nevertheless, a study including 44 
overweight individuals (BMI between 25-35 Kg/m
2
), did not report a significant 
amelioration in glucose levels following 6 weeks of daily consumption of cocoa 
drinks containing 805 mg of flavanols (Njike et al. 2011). Stote et al. (2012) also 
showed no significant effect of cocoa rich in flavanols on glucose metabolism. 
Although a recent study showed a significant lowering effect of cocoa consumption 
(30 g daily) on glucose levels (p = 0.029), the product contained a higher amount of 
dietary fibre (33.9 %), which have possibly influenced the results (Sarria et al. 2013). 
 
It is worth mentioning that the results of the meta-analyses of cocoa/DC on glucose 
and insulin resistance/sensitivity were most likely to show a beneficial effect of these 
products on IR but not on glucose levels. The meta-analysis of Shrime et al. (2011) 
included five studies (with healthy participants and patients), and reported a 
significant decrease in HOMA-IR (-0.94; 95% CI: -0.59, -1.29, p < 0.001)), with no 
significant effect on glucose levels and QUICKI. Similar results were noted in 
another meta-analysis of 6 trials (including healthy participants and patients), which 
documented that cocoa/DC supplementation induced a significant decrease in 
HOMA-IR (-0.67 µIU/ml; 95% CI: -0.98, -0.36), but had no effect on blood glucose 
levels or QUICKI, suggesting that the favourable effect of cocoa/DC on IR mainly 
occurs through the decrease in insulin secretion (Hooper et al. 2012). Yet, the non 
significant effect noted on QUICKI deserves more investigation. 
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Table 1.7: Characteristics and outcomes of studies analysing the effect of 
polyphenol-rich cocoa/chocolate on insulin resistance/insulin sensitivity 
Study Design Intervention Participants Duration Outcomes Signifi-
cance 
Grassi et al. 
2005 
 
Randomized 
crossover, open 
label study 
100g of DC with 
500mg of 
polyphenols v/s 
100g of white 
chocolate with no 
polyphenols 
7 men & 8 
women with 
BMI:22.6±3.0 
kg/m2 
33.9±7.6 years 
15 days of DC and 
white chocolate 
separated by a 7-
day washout 
period  
   HOMA-
IR 
   QUICKI 
  
   Fasting 
insulin 
levels  
P<0.001 
 
P=0.001 
 
P<0.0001 
 
 
Davison et al. 
2008 
Randomized 
parallel double 
blinded study 
Cocoa drink with 
902mg of 
flavanols v/s 
36mg of flavanols 
18 men, 31 
women  
BMI:32.8±1.1 
kg/m2 
44.4±4.4 years 
12 weeks of cocoa  
rich in flavanols 
or low in flavanols 
   HOMA-
IR 
 
   Fasting 
insulin 
levels 
 
 
 
 
P<0.005 
Al Moosawi 
et al. 2012 
Randomized 
crossover  
single blinded 
study 
20g of DC with 
500mg of 
polyphenols v/s 
20g  of DC with 
no polyphenols 
(placebo) 
21 men 
(BMI<25 
kg/m2), 21 
women 
(BMI>25 
kg/m2) 
 
4 weeks of DC 
and placebo DC 
separated by a 7-
day washout 
period 
   HOMA-
IR  
   QUICKI 
only in 
BMI>25 
kg/m2) 
 
No changes 
in fasting 
insulin 
levels 
P=0.041 
 
P=0.033 
 
Stote et al. 
2012 
Randomized 
crossover  
single blinded 
study 
28g of cocoa with 
four different 
doses of 
polyphenols (30, 
180, 400 and 
900mg of 
flavanols) 
10 men, 10 
women 
46 ± 2.3 years 
BMI 36.8±1.0 
kg/m2 
5 days of each 
dose of flavanols 
separated by a 10-
day washout 
period 
No changes 
in HOMA-
IR, QUICKI 
or insulin 
levels 
p>0.05 
Di Renzo et 
al. 2013 
Pilot study  100g of DC with 
2000mg of 
polyphenols 
15 women 
(BMI<25 
kg/m2) 
1 week of daily 
DC 
supplementation 
No control group 
No changes 
in HOMA-
IR or fasting 
insulin 
levels 
P>0.05 
DC: Dark chocolate, IR: insulin resistance, HOMA-IR: Homeostasis modelling assessment-IR, 
QUICKI: Quantitative insulin sensitivity check index. 
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1.6 Effects of cocoa/dark chocolate on lipid profile 
Data are still inconclusive regarding the link between cocoa/dark chocolate and 
serum lipids levels. In individuals with cardiovascular risk, Balzer et al. (2008) 
showed an inverse association between DC and LDL levels in normolipemic 
diabetics after ingestion of cocoa rich in flavanols (325 mg) for 4 weeks (by 7.82 %, 
p= 0.0063). Mellor et al. (2010) reported an increase in HDL in diabetics 
administered PRDC for 8 weeks (by 6.8%, p= 0.04), with no significant changes in 
other serum lipid levels. In the hypertensive population, the consumption of 100g of 
chocolate rich in polyphenols (500 mg) for 2 weeks decreased total cholesterol by     
7 % , and LDL by 12 % (p<0.05) (Grassi et al. 2005b). As for hypercholesterolemic 
individuals, a decrease in serum cholesterol and LDL levels (by 2% and 5.8%, 
respectively, p<0.05) was noted after the consumption of DC bars (containing             
360 mg of flavanols) daily for a period of 4 weeks (p<0.05) (Allen et al. 2007). In 
participants with high baseline LDL administered cocoa with doses of polyphenols 
ranging from 140 mg to 281 mg, serum LDL levels decreased (by 4 - 5 %, p< 0.05) 
and HDL levels increased (by 4.7 - 8%, p= 0.055) in a dose dependent manner  
(Baba et al. 2007a). 
 
As for studies carried out on participants with no cardiovascular risk, results have 
been controversial. There was no significant change in serum lipids (TC, TG, HDL 
and LDL) following the consumption of dark chocolate containing 500 mg of 
polyphenols for a period of 2 weeks (Al Moosawi et al. 2010), or 4 weeks (Al 
Moosawi et al. 2012). Likewise, several studies have not identified a significant 
change in lipid profile in healthy subjects after the consumption of cocoa or DC for a 
period ranging from 2-6 weeks (Mathur et al. 2002; Engler et al. 2004, Grassi et al. 
2005; Muniyappa et al. 2008; Nogueira et al. 2012; West et al. 2013; Ibero-Baraibar 
et al. 2014). Similar results were reported by the study of Neufingerl et al. (2013), 
which suggested that the HDL increasing effect and the LDL lowering effect of 
cocoa are mainly attributed to a high amount theobromine (850 mg of theobromine 
in this study), rather than to the implication of polyphenols. 
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On the other hand, few studies have shown an improvement in serum lipid levels 
following cocoa/DC supplementation in individuals with no disease risk. Baba et al. 
(2007b) administered a drink containing either cocoa powder and sugar (intervention 
group) (with a total of 766.1 mg of polyphenols) or a sugar drink (placebo group) to 
23 healthy subjects for 12 weeks, and showed a significant increase in HDL levels 
by 24%, and a decrease in LDL levels by 12.6% in subjects assigned the cocoa 
powder drink (p<0.001). Also, a crossover study documented that the consumption 
of dark chocolate and cocoa powder (containing a total 466mg of flavanols) for 4 
weeks results in an increase in HDL by 4 % (by 0.05 mmol/l) (p = 0.02) (Wan et al. 
2001). Additionally, a study performed on 45 healthy volunteers aged from 19-49 
years, showed that the intake of 75g of dark chocolate rich in polyphenols (418 mg 
of polyphenols) for a 3-week period induced an increase in HDL by 14% (Mursu et 
al. 2004). The contribution of flavanols to the hypolipemic effect is reinforced by the 
study of Fraga et al. (2005), which reported that the daily consumption of milk 
chocolate containing 168 mg of flavanols by 28 healthy male soccer players 
decreased TC by 11% (p = 0.009) and LDL levels by 15 % (p = 0.02), while there 
was no change in HDL levels at the end of the 2-week intervention (p = 0.2) (Fraga 
et al. 2005). It is worth pointing out that the significant lowering effects of cocoa/DC 
on serum lipids noted in trials were mostly clinically relevant. This is based on 
previous studies which stated that a decrease in cardiovascular risk is observed when 
LDL levels drop by 1% (Jia et al. 2010), and HDL levels increase by 10 mg/dl (Ali 
et al. 2012) (0.026 mmol/l). 
The previous results, suggest that, even with the considerable lower amount of fat in 
cocoa compared to DC, both products have been reported to lower serum lipid 
levels. A meta-analysis stratifying the studies according to the type of cacao product 
may be more reliable in showing differences in response to intervention based on the 
administration of cocoa or DC.  
 
Several meta-analyses aiming to review the effect of cocoa/DC on serum lipids have 
been performed, and included studies on normo and hypercholesterolemic 
individuals. The meta-analysis of Jia et al. (2010) included 8 studies and noted a 
significant decrease in LDL levels (-5.87 mg/dl (95% CI; -11.13, -0.61, p<0.05)) 
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following cocoa/DC consumption, with a marginal decrease in TC levels that did not 
reach statistical significance (-5.82 mg/dl; 95% CI: -12.39, 0.76, p= 0.08). A meta-
analysis of 10 studies reported similar results: serum TC (- 6.23 mg/dl (95% CI:         
-11.6, -0.85, p<0.05) and LDL levels (- 5.9 mg/dl; 95% CI: -10.47, -1.32, p< 0.05) 
decreased, whereas no significant effects on HDL and TG levels were noted (Tokede 
et al. 2010). However, in both meta-analysis, heterogeneity was described as a 
drawback, and the beneficial effect on lipid profile was no longer significant when 
low quality studies were excluded (Jia et al. 2010; Tokede et al. 2011). Moreover, it 
seems that studies with short duration (2 weeks) were more effective in decreasing 
lipid levels than longer term studies. This was mainly explained by the decrease in 
adherence observed in long-term studies (Tokede et al. 2011). The baseline health 
status is also predictive of the outcomes. A decrease in LDL and TC levels was only 
noted in patients with high cardiovascular risk but not in healthy subjects (Jia et al. 
2010; Tokede et al. 2010). This effect is plausible due to the fact that individuals 
with cardiovascular risk have usually dyslipidemia or abnormalities in lipid 
metabolism (Nathan 1999); hence it is more likely that their serum lipid levels will 
be improved. Moreover, flavanol doses less than 500 mg seem to be more effective 
in lowering LDL levels than doses higher than 500 mg (Tokede et al. 2011). 
However, Jia et al. (2010) showed a significant decrease in TC and LDL levels only 
when doses of flavanols were less than 260 mg. This may be due to the fact that a 
high amount of polyphenols can counteract the benefits of polyphenols on lipid 
profile (Jia et al. 2010). This outcome corresponds with a finding of an animal study 
which showed that cocoa may lessen plaque formation at low doses, while it did not 
cause this effect at high cocoa doses (Vinson et al. 2006). Yet, the optimal dose of 
polyphenols supposed to have beneficial effects on lipid profile has not been yet 
determined (Jia et al. 2010).   
 
The mechanisms by which cocoa/DC exert beneficial effects on lipid profile have 
not been clearly elucidated. Flavonoids were shown to inhibit the intestinal 
absorption of cholesterol in rats (Ikeda et al. 1992), to increase the hepatic 
expression of LDL receptors (Pal et al. 2003), and to inhibit the synthesis of LDL 
(Wilcox et al. 2001) in human hepatic cells. An in vitro study showed that 
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polyphenols activate AMPKα1 and AMPKα2 phosphorylation in human hepatic 
cells, which resulted in a decrease in lipid accumulation in these cells (Zang et al. 
2006). It was also shown that in rats fed a high cholesterol diet, cocoa powder was 
able to increase the faecal excretion of cholesterol (Baba et al. 2007a). The 
polyphenol metabolites in the colon might also be involved in decreasing cholesterol 
levels. For instance, it was shown that 3-dihydroxytoluene, a flavanol metabolite 
produced in the colon, inhibits the incorporation of acetate into cholesterol in the 
liver cells of rats, and therefore inhibits cholesterol synthesis (Glässer et al. 2002). 
Yet, these mechanisms have not been supported in human studies. A decrease in 
ApoB (the major LDL and VLDL protein) and a subsequent decline in serum LDL 
levels were albeit noted in humans (Baba et al. 2007a). 
Finally, it was hypothesized that there might be other components in DC responsible 
for the potential beneficial effects. For instance, in addition to the effect of 
theobromine, cocoa butter is an important source of oleic acid, which exerts a 
positive effect on lipid profile (Corti et al. 2009). Moreover, a study reported that 
substituting a carbohydrate snack with a milk chocolate bar resulted in an increase in 
serum HDL levels and a decrease in TG levels. This study suggested that refraining 
from eating the carbohydrate snack exerted beneficial effects on lipid levels. These 
effects were not particularly related to chocolate consumption (Kris-Etherton et al. 
2002). 
 
1.7  Effects of cocoa/dark chocolate on blood pressure 
The link between cocoa and blood pressure has been first identified from research 
undertaken on the Kuna Indians of Panama, who were known to consume large 
quantities of cocoa (at least three 10-oz servings of cocoa per day) (McCullough et 
al. 2006). This amount provides more than 900 mg of flavanols daily (Bayard et al. 
2007). The kuna Indians had low incidence of high blood pressure despite their high 
sodium intake (McCullough et al. 2006), with a mean SBP/DBP around 110/70 
mmHg (Hollenberg 2006). Researchers suggested this protective effect is not 
genetic, as migration of the Kuna Indians to the urban areas has increased the 
prevalence of hypertension among them. This was explained by the change in their 
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dietary habits and lifestyle, such as the increase in smoking status and stress levels, 
and particularly the decrease in their cocoa intake, which became 10-fold lower than 
the Indians living in the indigenous islands (McCullough et al. 2006).      
The beneficial effect of cocoa on blood pressure was primarily reported in a 
correlational study on 470 elderly men with no history of CVD. Men with the 
highest tertile of cocoa intake (4.18 g/day) demonstrated a lower SBP (p=0.0008) 
and DBP (p=0.0001) than men in the lowest tertile of intake (no cocoa consumption) 
(Buijsse et al. 2006). 
Many intervention studies were carried out on cocoa/DC and blood pressure, mainly 
in the hypertensive population. DC supplementation was mostly effective in 
decreasing blood pressure in hypertensives administered doses of flavanols ranging 
from 300-1052 mg for a period of 2-6 weeks (Taubert et al. 2003; Grassi et al. 2008; 
Davison et al. 2010; Heiss et al. 2010; D'El-Rei et al. 2013). Other studies, on the 
other hand, did not report a significant effect of cocoa/DC on blood pressure 
(Muniyappa et al. 2008; Ried et al. 2009).  
 
Nonetheless, clinical trials studying the effect of dark chocolate or cocoa on blood 
pressure in adults with no type 2 diabetes, hypertension and CVD are still 
conflicting. Al Faris (2008) reported a significant decrease in SBP (from 115.9 ±12.6 
mm Hg to 107.5 ± 8.6 mm Hg), and DBP (from 73 ± 9.9 mmHg to 67.7 ±9.7 mmHg) 
following the consumption of 100 g of dark chocolate rich in polyphenols (500 mg) 
for two weeks (p<0.05) (Al-Faris 2008). Similar results were documented by Al 
Moosawi et al. (2010): a decrease in SBP (from 119.38 ± 10.51 mm Hg at baseline 
to 112.4 ± 9.51 mm Hg) and DBP (from 78.62 ± 7.74 mm Hg at baseline to 73 ± 
5.06 mm Hg) after 2 weeks of daily DC consumption (20g) containing 500 mg of 
polyphenols (p<0.05) (Al Moosawi et al. 2010). However, in a crossover study, 
Grassi et al. (2005) demonstrated a decrease in SBP after consuming 100 g of DC 
(500 mg of polyphenols) for 2 weeks (107.5 ± 8.6 mmHg after DC consumption 
versus 113.9 ± 8.4 mm Hg after white chocolate group at the end of the study, 
p<0.05), while DBP did not significantly change. In line with these findings, 500 mg 
of polyphenols in DC were effective in decreasing SBP in normal weight women by 
3.41 ± 6.08 mmHg and by 4.48 ± 7.82 mmHg in overweight women (p<0.05), while 
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the effect on DBP was only positive in overweight women (DBP significantly 
decreased by 3.22 ± 3.75 mmHg). It was documented that overweight females better 
respond to the DC blood pressure lowering properties (Al Moosawi et al. 2012). 
Fraga et al. (2005) reported that 168 mg of flavanols induced a significant decrease 
in DBP by 5 mm Hg (p= 0.01), while the decrease in SBP did not reach statistical 
significance (p= 0.06). Similar results were reported by a study undertaken on 49 
overweight and obese participants who were randomly assigned to receive a high 
flavanol cocoa drink (containing 902 mg of flavanols) or low flavanol cocoa drink 
(36 mg of polyphenols) for a period of 12 weeks. In the high flavanol cocoa drink, a 
decrease in DBP by 1.6 mm Hg (p= 0.04) with no change in SBP was noted 
(Davison et al. 2008). As it has been shown that clinically relevant reductions in 
blood pressure can be considered when changes exceed 5 mmHg (Glynn et al. 2002), 
most of the significant changes in blood pressure noted in previous studies were also 
clinically relevant. 
However, several studies failed to report a lowering effect of cocoa/DC on BP (blood 
pressure) in normotensive individuals. The trial of Murphy et al. (2003) did not note 
a significant effect on BP in participants administered 234 mg of flavanols and 
procyanidins. Same outcome was noticed in the studies of Engler et al. (2004) (259 
mg of flavonoids), Crews et al. (2008) (754.71 mg of proanthocyanidins), Shiina et 
al. (2007) (550 mg of flavanols), Njike et al. (2011) (805 mg of flavanols), 
Neufingerl et al. (2013) (325 mg of flavonoids) and (Di Renzo et al. 2013) (2000 mg 
of polyphenols).  
In view of these conflicting outcomes, the results of meta-analyses might be 
effective in analysing inconsistencies and generalizing results. Few meta-analyses 
looked at the effect of cocoa/DC on blood pressure (A summary is provided in table 
1.8). 
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Table 1.8: Characteristics of meta-analyses assessing the effect of cocoa/DC on 
blood pressure 
Meta-analysis Number of 
studies 
Baseline health 
 Status in studies 
Active 
ingredients 
polyphenols 
range (mg) 
Duration Results 
Taubert et al. 
2007 
5 3 normotensives/ 
2  hypertensives 
 
 
213 – 500 2 weeks SBP (-4.7 mmHg) 
(p=0.002) 
DBP (-2.8 mmHg) 
(p=0.006) 
Desch et al. 
2010 
10 5 normotensives/           
5 hypertensives 
30-902 2-18 weeks SBP (-4.75mmHg)  
DBP (-2.5 mmHg) 
(p<0.001) 
Ried et al. 
2010 
13 10 normotensive/   
3 hypertensives 
30-1008 2-18 weeks SBP (-3.2mmHg)  
p=0.001) 
DBP (-2.0 mmHg) 
(p=0.003) 
Shrime et al. 
2011 
22 11 normotensive/ 
11 hypertensives 
30-1080 2-18 weeks SBP (-1.63 mmHg)  
p=0.033) 
No change in DBP 
Hooper et al. 
2012 
22 10 normotensive/ 
12 hypertensives 
30-1080 2-18 weeks No change in SBP 
DBP (-1.6 mmHg 
(p<0.05) 
Ried et al. 
2012 
20 10 normotensive/ 
10 hypertensives 
30-1080mg 2-18 weeks SBP (-2.77 mmHg)  
p=0.005) 
DBP (-2.2 mmHg) 
(p=0.0006) 
SBP: Systolic blood pressure, DBP: Diastolic blood pressure 
As showed in table 1.8, the majority of meta-analyses showed a potential effect of 
cocoa/DC on decreasing blood pressure. However, the results are limited by the large 
heterogeneity of the studies. This includes a difference in the number of subjects, 
amount of polyphenols (flavonoids) and the study duration. In addition, most of the 
studies lasted for 2-8 weeks, while Taubert et al. (2007) is the only study that lasted 
for 18 weeks. Yet, excluding the latter study did not significantly affect the results 
(Ried et al. 2012). 
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While two meta-analysis showed no correlation between polyphenol dose, duration, 
BMI and the change in blood pressure (Ried et al. (2010), another meta-analysis 
concluded that studies lasting 2 weeks showed a significant decrease in blood 
pressure, while studies lasting for a longer period did not note this effect. In addition, 
the stratification of studies according to the amount of sugar present in the 
cocoa/dark chocolate product had an influence on the results. This was demonstrated 
in the meta-analysis of Ried et al. (2012), which shows that low sugar content in the 
experimental cocoa/DC (less than 10g/day) had a larger beneficial effect than the 
ones using higher amounts of sugar. This meta-analysis also showed a more 
pronounced effect on blood pressure when participants were younger, and when a 
polyphenol-free placebo product was used instead of a placebo product low in 
polyphenols (Ried et al. 2012).  
Nevertheless, the meta-analysis of Ried et al. (2010; 2012) showed that that 
cocoa/DC was effective in decreasing blood pressure in pre-hypertensive and 
hypertensive subjects, but not in normotensive subjects. No other meta-analyses 
stratified participants according to their health status, and tested the influence of this 
factor on blood pressure results after cocoa/DC supplementation. 
 
In the presence of a beneficial effect, the dose and fraction of flavanols supposed to 
lower blood pressure is still unclear. It was recently suggested by the EFSA that the 
consumption of 200 mg of flavanols daily might have a beneficial effect on 
endothelium-dependent vasodilation, and could possibly result in the decrease in 
blood pressure. This effect could be achieved by the consumption of 10g of flavanol-
rich chocolate or 2.5g of high-flavanol cocoa (EFSA 2012). As for the flavanol 
fraction, a meta-analysis of 70 studies showed that epicatechin is the main flavonoid 
responsible for decreasing blood pressure. It was reported that the consumption of 
chocolate or cocoa containing 25 mg of epicatechin was effective in deceasing SBP 
by 4.1 mm Hg and DBP by 2 mm Hg (Ellinger et al. 2012). However, the meta-
analysis of Hooper et al. (2012) documented a significant effect on SBP and DBP 
only when the dose of epicatechin was higher than 50 mg. In particular,                                
–(-) epicatechin is the main stereoisomer responsible for an effect on NO and 
vasodilatation, unlike +(-) epicatechin and –(-)catechin (Ottaviani et al. 2011). 
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Procyanidins were also shown to exhibit vasodilative and blood pressure lowering 
effects (Taubert et al. 2007). Indeed, the fact that a meta-analysis showed a lowering 
effect of cocoa but not tea on blood pressure was suggested to be due to the 
difference in polyphenol composition between cocoa and tea; the blood pressure 
lowering effect might be attributed to the procyanidin fraction of flavanols that is 
abundant in cocoa, but not in tea (Taubert et al. 2007).  
The mechanism underlying the effect of dark chocolate/cocoa on blood pressure may 
be explained by the increased availability of nitric oxide and the subsequent increase 
in vasodilatation (Grassi et al. 2005). However, a vasodilative effect does not 
necessarily imply a blood pressure lowering effect unless it simultaneously decreases 
the renal pressure threshold responsible for sodium homeostasis (Egan et al. 2010). 
This might actually explain the mechanism by which cocoa polyphenols improve 
insulin sensitivity and endothelial function through vasodilatation, but do not exert 
blood pressure lowering effects (Grassi et al. 2005; Wang-Polagruto et al. 2006; 
Balzer et al. 2008). Cocoa flavanols can also raise vasodilatation independently of 
NO, by increasing substances like prostacyclin and endothelium-derived 
hyperpolarizing factor (Corti et al. 2009).  Another proposed mechanism is the 
implication of the Renin-Angiotensin system through the inhibition of the ACE, 
suggesting that foods rich in flavonoids can mimic the effect of ACE inhibitors 
without the medications causing side effects (Actis-Goretta et al. 2003; Lavoie and 
Sigmund 2003). This happens by a competition between flavonoids and the substrate 
for the active site of the enzyme (Actis-Goretta et al. 2003). However, this theory 
was doubted due to the low concentration of epicatechin achieved in the human 
plasma (nanomolar range) (Baba et al. 2000; Holt et al. 2002), which makes it less 
likely to inhibit ACE. Furthermore, the associated decrease of S-nitroglutathione (a 
vasodilatative) with BP after DC consumption, suggests an implication of this 
marker in lowering blood pressure (Taubert et al. 2007).  
 
Interestingly, the lowering effect on blood pressure might also be caused by a 
“placebo effect” as explained by the meta-analysis by Egan et al. (2010), which 
reported a decrease in blood pressure in 6 of 7 open-label studies, but only in 1 of 6 
double-blind studies. This suggests that the positive outcome might be explained by 
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individual expectations of a positive effect. The most plausible evidence is the study 
undertaken by Taubert et al. (2007), which reported that a dose of 30 mg of 
polyphenols is effective in decreasing BP. This dose, considered negligible, might 
have led to a decrease in BP due to the use of white chocolate in the placebo group, 
thus participants were aware of the fact that they constituted the intervention group.  
 
Lastly, the non significant effect of cocoa polyphenols on blood pressure has also 
few explanations: It was suggested that –(-)catechin (which is produced by 
epimerization of epicatechin during processing of cacao beans) may counteract the 
blood pressure lowering effects of –(-)epicatechin (Egan et al. 2010).  Also, the dose 
of flavanols required to induce changes in blood pressure might be high. For 
instance, Davison et al. (2010) showed that a dose of flavanols equivalent to          
1052 mg can reduce blood pressure in participants with mild hypertension, while the 
doses of 33, 372 and 712 mg did not induce such effect. This matches with the fact 
that cocoa powder consumed by the Kuna indians contained 3.6% of flavanols, while 
the DC in the market usually contains 0.5 % of flavanols (Chevaux et al. 2001), 
which might be less likely due induce a decrease in blood pressure. 
 
1.8 Effects of cocoa/dark chocolate on glucocorticoid metabolism 
Limited research previously tested the effects of polyphenols on glucocorticoid 
metabolism, and very few studies assessed the effects of cocoa polyphenols on 
cortisol and cortisone levels. Glucocorticoid metabolism plays a particular role in the 
MS (Masuzaki et al. 2001), thus identifying beneficial effects on cortisol levels 
might help in preventing or delaying the occurrence of MS. Green tea polyphenols 
were shown to inhibit glucocorticoid gene expression (Abe et al. 2001). Similar 
effects were noticed by another study on chlorogenic acid (Arion et al. 1997). Also, 
tea polyphenols exerted an inhibitory effect on 11 β HSD 1 (Hindzpeter et al. 2014), 
and flavonone derivatives were potent inhibitors of this enzyme (Miguet et al. 2006). 
These results suggest a potential effect of polyphenols on cortisol metabolism, yet it 
is important to be aware of the different composition of the polyphenol fraction in 
cocoa compared to the other polyphenols tested.  
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Regarding research on DC, a study including 30 subjects assigned to receive 40g of 
DC for 2 weeks, showed a decrease in the urinary excretion of cortisol along with a 
decrease in urinary stress hormones (adrenaline, noradrenaline and normetanephrine) 
(Martin et al. 2009). However, a pilot study conducted on overweight and obese 
subjects did not note a significant change in urinary cortisol and cortisone levels, nor 
in the cortisone-to-cortisol ratio (indicator of 11 β-HSD1 activity) after 14 days of 
daily consumption of polyphenol-rich dark chocolate (with 500 mg and 1000 mg 
doses of polyphenols) (Al Moosawi et al. 2010). Similar results were noted after 4 
weeks of PRDC (500g) consumption. However, dark chocolate low in polyphenols 
increased salivary cortisol in overweight and normal weight females at the end of 
study (Al Moosawi et al. 2012). 
 
The mechanism responsible for the potential beneficial effect of polyphenols on 
cortisol metabolism remains unclear. It could be attributed to the fact that 
polyphenols inhibit Glucose-6-phosphatase activity, and therefore reduce the 
formation of NADPH, which is responsible for the regeneration of 11β-HSD1. This 
results in a decrease in the activity of 11β-HSD1, and a subsequent decrease in 
cortisol levels (Arion et al. 1997). Furthermore, polyphenols were shown to decrease 
corticosteroid-induced oxidative stress in chicken treated with corticosterone, 
providing another mechanism by which polyphenols may inhibit oxidative stress and 
cortisol (Eid et al. 2003). Further studies are needed to elucidate the effect of cocoa 
polyphenols on glucocorticoid metabolism, as well as the potential mechanisms 
involved. 
1.9 Effects of cocoa/dark chocolate on fat metabolism, body weight and 
obesity 
While many human studies reported benefits of DC on cardiovascular health, these 
effects might be limited by the high fat and sugar content of DC (Miller et al. 2006; 
McShea et al. 2008). In fact, chocolate provides a considerable high amount of 
energy, which may lead to weight gain if not introduced in the context of a balanced 
controlled-calorie diet, suggesting the importance of moderation in avoiding side 
effects.  
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However, there has recently been an emerging research on the effects of polyphenols 
in counteracting obesity, and on the role of polyphenols in body weight control. 
Dietary polyphenols have been suggested as one of the complementary approaches 
to manage obesity, due to the ability of some of these components like catechin, 
curcumin, anthocyanins and resveratrol to modify molecular and physiological 
pathways implicated in adiposity and energy metabolism
 
(Meydani and Hasan 2010). 
The implication of polyphenols in body weight control might be particularly 
important since despite weight-loss interventions, it is estimated that 68 % of the 
American adult population are still overweight or obese (Flegal et al. 2010). In 
addition, the modest effect of hypocaloric diets on reducing weight mainly due to 
poor compliance (Foster et al. 2005), raises the need for strategies that target long-
term interventions and may therefore help in long-term weight maintenance. 
Green tea polyphenols (mainly catechin) have been previously shown to decrease 
weight in adults after 6 weeks of daily supplementation (Yang et al. 2012). This 
effect was not attributed to caffeine, as the supplementation of cocoa tea (a 
decaffeinated tea plant) to mice has attenuated the adverse effects of a high-fat diet 
induced obesity, including the increase in body weight and plasma lipid levels (Yang 
et al. 2013). In addition, lemon flavonoids inhibited body weight gain and fat 
accumulation in the adipose tissue of mice fed a high fat diet for 12 weeks (Fukuchi 
et al. 2008). Quercetin-rich onion peel extract was also shown to inhibit adipogenesis 
in preadipocytes (Moon et al. 2013). 
The potential effects of cocoa polyphenols on obesity were mainly studied in animal 
and in vitro studies, and the contribution of human studies remains relatively limited. 
A summary of these potential effects is presented in Figure 1.20. 
 
Animal studies 
While testing the effects of cocoa on several conditions such as atherosclerosis in 
rats, it was observed a lower adipose tissue weight in rats fed a cocoa-rich diet, 
compared to those fed a diet free of cocoa, suggesting that cocoa might be implicated 
in obesity. This led to more focused studies on the effect of cocoa on body weight 
control. Twenty rats were fed an isocaloric high fat diet including either a real cocoa 
or a mimetic one (with a similar composition to cocoa in terms of moisture, 
 91 | P a g e  
 
carbohydrate, protein, fat and fibre) for a period of 3 weeks. Results showed a lower 
body weight gain ( by 13.6 %) and mesenteric white adipose tissue (MES-WAT) 
weight gain in rats fed with a real cocoa compared to rats fed a mimetic one (p<0.05)
 
(Matsui et al. 2005). In support of this data, another study undertaken on 44 mice 
who were divided into 4 groups and administered either a normal diet, a high fat diet, 
or a high fat diet with 2 different doses of cocoa polyphenol extract (CPE) for a 
period of 5 weeks, showed less gain in body weight (by 5.8% and 12.6% in a dose 
dependent manner) and in the liver and epididymal fat mass in mice administered 
CPE (p<0.05)
 
(Min et al. 2012). A recent study also found similar results: a lower 
body weight gain (by 16%) and WAT weight gain was noted in mice fed a high fat 
diet with cocoa for 10 weeks, compared to rats fed only with a high fat diet (p<0.01) 
(Gu et al. 2013). Similarly, cocoa liquor procyanidins (CLPr) were shown to reduce 
body weight gain and fat accumulation in the adipose tissue of obese diabetic mice 
when provided with a high fat diet for a period 13 weeks (p<0.05) (Yamashita et al. 
2012), whereas CLPr along with a high fat diet did not attenuate weight gain in 
diabetic obese mice assigned to a similar protocol for 3 weeks (Tomaru et al. 2007).  
With the aim of investigating the molecular mechanisms triggering the influence of 
cocoa on the metabolism of lipids, an analysis of the gene expression in the  liver 
and MES-WAT of rats showed that in the liver, cocoa decreases the expression of 
genes involved in the synthesis of  fatty acids (such as fatty acid synthase), as well as 
the expression of genes involved in the biosynthesis of cholesterol (such as 7-
dehydrocholesterol reductase, squalene synthase and squalene epoxidase)
 
(Matsui et 
al. 2005). The mechanisms involve the transcription factors PPARs. In MES-WAT, 
cocoa induces a decrease in the expression of genes implicated in fatty acid transport 
(like fatty acid transporter and Apo E), along with PPAR-γ, as well as in the 
expression of genes involved in fatty acid synthesis (such as fatty acid synthase and 
enoyl-coA hydratase) (Matsui et al. 2005). It was also stated that polyphenols might 
activate PPAR-γ in hepatocytes leading to an increase in fatty acid oxidation 
(Goldwasser et al. 2010).  
Yamashita et al. (2012) indicated that CLPr may increase the gene and protein 
expressions of the uncoupling proteins (UCPs). UCP-1 (which plays a role in 
thermogenesis in the brown adipose tissue), UCP-2 in white adipose tissue, and 
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UCP-3 in skeletal muscle (which are both involved in the regulation of energy 
metabolism). The effect on UCPs is explained by the increased phosphorylation of 
AMPKα, which is involved in the increase in fatty acid oxidation (Yamashita et al. 
2012). Gu et al. (2013) also suggested that cocoa powder decreases lipid absorption 
and leads to a decrease in body weight gain.  
 
Furthermore, the lowering effect on body weight might be suggested to be due to the 
increase in energy expenditure through the increase in the consumption of oxygen 
(VO2) and the excretion of carbon dioxide (VCO2). This was noted in an animal 
study in which rats were supplemented with flavanols extracted from cacao (0.2%) 
for 2 weeks. This effect was explained by the stimulation of AMPK in skeletal 
muscle, which is activated by PGC1-α , the latter being involved in thermogenesis 
(Osakabe 2013). 
Moreover, the potential effect of polyphenols on body weight control was suggested 
to be attributed to the central nervous system through the modulation of 
neuropeptides implicated in satiety and food intake (Panickar 2012). Research is still 
very limited regarding this association, but the theory was mainly considered due to 
the ability of some polyphenols (like epicatechin and resveratrol) to cross the blood 
brain barrier (Panickar 2012). In fact, mice treated with resveratrol demonstrated a 
decrease in NPY and AgRP (Agouti-related protein) (a neuropeptide that induces 
obesity) in a dose dependent manner (Hamao et al. 2011). In addition, decaffeinated 
coffee rich in chlorogenic acid was shown to increase the postprandial secretion of 
GLP-1 (Johsnton et al. 2003), which may induce satiety by inhibiting gastric 
emptying (Flint et al. 1998). Moreover, isoflavone supplementation increased 
peptide Y (PYY) (satiety hormone that decreases food intake) (Weickert et al. 2013). 
Studies investigating the effect of cocoa polyphenols on neuroregulatory peptides are 
needed to identify any potential effect of these polyphenols on satiety.  
In view of all the facts exposed above, animal studies provide an important rationale 
for carrying out human studies analysing the associations between cocoa 
polyphenols and body weight. However, it is important to acknowledge the lack of 
evidence of the presence of biologically active BAT in humans, which has explained 
a part of the weight lowering effect of cocoa polyphenols in rodents through UCP1. 
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Furthermore, -(-)epicatechin glucuronide, an important metabolite of                           
-(-)epicatechin, has been noted to be differently metabolized between humans and 
animals (Natsume et al. 2003). This metabolite has been deemed to have a lower 
antioxidant capacity in humans compared to rats (Natsume et al. 2004). In addition, 
body weight control differs between free living humans and animals (Liebel 2008), 
which makes it difficult to compare the results between the 2 species. 
 
In vitro studies 
Cocoa polyphenol extract (CPE) (obtained from the extraction of polyphenols from 
50g of cocoa powder) was reported to inhibit the primary stage of adipogenesis in 
preadipocytes 3T3 L1 derived from mice, and to decrease the accumulation of lipids 
in these cells in a dose dependent manner (p<0.05). It was shown that CPE inhibits 
diet-induced adipogenesis in cells by suppressing mitotic clonal expansion, a step 
that enables DNA remodelling for gene expression during the development of fat 
cells. The mechanism involves a decrease in  mRNA expression of PPAR-γ and 
C/EBPα  (Ccaat-enhancer-binding proteins) (Min et al. 2012) (both being 
transcription factors in adipogenesis (Rosen et al. 2002), together with the decrease 
in mRNA expression of fatty acid synthase in these cells
 
(Min et al. 2012). The 
results might suggest a possible role of cocoa in preventing weight gain in human 
adults, as studies showed that the expansion of adipose tissue in adults can result not 
only from increased adipocyte size but also from increased adipocyte number 
(Gregoire et al. 1998; Gregoire, 2011). 
Min et al. (2012)
 
proposed that the inhibitory effect on lipid accumulation may 
possibly be due to the fact that CPE inhibits insulin receptor kinase activity in 
adipose tissue, which subsequently suppresses ERK (extracellular signal-regulated 
kinase). The latter cascade plays an essential role in the differentiation of adipocytes. 
 
Moreover, findings from “in vitro” studies showed that polyphenols from teas and 
berries inhibit digestive enzymes, providing a justification for investigating the 
implication of cocoa polyphenols in the digestion of fats and carbohydrates. In fact, a 
cell study investigated the effect of various doses of cocoa extracts (containing 
different amounts of polyphenols) on the digestive enzymes: pancreatic α-amylase 
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(involved in the breakdown of starch), pancreatic lipase (hydrolyzes TG), and 
pancreatic phospholipase A2 (implicated in the digestion of phospholipids), which 
were isolated from a porcine pancreas. Results showed that cocoa extracts inhibit the 
activity of these enzymes in a dose-dependent manner. These studies suggest that 
cocoa polyphenols may interfere with the breakdown and absorption of 
carbohydrates and lipids, thus providing one of the mechanisms by which cocoa and 
DC may reduce obesity. These findings suggest that cocoa/DC might act as anti-
obesity agents such as Orlistat by targeting digestive enzymes, and decreasing the 
absorption of macronutrients (carbohydrates and lipids) (Gu et al. 2011). Yet, the 
optimal doses supposed to induce this effect in humans remain undetermined. 
 
Human studies 
Human studies are still unclear on the relationship between cocoa/DC and obesity. 
Regarding the effects of DC on satiety, a study demonstrated that the ingestion of 
30g of dark chocolate (containing 85% of cocoa) by 12 normal weight healthy 
females increased satiety and decreased hunger, which was verified by scoring 
appetite on a VAS (visual analogue scale) at different intervals, and up to one hour 
after consuming the chocolate (P<0.01). However, there was no control group in this 
study, and no significant change in the blood satiety hormone levels CCK 
(cholecystokinin), ghrelin and GLP-1 compared to baseline was noted. In the second 
part of this study, females were divided into 2 groups and randomly assigned to 
either smell the same type of chocolate (experimental group), or perform no smelling 
(control group). The results showed a decrease in appetite and an inverse correlation 
between ghrelin and appetite in the experimental group (p<0.01) (Massolt et al. 
2010). Furthermore, a crossover study including 16 healthy males showed that eating 
100g of dark chocolate 2 hours before serving an “ad libithum” meal, decreased food 
and energy intake by 8% (p= 0.01), and promoted higher satiety scores (p= 0.02) 
when compared to eating the same amount of milk chocolate before the “ad 
libithum” meal on another day. However, since the amount of polyphenols in DC 
was not specified in the latter two studies, the implication of PPs in inducing satiety 
is unclear. The satiety effect might also be due to the high cocoa content in dark 
chocolate, which has an intense flavour that lessens the eating desire
 
(Sorenson and 
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Astrup 2011). Additionally, the high fat content of dark chocolate (Oliviero et al. 
2009) increases gastrointestinal transit time, and may raise the levels of satiety 
hormones (Samra 2010). However, Massolt et al. (2010) did not note a significant 
change in satiety hormones levels (like CCK and GLP-1) after DC consumption. 
Further studies are required to determine the effect of DC on satiety. 
Also, a cross-sectional study investigating the effects of chocolate consumption on 
BMI and including 1018 healthy men and women aged between 20-85 years, showed 
that with or without adjustment of confounding factors like age, sex, depression, 
saturated fatty acid, fruit, vegetable, and calorie intakes, individuals with high 
frequency of chocolate consumption had a lower BMI (p=0.01 unadjusted), but 
surprisingly a higher calorie and saturated fatty acid intake. Moreover, the amount of 
chocolate consumed was not positively or negatively correlated with BMI
 
(Golomb 
2012). Nonetheless, there was no differentiation between the consumption of DC and 
other types of chocolate, and since this study is cross-sectional, the association 
between chocolate consumption and BMI cannot be conclusive. In addition, the 
lower body weight observed in regular chocolate eaters (Golomb 2012) might not be 
due to the chocolate in particular, but to the sweet snack that reduces cravings and 
enhances diet satisfaction over the long term. This was demonstrated by a pilot study 
performed on 26 overweight and obese premenopausal women who were 
administered either a non-chocolate snack or a dark chocolate snack daily for 18 
weeks along with a reduced-calorie diet. The study showed that the two snacks were 
equally effective in helping to decrease body weight, body fat, and waist and hip 
circumferences in overweight and obese women (p <0.001), as they lower the 
probability of rebound effect upon re-introducing the food, after restricting it for a 
certain amount of time
 
(Piehowski et al. 2011). This notion was reinforced by 
research on eating behaviour, which demonstrated a marginally significant 
association between exposure to food temptations and a healthier food choice        
(p= 0.056) compared to a control state (Kroese et al. 2009), and can increase body 
weight control. Another possible explanation to the inverse correlation between 
chocolate consumption and body weight might be attributed to socio –economic 
factors, as it has been shown in a cross-sectional study that participants with a high 
socio-economic level have usually a lower body weight and a more frequent 
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chocolate consumption compared to people with low socio-economic status (p=0.01)
 
(Hodgson et al. 2008). Hence, it would be important to verify this association in 
future cross-sectional studies.  
 
In line with the effect of polyphenols on energy expenditure in mice, polyphenol 
supplementation (resveratrol + EGCG) for 3 days increased energy expenditure 
(assessed by indirect calorimetry) in 18 overweight volunteers (Most et al. 2013). In 
addition, epicatechin-rich cocoa increased mitochondrial biogenesis and oxidative 
phosphorylation in type 2 diabetic patients when administered epicatechin-rich cocoa 
(100g /day for 3 months) (Taub et al. 2012). Furthermore, the supplementation of a 
single dose of epicatechin-derived cocoa (1 mg/Kg) showed an increase in fat 
oxidation in 20 adults, which was demonstrated by a decrease in their respiratory 
quotient (Gutiérrez-Salmeán et al. 2014). These studies constitute an important 
rationale for carrying out more studies testing the effect of cocoa polyphenols on 
energy expenditure in humans. 
 
Additionally, it was documented that DC increases the availability of NO
 
(Field et al. 
2011), which enhances adipose tissue lipolysis, inhibits the synthesis of fatty acids, 
and enhances glucose and fatty acid oxidation
 
(Jobgen et al. 2006). This provides 
another mechanism for the effect of DC on obesity, and supporting a link between 
blood pressure, glucose and body weight through a NO-related mechanism. The 
association between obesity and endothelial function was supported by an animal 
study, which showed that the supplementation of diabetic Zucker rats with L-
arginine for 10 weeks increased the production of NO, and decreased weight gain in 
this group, while no changes were observed in the group administered alanine (Fu et 
al. 2005).  
 
In contrast, randomized clinical trials lasting from 2-8 weeks did not report 
significant changes in weight following the regular consumption of DC with daily 
amounts ranging from 20-50g a day, and comprising 259-2135mg of polyphenols 
(West et al. 2013; Al Moosawi et al. 2012; Nogueira et al. 2012; Njike et al. 2011; 
Al Moosawi et al. 2010; Ried et al. 2009; Allen et al. 2008; Grassi et al. 2005; 
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Engler et al. 2004). However, a recent study showed that 7 days of cocoa 
supplementation with 2000 mg of polyphenols did not significantly affect BMI but 
resulted in a decrease in waist circumference (p≤ 0.05). (Di Renzo et al. 2013). This 
is probably the only study that documented such results, which significance remains 
under question due to the short study duration and the absence of a control group. 
The fact that BMI did not significantly change in the previous studies might be due 
to the study duration, which was not sufficient to identify changes in anthropometric 
measures. Also, all the previous studies had in common the assessment of 
anthropometric measures as a part of a routine measurement and not as a primary 
outcome in studies, hence it might not have been an emphasis on replacing cocoa/DC 
by another food of similar energy. In addition, most of the participants of these 
studies were normal weight, thus it is less likely that a change in weight occurs 
following the intervention. On the other hand, consuming 25g of DC daily for 3 
months (125 mg of polyphenols) resulted a slight increase in body weight (0.8 kg)  
(p=0.03)
 
(Desch et al. 2010), a change that was not observed after the consumption 
of 6.3 g of DC containing 30 mg of polyphenols daily for 18 weeks (Taubert et al. 
2007). Further human controlled intervention studies are essential to investigate the 
effect of DC on weight. 
  
It is worth mentioning that it is not clear yet which amounts and type(s) of 
polyphenols / flavanols in cocoa/DC could decrease body weight/body fat in 
humans, as well as the mechanisms involved. In a mouse study, the administration of 
2 mg/kg/day of DC-derived epicatechin improved aerobic metabolism and fat 
oxidation (Nogueira et al. 2011). In the 10-week study by Gu et al. (2013), which 
showed a favourable effect of cocoa on reducing obesity in mice, it was suggested 
that the dose of cocoa supplementation is equivalent to a daily amount of 54g of 
cocoa powder in humans (provides around 221.4 Kcal), which contains 24.84 mg of 
epicatchin and 513 mg of polyphenols. In addition to epicatechin, a study showed 
that procyanidins exert a higher obesity counteracting effect than epicatechin when 
these flavanols were administered to obesity-induced mice for a period of 12 weeks 
(Dorenkott et al. 2014). Quercetin was also attributed anti-obesity properties by 
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inhibiting adipogenesis in preadipocytes in vitro and causing apoptosis in mature 
adipocytes (Ahn et al. 2008). 
Lastly, DC contains caffeine (Stark et al. 2006), which was previously presented as 
having a weight reducing effect (Zheng et al. 2004), thus it is important to closely 
match between the caffeine content of the control and the treatment products.  
 
In view of the inhibitory effects of cocoa polyphenols on induced-obesity in animals 
and on adipose tissue differentiation in cell studies, it could be suggested that cocoa 
polyphenols are effective in counteracting obesity. However, the non significant 
change in body weight in humans renders the investigation of the effect of cocoa 
polyphenols in the context of a hypocaloric or normocaloric diet essential in order to 
identify the mechanism of action of these polyphenols, and whether they are only 
implicated in countering the gain in weight in individuals. Furthermore, it is 
important to determine whether the higher fat content of DC compared to cocoa can 
affect the weight counteracting properties of cocoa polyphenols, particularly that no 
animal studies have previously investigated the effect of DC on obesity. 
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Intervention        In vitro studies                               Human studies                Animal studies 
 
Product                     Cocoa                                         Dark chocolate                           Cocoa 
 
                                                                                                                                                                  
                             
                                                                                  
                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.20: Possible implications of cocoa/dark chocolate in body weight 
control 
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1.10 Proposed investigations 
The design of the proposed investigations was based on the following statements: 
 Obesity and its complications are rising worldwide (CDC 2009a). 
 Diet has been shown to have a significant impact on the prevention of obesity 
and associated chronic diseases (CDC 2009a). 
 A small reduction in risk factors for type 2 diabetes and CVD has been 
associated with a substantial decrease in the occurrence of these diseases 
(Whelton et al. 2002; Mclnnes et al. 2005). 
 Cocoa polyphenols have been largely studied for their favourable effects on risk 
factors for type 2 diabetes and CVD (Katz et al. 2011). 
 Dark chocolate, a common snack, is a polyphenol-rich food (Bravo et al. 1998).  
It was then hypothesized that a single dietary factor could exert a potential beneficial 
effect on health. Therefore, the aim of this research was to investigate the influence 
of PRDC (polyphenol-rich dark chocolate) on anthropometric, biochemical, 
nutritional and physiological markers in normal weight and overweight adults. For 
this purpose, two studies were carried out: the first study principally examined the 
effect PRDC on insulin sensitivity in normal weight and overweight adults, whereas 
the second study investigated the effect of PRDC on body weight in the adult 
overweight and obese population. A summary of the proposed studies is presented in 
table 1.9. 
1.10.1 Study I: Effect of polyphenol-rich dark chocolate on insulin sensitivity in 
normal weight and overweight adults 
1.10.1.1 Rationale for study 
There has been a considerable amount of research on the effects of polyphenols and 
dark chocolate on health, and their potential role in the modulation of risk factors for 
type 2 diabetes and CVD (Jia et al. 2010; Hooper et al. 2012; Ried et al. 2012). 
However, results are still conflicting. Thus, recognizing the potential benefits of DC 
on these risk factors is important to help the public make informed choices. 
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To our knowledge, only five human studies tested the effects of daily DC 
supplementation on insulin levels and insulin resistance/sensitivity in individuals 
with no diagnosed diabetes, hypertension and CVD (Grassi et al. 2005; Davison et 
al. 2008; Al Moosawi et al. 2012; Stote et al. 2012; Di Renzo et al. 2013). This 
limited number of studies is insufficient to identify an implication of PRDC in the 
prevention of IR and/or type 2 diabetes. As for serum lipids (TC, TG, HDL and 
LDL), few studies noted a favourable effect of PRDC on lipid profile in healthy 
individuals (Mursu et al. 2004; Baba et al. 2007b), while others (Mathur et al. 2002; 
Grassi et al. 2005) mostly showed no significant effect. Additionally, oxidative stress 
was linked to the occurrence of many chronic diseases (Urquiaga and Leighton 
2000), and the limited studies showed an inverse association between PRDC 
consumption and oxidised LDL (Wan et al. 2001; Lettieri-Barbato et al. 2012). 
Hence, further studies are needed to elucidate this effect. Also, CVD were described 
as an inflammatory condition (Shah and Prediman 2009), and correlational studies 
found an inverse association between flavonoid/DC consumption and inflammation 
(Chun et al. 2008; Gisueppe et al. 2008). Thus, more intervention studies are needed 
particularly because of the discrepancy in the results between correlational and 
intervention studies (Intervention studies mostly showed no significant effect of DC 
on inflammation (Mathur et al. 2002; Allen et al. 2008; Nogueira et al. 2012). 
Testing hs-CRP levels was considered due to the fact that it is an important marker 
of inflammation, and a strong predictor of coronary artery disease (Jousilahti et al. 
2001). Furthermore, few studies reported a decrease in blood pressure after the 
consumption of DC in normotensive individuals (Al Faris 2008; Al Moosawi et al. 
2010), while many others showed no significant effects (Murphy et al. 2003; Engler 
et al. 2004).  
Moreover, cortisol was shown to be implicated in IR, and the enzyme 11β-HSD 1 
was responsible for increasing cortisol production and exacerbating obesity 
complications (Stulnig and Waldhausl 2004). As polyphenols were previously 
reported to lower cortisol excretion (Martin et al. 2009) and the activity of           
11β-HSD 1 (Hindzpeter et al. 2014), measuring cortisol levels and the activity of 
11β-HSD 1 (by the means of cortisol/cortisone ratio) would identify any potential 
decrease in this enzyme activity following the consumption of DC rich in 
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polyphenols. This is important because very few studies have been conducted on 
cocoa polyphenols and cortisol. 
In addition, with the emerging animal and in vitro studies on cocoa/DC and their 
weight lowering properties (Matsui et al. 2005; Gu et al. 2012), it was aimed to test 
the effect of 4 weeks of PRDC supplementation on body weight and waist 
circumference in the context of a normocaloric diet. 
 
In relation to baseline BMI status, it was shown in a previous study that normal 
weight and overweight individuals might respond differently to DC supplementation 
(Al Moosawi et al. 2012). Therefore, this study aimed to identify any potential 
difference in the response to intervention based on BMI status. This would be 
beneficial in possibly including this snack in future dietary strategies that aim to 
prevent further complications in the overweight and obese population. This study 
aims to investigate and possibly compare the results to the study held by Al Moosawi 
et al. (2012), in which the same type and daily amount of DC was used, and a 
lowering effect on HOMA-IR and blood pressure was only noted in overweight and 
obese individuals following PRDC consumption. 
Lastly, recognizing the importance of prevention in reducing the prevalence of 
chronic conditions and improving the health and quality of life of nations (CDC 
2011) was an important rationale for including participants with no hypertension, 
type 2 diabetes and CVD. Hence, this study might help in developing prevention 
strategies for reducing the incidence of these diseases. 
 
1.10.1.2 Aims and Objectives 
The aim of this study was to assess the effect of PRDC on insulin sensitivity in 
normal weight and overweight adults. 
 
Objectives 
 To determine the effect of PRDC consumption on the following outcomes: 
              -Primary outcome: Insulin sensitivity (determined by HOMA-IR and 
               QUICKI)                                                                                
 103 | P a g e  
 
              -Secondary outcomes: 
a. Glucose levels 
b.Lipid profile (serum TC, HDL, LDL and TG levels) 
c. Oxidised LDL levels 
d.Hs-CRP levels 
e. Blood Pressure 
f. BMI and Waist circumference 
g.Salivary cortisol levels 
h.11 β-HSD1 enzyme activity (salivary cortisol/cortisone ratio) 
 To determine the impact of BMI (BMI between 18-24.9 kg/m2 and over 25 
kg/m
2
) on the outcomes following PRDC consumption.  
1.10.1.3 Hypothesis 
Regular consumption of PRDC might improve insulin sensitivity and LDL oxidation 
in the normal weight and overweight adult population. 
 
1.10.2 Study 2: Effect of polyphenol-rich dark chocolate on body weight in 
overweight and obese adults 
1.10.2.1 Rationale for study 
As little or no studies in the literature previously investigated the effect of 12 weeks 
of PRDC on body weight and composition, testing the feasibility of the protocol by 
doing a small scale study was crucial, as suggested by Arnold et al. (2009). This was 
mainly to provide preliminary results for a larger study, and information about the 
validity of the proposed study design (including frequency of appointments) and the 
suggested methods (including questionnaires (food frequency questionnaire, physical 
activity questionnaire) and inclusion and exclusion criteria) (Thabane et al. 2010). 
Finally, results of this study were intended to be used to perform sample size 
calculations for a large trial.  
 
The investigation of the effect of PRDC rich in polyphenols on body weight was 
based on: 1) Polyphenols, and particularly cocoa polyphenols, were recently 
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involved in the modification of molecular and physiological pathways implicated in 
adiposity and energy metabolism (Matsui et al. 2005; Yamashita et al. 2013). 2) DC 
is a high source of polyphenols (McShea et al. 2008). 3) Diet and exercise were 
shown to be effective in the treatment and prevention of obesity
 
(Glanville et al. 
1997; NHS 2012b). However, the lack of willpower and the failure to maintain the 
weight loss for a long term (Foster et al. 2005; Weiss et al. 2007) rendered these 
strategies sometimes inefficient in treating or preventing obesity. Therefore, 
complementary approaches might exert a significant implication in weight 
management. 4) Even a modest loss in weight (5-10 %) was associated with a 
decrease in risk factors for diabetes type 2 and CVD (Resnick et al. 2000; Wing et al. 
2011). Consequently, the identification of weight lowering properties of PRDC could 
possibly help in decreasing risk factors for chronic diseases. 
  
The effect of cocoa polyphenols on counteracting obesity was previously reported by 
several animal studies which documented an inhibitory effect of cocoa on fatty acid 
gene synthesis (Matsui et al. 2005; Gu et al. 2013; Min et al. 2013). In addition, in 
vitro studies reported an effect of cocoa extracts on the inhibition of digestive 
enzymes involved in the hydrolysis of carbohydrates and lipids (Gu et al. 2011). 
These effects have not been yet evidenced by human intervention studies. Also, an 
epidemiological study found an inverse association between chocolate consumption 
and BMI in 1018 adults with no known diseases (Golomb 2012), and highlighted the 
need for randomized trials to assess the relationship between cocoa polyphenols and 
body weight. As for waist circumference, it was shown to be decreased after one 
week of daily DC supplementation (–1.24 ± 1.45 cm, p ≤0.05) in 15 adult women 
(Di Renzo et al. 2013). Hence, it was important to test the long term effect of PRDC 
on WC. 
 
Furthermore, an increase in basic metabolic rate (BMR) (by 42 Kcal/22h, p< 0.05) 
was noted in mice fed flavanol-derived cocoa for 2 weeks  (Osakabe 2013), while 
another study showed an increase in lean muscle mass and oxidative phosphorylation 
in mice administered epicatechin-derived cocoa  (Nogueira et al. 2011). Hence, 
estimating energy expenditure and body composition might provide an explanation 
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for any potential changes in anthropometric measures and energy expenditure 
resulting from an increase in lean muscle mass. 
 
This study aimed to investigate the effect of DC supplementation on body weight 
when incorporated into a regular diet, and not as a part of a reduced Calorie diet or in 
addition to exercise. This intended to identify whether the lowering effect on body 
weight- if occurred- is due to the consumption of a sweet snack which enhanced diet 
satisfaction (Piehowski et al. 2011) (in this case, weight might decrease in both 
placebo and PRDC groups), or to the implication of polyphenols, but not to the effect 
of a hypocaloric diet. Thus, a polyphenol-rich snack was compared against a low-
polyphenol snack to test if PRDC produces unique effects when incorporated into a 
normocaloric diet. This might provide evidence for testing the implication of PRDC 
in weight loss regimens.  
Furthermore, the study of Al Mossawi et al. (2012) showed an increase in BMI 
following placebo DC consumption (which had a similar macronutrient composition 
to the placebo DC used in this study). Therefore, it was important to test the 
detrimental effect of a low-polyphenol chocolate on body weight when administered 
for a long term (12 weeks). 
 
Since oxidative stress was related to the occurrence of many diseases such as 
hypertension and CVD (Urquiaga and Leighton 2000), identifying the antioxidant 
properties of DC was considered. This was examined by analysing total polyphenols 
in the urine (through the Folin-Ciocalteu method), and total antioxidant capacity 
(through the ferric-reducing antioxidant power (FRAP) method). The latter two 
parameters were also used as biomarkers of compliance to intervention. 
As for glucocorticoid metabolism, cortisol was related to obesity complications, and 
was reported to increase food and energy intake (Dallman et al. 2004), and to induce 
IR via inducing gluconeogenesis. In addition, the enzyme 11β-HSD 1 is highly 
expressed in the adipose tissue of obese individuals, and is responsible for increasing 
cortisol production and exacerbating obesity complications (Stulnig and Waldhausl 
2004). As polyphenols were reported to lower cortisol (Martin et al. 2009) and 11β-
HSD 1 activity (Hindzpeter et al. 2014), measuring cortisol levels and the activity of 
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11β-HSD 1 in the urine was considered to identify any significant change in these 
parameters following the consumption of DC rich in polyphenols.  
 
Furthermore, the supplementation of a single dose of DC was linked to a decrease in 
appetite (Sorenson and Astrup 2011). Hence, obtaining qualitative data on the long 
term changes in appetite will provide rationale for studies to test the effect of PRDC 
on satiety hormones (such as cholecystokinin and PYY). Lastly, the concept of 
whether exposure to food temptations (sweet snack) results in a healthier food 
(Kroese et al. 2009) was tested through looking at changes in the intake of sugar and 
saturated fatty acids throughout the intervention. 
 
This study also aimed to look at the practicality of the daily long term (12 weeks) 
consumption of 20g of DC daily. As some complaints regarding chocolate 
consumption in studies lasting from 2-8 weeks were noted (Ried et al. 2012), it was 
important to test the long term side effects of chocolate consumption on a small 
number of participants. This might help making suitable recommendations for future 
large studies. 
1.10.2.2 Aims and Objectives 
The overall aim of this study was to determine the effect of PRDC on body weight 
and overweight and obese adults.  
a. Scientific objectives 
     a.1. To determine the effect of long term PRDC supplementation on the 
             following outcomes:     
               
             Primary outcome: 
 Body Weight  
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Secondary outcomes:  
 Body Fat percentage 
 Waist circumference  
 Cortisol levels in the urine 
 Activity of 11 β-HSD1 (urinary cortisol-to-cortisone ratio) 
 Basic metabolic rate (BMR) 
 Lean body mass (LBM) 
 Total polyphenols in the urine (determined via Folin-Ciocalteu 
method)     
 Total antioxidant capacity in the urine (determined via FRAP 
assay) 
 
      a.2. To determine the effect of placebo DC supplementation on the 
             primary and secondary outcomes 
 
b. Feasibility objectives 
    b.1. To determine the practicability of the study procedures by assessing: 
o Study design 
o Drop out rates 
o Compliance rates 
o Data collection tools and questionnaires 
o Side effects of placebo / treatment 
                b.2. To determine the sample size needed to conduct a large trial based on 
the primary outcome measure.  
 
1.10.2.3 Hypothesis 
Long term consumption of dark chocolate (12 weeks) may reduce body weight in the 
adult overweight and obese population 
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Table 1.9: Summary of the proposed studies 
 Arms Design Duration Primary outcome 
Study I Two arms : 
 DC rich in polyphenols (500 
mg) 
 DC with low amount of 
polyphenols (placebo) 
Parallel 
placebo- 
controlled 
Trial 
4 weeks Insulin sensitivity 
(determined by 
HOMA-IR and 
QUICKI) 
Study II Two arms : 
 DC rich in polyphenols (500 
mg) 
 DC with low amount of 
polyphenols (placebo) 
Parallel 
placebo- 
controlled 
trial 
16 weeks Body weight 
(BMI) 
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 CHAPTER 2: GENERAL MATERIALS AND METHODS 
2.1 Ethical approval 
The ethical approval for the two studies was granted by Queen Margaret University 
ethics committee. The studies were performed according to the declaration of 
Helsinki (WMA 2013). Participants were provided a written information sheet, and 
were asked to sign a written consent form before taking part. The first and second 
studies were registered on clinicaltrials.gov as NCT01749020 and NCT01749852, 
respectively. Handling of data was managed according to the Data Protection Act 
(1998) (Legislation 1998).  
2.2 Nutritional and chemical composition of the experimental dark chocolate  
A summary of the nutritional and chemical composition of the placebo DC and the 
PRDC used in both research studies is presented in Table 2.1. The products were 
provided free of charge by Barry-Callebaut Company, Belgium. The amount of 20g 
is the daily portion that was given to participants in both trials. PRDC (500 mg of 
polyphenols) was produced via a method called “Acticoa” - trademark of Barry 
Callebaut-, which aims to naturally preserve polyphenols in different steps of the 
manufacturing chain (Barry Callebaut 2010). The two types of chocolate looked 
identical, and contained 63.5% of cocoa solids. In order to avoid confounding 
factors, the two dark chocolate types (placebo and control) were fairly matched for 
macronutrient and micronutrient content, and contained similar amounts of caffeine 
and theobromine. Thus, they only differed by polyphenol content.  
 
To validate the data provided by the company, the analysis of flavanols for the two 
types of chocolate was also performed at the “James Hutton institute”, Dundee (Dr 
Gordon Mcdougall). The LC-MS (Liquid chromatography–mass spectrometry) 
method was carried out to determine the total flavanol content and flavanol fractions 
in both chocolate types. The content of theobromine and caffeine was also 
determined using LCMS.  
For this method, extraction of samples was required. The chocolate samples were 
stored at -20
o
C, then grounded to a powder in an electric coffee mill in a cold room 
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(< 5
o
 C). Three samples of 0.5g of each of the two types of chocolate were 
subsequently weighed into labelled tubes. These samples were then extracted with     
5 ml of 50 % acetonitrile/ultra pure water containing 0.2 % (v/v) formic acid, vortex 
mixed (3 times for 15 seconds each, full speed), and sonicated for 5 minutes in ice-
cold water. After centrifugation (10 mins, 4000 rpm, 5 
o
C), the supernatants were 
removed to fresh tubes and the pellets re-extracted with further 7.5 ml of 50 % 
acetonitrile/ultra pure water containing 0.2 % (v/v) formic acid. Samples (1 ml) were 
then dried in a speed vac by rotary evaporation, resuspended in 5 % acetonitrile 
before being subjected to the LC-MS method. 
An LCQ-DECA system, comprising a Surveyor auto-sampler, a pump, a photo diode 
array detector (PDAD) and a Thermo Finnigan mass spectrometer ion trap was used 
for LC-MS. Solvent A was ultra-pure water containing 0.1% formic acid (v/v), and 
solvent B was acetonitrile containing 0.1 % formic acid (v/v). 20 μl of each sample 
were eluted on a gradient of: t= 0-5mins, 0% B; 5-35 minutes, 0–40 % B, followed 
by a wash to 100% B with the gradient returning to the starting conditions at 50 
minutes. A C18 column (Synergi HydroC18 with polar end capping, 2 mm X 150 
mm, Phenomenex Ltd.) was used at 200μl/min, and the three discrete channels were 
scanned by the PDAD (280, 365 and 520 nm). An electrospray ionisation interface 
was fitted to the LCQ-DECA LC–MS, and the samples were analysed in positive and 
negative modes. There were 2 scan events: full scan analysis, followed by data 
dependent MS2 of the most intense ions using collision energies (source voltage) of 
35 % in wideband activation mode. Catechin and cyanidin-3-O-glucoside were used 
to tune the MS detector for negative and positive modes respectively. Components 
were identified using literature data (Gu et al. 2006), and their content was assessed 
against epicatechin. The differences in the amounts of flavanols and methylxanthines 
between placebo DC and PRDC are illustrated in Figure 2.1, and the quantification 
of the amount of flavanols is presented in Table 2.2. The results fairly matched with 
the company’s data and confirmed the elimination of the possible confounding 
factors of caffeine and theobromine.  
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Table 2.1: Nutritional and chemical composition of the experimental dark 
chocolate 
      Components (per 20g daily portion) PRDC Placebo DC 
Energy (kcal)  102 102 
Total fat (g)  7.34 7.34 
Carbohydrates (g)  7.44 7.44 
Protein (g)  1.34 1.34 
Total flavanols (mg)  400 < 60 
Epicatechin (mg) 85 12 
Catechin (mg) 15 2 
Caffeine (mg)  15 15 
Theobromine (mg)  150 150 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate. Data obtained from Barry-
Callebaut company, Belgium. Total flavanols, epicatechin and catechin were analysed via 
LCMS method (Liquid chromatography–mass spectrometry). The amount of total 
polyphenols in the PRDC (500 mg) was assessed by Folin-Ciocalteu method, as provided by 
the company.The amount of 20g is the daily amount provided to participants in both trials.  
 
 
Figure 2.1: Differences in polyphenol and methylxanthine contents between 
placebo DC and PRDC 
Caff Asp: N-caffeoyl-l-aspartate, EC: Epicatechin. DC (dark chocolate) represents the 
PRDC (Polyphenol-rich dark chocolate) and placebo represents the placebo DC.  Samples 
were analysed at James Hutton institute via LCMS (Liquid chromatography–mass 
spectrometry) and quantified by peak area. EC2a, EC2b, EC3, and EC4 represent the 
number of EC units– EC2a and b are epicatechin isomers. 
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Table 2.2: Quantification of flavanols in the placebo DC and the PRDC   
 Component  Content (mg of epicatehin equivalents/20g portion) 
  PLACEBO PRDC ±SE ±SE 
Catechin 7.04 34.67 0.17 0.42 
EC2a 14.10 76.87 0.34 0.94 
EC2b 5.56 21.61 0.12 0.26 
Epicatechin 21.35 107.27 0.54 1.31 
EC3 7.04 37.57 0.17 0.46 
EC4 7.01 47.52 0.20 0.58 
EC5 and greater* 5.43 69.13 0.15 0.09 
TOTAL mg of 
flavanols /20g portion 
67.53 394.64 0.24 0.58 
*The estimation of the contribution of the larger components might be inexact. EC: 
epicatechin, PRDC: Polyphenol-rich dark chocolate. Samples were analysed at James 
Hutton institute via LCMS (Liquid chromatography–mass spectrometry). EC2a, EC2b, EC3, 
and EC4 represent the number of epicatechin units. EC2a and b are epicatechin isomers. 
The values are averages of three determinations and are expressed in mg of epicatehin 
equivalents ± standard error (SE). The amount is per 20g portion. 
 
2.3 STUDY I 
2.3.1 Study population 
2.3.1.1 Recruitment and selection of participants 
Volunteers were recruited via several means: QMU University Moderator (emails 
sent to all staff and students at QMU), flyers and posters in community and sports 
centres in Edinburgh and Musselburgh, hospitals in Edinburgh, colleges and 
universities in Edinburgh, as well as via word-of-mouth.  
 
Inclusion and exclusion criteria 
Participants were recruited and studied with no restriction to race or socioeconomic 
status according to the following criteria:  
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Inclusion criteria 
-Adults with no history of hypertension, type 2 diabetes or CVD. 
-BMI between “18-24.9 kg/m2” and BMI between “25-34.9 kg/m2”. 
- Males and Females  
-Age: 18-65 years 
 
Exclusion criteria 
-Participants with CVD, hypertension or diabetes 
-Participants taking medications that affect insulin, glucose, lipid, hs-CRP and/or 
blood pressure levels 
-Participants taking dietary supplements containing high doses of antioxidants  
-Postmenopausal women taking HRT (Hormone Replacement Therapy)  
-Participants who recently participated or are currently on a weight management 
program 
-Smokers and heavy alcohol drinkers (defined as more than 15 drinks/week for men 
and more than 8 drinks for women (CDC 2014)). 
-Participants with regular consumption of cocoa or DC (> 1 serving/week) (Taubert 
et al. 2007). 
 
2.3.2 Determination of sample size 
The proposed analysis is an ANCOVA. Therefore, for sample size estimation, the 
calculation followed that of Borm et al. (1997) where we first calculate the sample 
required for an independent t-test and then modify this accordingly; recognising that 
given a pre-post design, there is less error. The assumed pre-post correlation required 
for the second part of the calculation was set at 0.6, which seems a reasonable 
assumption. Therefore, a sample size of 45 in each group with 80% power and using 
a two group t-test with a 0.05 two-sided significance level was needed to detect an 
effect size of 0.6. Adjusting for the non-independence of the pre-post calculations 
with an assumed pre – post correlation of 0.6, the number required for this given 
effect size was reduced to 30 per group, or 60 in total. With an estimated attrition of 
approximately 15 to 20%, the aim was to recruit 74 persons in total. Although the 
 114 | P a g e  
 
original purpose was to determine the sample size based on the results of the study 
undertaken by Al Moosawi et al. (2012), which showed that PRDC containing 500 
mg of polyphenols reduces HOMA-IR in female adults, this was not possible due to 
the fact that all data were stratified between normal weight and overweight 
participants. However, the principal objective of this study was to determine the 
effect of PRDC on HOMA-IR in the general population. Stratifying participants 
according to weight status was indeed a secondary outcome. In addition, the original 
data from the latter study was 1discarded upon completion of the study due to ethical 
considerations. Hence, the use of these data was not possible at this stage, and the 
determination of sample size was carried out via the above method.  
2.3.3 Study design 
A feasibility study (including 6 participants) was first carried out to ensure the 
possibility of carrying out the intervention with the current experimental design. All 
measurements were taken, and the intervention lasted for 4 weeks. The data collected 
from the six participants were then added to the main study.  
The main study is a randomized single-blinded placebo controlled pre-post 
intervention parallel study with 2 arms where participants received one of the 2 
different types of DC according to the following:  
 
Type A: Placebo DC (low in polyphenols) 
Type B: DC rich in polyphenols (500 mg)   
 
Randomization was implemented using sealed envelopes based on the protocol 
described by Doig and Simpson (2005). Participants were stratified on one factor 
(BMI). Seventy-four standard-sized sheets were marked by either P (Placebo)-37 
sheets or D (PRDC)-37 sheets, coupled with O: Overweight or N: Normal weight. 
Sheets were labelled by codes (PN1-PN19; PO1-PO18; DN1-DN19 and DO1-
DO18). The codes PO1-PO18 and DO1-DO18 were placed in the “overweight 
strata” container, and the codes PN1-PN19 and DN1-DN19 were placed in the 
“normal weight strata” container. The sheets were inserted into unlabelled envelopes 
and sealed. Then, the researcher chose an envelope from the overweight strata 
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container if the participant was overweight, or an envelope from the normal weight 
strata container if the participant was normal weight.  
Participants were provided an information sheet and asked to sign a consent form 
(Appendix 1) before the beginning of the study. Volunteers were then requested to 
visit Queen Margaret University clinical Lab, where the study was held. Each of the 
two appointments lasted for 25-30 minutes (View Table 2.3 for the timeline of the 
appointment). Participants randomly received 20g of DC daily (Type A or B) for a 
period of 4 weeks. Blood and saliva samples, blood pressure and anthropometric 
measurements were taken before the start and at the end of the intervention (after 4 
weeks). A general questionnaire (Appendix 2) and questionnaires related to physical 
activity (Appendix 3) and acceptability (Appendix 4) were requested to be filled. 
Participants were asked to maintain their usual diet and physical activity throughout 
the intervention period. A diet adjustment was also considered so that DC substitutes 
another food of similar energy. The researcher helped in providing dietary advice for 
participants to help them achieve this goal. This happened by asking participants 
about the types of snacks usually consumed. Suggestions for replacing a part of the 
snack or the overall snack by the experimental DC were then provided. To monitor 
changes in dietary intake, participants were asked to fill a 3-day diet diary (Appendix 
5) at baseline and during the third week (View Figure 2.2 on study design) (The 
details of collected data are presented in section 3.3.5). 
 
Before attending the appointment, participants were asked to: 
  -Be on a fasting state (which is defined as the restriction from eating or drinking 
any liquids for a period of 8 hours (Diabetes UK 2013). 
  -Avoid drinking alcohol for the past 24 hours 
  -Consume the last dose of DC at least 12 hours before the second appointment 
  -Refrain from doing a high level of physical activity at least 12 hours prior to the 
visit  
  -Avoid or reduce eating high quantities of foods rich in flavonoids (>4 mg/100g of 
selected foods, knowing that a medium content of flavonoids in foods is between 4-
9.9 mg/100g and a high content constitutes more than 10mg/100g of selected foods 
(O’byrne et al. 2002)) one week before the start (run-in phase) and subsequently for 
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the duration of the study. Examples include red wine, blackberry, blueberries, tea as 
well as dark chocolate and cocoa products (View Appendix 6 for the list of foods 
rich in flavonoids that was provided to participants). 
 
Table 2.3: Timeline for Study I appointments 
 Minutes 
Introduction 3 
Anthropometric measures 5 
Blood Pressure 11 
Blood withdrawal 3-8 
Questions 3 
Total 25-30 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Anthropometric 
measures 
(weight, height, 
waist 
circumference) 
 
Blood Pressure 
 
Saliva samples 
collection 
 
Blood sample 
collection 
 
General 
Questionnaire 
 
3-day diet 
diary 
collection 
 
3-day diet  
diary 
collection  
 
Run-in phase Week 0 Week 3 Week 4 
Anthropometric 
measures 
(weight, height, 
waist 
circumference) 
 
Blood Pressure 
 
Saliva samples 
collection 
 
Blood sample 
collection 
 
Physical 
activity 
questionnaire 
 
Acceptability 
questionnaire 
 
Figure 2.2: Study I design 
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2.3.4 Justification for the chosen methods 
2.3.4.1 Study duration  
The choice of the study duration was primarily based on the previous study held by 
Al Moosawi et al (2012), which reported a significant decrease in HOMA-IR 
following four weeks of daily consumption of PRDC (500 mg of polyphenols). In 
addition, Di Renzo et al. (2013) and Stote et al. (2007) did not note a decrease in 
HOMA-IR after 5-7 days of PRDC supplementation with doses of polyphenols 
varying between 22-900 mg of flavanols. It was therefore suggested that a longer 
duration is needed to induce an effect on insulin metabolism. Although the study of 
Grassi et al. (2005) showed an improvement in HOMA-IR after 2 weeks of daily 
dark chocolate consumption (with 500 mg of polyphenols), testing the effect of 
PRDC on insulin responses over a longer period was aimed. This was particularly 
important to identify the possibility of an adaptation effect to the quantity of 
polyphenols over time, which was previously suggested (Al Moosawi et al. 2012). 
Additionally, it was reported that an adequate time to detect potential changes in 
different markers is needed. For instance, serum lipid levels become stable after a 3-
week dietary intervention. Consequently, a 4-week study might be suitable to 
increase reliability of end point measurements (Monsen and Van Horn 2007). 
 
2.3.4.2 Study design 
The choice of a parallel design was based on the advantages of this design compared 
to a crossover design. In parallel studies, participants are allocated one study 
treatment for the whole period of study, whereas in crossover trials, participants are 
assigned all the treatments of the study. Several factors may affect the choice of 
study design (like the objective and duration of the study, the length of washout 
periods, the time needed to induce an effect, and the number of treatments) (Monsen 
and Van Horn 2007). Parallel studies have the potential advantage of convenience 
due to the shorter overall study duration, which results in a lower dropout rate and a 
higher adherence to study protocol compared to crossover trials. In addition, the 
analysis is more straightforward, and the precision of this design can be enhanced by 
the use of statistical adjustments for baseline measurements (Bailar and Loaglin 
 118 | P a g e  
 
2009). Furthermore, a parallel design allows the comparison between different dose 
levels of a treatment in one study (Richens 2001). Moreover, the absence of a carry-
over effect and an order effect (defined by an influence of the first treatment on the 
response to the second treatment (Richens 2001)) are the main advantages of parallel 
trials compared to crossover trials (Monsen and Van Horn 2007). Nonetheless, it is 
important to be aware of the disadvantages of a parallel design, like the need for a 
high number of participants (Bailar and Loaglin 2009), and the increase in 
interparticipant variation (since the participant does not serve as his own control) 
(Monsen and Van Horn 2007). These limitations constitute the reasons why 
crossover studies can be considered more powerful than parallel studies (Bailar and 
Loaglin 2009). However, although both parallel and crossover trials might be subject 
to expectation bias resulting in a positive response to placebo (placebo effect) or a 
negative response to treatment (nocebo effect), there is some evidence to suggest that 
due to a carry-over effect, crossover studies are unblinded and therefore, result in a 
lower placebo effect and a higher treatment effect than parallel trials (Feys et al. 
2012). 
Therefore, the decision of adopting a parallel design was mainly based on the 
absence of carry-over and order effects. Additionally, the possible length of the 
washout period required to minimize the carry-over effect of polyphenols was 
estimated to be around 2 weeks in some studies (Grassi et al. 2005; Al Moosawi et 
al. 2010; De Bock 2013). This duration, along with the study period (4 weeks) made 
it more convenient to opt for a parallel design in order to maintain participants’ 
commitment and decrease attrition rates (Dash et al. 2012). 
 
2.3.4.3 Quantity and polyphenol content of DC 
The quantity of DC (20g) was selected as it is a small quantity, commonly 
considered less than a serving of dark chocolate (a serving of DC is considered to be 
around 32g (ADA 2007), or between 25-50g (Lewis et al. 2010)), and providing 
around 102 Kcal. This amount of energy contributes to no more than 6% of the daily 
women’s intake and 4% of the daily men’s intake (CDC 2011b). In addition, a recent 
study aiming to quantify a moderate daily candy intake, showed that 50-100 calories 
per day constitute a reasonable intake of candy. This amount is based on the 
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recommendations of health authorities for fat, sugar and calorie intake, and varies 
depending on energy needs (Hornick et al. 2014). Consequently, the energy content 
in the experimental DC study was not supposed to cause major increases in daily 
energy intake in both genders.  
The choice of the dose of polyphenols (500 mg) was based on its ability to improve 
insulin sensitivity in the studies of Grassi et al. (2005) and Al Moosawi et al. (2012). 
Also, many studies discussed the threshold effect of 500 mg of polyphenols (Al 
Moosawi et al. 2010; Shrime et al. 2011; Tokede et al. 2011), as well as the potential 
side effects (such as gastrointestinal discomfort and nausea (Chow et al. 2003; Mead 
2007)) and the decrease in palatability (Al Moosawi et al. 2010) resulting from a 
higher polyphenol dose. 
 
2.3.5 Data collection and processing 
2.3.5.1 Questionnaires 
a. General Questionnaire 
Participants answered a brief questionnaire which covered information on social 
characteristics, lifestyle habits and medical history (Appendix 2). This was mainly 
designed to understand the characteristics of the population, and to ensure all 
participants complied with the inclusion criteria, explained in detail in the 
information sheet. 
b. Physical activity questionnaire 
This short questionnaire was filled twice during the intervention to identify whether 
participants maintained the same level of physical activity during the study period 
(Appendix 3). The baseline physical activity questions were included in the general 
questionnaire and filled prior the first appointment. Hours of physical activity were 
then transformed into MET (Metabolic equivalent task) units/week. MET is defined 
as the ratio of the metabolic rate of the exercise to the resting metabolic rate. It is 
postulated that one MET corresponds to the energy when seated at rest. MET is 
mainly calculated to evaluate the actual physical activity based on its energy 
expenditure, particularly that individuals engage in different types of exercise 
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activities throughout the week (USC 2003). Therefore, assigning a value for each 
type of physical activity based on its intensity will allow the comparison between 
physical activity levels of participants. Each hour of reported physical activity was 
quantified into MET per hour based on the type of activity (Table 2.4), and the sum 
of weekly hours was considered to determine METs/week.  
 
Table 2.4: Metabolic equivalent tasks for common physical activities  
Activity MET/hour 
Walking                                              Slowly (1.86 mph) 1.8 
                                                            Briskly (3.11 mph) 3.2  
                                                            Briskly (4.4 mph) 5.3 
Jogging                                                             5.6 mph 8.8 
                                                                          6.8 mph 11.2 
Running                                                            8 mph 12.9  
                                                                          9.32 mph 14.6 
Badminton 3 – 4 
Aerobic dancing                                                    Low 3.9 
Medium 6.0 
Ballet dancing 6 – 8 
Yoga 3.2 
Basketball 11.1 
Bicycling 4.8  
Football 6-7 
Volleyball 6 
Hiking 6 
Horse riding 3.2 - 8.6 
Weightlifting 3 – 7 
Rugby 12.6 
Tennis 6 – 8 
Swimming 6.8 
(Adapted from Jette et al. 1990) 
MET: Metabolic equivalent task; Mph: miles per hour.  MET values are per hour of physical 
activity 
 
c. Acceptability questionnaire  
Acceptability questionnaire was designed to obtain qualitative data from participants 
on whether they found it acceptable to consume the dose of dark chocolate daily, and 
if they will keep consuming the chocolate frequently following the intervention 
(Appendix 4). 
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2.3.5.2 Anthropometry 
Anthropometric measurements were taken at baseline and week 4, and included 
weight, height, and waist circumference. 
 
a. Height  
Height was measured with person bare foot using a stadiometer. Participants were 
asked to have minimal clothes so that the posture is clear, and to stand in a straight 
position, the head being in the Frankfurt plane, and the palms facing the thighs. 
Volunteers were requested to have their knees straight and their feet together, with 
their shoulder blades, heels and buttocks vertically in contact with the stadiometer 
(Gibson 2005) (Figure 2.3). Measurements were taken twice and repeated if they 
differ by more than 0.5 cm (Daniels et al. 2000). 
 
 
Figure 2.3: Position of the body during height measurement 
(CDC 1988)  
 
 122 | P a g e  
 
b. Weight  
Weight was measured in the morning at fasting using an electronic scale (Tanita BF-
559, Body Fat Monitor/Scale) positioned on a flat surface. Participants were asked to 
stand on the scale barefoot and with light clothing (Gibson 2005). Measurements 
were taken twice and repeated a third time if the first 2 measurements differed by 
more 0.3 Kg (Daniels et al. 2000). 
The body mass index (BMI) was then calculated: 
                                  Weight  
Body Mass Index = 
       (Kg/ m
2
)              (Height)
2
  
 
Also known as Quetelet index, BMI is commonly used to determine weight status in 
adults (Gibson 2005), and its relationship with the occurrence of diseases (Table 
2.5). BMI, CVD risk factors and CVD increase in a linear manner (Lamon-Fava et 
al. 1996). The advantages and drawbacks of BMI have been discussed in section 
1.1.2.1.   
 
Table 2.5: Relationship between BMI and disease risk  
Classification BMI Category (kg/m
2
) Risk of developing health problems 
Underweight < 18.5 Increased 
Normal Weight 18.5 - 24.9 Least 
Overweight 25.0 - 29.9 Increased 
Obese class I 30.0 - 34.9 High 
Obese class II 35.0 - 39.9 Very high 
Obese class III >= 40.0 Extremely high 
(Gibson 2005) 
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c. Waist circumference 
Waist circumference was measured via a metal measuring tape, and was placed 
around the waist at the middle point between the lowest rib and the top of the hip 
bone. The tape was snug (without compressing the skin) and parallel to the floor 
(WHO 2008). For some obese participants with whom it was difficult to find the 
waist narrowing, the measurement was taken at the umbilical level, as described by 
Lohman et al. (1988). 
Participants were asked to stand with arms at the sides, and to put their feet together.  
Measurements were taken twice after normal expiration, based on the protocol 
described in the WHO report, and repeated if there is a difference of more than 1cm 
between the 2 values (WHO 2008).  
WC is an important predictor of disease risk, and is strongly correlated to obesity-
related complications (Rexrode et a. 1998). Studies have shown that BMI and WC 
are two independent predictors of mortality risk, and they exert separate effects on 
the complications of morbidity (Janssen et al. 2004). Hence, for a similar BMI, 
individuals with a higher WC are at higher risk of diseases. In addition, individuals 
with a normal BMI and a high WC are at increased disease risk (NHLBI 2000). 
Measuring BMI and WC in this study allowed the analysis of a linear relationship 
between the two parameters. Also, WC measurement helped in overcoming the 
drawbacks of BMI in assessing all individuals with a high risk of metabolic 
complications.  
 
Although some studies discussed the importance of waist-to-hip ratio (WHR) in 
predicting cardiovascular risk (De Koning et al. 2007) and type 2 diabetes risk (Qiao 
and Nyamdorj 2009), other studies showed that WC is more correlated with 
abdominal fat and total fat than WHR (Daniels et al. 2000). Also, WC is more 
associated with visceral obesity-associated complications than WHR, the latter being 
recognized as the pear-shaped obesity type (Cheng 2005). This made WC a better 
choice in research settings, and the sole instrument for measuring waist in this study. 
The cut-offs for WC were first defined to be ≥102cm in men and ≥88cm in women 
(WHO 2008).  The International diabetes federation, in a position statement about 
the metabolic syndrome, lowered the ranges of WC, and adapted them to several 
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ethnic groups (IDF 2005) (Figure 2.4). This definition was shown to be more 
sensible in predicting cardiovascular risk (IDF 2005), and was considered by this 
study to determine individuals at high metabolic risk. 
 
 
Figure 2.4: Classification of waist circumference based on ethnicity  
(IDF 2005). ATP III: Adult treatment panel III. 
2.3.5.3 Blood pressure 
Blood pressure was measured using a digital sphygmomanometer (Omron MS-1), 
with the participants in a seated position, after resting for 10 minutes. For the sake of 
standardization, blood pressure was measured using the right arm after being rested, 
based on the CDC recommendations. The arm was positioned in a way that the 
midpoint of the upper arm was as the same level as the heart (CDC 2009b), and the 
cuff was placed 2-3 cm above the pulsation of the brachial artery (O’Brien et al. 
1997).  
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Measurements were taken three times and the average was considered. The 
classification of blood pressure was based on the NICE classification for blood 
pressure (Classification cited in Table 1.2).  
 
2.3.5.4 Haematological tests 
a. Venepuncture and processing of serum samples 
Samples of blood were collected from the anticubital vein with minimal stasis by a 
butterfly needle (Vacuette®, Greiner bio-one), using 3 vacutainers of EDTA 
(Ethylene Diamine Tetra Acetic Acid) (9 ml), Sodium Heparin (9 ml) and Sodium 
Fluoride/Potassium Oxalate (2 ml) (Vacuette®, Greiner bio-one). The blood sample 
drawn at each time was around or less than 20 ml.  The samples were then ringed, 
and immediately centrifuged for 10 min at 3000 rpm (Revolutions per minute) and    
4 
o
C (Thermo Scientific Heraeus Primo R centrifuge). The supernatant serum was 
then harvested, and stored frozen in polystyrene tubes at -80 
o
C for later analysis.  
b. Fasting glucose and insulin levels, HOMA-IR and QUICKI 
Blood samples were allowed to completely thaw overnight at 4 
o
C, and insulin was 
analysed using ELISA (Enzyme-linked immuno-sorbent assay) insulin kits (Genway 
Biotech, Inc) at QMU lab. Reagents and standards were purchased. 
Insulin ELISA is a sandwich technique based on the principle of solid phase two-site 
enzyme immunoassay, in which two monoclonal antibodies react against antigenic 
determinants of insulin. To perform this method, 25µl of insulin samples, control and 
standards were dispensed into microwells, and 100 µg of working insulin enzyme 
conjugate was added to all wells. This step was followed by mixing and incubation 
for 60 minutes at room temperature (18-26
o
 C), to allow insulin to react with the 2 
antibodies: the enzyme HRP (Horseradish peroxidase)-conjugated anti-insulin 
antibody and the anti-insulin antibody, which are both coated in the microwells. The 
amount of antibodies that bind to the conjugate varies depending on insulin 
concentration. Subsequently, wells were washed 3 times with a wash buffer (to 
remove the unbound enzyme labelled antibody), and 100 µl of TMB 
(Tetramethylbenzidine) substrate was added to all wells. Incubation was allowed 
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again for 15 minutes. The HRP complex was then identified by its reaction with the 
substrate and the development of blue colour, which intensity is inversely 
proportional to insulin concentration in the samples. The reaction was stopped by the 
addition of a stop solution (50 µl of acid) and mixing. The concentration was 
determined by comparing the absorbance of the samples against the standards using 
a microplate reader at    450 nm (Dynex technologies MRX microplate reader). 
 
The analysis of glucose samples was undertaken at QMRI (Queen’s Medical 
Research Institute) - Edinburgh using an automated platform (Cobas UK).  
Measurement of fasting blood glucose was intended for: 1) The validation that 
participants adhered to the inclusion criteria and were non diabetic. 2) The use of 
fasting blood glucose values to determine insulin resistance/sensitivity markers 
(HOMA-IR and QUICKI calculations). 3) The monitoring of the effect of placebo 
DC/PRDC on glucose levels. 
  
Although of clinical importance, it is important to be aware of the limitations of 
blood glucose test, particularly because of the day-to day intraindividual fluctuations 
in glucose levels, which might vary between 5.7 - 8.3 % in a non diabetic person 
(Sacks 2011). Other limitations include acute stress or illness preceding the test 
(might lead to transient hyperglycemia), or the adoption of a hypocaloric diet few 
days before the test (might underestimate actual blood glucose levels). Analytical 
variations as well as the source of blood (capillary or venous) might also result in 
potential differences between studies. In fact, capillary blood glucose levels can be 
20-25 % higher than venous blood levels (Sacks 2011). The cut-offs for fasting 
glucose levels are between 3.9-5.5 mmol/l. Levels higher than 5.6 mmol/l suggest a 
prediabetes state, whereas levels above 7 mmol/l represent a diagnosis for diabetes 
(Diabetes UK 2013). 
 
The fasting plasma glucose and insulin levels were then used to assess insulin 
resistance/sensitivity via HOMA-IR and QUICKI, which were calculated according 
to the following equations: 
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HOMA-IR= (Fasting Glucose (mmol/l) x Fasting Insulin (µIU/ml) /           
                      22.5)  (Mathews et al. 1985) 
 
            QUICKI= 1/ [log (I0) +log (G0)]  
          I0 is fasting insulin (µIU/ml) and G0 is fasting glucose (mmol/l) (Katz et al.    
          2000). 
                                                                        
HOMA-IR and QUICKI are the most commonly used methods for the determination 
of insulin sensitivity and IR. The higher the HOMA-IR index, the lower the insulin 
sensitivity and the higher the IR (Bonora et al. 2002). The cut-offs for HOMA-IR 
have not been clearly established as in the case of serum lipids and glucose levels. 
Studies define a normal HOMA-IR as below 3.80 (Qu et al 2011), 3.60 (Stern et al 
2005), or even below 2.5 according to the American diabetes association (ADA 
2010). QUICKI was shown to be an accurate index of insulin sensitivity in humans, 
and its cut-offs are also not clearly established. An increase in QUICKI predicts an 
increase in insulin sensitivity (Chen et al. 2005). It is estimated that the cut-offs for 
QUICKI are above 0.357 (Hydrie et al. 2012; Hřebíček et al. 2002), or 0.4 (Baldelli 
et al. 2007).  
HOMA-IR was reported to be a more accurate index than QUICKI in assessing 
IR/insulin sensitivity (Keskin et al 2005; Kurtoglu et al 2010). Other studies 
documented that QUICKI is more reliable than HOMA-IR (Chen et al 2005; Antuna-
Puente et al 2008). Yet, more studies found that these two indices are equally 
sensitive in assessing IR/insulin sensitivity (Cutfield et al. 2003; Menik et al 2006). 
Therefore, assessing both parameters might help in providing reliable results for 
insulin responses throughout the chocolate intervention.  
 
The estimation of HOMA-β index as an indicator of pancreatic β-cell function might 
also be useful in determining any potential change in the activity of β-cells resulting 
from changes in insulin and/or glucose levels. HOMA- β was calculated according to 
the following: 
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HOMA-β= (20 * Fasting Insulin (µIU/mL) / (Fasting glucose (mmol/l) - 3.5)  
         (Matthews et al 1985) 
 
Also called homeostatic responsivity index, HOMA-β constitutes a simple tool for 
assessing pancreatic β-cell function. However, the limitations of this test remain in 
the fact that it measures insulin secretion under non stimulated conditions. Therefore, 
the measurement of HOMA-β is based on the prevalent insulin action (fasting state) 
(Cobelli et al. 2007). 
 
c. Serum lipid profile (TC, HDL, LDL and TG) 
The fasting blood lipids (Total Cholesterol, HDL and TG levels) were analysed at 
QMRI, Edinburgh. Samples were processed using an automated platform (Cobas 
UK). The normal ranges for lipids in healthy individuals are presented in table 2.6. 
 
LDL levels were then calculated via Friedewald’s formula: 
LDL-C=TC-HDL-C – (TG/2.2) (Vujovic et al. 2010) 
Measurement of lipid levels was collected at a fasting state, due to the fact that TG 
levels remain elevated few hours following a meal (Nigam 2011). This avoided 
misleading evaluation of TG levels, and consequently LDL levels. Other factors that 
might affect lipid levels include prolonged application of tourniquet (might increase 
cholesterol), and infection or inflammation preceding the test (might decrease 
cholesterol and HDL levels) (Alvarez and Ramos 1986). This might influence the 
monitoring of changes in lipid levels throughout the intervention. 
Table 2.6: Normal serum lipid levels ranges 
Lipids levels Normal ranges (mmol/l) 
Total cholesterol levels. < 5.0 
LDL levels <3.0 
HDL levels >1.0  
Triglyceride levels <1.7 
(Adapted from NHS 2013). HDL: High density lipoproteins, LDL: Low density lipoproteins 
 129 | P a g e  
 
d. High sensitivity CRP (Hs-CRP) 
This marker was analysed at QMU lab via high sensitivity enzyme immunoassay 
(ELISA method) (Genway Biotech Inc). This assay uses a mouse monoclonal anti-
CRP antibody and a goat anti-CRP antibody as an antibody-enzyme conjugate 
solution. The test consists of a reaction between the CRP molecules in the blood 
samples and the two antibodies during incubation. The amount of antibodies that 
bind to the conjugate varies depending on CRP concentration. The unbound 
antibodies are then removed, and the complex CRP-antibodies is allowed to react 
with a substrate, and the reaction is stopped by the addition of an acid. 
For this assay, blood samples were allowed to completely thaw overnight at 4 
o
C. 
Reagents were purchased. Samples were diluted 50 times with a sample diluent, and 
10 µl of each sample was dispensed into the microwells (microwells were coated 
with mouse monoclonal anti-CRP antibody) along with 100 µl of CRP enzyme 
conjugate reagent, and incubated for 45 minutes. The plates were then washed five 
times, and TMB substrate reagent (100 µl) was added and allowed to incubate for 20 
minutes, leading to the development of blue colour. The concentration of CRP in the 
samples is inversely proportional to the intensity of blue colour of blood samples. 
The reaction was then stopped by the addition of 100 µl of 1N HCl, changing the 
colour to yellow. The concentration was determined by comparing the absorbance of 
the samples against the standards using a microplate reader at 450 nm (Dynex 
technologies MRX microplate reader). 
Hs-CRP has been shown to be a strong predictor of stroke and myocardial infarction 
in healthy men and women, and its importance is rising regarding primary 
prevention (Ridker 2001). It has been suggested that hs-CRP levels <1 mg/l 
represent a lower relative risk of future CVD risk, while levels between 1-3 mg/l and 
over 3 mg/l represent a moderate and high risk, respectively. Despite its importance 
in clinical settings, measurement of hs-CRP is subject to between subject and within-
subject standard deviation (McCormack and Allan 2010). It has even been stated that 
a change in hs-CRP levels can only be effectively considered if the magnitude of 
increase and decrease of this marker is by at least 120% (Macy et al. 1997). Also, 
levels can be reliable when this measurement is taken for the same subject on 10 
different blood sample occasions (Campbell et al. 2002). Furthermore, cases like 
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acute infections or inflammatory conditions such as rheumatoid arthritis might 
increase hs-CRP levels (Ridker 2001). Therefore, an elevation in hs-CRP might be 
non specific, and should only be interpreted along with patient history and a 
comparison with other hs-CRP values from the same person.   
 
e. LDL oxidation levels 
LDL oxidation levels were analysed at QMU lab using the Human LDL ELISA 
Quantification Kits (Genway Biotech, Inc) at QMU lab. Reagents were purchased. 
Assay optimization was first performed to ensure samples fit in the specified 
detection range.  
For this assay, blood samples were first allowed to completely thaw overnight at        
4 
o
C. The process started by coating the plates with 100 µl of capture antibody 
(diluted in coating buffer), and incubating for 60 minutes. This was followed by 
washing the plates (3 times) and adding 200 µl of block buffer to all wells. 
Afterwards, solutions of protein calibrator (containing human LDL antigen) and 
diluted samples (samples were diluted 30 times) were assigned into the wells, and 
incubated for 60 minutes. Following the second incubation, wells were washed 5 
times, and 100 µl of detection antibody (HRP-conjugated anti-LDL antibody) was 
added to all wells. After washing the plates again for 5 times, 100 µl of TMB 
solution (substrate) was added to all wells. The plates were incubated again for 20 
minutes, to allow the development of blue colour which intensity is inversely 
proportional to LDL concentration in the sample. The reaction was stopped by the 
addition of 100 µl of stop acid solution. The concentration was determined by 
comparing the absorbance of the samples against the standards via a microplate 
reader at 450 nm (Dynex technologies MRX microplate reader). 
 
Regarding normal serum oxidised LDL levels, results are still conflicting. A study 
showed that in healthy individuals, the mean value of oxidised LDL was 95.32 ±       
37.85 ng of ox-LDL/ml (Koubaa et al 2007). Another study showed that the mean 
oxidised LDL levels in 120 healthy individuals were 78 ± 23.7 ng/ml, while these 
levels were 139.6 ± 52.2 ng/ml in diabetics (Koubaa et al 2011). It won’t be entirely 
reliable to assess cardiovascular risk based on the values of oxidised LDL, but this 
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test would most likely be a valid tool to monitor the effect of an intervention over 
time. 
 
2.3.5.5 Saliva tests 
For the analysis of cortisol and cortisone levels, participants were asked to provide 2 
saliva samples on each appointment: The first sample upon waking and the second 
sample at noon. Participants were instructed to provide sufficient amounts of saliva 
by spitting into a collection tube, and to avoid being stressed the time they gave the 
samples. They were also asked to avoid drinking alcohol during the collection day. 
Samples were then stored frozen at -18
o
C for later analysis. 
 
The analysis of steroids from saliva has been an increasingly used method, as it is 
simple and non invasive (Groschi 2008). It also presents advantages over the 
analysis of steroids in the urine due to the burden associated with urine collection 
(Yehuda et al. 2003). Studies showed that a saliva sample at wake-up provides 
nearly a good estimate of the 24-hour urinary cortisol excretion, as well as the 
overall daily cortisol production (Neary et al. 2002; Yehuda et al. 2003). Another 
study showed that the reliability of saliva in measuring cortisol levels is higher when 
several saliva samples are collected at different intervals during the day (Groschi 
2008). These studies suggest that saliva may be alternative to urine in analysing 
glucocorticoid hormones (Yehuda et al. 2003), and subsequently the activity of 11-β 
HSD1.  
 
The activity of the enzyme 11β-HSD1 was determined by the ratio cortisol/cortisone. 
An increase in this ratio suggests an increased expression of this enzyme, and 
consequently an increased regeneration of cortisol from cortisone in the liver and 
adipose tissue (Sigurjonsdottir 2009). 
 
a. Extraction  of saliva samples 
Saliva samples were first thawed and centrifuged at 3000 rpm for 10 minutes to get 
rid of any impurities. Afterwards, an aliquot of 250 µl of saliva was pipetted into 
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Fisher extraction tubes. Diethylether was then added (up to 1.5 ml), and the samples 
were vortexed by a multi-tube vortexer for 10 minutes, and stored at -80
o
C for 6 
minutes. Freezing allowed the separation of the aqueous fraction from the ether-
steroid fraction, the latter one being decanted into Pyrex glass tubes. The ether was 
then evaporated using nitrogen. After evaporation, the samples were reconstituted 
with 250 µl of assay buffer (concentration equal to the saliva sample), vortexed 
again by a multi-tube vortexer, and left in the fridge overnight at 4
 o
C. The samples 
were then ready for the ELISA assay. 
 
b. Cortisol and cortisone levels: ELISA assay 
               b.1. Principle of ELISA assay 
Cortisol and cortisone levels were analysed through the “in-house ELISA method” a 
method developed by Al-Dujaili (2006). The method is an indirect competitive 
double-sandwich ELISA between the conjugate (antigen) and cortisol/cortisone in 
the samples for the antibodies binding sites. The amount of antibodies that bind to 
the conjugate varies depending on the cortisol/cortisone concentrations. The bound 
hormones are detected by the addition of a substrate and the production of a blue 
colour. The colour intensity is inversely proportional to cortisol/cortisone 
concentrations in the samples. Stopping the reaction by the addition of an acid allows 
the determination of the concentration of glucocorticoids by comparing the 
absorbance of the samples against the standards via a microplate reader. 
  
b.2. Preparation of reagents 
For this method, coating buffer, wash buffer, block buffer, assay buffer, enzymes, 
antibodies and standards were prepared in the Lab, whereas the substrate was 
purchased. 
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Coating buffer 
Coating buffer was prepared by adding PBS (phosphate buffer saline) to distilled 
water (1 : 1.5 dilution). The buffer was stored at 4
o
C for later analysis.  
 
            Wash buffer 
Wash buffer was prepared by adding 0.5 ml of Tween 20 solution (soap) to 800 ml 
of distilled water and 200 ml of PBS solution (1:5 dilution). 
 
            Block buffer 
Block buffer was prepared by adding 0.5 g of BSA (bovine serum albumin) to 100 
ml of PBS (0.5 % concentration). 
 
            Assay buffer 
Assay buffer was prepared by diluting block buffer five times (1:5 solution) 
 
            Preparation of antibodies 
The preparation of antibody solutions was made by adding 11 ml of assay buffer to 
50 µl of cortisol/ cortisone antibodies (1/ 20000 solution). 
 
            Preparation of enzymes 
Enzymes were prepared by adding 11 ml of assay buffer to 10 µl of anti-sheep 
enzyme (1:10000 for cortisol), and to 20 µl of anti-rabbit enzyme (1:5000 cortisone). 
 
           Preparation of standards 
The preparation of standards was made by performing serial dilutions of the cortisol 
and cortisone stocks in assay buffer. For cortisol, the following concentrations were 
generated: 0, 2.5, 10, 50, 250 and 1000 ng/ml. For cortisone, the concentrations of 
the standards were 0, 0.5, 1.0, 2.5 and 10 and 50 ng/ml. 
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b.3. ELISA assay 
First, 96-well microplates were coated with cortisol/cortisone conjugates. This was 
done by diluting 50 µl (0.5 mg/ml) of cortisol-conjugated to BSA or 50µl 
(0.5mg/ml) of cortisone-conjugated to 20 ml of coating buffer, and adding 200 µl of 
diluted cortisol-conjugated to BSA or 180 µl of cortisone-conjugated solution to the 
wells (Al Dujaili et al. 2012). The plate was allowed to incubate overnight at 4
o
C.  
The next day, fluid was discarded from the microplates, which were washed 4 times 
with 250 µl of wash buffer. Then, 200 µl of bloc buffer was added to the 
microplates, the latter were then covered and incubated for 1 hour at 37
 o
C.  The 
fluid was subsequently discarded, and 50µl of saliva samples were added to the 
plates, along with 100 µl of antibody (anti-sheep for cortisol and anti-rabbit for 
cortisone). The plates were covered and allowed to incubate in a dark place for 2 
hours at room temperature. Following incubation, the fluid was discarded again, and 
the plates washed 4 times with 250 µl of wash buffer. Then, 100 µl of enzyme was 
added (anti-sheep for cortisol and anti-rabbit for cortisone) to the microplates, which 
were allowed to incubate again for one hour at room temperature and in a dark place. 
Microplates were then washed again four times, and 100 µl of substrate solution was 
added, followed by 15 minutes incubation. During this time, a light blue colour was 
developed, and the reaction was stopped by adding 50 µl of stop solution (2 M 
H2SO4). The absorbance was read at 450 nm using a microplate reader (Dynex 
technologies MRX microplate reader).  
 
2.3.6 Compliance and diet diaries collection 
In order to assess changes in dietary intake following DC consumption, participants 
were asked to provide a 3-day diet diary (two weekdays and one weekend) during 
the run-in period and at week 3 (Appendix 5). Information on how to fill the diet 
diaries were provided by the researcher. Diet diaries were then analysed using the 
Netwisp Software V3.0 (Tinuviel software) for total energy, carbohydrate, fat and 
protein. 
Diet diaries represent a simple and easy method to collect food intake, and it does 
not depend on memory. The multiple-day diet diary provides a better estimate of the 
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habitual intake of participants, compared to 24-hour recall or 1-day diet diary. 
However, this method is limited by the non compliance due to the time and effort 
needed to record food intake, and the possible change in dietary intake during the 
recording to decrease burden and complexity (Lee and Nieman 2010). Also, the flat 
slope effect (underestimation of large portion sizes and overestimation of small 
portion sizes) (Garriguet 2008) might produce bias in actual food intake. This might 
threaten the efficacy of this method in assessing diet (Bothwell et al. 2009).  
The validation of diet diaries has been previously made via several methods such as 
doubly-labelled water, estimation of nitrogen excretion and estimation of energy 
expenditure. Studies have mainly showN an underestimation of actual energy intake 
and an underreporting in the general population by a mean of 22 % (Garriguet 2008). 
Many factors have been associated with underreporting, such as age, sex and 
socioeconomic and psychological factors. In fact, women compared to men, and 
physically active individuals have been documented to have a higher level of 
underreporting. However, the highest degree of underreporting was observed in 
obese individuals, whom reported energy intake constituted 59 ± 24 % of their 
energy expenditure (Garriguet 2008). These factors might affect the validity of diet 
diaries in assessing energy intake. 
Nonetheless, since there is no best method for analysing food intake (Lee and 
Nieman 2012), diet diaries are still widely used in research studies to estimate 
changes in dietary intake throughout interventions (Wrieden et al. 2003). 
 
Compliance to the study protocol was assessed: 1) through the 3-day diet diary and 
physical activity questionnaire 2) by the return of the empty chocolate containers at 
the end of the intervention and 3) by directly asking participants whether they have 
consumed all the samples of chocolate daily as required. As far as we know, there is 
no previous description of a high compliance to a DC intervention. Therefore, a high 
compliance was defined in this study by the intake of 85 % or more (equivalent to 
missing no more than one sample a week) of the chocolate throughout the study. 
  
 136 | P a g e  
 
2.3.7 Statistical analysis 
Continuous normally distributed data were expressed as mean ± SD, unless 
otherwise stated (95% confidence intervals and interquartile range (IQR) when 
appropriate). Data were analysed using SPSS for Windows version 19.0 (SPSS, 
Chicago, IL). For within group comparisons, changes from baseline were analysed 
using a student’s paired t-test. Differences in baseline characteristics between groups 
were examined using a two-tailed samples independent t-test. For between-group 
differences, analysis of covariance (ANCOVA) was carried out to adjust for 
potential baseline differences. Paired t-tests and independent t-tests on the Netwisp 
software (V 3.0) were used to assess within group differences and baseline 
differences, respectively between the 2 groups with regards to energy, protein, fat 
and carbohydrates. The relationship between selected variables was examined using 
Pearson’s product-moment correlation coefficient (r). Non parametric data were 
analysed using Wilcoxon and Mann Whitney tests. Significant changes were set at 
p≤ 0.05. 
 
2.4 Study II 
2.4.1 Study population 
Advertisement for the study was made via QMU university moderator as well as 
community centres in East Lothian, hospitals in Edinburgh, gyms in Musselburgh 
and word-of mouth.  
 
Inclusion and exclusion criteria 
Fourteen volunteers without restriction to race or socioeconomic status were 
recruited according to the following criteria: 
 
Inclusion criteria 
- Overweight with no history of diabetes, hypertension or CVD 
- BMI between 25 – 34.9 Kg/m2 
- Males and Females  
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- Age: 18-65 years 
 
          Exclusion criteria 
-Participants with cardiovascular diseases, hypertension or diabetes 
-Participants taking medications that affect insulin, glucose, lipid or blood 
pressure levels 
-Participants taking dietary supplements containing high doses of 
antioxidants  
-Postmenopausal women taking HRT (Hormone Replacement Therapy)  
-Participants who recently participated or are currently on a weight 
management program 
-Smokers and heavy alcohol drinkers (defined as more than 15 drinks/week 
for men and more than 8 drinks/week for women (CDC 2014)) 
-Participants with regular consumption of cocoa or DC (> 1 serving/week) 
(Taubert et al. 2007). 
2.4.2 Determination of sample size for the small scale study 
In order to get an approximate number of participants for this study, the 
determination of sample size was based on its ability to have 80% power to detect an 
effect size of 1.325 using a two group t-test with a 0.050 two-sided significance 
level. Hence, for a two group trial, the total sample size required was 20, and with 
30% attrition (based on a weight loss study by Drummond et al. 2004), 28 
participants were supposed to be recruited in total. 
2.4.3 Estimation of sample size for a larger study based on Study II results  
One of the aims of this study was to estimate a sample size for a larger scale study. 
Delucchi (2004) discussed the importance of appropriately estimating sample size to 
perform a meaningful study. Commonly, the determination of the number of 
participants necessary to detect an effect is done via conducting a power analysis, 
given the availability of an effect size from previous studies (IDRE 2014). Power 
analysis has also few disadvantages, like the lack of generalizability of this tool, as it 
depends on the type of statistical analysis used. When running a power analysis, it is 
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recommended to use different values of means and standard deviations in order to 
obtain a range of numbers of sample sizes (IDRE 2014). Many references for sample 
size calculations were suggested in the literature (examples Muller et al. 1992; 
Machin et al. 1997; Rochon 1998).  
 
2.4.4 Study design 
This study is a randomized single-blinded placebo controlled pre-post intervention 
parallel study with 2 arms where participants received two different types of DC 
according to the following: 
 
Type A: Placebo DC (low in polyphenols) 
Type B: DC rich in polyphenols (500 mg) 
 
Randomization was implemented using sealed envelopes based on the protocol 
described by Doig and Simpson (2005). Twenty-eight standard-sized sheets were 
marked by either P (Placebo)-14 sheets or D (Dark chocolate rich in polyphenols)-14 
sheets. The sheets were inserted into unlabelled envelopes and sealed and placed into 
a container. Then, the researcher chose an envelope for each participant. 
Participants were provided an information sheet and asked to sign a consent form 
(Appendix 7) before the start of the study. The study took place at QMU clinical lab. 
Each of the 3 appointments and the follow-up appointment lasted no more than 20 
minutes. Participants randomly received 20g of DC daily (Type A or B) for a period 
of 12 weeks. Anthropometric measurements (height, weight, WC, and body 
composition) were taken during each visit, and a 24-hour urine sample collection 
was required the day before each of the first 3 appointments (View table 2.7 for the 
timeline of each appointment). A follow-up appointment four weeks after the end of 
intervention was planned to identify whether any changes in anthropometric 
measures were maintained. 
A general questionnaire (Appendix 8) was filled by participants during the run-in 
phase. To assess flavonoid intake, a food frequency questionnaire (FFQ) for 
assessment of flavonoid intake was filled four times throughout the intervention 
(Appendix 9). Volunteers were asked to maintain their usual diet and physical 
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activity one week before the start and throughout the study period. This was 
monitored through reporting diet diaries (at baseline and every four weeks) 
(Appendix 5), and filling a physical activity questionnaire (before the start and every 
6 weeks) (Appendix 10). A diet adjustment was considered so that DC substitutes 
another food of similar energy. The researcher provided dietary advice for 
participants to help them achieve this goal. This happened by asking participants 
about the types of snacks usually consumed. Energy composition of these snacks 
was assessed, and substitutions based on food energy content were suggested by the 
researcher. A short questionnaire on the acceptability of the treatment and the 
potential change in appetite was filled during the 3
rd
 appointment (Appendix 11) 
(View Figure 2.5 for the study protocol). Volunteers were requested to refrain from 
consuming any other type of dark chocolate or cocoa for the whole period of the 
study. Females were asked about the date of their menstrual cycle on each 
appointment. The details of all data collected are discussed in section 3.4.6. 
 
Before attending the appointments, participants were asked to: 
-Be on a fasting state (defined as to refrain from eating or drinking any liquids for a 
period of 8 hours (Diabetes UK 2013). 
-Avoid taking high quantities of caffeine from caffeine rich sources (mainly coffee 
and tea) 12 hours before the appointment 
-Avoid drinking alcohol for the past 24 hours. 
Table 2.7: Timeline for Study II appointment 
 Minutes 
Introduction 5 
Height and weight 
measurements 
3 
Waist circumference 
measurement 
4 
Bioelectrical 
impedance 
6 
Questions 2 
Total 20 
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         Week 0                     Week 4                   Week 6                                   Week 8           Week 12                  Week 14  
 
Visit 1                                                               Visit 2                                                             Visit 3                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FFQ: Food Frequency questionnaire.  
Anthropometric measures included weight, height, waist circumference and body 
composition. 
 
2.4.5 Justification for the chosen methods 
2.4.5.1 DC dose and study duration 
No previous human studies have discussed the dose of DC and polyphenols 
supposed to induce an effect on body weight. There has been one study performed 
on 26 overweight and obese premenopausal women, who were administered either a 
dark chocolate snack or non-chocolate snack daily for 18 weeks. This study showed 
that a sweet daily snack, whether it is dark chocolate or non chocolate, helps in  
decreasing body weight, body fat, and waist and hip circumference in overweight 
and obese women (Piehowski et al. 2011). Yet, it was not possible to rely on it to 
determine the duration of the study, as no assessment of the dependant variables 
(BMI, WC and body composition) was undertaken at different intervals of the study, 
hence it was not clear whether changes were significant before week 18, e.g. at week 
  Run-in-period 
Anthropometric 
measures 
 
24-hour urine 
collection 
 
 Physical activity 
questionnaire 
 
 FFQ for 
assessment of 
flavonoid intake 
 
“Acceptability of 
treatment” 
questionnaire 
Anthropometric 
measures 
 
Physical activity 
questionnaire 
 
FFQ for 
assessment of 
flavonoid intake 
 
Anthropometric 
measures 
 
24-hour  urine 
collection 
 
Anthropometric 
measures 
 
24-hour urine 
collection 
 
Physical activity 
questionnaire 
 
FFQ for assessment of 
flavonoid intake 
 
General 
Questionnaire 
 
3-day diet 
diary 
collection 
 
FFQ for  
assessment of 
flavonoid 
intake 
 
3-day 
diet 
diary  
 
3-day 
diet 
diary  
 
 
3-day 
diet 
diary  
 
 
 Week 16   
     Figure 2.5: Study II protocol 
 Follow-up   
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6 or 12. Moreover, the polyphenol content of the chocolate was not quantified, and 
the design of the study is different as it addresses the effect of daily sweet snack 
consumption versus dark chocolate consumption on anthropometric measures, when 
these 2 snacks were incorporated into a reduced calorie diet. 
In order to determine the study duration, data on previous studies performed on 
green tea (rich in polyphenols) and its effect of body weight were used. Three studies 
aiming to determine the effect of daily green tea supplementation (containing about 
500-600 mg of polyphenols) on anthropometric measures were shown to lower body 
weight, waist circumference and body fat mass after 12 weeks of daily 
supplementation (Grove et al. 2010). Knowing that green tea does not provide 
energy, the purpose of the study was to substitute DC by another food in order to 
maintain the daily energy intake of participants. Also, it is known that polyphenols in 
cocoa/DC have a different composition than green tea. In addition to its                       
-(-)epicatechin content, tea contains 30 - 50 % of EGCG (Grove et al. 2010). Hence, 
information from these studies was mainly used to get an approximate idea of the 
study duration.  
 
Regarding the dose of DC and polyphenols, an animal study noted that a weight- 
lowering effect could be possibly achieved in humans by consuming 50g of cocoa 
daily (provides 182 Kcal; the amount of polyphenols was not specified)) (Matsui et 
al. 2005). Another animal study stated that this amount is equivalent to 54 g of cocoa 
powder (provides 221.4 Kcal and contains 513 mg of polyphenols and 24.84 mg of 
epicatechin) (Gu et al. 2013). 
In view of these data, the choice of a 20g daily dose of chocolate containing 500 mg 
of polyphenols with 85 mg of epicatechin and providing 102 Kcal was tested for its 
ability to induce a decrease in weight in humans over a period of 12 weeks. 
 
2.4.5.2 Study design 
The choice of a parallel design was primarily based on the long study duration (12 
weeks) (View section 3.3.4.2 on the advantages of parallel studies compared to 
crossover studies). This made the choice of a crossover design impractical due to the 
high commitment asked from participants. In addition, the washout period expected 
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to eliminate carry over effects between the two treatments could range between 2 
and 6 weeks in studies lasting 8-12 weeks (Ried et al. 2009; Sathyayapalan et al. 
2010; De Bock 2013). Therefore, the choice of a parallel study was deemed to be 
beneficial in avoiding an increase in dropouts and a decrease in compliance (Dash et 
al. 2012).  
 
2.4.6 Data collection and processing 
2.4.6.1 General questionnaire and Food frequency questionnaire  
The general questionnaire was described in section 2.3.5.1 and presented in appendix 
8. Similarly to Study 1, the questionnaire covered information on social 
characteristics, lifestyle habits and medical history, and was designed to ensure 
participants met the study requirements. 
 
Participants noted their actual intake of flavonoid-rich foods in a FFQ with 43 food 
items adapted from USDA database of the flavonoid content of selected foods 
(2011a) (Appendix 9). Foods with a medium and high content of flavonoids (more 
than 4 mg/100g of foods) were included (a medium content of flavonoids in foods is 
between 4 - 9.9 mg/100g and a high content constitute more than 10mg/100g of 
selected foods (O’byrne et al. 2002)). A portion size based on the average serving for 
each food was stated, and participants were asked to tick one of the nine options 
ranging from “Never or less than once a month” to “more than 6 per day”. Each food 
item was assigned a score based on the average intake in the following way:  
 
Never or less than once a month: 0 
1-3 per month: 2 
Once a week: 4.28 
2-4 per week: 12.86 
5-6 per week: 23.57 
Once a day: 30 
2-3 per day: 75 
4-5 per day: 135 
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More than 6 per day: 180 
 
A score was also assigned to whether the food was medium or high in flavonoids, so 
that foods containing 4- 9.9 /100 g of foods were given a score of 1, and foods with 
content higher than 10 mg/100g of foods were given a score of 2. Participants were 
asked to fill the FFQ four times throughout the intervention. An increase in flavonoid 
intake was positively correlated to an increase in FFQ score. 
FFQ is considered a simple and easy way to determine dietary intake (Santos-Buelga 
2010). Many studies have previously discussed the validity and reproducibility of 
FFQ in assessing polyphenol intake (Hakim et al. 2001; Rautiainen et al. 2008; Vian 
et al. 2013). A significant association between FFQ for assessment of polyphenol 
intake and urinary polyphenol excretion (pearson’s (r) = 0.23; p = 0.01) (Vian et al. 
2013), as well as between FFQ for assessment of polyphenol intake and FRAP levels 
(pearson’s (r), p<0.05) (Rautiainen et al. 2008) were previously noted. FFQ was also 
validated for assessing flavonoid intake (Otaki et al. 2009). Nonetheless, the ability 
of FFQ to assess dietary intake was criticized. This was mainly explained by the bias 
in self-reporting related to the quantification of portions by participants. Commonly, 
participants tend to overestimate their intake of healthy foods like fruits and 
vegetables (Spencer et al. 2008), which can lead to an overestimation of the intake of 
polyphenols. This makes it difficult to assess the correlation between diet and 
diseases (Byers 2001). Furthermore, the big variety of products in the market as well 
as the different ingredients and cooking techniques produce errors in the ability of 
FFQ to accurately assess polyphenol intake. Yet, despite its limitations, FFQ is still 
considered a valid and useful tool to determine changes in flavonoid intake (Santo-
Buelga et al. 2010) 
It is important to mention that FFQ used in this study did not aim to analyze the total 
flavonoid intake in this population, but to compare the intra individual changes in the 
intake of flavonoids throughout the study. Therefore, low flavonoid foods                    
(< 4 mg/100 g of selected foods) were not included. 
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2.4.6.2 Physical activity and acceptability questionnaires 
The questionnaires were described in section 3.3.5.1. Physical activity questionnaires 
were filled four times during the intervention (Appendix 10). Baseline physical 
activity questions were included in the general questionnaire. Hours of physical 
activity were then transformed into MET/week. Data regarding acceptability of dark 
chocolate consumption and the willingness to continue having chocolate after the 
study were obtained. A question about potential changes in appetite throughout the 
study was also included (Appendix 11).  
 
2.4.6.3 Anthropometry 
a. Height, weight and waist circumference 
The description of these methods is presented in section 3.3.5.2. 
b. Body composition 
Body fat percentage and LBM were measured via bioelectrical impedance (BIA) 
using the BODYSTAT 1500 MDD (BODYSTAT®). This machine also provided a 
measure of total body water (TBW).  
Measurements were taken in a warm room, with participants lying in the supine 
position. Sets of electrodes were placed on the right hand and right foot, and 
measurements were taken with no parts of the body touching one another. 
BIA measures impedance (defined as an opposition to a flow of a current) by 
involving a small electric current passing through the body at a speed that is 
dependent on body composition. Water and ions are good conductors of the 
electricity, thus muscles and bones are more conductive than adipose tissue. The 
higher the lean body mass, the higher the conductivity and the lesser the impedance. 
On the other hand, fat mass is inversely correlated with conductivity, and directly 
correlated with impedance (Dehghan and Merchant 2008). 
 
BIA was reported to be a reliable instrument for the assessment of body composition 
as it is quick, simple and non invasive (Walter-Kroker et al. 2011). BIA presents less 
intra and inter-observer error compared to other techniques such as skinfold 
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thickness and waist circumference, and it has been validated against reference 
methods in the Caucasian population (Lopez et al. 2012). It was estimated that BIA 
is highly reproducible with less than 1% error (Segal et al. 1991). BIA can be 
confounded by factors such as exercise (less than 2-3 hours before measurement) and 
food consumption (less than 3 hours prior to the test). In addition, BIA technique 
may be affected by the hydration status of individuals (can affect the estimation of 
fat free mass) (Lukaski et al. 1986), environmental factors (like skin temperature 
which implies an inverse correlation between skin temperature and impedance 
(Gudivaka et al. 1996)), and the menstrual cycle in women (which may result in a 
higher within-subject difference compared to men, due a change in the hydration 
status throughout the cycle (Dehghan and Merchant 2008). Desirable ranges of fat 
are presented in table 2.8.  
 
Table 2.8: Desirable ranges of body fat percentage in adult males and females 
Classification Males Females 
Unhealthy (too low) ≤ 5% ≤ 8% 
Acceptable (lower end) 6-15% 9-23% 
Acceptable (upper end) 16-24% 24-31% 
Unhealthy (too high) ≥25% ≥32% 
Adapted from Lee and Nieman (2010). Ranges are for individuals aged 18 years and older 
and based on gender.  
 
c. Basic metabolic rate (BMR) 
BMR was estimated via the BIA machine after an overnight fast and 12 hour 
abstinence from exercise. As the accurate measurement of BMR requires methods 
such as indirect calorimetry which measures oxygen consumption (VO2) and carbon 
dioxide production (VCO2) (McClave and Snider 1992), the values obtained via BIA 
machine provide estimations based on the formula of Brozek and Grande (1955). 
This formula uses lean body mass to calculate BMR rather than total body weight. 
BMR is affected by several factors such as caffeine intake, exercise, and anxiety. 
Repeated measures of this test on two days and preferably in the morning, are likely 
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to provide more accurate results (Haugen et al. 2003). Studies have previously 
documented the practicality of BIA in estimating changes in BMR levels in routine 
measurements (Barak et al. 2003; Altay et al. 2012), making it a useful tool for 
assessing changes in energy expenditure during this study. 
 
2.4.6.4 Urine tests 
a. Processing of urine samples 
Urine samples were first collected and frozen at -18
o 
C. Prior to analysis, samples 
were thawed at 4
 o 
C and centrifuged at 6000 rpm to get rid of any impurities, and 
used for conducting the FRAP, Folin-Ciocalteu and ELISA methods.  
 
b. Cortisol and cortisone extraction 
Before conducting the ELISA method, cortisol and cortisone were extracted based 
on the technique described by Al Dujaili (2006). 1ml of urine was added to 8 ml of 
dichloromethane, and the mixture was vortexed for 10 minutes using a V400 multi-
tube Vortexer. Subsequently, sodium hydroxide (NaOH) was added to the mixture 
and the samples were inverted 3 times. NaOH was then discarded and hydrochloric 
acid (HCl) was added and discarded again. This procedure was repeated while 
replacing NaOH and HCl with water. The resultant sample containing a high amount 
of steroids was transferred to Pyrex glass tubes, and dichloromethane was evaporated 
using Nitrogen. Samples were then reconstituted with 1 ml of assay buffer and left 
overnight at 4
 o 
C. 
The principle of ELISA method for the determination of cortisol and cortisone levels 
is described in section 3.3.5.5. 
 
The use of urine samples for the determination of glucocorticoids levels is mainly 
due to the fact that it is a non invasive technique (Yehuda et al. 2003), and is highly 
correlated to blood cortisol (Neary et al. 2002). In fact, a 24-hour sample provides a 
good estimate of the amount of cortisol secreted by the adrenals over a complete 
circadian cycle. However, some limitations are inherent to this method. Some 
unidentified substances might interfere with the extraction of cortisol, and lead to 
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falsely high cortisol values. Also, the burden of collecting urine may result in a 
decrease in adherence, and might consequently affect the reliability of this test 
(Yehuda et al. 2003). 
 
c. Total antioxidant capacity: Ferric-reducing antioxidant power assay 
Ferric-reducing antioxidant power (FRAP) assay is a method used to assess the 
antioxidant capacity in foods and biological samples. The principle is based on the 
analysis of reduced agents based on electron transfer (e) according to the following 
reaction: 
 
Probe (oxidant) + e (from antioxidant)              Reduced probe + oxidised antioxidant 
 
In this reaction, the probe is an oxidant (ferric-2,4,6-tri-2-pyridyl-s-triazine complex 
(Fe
3+
 TPTZ) that takes off an electron from the antioxidant, causing its change in 
colour to blue. Therefore, the measurement of the antioxidant capacity of phenols 
against the oxidant will measure the ability of the solution to reduce Fe
3+
 TPTZ to 
Fe
2+
 TPTZ. The magnitude of change of colour is proportional to the antioxidant 
concentration, and the reaction reaches its endpoint when the change in colour stops. 
FRAP assay is carried out under acidic solutions to maintain iron solubility.  
   c.1. Preparation of reagents 
For this technique, reagents including ferrous sulphate standards, acetate buffer, 
hydrochloric acid, ferrous sulphate, TPTZ, and ferric chloride solutions were 
prepared in the Lab. 
 
   Ferrous sulphate standards: To prepare the standard test tubes, 0.278g of ferrous 
sulphate was diluted in 1 L of deionized water (1 mM). Then, serial dilutions were 
performed to produce the standards showed in Table 2.9. These standards were used 
to produce the standard curve. 
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Table 2.9: Ferrous sulphate standards 
Standard 
concentration (mM) 
Ferrous sulphate solution 
(ml) 
Distilled water (ml) 
0.1 1.0 9.0 
0.2 2.0 8.0 
0.4 4.0 6.0 
0.6 6.0 4.0 
0.8 8.0 2.0 
1.0 10.0 0.0 
 
 
  Acetate Buffer (300 mM, pH 3.6) was prepared by the dissolution of 3.1 g of 
sodium acetate and 16 ml of glacial acetic acid into 1 L of deionized water. 
 
  Hydrochloric Acid (40 mM) was prepared by adding 3.64 ml of concentrated 
hydrochloric acid (36%, 12 M) to 1 L of deionized water. 
 
  Ferrous sulphate (1mM) was prepared by adding 0.278 g of ferrous sulphate to      
1 L of deionized water. 
 
  TPTZ (Ferric-2, 4, 6-tri-2-pyridyl-s-triazine) (10 mM) solution was prepared by 
adding 0.031g of TPTZ in 10 ml of 40 mM HCl  
 
  Ferric Chloride (20 mM) was prepared by dissolving 0.054 g of ferric chloride 
into 10 ml of deionized water. 
 
  Working FRAP solution was made by adding the following into a 250 ml glass 
bottle: 100 ml acetate buffer, 10 ml Ferric chloride, 12 ml distilled water and 10 ml 
TPTZ. 
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   c.2. FRAP assay 
The FRAP technique consists of adding 10µl of standards and urine samples (diluted 
10 times) into a 96-well plate, followed by the addition of 250 µl of working FRAP 
solution to all wells. The plate was incubated in the oven (set to 37
o
C) for 4 minutes, 
and read on the micro plate reader (Dynex technologies MRX microplate reader) at 
600 nm. The change of absorbance was due to the combination of the reducing 
capacity of all the reacting antioxidants in the sample. The mean concentration of 
Fe
2+
 produced was expressed in mmol/l (and then converted into mmol/day) and 
calculated using the following equation: 
 
[FRAP] = p [Abs sample – b] / m 
P = dilution factor of original sample 
Abs sample = absorption at 600 nm 
b = intercept from standard curve 
m = slope from standard curve 
The FRAP method represents a recognized index of antioxidant power, and its 
advantages remain in the high reproducibility of results and the fact that it is speedy, 
simple and inexpensive (Benzie and Strain 1996). However, many limitations are 
inherent to this method. First, the FRAP technique is based on the fact that all redox 
reactions are complete within 4-6 minutes, albeit some polyphenols need a longer 
reaction time to be detected (around 30 minutes). Also, the FRAP assay is only 
capable of measuring the reducing capacity of the solution based on the ferric ion, 
hence it lacks specificity and is unable to measure thiol antioxidants (Prior et al. 
2005). In addition, phosphates and sulfates, largely available in biological fluids, can 
bind to Fe
3+
 and reduce its reduction to Fe
2+
 (Cornelli et al. 2011), resulting in a 
possible overerestimation of the amount of antioxidants in the urine sample. 
 
d. Total polyphenols in the urine: Folin-Ciocalteu method 
Folin-Ciocalteu method is used to determine total polyphenols in the urine. Phenols, 
in addition to other oxidised substances, are determined by producing a blue colour 
due to the reaction with yellow heteropoly-phosphomolybdate-tungstate anions (in 
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the Folin-Ciocalteau reagent). To illustrate, under basic conditions (pH=10), phenols 
are dissociated to give phenolate anions, which can reduce the Folin-Ciocalteau 
reagent through an electron transfer mechanism, leading to the development of blue 
colour. 
        d.1. Preparation of reagents 
For this method, gallic acid standards, sodium carbonate and Folin and Ciocalteau 
reagent solutions were prepared in the lab. 
 
  Gallic Acid standards 
 
Gallic acid (500 mg) was added to 1 L of distilled water to produce the stock. Then, 
serial dilutions were performed to produce the standards shown in table 2.10. These 
standards were used to produce the standard curve. 
Table 2.10: Gallic acid standards  
Gallic acid (mg) Gallic acid solution (ml) Distilled water (ml) 
500 10  0 
400 8 2 
300 6 4 
200 4 6 
100 2 8 
50 1 9 
 
 
Sodium Carbonate solution was prepared by adding 115 g Na2CO3 into 1 L of 
deionized water.  
 
The Folin and Ciocalteau reagent was prepared by adding 100 ml of Folin’s reagent 
to 900 ml distilled water (1:10 dilution). 
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                    d.2. Folin and Ciocalteau assay 
For this assay, 100 µl of each urine sample (diluted 10 times), 5 ml of Folin’s 
reagent, and 0.9 ml of distilled water were added to test tubes and left for 5 min. 
Then, 3.5 ml of Na2CO3 was added and left to develop for 2 h. This step was 
followed by measuring the absorbance for each sample at 765 nm against a water 
blank on a spectrophotometer. The concentration of total phenolics was calculated by 
comparing the optical density of samples against the standard curve prepared with 
gallic acid. Results were expressed in mg/l of GAE, and then converted into mg of 
GAE/day. 
 
The Folin-Ciocalteu method has been previously used as an indicator of polyphenol 
content, and represents many advantages related to its convenience, reproducibility 
and simplicity. The limitations of this method remain in its non specificity to 
phenolic compounds, as other components such as vitamin C and copper can reduce 
the Folin-Ciocalteu reagent, and therefore overestimate the phenolic content the 
sample (Berker et al. 2010).  
 
In view of the potential limitations of the FRAP and Folin-Ciocalteu techniques in 
assessing changes in polyphenols in the urine, the use of both methods might give an 
estimation of any potential change in antioxidant capacity and in the amount of 
polyphenols resulting from PRDC consumption. 
 
2.4.7 Compliance and diet diaries collection 
Compliance was assessed by 1) The measure of total polyphenols and antioxidant 
capacity in a 24-hour urine sample before, during and at the end of the intervention. 
2) Counting the empty plastic bags and asking participants whether they have 
consumed all the doses of chocolate as required. 3) Monitoring fluctuations in the 
participants’ diet and physical activity through the collection of diet diaries 
(Appendix 4) and physical activity questionnaires (Appendix 10). A high compliance 
was defined by the intake of 85 % or more (equivalent to missing no more than one 
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sample a week) of the experimental chocolate throughout the intervention (section 
3.3.6 provides additional information about compliance and diet diaries) 
 
2.4.8 Statistical analysis 
Continuous normally distributed data are expressed as mean ± SD. Data were 
analysed using SPSS for Windows version 19.0 (SPSS, Chicago, IL). For multiple 
comparisons, data were analysed using mixed model ANOVA (Analysis of variance) 
with time (week 0, week 6, week 12 and then week 0, week 6, week 12 and week 16) 
as within subject factor, and treatment (placebo DC/PRDC) as between subject 
factor. For significant differences, changes over time were assessed via pairwise 
comparisons using Bonferroni test. Energy, protein, fat and carbohydrate intakes 
were analyzed using repeated measures ANOVA. The correlation between selected 
variables was examined through Pearson’s product-moment correlation coefficients 
(r). Significance was set at p≤ 0.05. Sample size calculation for a large trial was 
calculated based on 80% power and a two-sided significance level of 0.05. 
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 CHAPTER 3: INTRA-OBSERVER RELIABILITY OF WAIST 
CIRCUMFERENCE MEASUREMENT 
Before exposing the results of the conducted studies, this chapter will discuss the 
intra-individual error of measurement study that was carried out in order to assess 
the reliability of WC measurement. 
 
Anthropometry is widely used in epidemiological and clinical studies as a simple 
tool to assess adiposity and weight status due to the fact that it is quick, non invasive 
and inexpensive (Ulijaszek and Kerr 1999). Nevertheless, due to the inadequacies in 
instruments, the inabilities in recording the measures (Arroyo et al. 2010), the lack of 
trained anthropometrists and the high intra and inter-error variability (Geeta et al. 
2009), anthropometric measurements represent a high degree of error that affects 
precision and reliability (Sicotte et al. 2010). This error is particularly high when 
compared to other techniques such as haematological methods (Geeta et al. 2009). 
Error of measurement is defined as the degree of difference between repeated 
measures (Verweij et al. 2012). 
 
Despite the importance of anthropometric measurements in clinical and community 
settings, there have been few reliability studies assessing errors of these 
measurements in the adult population (Geeta et al. 2009; Arroyo et al. 2010). 
Estimating errors in anthropometry is particularly important to improve 
measurements and properly estimate the correlation between variables in clinical 
trials (Bland and Altman 1986).   
   
WC has been increasingly used to monitor the effect of an intervention on 
anthropometric measures (Verweij et al. 2012). However, as mentioned in section 
1.1, because of the lack of a uniform protocol for the measurement of WC (Mason 
and Katzmarzyk 2009) (fourteen protocols have been identified (Geeta et al. 2009)), 
BMI is still the most widely used tool for assessing weight status. As simple as it 
seems, measurement of WC by clinicians has been reported to be difficult (Mason 
and Katzmarzyk 2009). Training anthropometrists, repeating measurements (two 
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times and preferably 3 times), and establishing a uniform protocol are necessary to 
reduce the error (Verweij et al. 2012).  
Studies assessing measurement error in WC are limited. Therefore, it has been 
suggested that researchers carry out their own reliability studies to ensure accuracy 
(Pelletier et al. 1991), reliability and precision of WC measurement.  
Intra observer precision is defined as the degree of difference between measures 
carried out on the same person by the same observer, whereas inter observer 
precision is the extent of difference when the measurement is conducted by two or 
more observers (Ulijaszek and Kerr 1999). In addition, the terms validity and 
reliability have been used to define error of measurements in anthropometric 
measures. Validity refers to the degree of which the true measurement is achieved, 
while reliability is defined as the ability of differentiation between participants of the 
same study regardless of the error of measurement (Geeta et al. 2009; Verweij et al. 
2012). 
Many measures of validity and reliability are available, such as technical error of 
measurement (TEM), intra-correlation coefficient (ICC), and coefficient of reliability 
(R). The use of these methods together allows a better estimate of the precision of 
anthropometric measurements (Geeta et al. 2009; Arroyo et al. 2010). 
 
3.1 Rationale for the intra-observer reliability study 
The reasons for conducting the reliability study arose from: 1) The importance of 
WC in assessing disease risk (Snijder et al. 2006). 2) The high potential error in WC 
measurement (Geeta et al. 2009). 3) The fact that studies I and II involved assessing 
the correlation between changes in anthropometric measures and risk factors for type 
2 diabetes and cardiovascular diseases. Therefore, determining the accuracy, validity 
and precision of WC measurement was necessary to ensure differences in values 
between appointments were not to due to a high degree of error.   
3.2 Objective 
The objective of this study was to estimate the extent of intra-observer precision for 
waist circumference measurement. 
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3.3 Materials and methods 
A sample of 10 volunteers participated in the study. The study was conducted by the 
same researcher who measured waist circumference on two different occasions. To 
limit the day-to-day variability in WC, participants made the two appointments in the 
same day. 
Participants were asked to attend the first appointment at least 2 hours after having a 
meal. WC was measured twice. Participants were then asked to come back in a 
period of 30 minutes while having no food or drink during this time. Measurement of 
WC was also performed twice, and the average of each of the two measurements 
taken at the same time was calculated. The data collection was intended to hide the 
results immediately by the researcher after measurement 1 to minimize bias. Asking 
participants to come back after 30 minutes was mainly to avoid the researcher 
recalling the numbers.  
Waist circumference was measured via the same metal measuring tape according to 
the protocol described in section 3.3.5.2. As this study only aimed to assess the intra-
error of measurement of WC, no other measurements were taken. 
 
The intra-examiner precision was determined by using four different estimates as 
suggested in the literature: TEM, the relative TEM (rTEM), ICC and coefficient of 
reliability (R) (Geeta et al. 2009; Arroyo et al. 2010).  
 
a) The Technical error of measurement was calculated using the following 
formula: 
 
                                                      TEM = √ ∑(d2) / 2N 
 
TEM is defined as the standard deviation between measures, where d represents 
deviations and N is the number of volunteers measured. TEM is considered an index 
of accuracy, and the most commonly used indicator for measuring error and 
precision in anthropometry (Arroyo et al. 2010). The higher the precision of the 
measurement implies a lower TEM (Geeta et al. 2009). As far as we know, no 
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acceptable range of TEM for WC has been previously described in the literature. 
However, acceptable values of rTEM (see below) have been cited. 
 
b) Relative TEM (rTEM) iss used to calculate the error as a percentage of the 
average of measures of WC:  
 
                                                     rTEM = (TEM / VAV) * 100 
 
VAV is the variable average value which corresponds to the mean of measurements 
for WC for volunteers. The acceptable variability for intra examiner TEM for WC 
has been estimated to be no more than 1.5 % for beginner anthropometrists, and no 
more than 1% for skilful ones (Perini et al. 2005).  
 
c) The ICC is used to assess the degree of similarity between measurements 
(Geeta et al. 2009), by determining the variance between the samples. ICC is 
calculated on SPSS software (Bruton et al. 2000). It is suggested that R<0 
implies no reliability, whereas values between 0.4 and 0.6 and 0.6 to 0.8 
show moderate and substantial reliability, respectively. Values close to 1 
indicate “nearly perfect reliability” (Geeta et al. 2009). 
 
d) The coefficient of reliability is measured to assess variability between 
subjects without considering the measurement error. R can vary between 0 
and 1. Values higher than 0.95 are considered highly precise (Arroyo et al. 
2010). The coefficient of reliability is calculated in the following way: 
 
 R= 1- (TEM
2
 / SD
2 
) 
 
            SD (standard deviation) represents the total variance within subjects (Arroyo    
            et al. 2010).  
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3.4 Statistical analysis 
The statistical analysis was performed using SPSS version (version 17, SPSS Inc. 
Chicago IL). Level of significance was set at p ≤ 0.05. 
3.5 Results 
 
Participants were all QMU staff and visitors. The mean age of the population was 
35.3 ± 3.14 years. The mean difference between the values at time 1 and time 2 was 
small (-0.05 ± 0.88 cm). The BMI of this population ranged between 18 and 31 
Kg/m
2
. The mean and standard deviation was 83.69 ± 9.59 cm for measure 1 and 
83.52 ± 9.89 cm for measure 2. The upper and lower limits of differences between 
the two measurements were between 1.15 and 0.15 cm, respectively. 
 
TEM: The intra examiner TEM was estimated to be 0.41. As for rTEM, which 
involves calculating deviations for each for the 10 volunteers, results are shown in 
table 3.1.  
Table 3.1: Relative TEM for study participants 
 P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 
Measurement 
Time 1 
64.75 
 
87.5 
 
77.25 92.35 93.85 85.2 90.15 73.65 79.8 92.35 
Measurement 
Time 2 
63.6 
 
87.75 
 
77.4 92.4 94 85.5 89 73 79.95 92.62 
Deviations (d) -1.15 0.25 0.15 0.05 0.15 0.3 -1.15 -0.65 0.15 0.27 
d
2
  1.32 0.063 0.023 0.0025 0.023 0.09 1.32 0.42 0.023 0.073 
∑d2 3.36          
TEM 0.41          
VAV 83.6          
rTEM % 0.49          
P: Participant, TEM: Technical error of measurement, rTEM: Relative TEM, VAV: Variable 
average value. For VAV, the average measurement of WC at two time points was calculated 
for each participant. The average for the 10 participants was then summed up and divided 
by 10. 
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The determination of ICC via SPSS software yielded a coefficient of 0.998. The 
coefficient of reliability was estimated to be R = 0.99. 
3.6 Discussion 
 
The findings of this study showed that the estimate of error rTEM (0.49 %) indicate 
a high level of accuracy (<1% (Perini et al. 2005)). In addition, the consistency 
between measures was shown to be excellent, as demonstrated by ICC which was 
found to be 0.998. The degree of reliability was also shown to be high (r = 0.99). 
Results indicate a lower intra-observer degree of error than the study of Geeta et al. 
(2009) (TEM and rTEM were 0.77 and 0.91 respectively), which used the same 
protocol of WC measurement, and was conducted by inexperienced dietitians on 10 
participants. The coefficient of reliability in the latter study (R = 0.999) was albeit 
similar to the current study.  
In addition, the differences in WC measurement closely match with the results of a 
meta-analysis of 9 studies, which showed that the intra error of measurement for WC 
ranged between 0.7 cm and 9.2 cm. This large difference was mainly explained by 
the unskilled physicians who performed some of these studies (Verweij et al. 2012). 
 
Furthermore, the difference between measurements taken at time 1 and time 2 in this 
study are below to what is considered clinically relevant, the latter term being 
defined as more than 5% decrease in WC over the short-term, and more than 3 % 
over the long term. This should correspond to a change of 3.5 cm for a WC of 70 cm, 
and 5.5 cm for a WC of 110 cm over the short term. Yet, the duration of the short 
and long terms were not specified. Therefore, considering that the values of WC 
generally range between 60 and 135 cm, clinically relevant short-term changes range 
between 3 - 6.8 cm, while clinically relevant long term changes range between 1.8- 
4.1 cm (Verweij et al. 2012). Consequently, this reliability study showed that it is 
possible to detect both short term and long term clinically relevant changes in WC 
despite the error of measurement. An important point to mention is that although it 
was reported that overweight and obese represent a higher error measurement of WC 
compared to normal weight individuals due to the difficulty in locating the bones, a 
larger decrease in waist circumference (for the same percentage) compared to normal 
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weight individuals is needed to detect a clinically significant change (Verweij et al. 
2012). 
As for the protocol of WC used in this study (the middle point between the lowest rib 
and the top of the hip bone), it has been stated in the meta-analysis of Verweij et al. 
(2012) that although 6 of the nine included studies included have used the same 
protocol, this way of measuring WC presents a higher degree of error compared to 
the measurement at the level of the lower rib. The latter site has been reported to be 
more easily measured. This is an important point to consider in the future in order to 
obtain a more accurate measurement of WC. 
 
The findings of this intra-observer study were effective in determining the reliability 
of WC measurement when performed by the same researcher in subsequent studies. 
Findings also imply that the measuring tape used in this study is a reliable instrument 
to be used in the following two trials. Nonetheless, this study is limited by the 
impossibility of hiding the purpose of the study from the researcher, which might 
have resulted in a bias. 
 
In conclusion, results suggest that measurement of waist circumference by the same 
researcher is accurate, as the intra-error of measurement in this study is minimal. It is 
then possible to perform this method to measure WC in studies I and II. Future 
studies should probably consider establishing a uniform protocol for the 
measurement of WC.  
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 CHAPTER 4: RESULTS AND DISCUSSION 
4.1 Study I 
4.1.1 Results 
4.1.1.1 Baseline and population characteristics 
Advertisement via the university email generated the highest rate of response to the 
study followed by word-of mouth. Sixty-one volunteers completed the trial. The 
study flow is illustrated in Figure 4.1. Regarding ethnicity, 88.5% of participants 
were Europeans while the rest were Chinese (3.3%), middle Easterns (3.3 %), 
Africans (1.6%) and south/central Americans (1.6%) and 1.6% of participants were 
described as having other ethnicities. As for occupation, 86.9% were students and 
13.1% were employed. Female participants represented 80.3% of the study 
population. One woman was postmenopausal. The baseline characteristics of the 
overall study population and split according to the type of intervention are presented 
in Table 4.1.  
Table 4.1: Baseline characteristics of the study population 
 Study population 
N=61 
Placebo group 
N=30 
PRDC group 
N=31 
Difference 
between 
groups 
Significance  
(p=    ) 
                        Mean ± SD   
Age (years) 28.82 ± 8.89 28.13 ± 8.98 29.48 ± 8.89 0.48 
BMI (Kg/m
2
)  23.92 ± 4.17 24.08 ± 3.78 23.77 ± 4.57 0.4 
WC (cm) 77.7 ± 10.52 76.83 ± 8.89 78.54 ± 11.98 0.17 
PRDC: Polyphenol-rich dark chocolate, WC: Waist circumference. Results are expressed as 
means ± SD. Data was analysed using an independent t-test. 
 
As shown in Table 4.1, no differences in baseline characteristics between the placebo 
and PRDC group were noted. In addition, there were no gender differences             
(p= 0.063) between the 2 groups. Based on the BMI classification, 22 participants 
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were overweight and 39 were normal weight. Among participants with              
BMI> 25 Kg/m
2
 (N=22), 17 were overweight (BMI< 30 Kg/m
2
) while the rest were 
obese. Three normal weight and 20 overweight participants had a high WC 
(classification of WC is presented in Figure 2.4), and were classified at increased 
risk of metabolic complications. BMI and WC seem to follow a linear model. There 
was a strong linear association between BMI and WC (r (Pearson’s) = 0.913, 
p<0.001) (Figure 4.2). 
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized controlled trial 
(RCT) (61 participants) 
64 Randomized participants 
18 excluded 
1 with high blood 
pressure 
1 with epilepsy 
1 allergic to 
chocolate 
components 
4 decided not to 
participate 
7 did not respond to 
the email sent 
4 did not attend the 
appointment 
Recruitment (University 
moderator, community centres, 
gyms, hospitals, universities…) 
82 responses 
3 dropouts 
1 put on migraine medications 
1 had a viral infection 
1 had to travel 
PRDC (500mg)  
N=31 
  
Placebo DC (low in 
polyphenols) N=30 
N=20 with 
BMI<25 kg/m
2
 
N=11 with 
BMI>25 kg/m
2
 
N=19 with 
BMI<25 kg/m
2
 
N=11 with 
BMI>25 kg/m
2
 
4 weeks 
Figure 4.1: Flow of Study I.  
PRDC: Polyphenol-rich dark chocolate 
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             Figure 4.2: Correlation between BMI and WC in Study I 
 WC: Waist circumference. WC (cm). BMI: values represent regression standardized  
predicted values. (r (Pearson’s) = 0.913, p<0.001). 
 
 
Regarding supplement intake, only one participant reported having a usual intake of 
dietary supplements to increase physical capacity (chondroitin). Furthermore, 57.1% 
of volunteers reported having a family history of chronic diseases such as diabetes, 
hypertension and/or cardiovascular diseases, and 19 females mentioned taking 
contraceptives. 
In relation to physical activity, 60.9% of the population mentioned practising more 
than 3 hours of exercise per week, and no significant differences in the baseline 
reported levels of physical activity (when converted to MET/ week) was noted 
between the placebo DC and the PRDC group (Placebo DC: 14.35 ± 14.01 
MET/week; PRDC: 21.08 ± 17.09 MET/week, p= 0.1). 
Four participants did not have their blood withdrawn due to difficulty in 
venepuncture. All participants had their blood pressure taken and they all provided 
saliva samples. However, five samples were excluded from the analysis due to the 
insufficient amount of saliva provided.   
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An independent t-test showed no differences in baseline measurements between 
placebo DC and PRDC groups regarding insulin (p= 0.5), glucose (p= 0.27), 
HOMA-IR (p= 0.41), QUICKI (p= 0.11), SBP (p= 0.96), DBP (p= 0.28) , serum 
lipids (TC (p= 0.7), TG (p= 0.98), HDL (p= 0.27) and LDL (p= 0.98)), hs-CRP              
(p= 0.59) and oxidised LDL levels (p= 0.45). In addition, there was no significant 
difference in the baseline levels between the 2 groups regarding cortisol (p=0.31), 
cortisone (p= 0.77) and 11- β HSD1 activity (p= 0.83) (Table 4.2). None of the 
variables violated the assumption of normality with the exception of cortisol, 
cortisone and the resultant cortisol/cortisone ratio (11-β HSD1). The latter 
parameters were then analysed using Wilcoxon and Mann whitney tests. 
 
Table 4.2: Baseline levels of assessed parameters between placebo DC and PRDC 
groups 
 Placebo DC PRDC 
Insulin (µIU/ml) 6.52 ± 3.83 5.83 ± 3.87 
HOMA-IR 1.42 ± 0.89 1.23 ± 0.84 
QUICKI 0.73 ± 0.15 0.86 ± 0.4 
Glucose (mmol/l) 4.84 ± 0.37 4.7 ± 0.55 
SBP (mmHg) 119.2 ± 11.85 119.03 ± 12.99 
DBP (mmHg) 77.37 ± 7.71 75.35 ± 6.76 
TC (mmol/l) 4.26 ± 0.79 4.17 ± 1.07 
LDL cholesterol (mmol/l) 2.23 ± 0.8 2.23 ± 0.97 
HDL cholesterol (mmol/l) 1.66 ± 0.35 1.56 ± 0.36 
TG (mmol/l) 0.83 ± 0.32 0.96 ± 0.37 
Oxidised LDL (ng/ml) 60.07 ± 16.66 63.68 ± 17.83 
Hs-CRP (mg/l) 1.35 ± 0.97 1.5 ± 1.04 
Cortisol (nmol/l) 3.34 ± 1.88 2.82 ± 1.49 
Cortisone (nmol/l) 4.39 ± 2.4 4.5 ± 3.03 
11-β HSD1 
(cortisol/cortisone ratio) 
0.99 ± 1.06 0.79 ± 0.46 
 
HOMA-IR: Homeostasis modelling assessment-IR, QUICKI: Quantitative insulin sensitivity check 
index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: Total cholesterol, LDL: Low 
density lipoprotein; HDL: High density lipoproteins, TG: Triglycerides, hs-CRP: high sensitivity C-
reactive protein, 11 β-HSD1: 11-beta hydroxysteroid dehydrogenase 1. There were no significant 
differences in baseline levels of assessed parameters between the 2 groups (p> 0.05). Results are 
expressed as mean ± SD. 
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4.1.1.2 Haematological assessment 
a. Insulin, glucose levels, HOMA and QUICKI 
Results showed a significant effect of PRDC on insulin levels (p< 0.001), HOMA-IR 
(p=0.003), and QUICKI (p< 0.001), but no significant effect on glucose levels       
(p= 0.16). Participants in the PRDC group had a significant decrease in insulin levels 
(from 5.83 ± 3.87 µIU/ml to 4.66 ± 3.86 µIU/ml), HOMA-IR (from 1.23 ± 0.84 to 
1.02 ± 0.85), and an increase in QUICKI (from 0.86 ± 0.4 to 1.98 ± 0.4) after four 
weeks. Interestingly, participants administered placebo DC had an increase in their 
insulin levels (from 6.52 ± 3.83 µIU/ml to 7.29 ± 4.52 µIU/ml, p= 0.014), HOMA-
IR (from 1.42 ± 0.89 to 1.69 ± 1.07, p=0.003), and a decrease in QUICKI (from 0.73 
± 0.15 to 0.69 ± 0.79, p=0.013). Also, glucose levels increased at the end of the 
study in the placebo DC group by 0.44 ± 1.08 mmol/l (p= 0.041) (Figures 4.3 and 
4.4 and 4.5).  
However, the positive effect on insulin sensitivity in the PRDC group was not 
associated with an amelioration of β-cell function estimated by HOMA-β (p= 0.49). 
Also, no significant change in this indicator was noted in the placebo DC group 
(p=0.7) as a result of an increase in insulin and glucose levels. 
 
As for the magnitude of association between markers of glucose and markers of 
insulin metabolism in the study population, pearson’s correlation showed a strong 
association between changes in insulin and changes in HOMA-IR (r= 0.904, 
p<0.001) and QUICKI (r= -0.502, p< 0.001). However, changes in glucose levels 
were not correlated to post-pre differences in HOMA-IR index (r=0.037, p= 0.79), 
and QUICKI (r= -0.2, p= 0.13). These results suggest that changes in insulin 
resistance/sensitivity in this study were principally correlated to changes in insulin 
levels. 
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Figure 4.3: Changes in insulin levels from baseline in the placebo DC and 
PRDC groups following the intervention 
* p<0.05.DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate. Data expressed as 
mean ± SEM. Bar charts represent the differences from baseline (post – pre) in the placebo 
DC and PRDC groups after 4 weeks. Data was analysed using paired-t-test. 
 
 
 
 
 
  
 
 
Figure 4.4: Changes in QUICKI and HOMA-IR indexes following PRDC 
consumption compared to placebo 
* Significant difference from pre intervention (baseline), p < 0.05. HOMA-IR: Homeostasis 
modelling assessment-insulin resistance, QUICKI: Quantitative insulin sensitivity check index, 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate. Data was analysed using paired-t-
test and expressed as mean ± SEM. 
 * 
 
 * 
 
 * 
 
 * 
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Figure 4.5: Changes in glucose levels in the placebo DC and PRDC after 4 
weeks. 
* Significant difference from pre intervention (baseline), p < 0.05. DC: Dark chocolate, 
PRDC: Polyphenol-rich dark chocolate. Results expressed as mean ± SEM. Data was 
analysed using paired-t-test. 
 
b. Lipid profile 
Results showed that TC, HDL and LDL levels did not significantly change 
throughout the intervention in both groups (p>0.05). However, there was a 
significant increase in TG levels in the placebo DC group. In the PRDC group, TG 
levels decreased but did not reach statistical significance (Table 4.3). 
 
 
 
 
 
 * 
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Table 4.3: Changes in serum lipid levels from baseline following the 
intervention 
Lipid 
levels 
(mmol 
/l) 
Pre-PRDC 
Mean ± 
SD 
Post-
PRDC 
Mean ± 
SD 
∆ (Post-
PRDC 
- Pre-PRDC) 
p Pre- 
placebo 
Mean ± 
SD 
Post-placebo 
Mean ± SD 
∆ (Post-
placebo 
- Pre-
placebo) 
p 
TC  4.17±1.07 4.23±0.98 0.059±0.76 0.68 4.26 ± 0.79 4.5 ± 1.15 0.24± 0.91 0.18 
LDL  
 
2.23±0.97 
 
2.22±1.06 -0.013±0.66 0.92 2.23 ± 0.8 2.35 ± 1.08 0.11 ± 0.73 0.43 
HDL 1.56±0.36 
 
1.64±0.34 0.08 ± 0.27 0.12 1.66 ± 0.35 1.73 ± 0.4 0.07 ± 0.24 0.12 
TG 0.83±.0.46 0.69±0.23 -0.15 ± 0.43 0.07 0.83 ± 0.32 0.96 ± 0.37 0.13 ± 0.23* 0.008 
*Significant difference from pre intervention (baseline), p< 0.05. DC: Dark chocolate, 
PRDC: Polyphenol-rich dark chocolate, TC: Total cholesterol, LDL: Low density 
lipoprotein, HDL: High density lipoproteins, TG: Triglycerides. Data was analysed using 
paired t-test and expressed as Mean ± SD. 
 
c. LDL oxidation levels  
A significant effect of treatment on oxidised LDL levels was only noted in the PRDC 
group (p= 0.042). Levels of oxidised LDL dropped from 63.68 ± 17.83 ng/ml to 
57.03 ± 14.08 ng/ml after PRDC consumption, while in the placebo group, no 
significant change in these levels occurred (Baseline: 60.07 ± 16.66 ng/ml, post 
intervention: 61.92 ± 16.34 ng/ml, p= 0.42) (Figure 4.6). 
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Figure 4.6: Changes in LDL oxidation levels from baseline following the 
consumption of PRDC and placebo DC.  
*p<0.05. PRDC: Polyphenol-rich dark chocolate, LDL: Low density lipoproteins. Bar 
charts represent the differences from pre intervention (baseline) in the placebo DC and 
PRDC groups after 4 weeks. Results expressed as means ± SEM. Data was analysed using 
paired-t-test. 
 
d. High sensitivity CRP (Hs-CRP) 
Results showed no significant changes in the inflammatory marker hs-CRP in both 
PRDC from baseline (from 1.35 ± 0.97 mg/l to 1.26 ± 0.88 mg/l; ∆= -0.46 ± 0.2 
mg/l, p= 0.32), and placebo DC groups (from 1.5 ± 1.04 mg/l to 1.54 ± 1.12; ∆= 
0.09 ± 0.8 mg/l,    p= 0.57) after 4 weeks. 
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4.1.1.3 Cortisol, cortisone levels, and the activity of the 11-β HSD1 
Results showed no significant changes in cortisol and cortisone levels, and in the 
activity of the enzyme 11-β HSD1 (cortisol/cortisone ratio), following the 
consumption of placebo DC or PRDC group (Table 4.4).  
     Table 4.4 : Changes in saliva cortisol and cortisone levels and in the activity   
      of 11-β HSD1 from baseline in the placebo DC and PRDC groups  
 Placebo (Mean 
difference ± 
IQR)  
p PRDC (Mean ± 
IQR) 
p 
Cortisol (nmol/l) 0.33 ± 0.96 0.1 0.11 ± 0.54 
 
0.27 
Cortisone (nmol/l) 0.37 ± 1.17 
 
0.22 -0.77 ±2.05 0.34 
11-β HSD1(Cortisol/ 
cortisone ratio) 
-0.14 ± 0.12 0.44 -0.2 ± 0.38 0.1 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate, 11 β-HSD1: 11-beta 
hydroxysteroid dehydrogenase 1. Data expressed as Mean difference (IQR: interquartile 
range). Changes from baseline were not significant in both groups after 4 weeks.                          
       
4.1.1.4 Blood pressure 
There were no significant changes in blood pressure following the intervention. In 
the placebo group, no significant changes from baseline in SBP (pre: 119.2 ± 11.95 
mmHg; post: 117.39 ± 9.98 mmHg, p= 0.14) or DBP (pre: 77.37 ± 7.71 mmHg; 
post: 77.13 ± 7.97, p= 0.8) were noted. Similarly, SBP (pre: 119.03 ± 12.99 mmHg, 
post: 119.07 ± 11.88 mmHg, p= 0.97) and DBP (pre: 75.35 ± 6.76 mmHg, post: 
75.52 ± 6.3, p= 0.88) did not significantly change in the PRDC group after 4 weeks. 
                                
4.1.1.5 Weight, BMI and waist circumference 
Analysis of differences from baseline showed that weight, BMI and WC did not 
significantly change in the PRDC group, whereas four weeks of daily DC 
consumption increased weight in the placebo DC group (Table 4.5). 
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 Pre-PRDC 
Mean ± SD 
Post-PRDC 
Mean ± SD 
∆ (Post-
PRDC 
- Pre-
PRDC) 
p Pre- placebo 
Mean ± SD 
Post-
placebo 
Mean ± SD 
∆ (Post-
placebo 
- Pre-
placebo) 
p 
Weight 
(Kg) 
70.26±16.04 70.25±16.32 -0.01±0.9 0.98 66.16± 12.43 66.6± 12.54 0.44± 0.86* 0.009 
BMI 
(Kg/m
2
)  
23.77± 4.57 23.76±4.65 -0.01±0.3 0.82 24.08±3.78 24.25±3.87 0.17 ±0.32* 0.007 
WC  
(cm) 
78.54±11.98 78.75±11.8 0.21± 1.7 0.5 76.83±8.89 76.96±8.98 0.13 ±0.84 0.42 
*Significant difference from pre intervention (baseline), p< 0.05. WC: waist circumference, 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate. Data analysed using paired   
t-test and expressed as Mean ± SD.  
 
4.1.1.6 ANCOVA measures 
In order to control for any potential baseline imbalances, and to identify significant 
differences between groups, ANCOVA measures were performed for the assessed 
parameters, with dependent variables being the post values, the covariates being the 
pre values, and the fixed factor being the type of intervention. Results showed 
significant differences between groups for HOMA-IR, QUICKI, Insulin, TG, 
oxidised LDL, BMI and weight, but not for waist circumference, glucose, blood 
pressure, hs-CRP, and other serum lipid levels. None of the above mentioned 
variables violated the assumption of heterogeneity (Levene’s test > 0.05). ANCOVA 
results are shown in Table 4.6. 
 
 
 
 
 
Table 4.5: Changes in anthropometric measurements in the placebo DC and PRDC 
groups following the intervention 
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Table 4.6: Differences between groups after adjusting for baseline values of 
assessed parameters in the placebo and PRDC groups 
     Placebo  DC            PRDC   
 Adjusted 
pre mean 
value for 
both 
groups 
Adjusted 
post mean 
value 
 
95% CI Adjusted 
post Mean 
value 
 
(95% CI Difference 
between 
groups 
p 
Glucose 
(mmol/l) 
4.77 5.23 (4.88, 5.59) 4.96  (4.61, 5.3) 0.27 
Insulin (µIU/ml) 6.17 6.93 (6.38, 7.5) 5.0 (4.46, 5.55) <0.001 
HOMA-IR 1.32 1.6 (1.44, 1.74) 1.12  (0.97, 1.27) <0.001 
QUICKI 0.8 0.66  (0.56, 0.76) 2.01  (1.9, 2.11) <0.001 
TC (mmol/l) 4.22 4.46  (4.16, 4.77) 4.26  (3.96, 4.57) 0.35 
LDL (mmol/l) 2.23 2.34  (2.08, 2.61) 2.22  (1.96, 2.48) 0.5 
HDL (mmol/l) 1.61 1.7  (1.6, 1.79) 1.68  (1.6, 1.77) 0.8 
TG (mmol/l) 0.83 0.96  (0.86, 1.06) 0.69  (0.59, 0.78) <0.001 
Oxidised LDL 
(ng/ml) 
61.88 62.97 (58.25, 
67.69) 
55.98 (51.26, 60.7) 0.041 
Hs-CRP (mg/L) 1.42 1.32  (1.1, 1.54) 1.48  (1.26, 1.7) 0.31 
SBP (mmHg) 119.13 117.32  (115.22, 
119.43) 
119.13  (117.06, 
121.2) 
0.23 
DBP (mmHg) 76.34 76.4  (74.57, 
78.22) 
76.23  (74.44, 
78.02) 
0.9 
Weight (Kg) 68.24 68.71 (68.39, 
69.03) 
68.21 (67.9, 68.52) 0.031 
WC (cm) 77.7 77.81 (77.3, 78.3) 77.92 (77.44, 78.4) 0.76 
BMI (Kg/m
2
) 23.92 24.1 (23.98, 
24.2) 
23.91 (23.81, 
24.02) 
0.028 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate, HOMA-IR: Homeostasis 
modelling assessment-insulin resistance, QUICKI: Quantitative insulin sensitivity check 
index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: Total cholesterol, 
LDL: Low density lipoprotein; HDL: High density lipoproteins, TG: Triglycerides, hs-CRP: 
high sensitivity C-reactive protein, 11 β-HSD1: 11-beta hydroxysteroid dehydrogenase 1, 
WC: waist circumference, CI: Confidence interval. Data expressed as adjusted means (pre, 
post values) and 95% CI (lower bound, upper bound). Results represent the differences 
between PRDC and placebo DC groups after adjusting for baseline differences. 
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As for glucocorticoid metabolism, the comparison of differences from baseline 
between the 2 groups (via Mann Whitney test) showed no significant difference in 
cortisol (p = 0.58), cortisone (p= 0.11) and 11-β HSD 1 activity levels (p= 0.34). 
 
4.1.1.7 Assessment of diet diaries and compliance 
All participants returned the empty containers, and 5 participants reported forgetting 
or skipping the intake of the daily amount of chocolate for at least once, and no more 
than 3 times during the whole intervention period. The compliance was estimated to 
be 86.58 %. This was calculated by counting the returned plastic bags, and asking 
participants about the number of times they have missed the daily portion of 
chocolate over the study period (28 days). The percentage of compliance was 
calculated for each participant, and the average percentage was considered for the 61 
participants.  
Reported physical activity levels (MET/ week) did not significantly change 
throughout the intervention in the placebo group (Pre: 14.35 ± 14.01; MET/week 
post: 13.32 ± 14.76 MET/week, p= 0.36) and the PRDC group (Pre: 21.08 ± 17.09 
MET/week; post: 20.37 ± 16.78 MET/week, p= 0.54). 
All participants provided self-reported diet diaries. Paired-sample analysis on the 
Netwisp software (V3.0) showed no significant differences in energy and 
macronutrient intake following the intervention in both groups. Participants whether 
on a placebo DC or PRDC, maintained their usual diet throughout the study (Table 
4.7). An independent t-test on Netwisp software was also carried out, and 
documented no significant differences in baseline energy and macronutrient intakes 
between the placebo group and the PRDC group (p>0.05).  
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Table 4.7: Mean differences in energy and macronutrient intakes between the 
run-in period and week 3 
  Run-in period Week 3 
Energy (Kcal) Placebo DC 
(N=30) 
1799 ± 522 1746 ± 416 
 PRDC (N=31) 1868 ± 564 1998 ± 644 
Carbohydrate (g) Placebo DC 
(N=30) 
226.9 ± 64 208.3 ± 58 
 PRDC (N=31) 233 ± 61 234 ± 62 
Protein (g) Placebo DC 
(N=30) 
64 ± 22.2 63.2 ± 19.5 
 PRDC (N=31) 73 ± 41.7 84 ± 49.5 
Fat (g) Placebo DC 
(N=30) 
73.2 ± 32 73.4 ± 25 
 PRDC (N=31) 72.6 ± 29.3 82.7 ± 34.3 
DC: dark chocolate, PRDC: polyphenol-rich dark chocolate. Results are expressed as        
mean ± SD. Differences were not significant (p>0.05). Data was analysed using paired t-
test. 
 
4.1.1.8 Subgroup analysis: Impact of BMI 
To identify any impact of weight status on the outcomes, a subgroup analysis based 
on BMI was performed. Data was split according to the type of intervention (placebo 
DC or PRDC) and weight (BMI<25 Kg/m
2
 and BMI>25 Kg/m
2
). The baseline 
characteristics of the population stratified according to these criteria are presented in 
table 4.8. 
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Table 4.8: Baseline characteristics of the study population split according to  
the study intervention and BMI 
  Placebo DC group 
N=30 (BMI<25 
Kg/m
2
, N=19; 
BMI>25 Kg/m
2
, 
N=11) 
PRDC group 
N=31 (BMI<25 
Kg/m
2
 N=20; 
BMI>25 Kg/m
2
, 
N=11) 
                         Mean ± SD 
Age (years) BMI<25 Kg/m
2
 24.95 ± 4.63  27.35 ± 7.34  
 BMI>25 Kg/m
2
 33.64 ± 11.94 33.36 ± 10.39 
BMI (Kg/m
2
)  BMI<25 Kg/m
2
 21.64 ± 1.56 20.96 ± 1.66 
 BMI>25 Kg/m
2
 28.3 ± 2.45 28.89 ± 3.58 
WC (cm) BMI<25 Kg/m
2
 71.21 ± 4.77 71.67 ± 5.48 
 BMI>25 Kg/m
2
 86.55 ± 4.96 91.02 ± 10.37 
WC: waist circumference, DC: Dark chocolate, PRDC: Polyphenol-rich dark 
chocolate. Results are expressed as mean ± SD. 
    
 
Analysis via Mann-Whitney test showed a significant age difference between the 2 
BMI categories in the group administered placebo DC (p=0.034), but not in the 
PRDC group (p=0.1).  
Regarding other variables, in the placebo DC group, there was a significant 
difference in baseline levels of SBP (p= 0.012), DBP (p= 0.015), insulin levels       
(p= 0.021), HOMA-IR (p= 0.024), QUICKI (p= 0.024), as well as in TC (p= 0.031), 
HDL (p= 0.055) and LDL (p= 0.003)) levels between normal weight and overweight 
participants. All the parameters were higher in the overweight group, while HDL 
levels were lower. While in the PRDC group, there was a significant difference in 
glucose levels (p= 0.015), as well as in TC (p= 0.034), HDL (p= 0.055), LDL        
(p= 0.04), TG (p= 0.003) and hs-CRP (p= 0.013) levels between the two BMI 
categories (in the overweight group, all the parameters were higher, whereas HDL 
levels were lower).  
Interestingly, participants whether normal weight or overweight did not significantly 
differ in self-reported baseline energy and macronutrient intake levels. In the placebo 
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group, no differences between the two BMI categories regarding energy (p= 0.72), 
protein (p= 0.43), fat (p= 0.91) and carbohydrate (p=0.72) were noted, similarly to 
the PRDC group (p= 0.46, p= 0.88, p= 0.21 and p= 0.56, respectively) (Table 4.9). 
Additionally, no significant differences in the baseline levels of physical activity 
(assessed by MET/week) were noted between the normal weight and the overweight 
category in the placebo DC (p = 0.16) and PRDC (p= 0.17) groups. 
 
Table 4.9: Differences in baseline energy and macronutrient levels between 
normal weight and overweight individuals in both placebo DC and PRDC 
groups 
          Placebo DC               PRDC 
  Mean  95% CI Mean  95% CI 
 
Energy (Kcal) BMI<25 Kg/m
2
 
BMI>25 Kg/m
2
 
1848 (1548, 2147) 
1719 (1474, 1965) 
1886 (1600, 2143) 
1837 (1504, 2164) 
Carbohydrates (g) BMI<25 Kg/m
2
 
BMI>25 Kg/m
2
 
234 (199, 269) 
238 ( 179, 252) 
238 (210, 266) 
225 (181, 269) 
Protein (g) BMI<25 Kg/m
2
 
BMI>25 Kg/m
2
 
65.35 (58.07, 72.64) 
60.0 (51.71, 68.29) 
78.18 (61.96, 94.39) 
83.47 (67.9, 99.04) 
Lipids (g) BMI<25 Kg/m
2
 
BMI>25 Kg/m
2
 
72.98 (57.75, 88.2) 
73.59 (49.25, 97.93) 
73.17 (59.11, 87.22) 
71.56 (51.74, 91.39) 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate, CI: Confidence interval. 
Results expressed as mean pre (95% CI: Lower bound, Upper bound).  
 
To determine differences in responses based on BMI, Mann Whitney test was 
performed. Mean differences (post – pre) were compared between the 2 BMI 
categories in each group. Results showed a significant impact of BMI on HOMA-IR 
only in the placebo group, while no significant other differences were noted. Results 
are shown in Table 4.10. 
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Table 4.10: Differences in responses to intervention based on BMI in the 
placebo DC and the PRDC groups 
       Placebo DC                PRDC  
  Mean diff  
(IQR) 
p value Mean diff 
 (IQR) 
p value 
Glucose (mmol/l) BMI<25 
BMI>25 
0.27 (0.83) 
0.73 (0.88) 
0.11 0.35 (0.7) 
-0.04 (1.13) 
0.39 
Insulin (µIU/ml) BMI<25 
BMI>25 
0.3 (1.04) 
2.2 (3.21) 
0.07 -1.35 (1.15) 
-1.25 (1.62) 
0.42 
HOMA-IR BMI<25 
BMI>25 
0.13 (0.39) 
0.63 (0.89)* 
0.017 -0.25 (0.47) 
-0.29 (0.56) 
0.85 
QUICKI BMI<25 
BMI>25 
-0.3 (0.08) 
-0.06 (0.06) 
0.24 0.96 (1.06) 
1.24 (1.05) 
0.38 
TC (mmol/l) BMI<25 
BMI>25 
0.9 (0.85) 
0.05 (0.85) 
0.35 0.17 (1.25) 
0.01 (0.7) 
0.73 
LDL (mmol/l) BMI<25 
BMI>25 
0.25 (1.14) 
-0.02 (0.78) 
0.7 -0.017 (1.32) 
-0.11 (0.59) 
0.44 
HDL (mmol/l) BMI<25 
BMI>25 
0.16 (0.49) 
-0.04 (0.15) 
0.25 0.09 (0.28) 
0.04 (0.37) 
0.58 
TG (mmol/l) BMI<25 
BMI>25 
0.13 (0.4) 
0.91 (1.37) 
0.59 -0.07 (0.4) 
-0.31 (0.55) 
0.13 
Hs-CRP (mg/L) BMI<25 
BMI>25 
0.9 (0.97) 
0.54 (1.32) 
0.56 0.25 (1.02) 
0.32 (1.2) 
0.35 
Oxidised LDL 
(ng/ml) 
BMI<25 
BMI>25 
0.9 (21.0) 
-3.59 (40.75) 
0.58 -0.25 (16.69) 
-9.82 (27.29) 
0.17 
SBP (mmHg) BMI<25 
BMI>25 
0.04 (10) 
-4.78 (12.5) 
0.09 -0.54 (0.7) 
 0.7 (6.3) 
0.22 
DBP (mmHg) BMI<25 
BMI>25 
 0.67 (8.0) 
-0.44 (8.0) 
0.87  0.62 (5.5) 
-1.3 (6.5) 
0.55 
Cortisol (nmol/L) BMI<25 
BMI>25 
0.26 (1.35) 
0.12 (1.33) 
0.32 -0.21 (0.76) 
0.48 (0.39) 
0.46 
Cortisone (nmol/l) BMI<25 
BMI>25 
0.28 (1.26) 
0.05 (1.47) 
0.96 -1.32 (2.59) 
-0.2 (1.72) 
0.38 
Cortisol/Cortisone 
ratio 
BMI<25 
BMI>25 
0.78 (0.21) 
-0.22 (0.34) 
0.22 0.12 (2.54) 
0.54 (1.26) 
0.64 
Weight (Kg) BMI<25 
BMI>25 
0.44 (1.05) 
0.52 (1.6) 
0.3 -0.2 (1.53) 
0.32 (1.42) 
0.47 
WC (cm) BMI<25 
BMI>25 
0.13 (1.0) 
0.25 (0.75) 
0.29 0.81 (0.68) 
-0.14 (1.98) 
0.24 
BMI (Kg/m
2
) BMI<25 
BMI>25 
0.12 (0.41) 
0.24 (0.48) 
0.36 -0.05  (0.44) 
0.059  (0.21) 
0.09 
 
 
 
*Significant difference in the response to intervention between the normal weight and 
overweight population in the placebo group, p<0.05. DC: Dark chocolate, PRDC: Polyphenol-
rich dark chocolate. HOMA-IR: Homeostasis modelling assessment-insulin resistance, QUICKI: 
Quantitative insulin sensitivity check index, SBP: systolic blood pressure, DBP: diastolic blood 
pressure, TC: Total cholesterol, LDL: Low density lipoprotein; HDL: High density lipoproteins, 
TG: Triglycerides, hs-CRP: high sensitivity C-reactive protein, 11 β-HSD1: 11-beta 
hydroxysteroid dehydrogenase 1, WC: waist circumference. Results are expressed as mean 
difference (IQR: Interquartile range). 
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For HOMA-IR, Wilcoxon test was performed while splitting the placebo group 
based on BMI and type of intervention. Analysis showed that the increase in 
HOMA-IR was only in the overweight group (p= 0.017), while it was not affected in 
the normal weight group (p= 0.11) following placebo DC consumption. 
 
4.1.1.9 Qualitative data 
Data regarding the acceptability of treatment were collected at the end of the 
intervention. Most of participants (. 65.6 %) found the dark chocolate consumption 
very acceptable, and 29.5 % found it somewhat acceptable, while the rest (4.9%) 
found it unacceptable. Interestingly, splitting participants whether they consumed 
PRDC or placebo with regards to acceptability, it was found that placebo DC was 
more acceptable than PRDC (Figure 4.7).  
The reasons for unacceptability (or for the decrease in the tolerance for the 
experimental chocolate) stated were mainly the dense colour of the chocolate which 
made it less appealing (1 participant in the PRDC), the bitterness and intense flavour 
(3 participants in the PRDC) and the texture (2 participants: 1 in the placebo DC 
group and 1 in the PRDC group). The latter participant stated that the consumption 
of drops instead of a bar gives the impression of taking a medicine and consuming a 
lot of chocolate. Other participants found the chocolate unacceptable because of its 
side effects: acne outbreaks (one participant in the placebo DC group), headache 
(one participant in the PRDC group), nausea, bloating, winds, stomach pain (one 
participant in the PRDC group). These complaints, although noteworthy, did not 
result in any dropout. As for other comments mentioned by volunteers, one 
participant stated that DC sometimes tended to decrease his appetite for sweets after 
lunch, but to increase his cravings on other occasions. Five participants found it 
impractical to consume this amount of chocolate everyday, and one participant 
preferred a higher percentage of cocoa. Also, 72.1% of participants mentioned that 
they will continue consuming dark chocolate frequently.  
Lastly, only 52.5% of participants were able to identify the assigned chocolate type, 
suggesting that the perception did not affect the outcomes. 
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Figure 4.7: Acceptability of treatment based on the type of intervention  
DC: dark chocolate, PRDC: Polyphenol-rich dark chocolate. 
 
In summary, the results of study I showed that PRDC reduced fasting insulin, 
HOMA-IR, oxidised LDL levels, and increased QUICKI. On the other hand, placebo 
DC increased fasting insulin, HOMA-IR, glucose, TG and levels, and reduced 
QUICKI. Stratification based on BMI factor did not affect the parameters, with the 
exception of HOMA-IR, which only increased in overweight participants. The 
consumption of placebo DC was claimed to be more acceptable than PRDC.  
 
4.1.2 Discussion  
The principal aim of this study was to determine the effect of DC rich in polyphenols 
on insulin sensitivity in the adult population. To improve the reliability of the results, 
the heterogeneity was limited by adhering participants to eligibility criteria, and by 
avoiding confounding factors such as medications, supplements containing high 
doses of antioxidants, smoking, heavy alcohol consumption, and regular cocoa/dark 
Placebo DC 
PRDC 
26.67% 
 
9.7% 
 
73.33% 
 
58.06% 
 
32.26% 
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chocolate consumption. In addition, the two types of chocolate were matched for all 
components (theobromine, caffeine, fibre and minerals (like potassium or 
magnesium)) except for polyphenol content. This excluded potential confounding 
effects resulting from constituents other than polyphenols. For instance, an animal 
study showed that theobromine decreased TG, LDL and total cholesterol, and 
increased HDL in rats (Eteng and Ettarh 2000). This was supported by a human 
study which reported a lowering effect of theobromine (850 mg) on LDL, and an 
increasing effect on HDL following 2 weeks of daily consumption (Neufingerl et al. 
2013). Caffeine was related to an increase in fat oxidation in humans (Acheson et al 
2004), and magnesium was claimed to have hypotensive effects (Jee et al. 2002). 
 
Insulin and glucose metabolism 
This study showed that PRDC supplementation significantly decreased insulin levels 
(by 1.17 ± 1.34 µIU/ml) and improved insulin resistance/sensitivity expressed by a 
decrease in HOMA-IR (by 0.2 ± 0.34), and an increase in QUICKI (by 1.12 ± 0.74) 
in adults. The improvement in insulin sensitivity was in accordance with the results 
of the studies of Grassi et al. (2005), Davison et al. (2008) and Al Moosawi et al. 
(2012), conducted on participants with no history of diabetes, hypertension or CVD. 
While Davison et al. (2008) included only overweight participants, and Al Moosawi 
et al. (2012) noted a beneficial effect merely in the overweight and obese population, 
the results match with the outcomes of Grassi et al. (2005), and showed a significant 
amelioration in IR in normal weight and overweight adults. Yet, the use of two types 
of DC in study I (that looked almost identical) presents advantages over the study of 
Grassi et al. (2005), which used white chocolate as a placebo. This eliminated a 
potential expectation bias resulting from an unblinded study. 
 
The results also correspond with the findings of a meta-analysis which reported that 
cocoa/DC supplementation induced a significant decrease in insulin levels (-2.65 
µIU/ml; 95% CI: -4.65, -0.65) and HOMA-IR (-0.67 µIU/ml; 95% CI: -0.98, -0.36) 
(Hooper et al. 2012). Compared to the meta-analysis, the magnitude of decrease in 
insulin levels and HOMA-IR was lower in this study. This might be attributed to the 
fact that the meta-analysis included studies with patients, who might have higher 
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levels of metabolic complications (Silver et al. 2007), and thus might be more 
affected by the cocoa/chocolate intervention (Moosawi et al. 2012). 
 
The favourable effects on insulin sensitivity might be attributed to the increase in the 
availability of NO (Grassi et al. 2005), and its subsequent effect on improving 
insulin signalling pathways (Bergandi et al. 2003). However, since there was no 
simultaneous change in blood pressure, the mechanism might not have involved an 
improvement of endothelial dysfunction, which in turn decreases insulin and blood 
pressure (Grassi et al. 2005). This suggests that PRDC might mediate IR through 
mechanisms other than the NO pathway. However, Egan et al. (2010) stated that the 
increase in NO bioavailability and vasodilatation do not imply an effect on blood 
pressure, unless this was accompanied by a decrease in renal pressure threshold for 
sodium hemostasis. Consequently, an improvement in insulin sensitivity might occur 
through a NO-mediated effect without affecting blood pressure. Nevertheless, NO 
levels/NOS enzymatic activity were not measured in this study, thus no definite 
conclusions regarding the mechanisms involved can be made. The decrease in 
carbohydrate absorption by cocoa polyphenols is also a suggested mechanism for the 
results noted. This includes the inhibition of digestive enzymes (Tadera et al. 2006), 
and/or intestinal glucose transporters (Cermak et al. 2004; Chen et al. 2007).  
Moreover, the implication of SCFA (the result of fermentation of undigested 
carbohydrates in the colon) in improving insulin sensitivity through increasing          
GLP-1 (which increases β-cell secretion and inhibits gastric emptying) can be 
proposed. Lastly, since HOMA- β did not significantly change in the PRDC group, 
this did not lead to an improvement of β-cell function. Yet, the limitations of this test 
remain in estimating pancreatic β-cell function under non stimulated conditions 
(Cobelli et al. 2007). Therefore, this test did not identify any possible amelioration in 
β-cell function in a non fasting state.   
 
However, it is not clear which fraction of polyphenols was responsible for improving 
IR. Although epicatechin was previously attributed most of the IR lowering 
properties (Rutter 2001; Xuelin et al. 2001), procyanidins were recently suggested to 
have the greatest countering effect on insulin resistance among flavanols (Dorenkott 
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et al. 2014). The amount of procyanidins supposed to improve IR was proposed to be 
equivalent to 2.03 mg/Kg in humans (Dorenkott et al. 2014). Determining the 
efficacy of this considerably low dose of procyanidins in lowering insulin resistance 
might have an important implication. This could help making future 
recommendations based on lower amounts of chocolate, and consequently lower 
energy content. This could also reduce the adverse effects resulting from the intake 
of a high quantity of polyphenols. Studies that compare the effect of cocoa liquor to 
doses of flavanols monomers and procyanidins might help in elucidating the 
implication of each flavanol fraction in insulin metabolism. In addition, as quercetin 
was suggested to be implicated in decreasing hyperinsulinemia (Li et al. 2013), it is 
not known whether the amount of quercetin in the experimental chocolate was 
sufficient to induce such effects. In this study, the quantity of quercetin in PRDC was 
not assessed, but it is known that the quercetin dose was less 100 mg in the 20g daily 
portion. Studies looking at the amount that could be involved in the favourable 
effects on insulin sensitivity might need to be considered. Notably, a decrease in IR 
resulting from a combined effect of different fractions of flavonoids could also be 
proposed.  
 
An important point to mention is that the hypoinsulinemic effect of cocoa 
polyphenols in this study corresponds to studies in the literature that found similar 
outcomes (Grassi et al. 2005; Davison et al. 2008), but contradicts other studies that 
showed an increase in insulin levels following cocoa/DC administration (Rutter 
2001; Grassi et al. 2008; Yamashita et al. 2013). Although this appears confusing, it 
was suggested that the effect of these polyphenols on insulin and carbohydrate 
metabolism depends on the context, which results in different mechanisms of action 
of polyphenols. For instance, following carbohydrate ingestion, the increase in 
insulin secretion occurs through the stimulation of GLP-1 by flavanols, resulting in a 
decrease in glucose levels (Dorenkott et al. 2014). On the other hand, the effect of 
flavanols on the improvement of insulin signalling pathways and the decrease in 
insulin needs might lead to a decrease in fasting insulin levels (Grassi et al. 2005; 
Davison et al. 2008). These clarifications might be helpful in designing studies that 
aim to assess the increasing or the lowering effect of these flavonoids on insulin 
levels.  
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Unlike the studies held by Al Moosawi et al. (2010; 2012), who used the same type 
and daily amount of chocolate, this study showed no significant effect of PRDC on 
glucose levels (p= 0.16). The difference in the results might be attributed to some 
factors such as the adoption of a crossover study design in the studies of Al Moosawi 
et al. (2010; 2012). This might have resulted in a higher treatment effect than a 
parallel design, due the fact that crossover studies could be unblinded because of a 
carry-over effect (Feys et al. 2012). Moreover, it was noted that the non significant 
effect on glucose levels could be attributable to the study duration. A meta-analysis 
of 11 trials showed that studies lasting less than 3 weeks were the ones that showed a 
decrease in blood glucose levels, due to a higher compliance compared to longer 
term studies. Other factors, such as the dose of epicatechin used could not justify the 
non significant effects obtained in this study, since the dose that was shown to exert 
a lowering effect on glucose levels ranged between 50-100 mg/day (Hooper et al. 
2012). In Study I, PRDC contained 85 mg of epicatechin. Furthermore, the results 
might be attributed to the fact that the decrease in blood glucose levels following 
PRDC consumption are mostly exhibited by a decrease in postprandial glucose 
levels. This was previously shown in the studies of (Gutiérrez-Salmeán et al. (2014), 
Grassi et al. (2008) and Al Jalil et al. (2008). This effect on postprandial glucose 
levels could be attributed to the procyanidin fraction (particularly oligomers) in 
cocoa. In fact, due to their low absorption, procyanidins might exert direct effects on 
glucose metabolism in the gastrointestinal tract, through several factors such as 
inhibiting carbohydrate absorption and decreasing the degradation of GLP-1. 
However, their effects on fasting glucose levels might be less effective (Dorenkott et 
al. 2014). Fractioning cocoa flavanols based on their degree of polymerisation is 
important to elucidate the mechanisms of action of these flavanols. In addition, 
measuring postprandial glucose levels might be important to identify the inhibitory 
effect of cocoa polyphenols on carbohydrate digestion and absorption. 
 
As a result, it could be suggested that PRDC (with 500 mg of polyphenols) exerts its 
beneficial effects on insulin metabolism by decreasing insulin levels and insulin 
resistance without affecting glucose levels and β-cell function. These findings are 
particularly important because of the role of IR in the metabolic syndrome (Blaha 
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and Elasy 2006), and its major role in increasing arterial stiffness and atherosclerosis 
(Webb et al. 2010). This study demonstrated that PRDC might have a future 
implication in type 2 diabetes, and might constitute a further step towards integrating 
this snack into dietary programs targeted to prevent this chronic disease.  
 
Blood pressure 
The current study did not lead to a significant change in SBP or DBP following the 
consumption of PRDC. The results did not match with the outcomes of the studies of 
Al Moosawi et al. (2010; 2012), in which the same amount of DC and polyphenols 
were used, and a significant decrease in SBP and DBP was noted. Yet, the second 
study indicated a decrease in DBP only in the overweight population. This difference 
might be mainly attributed to the different study design as reported by the meta-
analysis of Ried et al. (2010) on studies with cocoa and DC. This meta-analysis 
stated that crossover studies had a more pronounced effect on SBP and DBP than 
parallel studies. This supports the idea of a higher treatment effect noted in crossover 
studies compared to parallel studies, as stated by Feys et al. (2012). 
 
In addition, other factors such as the duration of the study might have led to such 
results. Two meta-analyses reported that the reduction in blood pressure occurred in 
studies lasting 2 weeks but not in studies lasting longer than this period (Ried et al. 
(2010; 2012). The reason might be attributed to the adaptation to the quantity of 
polyphenols, thus providing an explanation for the results obtained by Taubert et al. 
(2007), who used a small amount of polyphenols (30 mg) in the intervention group, 
and noted a significant decrease in blood pressure (SBP: −2.9 ± 1.6 mmHg and DBP: 
−1.9 ± 1.0 mmHg p<0.001) after 18 weeks. In the current study, blood pressure was 
not assessed at 2 weeks interval; therefore, it was not possible to evaluate the 
adaptation effect to the daily dose of 500 mg of polyphenols over time.   
On the other hand, it was stated that the dose of flavanols supposed to exert 
favourable effects on blood pressure might need to be high. In the 6-week study of 
Davison et al. (2010), the dose of 1052 mg of flavanols was the only amount 
effective in decreasing SBP and DBP, while the doses of 33, 372 and 712 mg did not 
induce such effect (in the current study, the dose of flavanols in PRDC was 400 mg). 
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This finding contradicts the idea of the adaptation to the quantity of polyphenols and 
the trial of Taubert et al. (2007). However, it is important to mention that the latter 
study was limited by the use of white chocolate in the placebo group. Therefore, the 
decrease in blood pressure might have been due to individual expectations and 
influence from peers, rather than to the effect of the small polyphenol dose (Egan et 
al. 2010). 
 
Nevertheless, the results of Study I correspond with one particular finding of the 
meta-analysis of Ried. (2012), which performed a subgroup analysis based on blood 
pressure status, and documented no significant effects of cocoa polyphenols on BP in 
normotensive participants (SBP/DBP less than 120/80 mmHg) (Ried et al. 2012). 
Other meta-analyses that documented a decrease in SBP and or DBP mostly included 
normotensive and hypertensive participants (Desch et al 2010; Ried et al. 2010; 
Hooper et al. 2012), and did not stratify studies according to the above mentioned 
criterion. 
Therefore, findings of this study suggest that PRDC might not have a lowering effect 
on blood pressure in normotensive individuals. To explore further, the original idea 
of the preventive effect of cocoa on blood pressure, which originated from the Kuna 
Indians living in remote islands might be misleading. In fact, the increase in blood 
pressure in this population upon migration to urban areas might not be only 
attributed to the decrease in cocoa consumption, but also to the change in their 
overall diet. The indigenous group of Indians used to consume four times as much 
fish, and twice as much fruit than the ones living in the rural areas (McCullough et 
al. 2006). Also, the increase in weight and obesity resulting from the adoption of an 
unhealthy diet, might have led to an increase in blood pressure in this population 
(Hall et al. 2001). Hence, the healthy levels of blood pressure in the indigenous 
Indians might have been a combination between a healthy diet and a healthy weight, 
rather than a particular contribution of cocoa.  
 
Furthermore, it was stated that the potential effect of cocoa/DC on blood pressure 
could possibly be attributed to components other than polyphenols. These 
components were responsible for the blood pressure lowering effects in previous 
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studies. For instance, a high dose of theobromine (979 mg) in flavanol-rich cocoa 
was effective in decreasing SBP in 42 healthy individuals, while no effect with a low 
theobromine flavanol-rich cocoa (106 mg of theobromine) was noted (Van den 
Bogaard et al. 2010). The PRDC in study I contained 150 mg of theobromine, which 
was less likely to exert an effect on blood pressure.  
 
Conversely, studies on hypertensives mostly showed a lowering effect on cocoa/DC 
on blood pressure (Taubert et al. 2003; Grassi et al. 2008; Davison et al. 2010). 
Although unclear, the mechanisms might include the inhibition of ACE by cocoa 
polyphenols (Katz et al. 2000; Actis-Goretta et al. 2003). Furthermore, as stated by 
Jia et al. (2010), patients with CVD diabetes and/or hypertension have in common 
some metabolic disorders such as inflammation, IR, dyslipidemia, and oxidative 
stress. Hence, by targeting inflammation and oxidative stress, cocoa polyphenols 
might help in decreasing blood pressure. This might provide an explanation for the 
blood pressure lowering properties of cocoa polyphenols in hypertensives. 
Therefore, it could be suggested that PRDC might help in normalizing high blood 
pressure levels in hypertensives, while it might possibly not affect normal blood 
pressure levels. Further long term studies are needed to elucidate these effects. 
 
Glucocorticoid metabolism  
This study did not note a significant change in cortisol and cortisone levels, and in 
the activity of 11-β HSD 1 enzyme. Results matched with the results of the studies 
undertaken by Al Moosawi et al. (2010; 2012), which showed no significant effects 
of PRDC on cortisol metabolism. However, findings did not correspond with the 
results of the study of Martin et al. (2009), which noted an improvement in 
glucocorticoid metabolism following two weeks of DC consumption. Results did not 
also correspond with other studies that reported a decrease in cortisol levels 
following polyphenol supplementation (Lee et al. 1996; Arion et al. 1997; Zhu et al. 
2012), as well as a decrease in the activity of the enzyme 11 β-HSD1 (Hindzpeter et 
al. 2014). This might be explained by the fact that polyphenols other than flavanols 
might favourably affect cortisol metabolism. Indeed, studies that mostly reported 
favourable effects on cortisol metabolism included tea polyphenols (Zhu et al. 2012), 
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grape juice polyphenols (Lee et al. 1996) or chlorogenic acid (Arion et al. 1997), 
known to have a different composition than polyphenols in chocolate.    
 
Cortisol was shown to be related to an increase in insulin levels. In diabetic animals, 
the inhibition of 11 β-HSD1 was associated with a decrease in glucose, insulin levels 
and HOMA-IR (Tomlinson et al. 2008). The fact that the activity of this enzyme did 
not significantly change, while HOMA-IR and insulin levels decreased in the PRDC 
group did not explain the findings. Nonetheless, it might be suggested that other 
confounding factors have not been controlled in the placebo and PRDC groups. For 
instance, a high fat intake is known to affect cortisol metabolism by increasing HPA 
activity (Drake et al. 2005), and a high sodium intake might increase urinary free 
cortisol levels (Chamarthi et al. 2007). Knowing that the analysis of diet diaries did 
not show a significant increase in fat intake during the intervention, results might be 
confounded by underreporting. In addition, it was not possible to obtain an accurate 
overview of sodium intake through the analysis of diet diaries, due to the fact that the 
food composition tables (2010) lacked many common foods. Hence, no accurate 
results could be obtained. Further studies evaluating the effect of PRDC on 
cortisol/cortisone levels are needed before concluding the lack of a lowering effect of 
PRDC on cortisol levels and 11 β-HSD1 activity. 
 
Lipid profile 
No significant changes in serum lipids levels were noted following the consumption 
of PRDC. The findings of this study fairly matched with many other studies on 
cocoa/DC supplementation and lipid profile (Mathur et al 2002; Engler et al 2004; 
Grassi et al 2005; Taubert et al 2007; Al Moosawi et al. (2010; 2012); Neufingerl et 
al. 2013). However, results did not correspond with other trials which reported a 
beneficial effect on serum lipid levels (Mursu et al. 2004; Fraga et al. 2005; Baba et 
al. 2007b; Balzer et al. 2008). The meta-analysis of Jia et al. (2010) explained the 
non significant effect on lipid profile by the fact that most of the recruited 
participants do not have history of CVD, diabetes or hypertension, which made 
cocoa/DC unlikely to induce significant changes in lipid levels. In fact, oxidative 
stress, which is common in individuals with cardiovascular risk, can lead to an 
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increase in cholesterol biosynthesis. The latter can be counteracted by antioxidants 
(Gesquière et al. 1999) such as cocoa polyphenols. In Study I, participants had 
normal cholesterol levels (less than 5 mmol/l). Therefore, the baseline health status 
of individuals might have led to the non significant results obtained. 
 
In relation to the daily amount of polyphenols, the dose of 500 mg might have led to 
the non significant effects in this study. A meta-analysis reported that a daily amount 
of polyphenols less than 260 mg was effective in inducing a favourable effect on 
serum lipid levels (Jia et al 2010), while a higher dose did not cause such effect. The 
meta-analysis of Tokede et al. (2011) noted a saturation effect with a dose of 500 mg 
daily. It was suggested that a high amount of PPs could counteract their beneficial 
effects on serum lipids (Jia et al. 2010).  The study duration might also have had an 
influence on the outcomes. Both meta-analyses of Tokede et al. (2010) and Jia et al. 
(2010) showed that studies lasting around 2 weeks demonstrated a significant effect 
on lipid profile, while this was not the case for studies of longer duration (more than 
4 weeks). This was also concluded by the meta-analysis of Hooper et al. (2012) 
which documented that studies with duration less than 3 weeks were the only ones 
effective in decreasing HDL, LDL and total cholesterol. Tokede et al. (2011) 
explained the findings by a decrease in compliance encountered in longer term 
studies. It is worth mentioning that, although non significant, there was a trend 
towards a decrease in LDL levels in the PRDC group in study I, along with an 
increase in LDL in the placebo group. Testing the parameters every 2 weeks would 
have been effective in determining a potential decrease in adherence arising from 
daily PRDC consumption for a period longer than 2 weeks.  
 
Furthermore, the non significant effects on lipid profile might be due to the fact that 
placebo DC and PRDC were controlled for theobromine. A high dose of 
theobromine (850 mg) increased HDL and decreased LDL levels in humans, while a 
lower dose of theobromine (150 mg) did not induce a significant effect (Neufingerl 
et al. 2013). Studies that did not note a significant effect on lipid profile (Grassi et al. 
2005a; 2005b) had a low amount of theobromine (170 mg), which was similar to the 
current study (150 mg). 
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Lastly, some of the studies that showed an improvement in lipid profile used higher 
levels of fat, and consequently higher levels of cocoa butter than study I. Indeed, 
cocoa butter contains 33 % of oleic acid (USDA 2011a) which was reported to 
improve lipid profile (Corti et al. 2009). The amount of fat in the experimental 
PRDC in Study I was 7.44g, compared to 11.5 g, 21.3 g. and 75 g in the studies of 
Baba et al. (2007b), Fraga et al. (2005), and Mursu et al. (2004), respectively. The 
latter studies were the ones that showed a beneficial effect of cocoa/DC on lipid 
profile. However, the implication of oleic acid in DC in improving serum lipid levels 
can be contradicted by the prooxidant effects of cocoa butter that have been 
previously reported. These prooxidant effects are due to the unsaturated fats of cocoa 
butter (40% of total fats), which are highly prone to oxidation. This might counteract 
the effect of oleic acid on improving serum lipid profile (Vinson et al. 2006). 
 
Based on the arguments exposed above, it is then possible to suggest that PRDC 
does not constitute a source of prevention against dyslipidemia. Further long term 
studies measuring serum lipid levels at different intervals (every 2 weeks), and with 
different doses of polyphenols are needed to elucidate the effect of PRDC on lipid 
profile in participants with no CVD. 
 
LDL oxidation levels 
This study showed that 500 mg of polyphenols in DC exert lowering effects on 
oxidised LDL levels (-6.65 ± 16.14 ng/ml, p= 0.042).  Results are compatible with 
most of the studies in the literature which showed that PRDC exerts a lowering effect 
on LDL oxidation (Osakabe et al 2001; Wan et al 2001; Baba et al 2007a; Baba et al 
2007b). The beneficial effect of PRDC on oxidised LDL levels along with its effect 
on IR might not be attributed to a change in physical activity or in the usual diet of 
participants, as the latter lifestyle factors did not significantly change throughout the 
intervention (as reported by participants). 
The decrease in LDL oxidation levels in this study is particularly important, as it 
suggests a potential role of PRDC (500 mg of polyphenols) in lowering oxidative 
stress, and consequently, in decreasing risk factors for many diseases such as CVD, 
hypertension and diabetes (Urquiaga and Leighton 2000).  
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The mechanism possibly involved the scavenging ability of polyphenols (Baba et al. 
2007b), and their binding to LDL particles, resulting in their protection from 
oxidation (Haslam 1981). Wan et al. (2001) explained that the long term exposure of 
LDL particles to flavonoids (e.g. 4 weeks) renders LDL less susceptible to oxidation 
(Wan et al. 2001). The effect of PRDC on LDL oxidation was previously suggested 
to be due to an increase in HDL which suppresses oxidation (Wan et al. 2001; Mursu 
et al. 2004) through the inhibitory effect of paraoxonase on PAF-AH oxidation. The 
latter increases the degradation of oxidised lipids in the arteries (Mertens and 
Holvoet 2001). However, there was no significant change in HDL levels in the 
PRDC group. HDL levels, albeit increased, remained non significant (0.08 ± 0.27 
mmol/l, p= 0.12) in contrast to the studies of Mursu et al. (2004) and Wan et al. 
(2001). It was postulated that HDL prevents the effect of LDL on monocyte 
infiltration (which is responsible of the development of fatty streak), and leads to a 
decrease in oxidised LDL levels (Mertens and Holvoet 2001).  Lastly, the 
implication of NO in the inhibition of LDL oxidation (Cooper et al. 2008) cannot be 
excluded. 
 
Studies that documented a lowering effect on LDL oxidation lasted 2 – 12 weeks, 
and used doses of flavonoids ranging from 174 - 651 mg (Osakabe et al 2001; Wan 
et al 2001; Baba et al 2007a; Baba et al 2007b). Hence, testing the impact of a lower 
dose of polyphenols (than 500 mg) on LDL oxidation in a longer term study might 
be helpful in making future recommendations using a lesser quantity of DC. 
 
Hs-CRP levels 
The current study did not show a significant effect of PRDC on hs-CRP levels. 
While epidemiological studies showed a positive correlation between this marker 
and CVD (Gisueppe et al. 2008), findings match with most of the intervention 
studies on dark chocolate, which showed no significant effects on hs-CRP levels 
(Mathur et al. 2002; Allen et al. 2008; Nogueira et al. 2012; Di Renzo et al. 2013). 
However, findings do not correspond with the studies of Hamed et al. (2008) and 
Stote et al. (2012), which reported a decrease in hs-CRP following cocoa/DC 
supplementation. Notably, the two latter studies were short term studies (5 days and 
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7 days, respectively), highlighting the possibility of an adaptation effect to the 
quantity of polyphenols in longer term studies. Also, since an epidemiological study 
showed that hs-CRP levels are lower in subjects consuming 1 serving of dark 
chocolate (20g) every 3 days compared to higher consumers (p< 0.0001) (Di 
Giuseppe et al. 2008), it can be hypothesized that a moderate consumption of 
chocolate might exert a lowering effect on inflammatory markers. This view is 
reinforced by the fact that most of the intervention studies involved daily 
consumption of chocolate (quantities ranging from 37g -100g with doses of 
polyphenols between 500 – 2135 mg), and showed no significant effects on hs-CRP 
levels. However, epidemiological studies do not analyse cause and effect, and can be 
confounded by many factors (CDC 2004) that are not related to chocolate. Therefore, 
testing the moderate consumption of DC on hs-CRP levels at various occasions 
(every week) is needed to elucidate the impact of PRDC on inflammation. 
 
As a link between oxidative stress and inflammation via a NO-related mechanism 
was previously discussed (Cooper et al. 2008), it can be suggested that a decrease in 
LDL oxidation susceptibility might be associated with a decrease in inflammation. 
The fact that hs-CRP did not significantly change might have several explanations. 
The mechanism underlying the beneficial effect on oxidised LDL might not have 
involved NO (such as an increase in antioxidant enzymes) (Rahman et al. 2006). 
However, since NO levels or NOS enzymatic activity were not analysed in this 
study, no definite conclusions could be made. Also, the short-half life and the rapid 
elimination of flavonoids from the plasma were suggested as the possible reason of 
the non significant effect of these polyphenols on many inflammatory markers 
including IL-1, IL-6, TNF-α and hs-CRP (Mathur et al. 2002). 
Nevertheless, one of the most plausible explanations to this result could be the 
reliability of hs-CRP test in detecting an increase or a decrease in inflammation 
following an intervention. In fact, the intra individual and inter individual variations 
related to this assay (Mccormack and Allan 2010) might have affected its accuracy. 
This suggests that although a strong predictor of coronary artery diseases (Ridker 
2001), hs-CRP could not provide reliable results when measured on a single 
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occasion. In this study, the fact that this test was only analysed at baseline and after 4 
weeks might have affected the identification of changes in hs-CRP over time. 
Further studies testing hs-CRP levels at different time points, while controlling for 
confounding factors (inflammatory conditions, acute infection etc…) might need to 
be considered before refuting a positive effect of PRDC on inflammation.  
 
BMI and waist circumference 
In the present intervention, no significant changes in BMI or WC following the 
consumption of PRDC were noted. Results matched with most of the intervention 
studies on PRDC lasting from 2-8 weeks, which assessed anthropometry as a part of 
a routine measurement (Engler et al 2004; Grassi et al. 2005; Kurlansdsky and Stote 
2006; Allen et al 2008; Ried et al 2009; Al Moosawi et al 2010; Njike et al 2011; Al 
Moosawi et al 2012; Nogueira et al 2012). In this study, changes in body weight did 
not occur as a result of a decrease in insulin resistance, but corresponded with the 
fact that no changes in the reported energy intake and physical activity were noted 
(p> 0.05).  
However, the increase in BMI only in the placebo group (as will be discussed later) 
but not in the PRDC group might suggest a possible counteracting effect of PRDC 
on the adverse effects of the fat and energy content of chocolate. This was previously 
suggested by Al Moosawi et al. (2012), which also noted an increase in BMI only in 
the placebo group following 4 weeks of daily consumption. In line with this, it was 
proposed that cocoa polyphenols might counteract the prooxidant effects of cocoa 
butter, and thus could help against an increase in weight as well an increase in 
insulin and glucose levels (Vinson et al. 2006). Results suggest the possibility of an 
inhibitory effect of cocoa polyphenols on lipid and carbohydrate absorption through 
the inhibition of digestive enzymes (Gu et al. 2011). This might have counteracted 
the increase in body weight in the PRDC group. 
The outcomes could possibly match with the findings of animal studies which 
showed that cocoa polyphenols reduced weight gain in animals when administered 
high fat diets (Matsui et al 2005; Min et al 2011; Yamashita et al 2012). Although 
the aim of Study I was to include the placebo DC/PRDC in the context of a 
normocaloric diet, the increase in BMI might suggest that this product was 
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consumed in addition to the usual diet of participants. The countering effect of cocoa 
polyphenols on the fat content of chocolate might have prevented an increase in 
weight in the PRDC group. 
The mechanism involved in the countering effect of PRDC on weight gain might be 
explained by the inhibitory effect of PRDC on fatty acid gene expression (Matsui et 
al. 2005) or on digestive enzymes (Dorenkott et al. 2014). As the possible 
mechanisms were only studied in animals, identifying these mechanisms in humans 
are then needed.   
 
WC did not significantly change following PRDC consumption. Although a recent 
study showed that one week of daily PRDC supplementation (100 g) induced a 
decrease in waist circumference ((–1.24 ± 1.45 cm, p ≤0.05) with no significant 
change in BMI (Di Renzo et al. 2013), this study is limited by many factors. In fact, 
the short term study, the small number of participants (15 participants) and the lack 
of a control group did not help making strong conclusions, and raise questions about 
the biological significance of this outcome.  
Due to the limited studies on PRDC and its effect on body weight/body fat/obesity, 
more research well controlled for energy intake and physical activity is needed. In 
addition, the identification of the potential dose and fraction of flavonoids supposed 
to induce a counteracting effect on weight gain need to be studied. 
 
Adverse outcomes of placebo DC 
On the other hand, placebo DC was shown to increase insulin levels, insulin 
resistance (demonstrated by a decrease in HOMA-IR and an increase in QUICKI), 
glucose, TG, and BMI levels in adults. These parameters were recognized as being 
risk factors for chronic diseases (Grundy et al. 2004). The increase in HOMA-IR 
(0.66 ± 1.26, p=0.03) and weight (0.57 ± 1.08 kg, p=0.011) following 4 weeks of 
placebo DC consumption was only reported by the study of Al Moosawi et al. (2012) 
in which the placebo DC was similar to Study I. However, this only occurred in the 
overweight group. Although non significant, the increase in insulin levels (p=0.07) 
and HOMA-IR (p=0.08) following 8 weeks of low-polyphenol chocolate 
consumption (<2 mg of epicatechin) was also noticed by Mellor et al. (2010). In 
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relation to lipid profile, the detrimental effect of low-polyphenol chocolate was 
reported by the study of Wang-polagruto et al. (2006), which showed that consuming 
a low flavanol cocoa drink (43 mg of flavanols) resulted in a decrease in HDL by 
9.6%, while an increase in HDL by 6.6 % was noted in the high flavanol cocoa drink 
(446 mg of flavanols). Also, Baba et al. (2007b) reported a beneficial effect of cocoa 
polyphenols on LDL oxidation, showed by a 9.4% increase in lag time after 12 
weeks of flavanol-rich cocoa consumption (p<0.001). However, a significant 
decrease (19.8%) in lag time for LDL oxidation was noted in participants in the 
control group (consuming 12g of sugar). 
 
The simultaneous change in insulin, HOMA-IR, QUICKI, glucose, TG and BMI 
levels might suggest a correlation between the markers. The increase in body fat was 
reported to increase IR, glucose and TG levels, as described by Kissebah et al. 
(1982). Indeed, the increase of fat and energy in the diet, might lead to an increase in 
free fatty acids. FFA could increase TG levels and possibly enhance hepatic glucose 
production (Brøns et al 2009; Jin et al. 2013) through an increase in total glucose 
output and the activity of glucose-6-phosphatase (stimulated by fatty acyl-CoA) 
(Lam et al. 2003). This might result in a greater insulin secretion, and a resultant 
increase in IR (Brøns et al. 2009). However, whether the increase in energy intake 
and the subsequent increase in body weight in this study were sufficient to induce 
this mechanism remain unclear. 
 
The outcomes noted following placebo DC supplementation were not accompanied 
by a change in cortisol metabolism, the latter being known to play an important role 
in the metabolic syndrome (Qi and Rodrigues 2007), and insulin resistance 
(Masuzaki et al. 2001). This contradicts the findings of the previous study of Al 
Moosawi et al. (2012), which noted an increase in salivary cortisol following 4 
weeks of placebo DC supplementation, along with an increase in fasting insulin and 
HOMA-IR. Results could be attributed to the presence of confounding factors such 
as fat and sodium intake, which might have masked changes in cortisol levels. 
Limited studies previously analysed the effect of low-polyphenol chocolate/PRDC 
 194 | P a g e  
 
on cortisol levels and 11 β-HSD1 activity. Hence, trials investigating this association 
are needed. 
 
The increase in BMI in the placebo DC was not associated with a significant change 
in the reported levels of physical activity. In addition, the analysis of diet diaries did 
not show a significant increase in energy intake between baseline and week 3 in the 
placebo DC and the PRDC groups. This might be mostly justified by underreporting, 
which is common in research studies (Bothwell et al. 1999).  Underreporting, along 
with overestimating physical activity, was previously documented by the study of 
Davison et al. (2008).  
Therefore, it could be suggested that participants of this study did not adhere to the 
dietary recommendations provided, and consumed the chocolate portion in addition 
to their diet, instead of replacing it by another food. Yet, the polyphenol content in 
the PRDC was able to counter the harmful effects of energy and fat in DC, while the 
placebo DC led to an increase in weight. 
 
Results suggest that ordinary chocolate products in the market might have 
unfavourable effects on health. In addition, the outcome on TG levels refutes the 
theory that chocolate consumption has at worst a neutral effect on lipid profile, and 
suggests that more attention should be accorded to chocolate deficient in 
polyphenols. These detrimental effects of placebo DC are novel and suggest that 
studies targeting the effect of low-polyphenol chocolate on anthropometric and 
biochemical markers are needed. Also, because of the chocolate processing methods 
that cause a considerable loss of polyphenols (McShea et al. 2008), the analysis of 
polyphenol content of DC brands in the market might be needed to identify the ones 
that are deficient in polyphenols. 
 
BMI strata  
The current study did not note a significant impact of BMI on the outcomes when 
assessed by Mann whitney test, except for HOMA-IR in the placebo group. As 
expected, overweight individuals showed higher levels of SBP (p= 0.021), DBP (p= 
0.034), insulin (p= 0.013), HOMA (p= 0,012), TC (p= 0.009), LDL (p= 0.002), HDL 
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(p= 0.003), TG (p= 0.003) and hs-CRP (p= 0.003) levels than normal weight 
individuals, and consequently a higher risk of metabolic complications (Silver et al. 
2007). It was postulated that a higher BMI is associated with a greater insulin 
resistance, due to the fact that excess fat in skeletal muscle disrupts the insulin 
signalling pathway, leading to hyperinsulinemia and increased blood pressure levels 
(Addison et al. 2008).  However, cortisol levels did not differ between normal weight 
and overweight individuals. It was previously shown that obesity causes an increase 
in the activity of HPA and cortisol levels, which eventually leads to an increase in 
insulin and TG levels (Ottoson et al. 1994). Also, visceral adipocytes have been 
reported to have more glucocorticoid receptors compared to subcutaneous adipocytes 
(Stulnig and Waldhausl 2004). Additionally, despite the fact that overweight and 
obese individuals are known to have a higher endothelial oxidative stress than 
normal weight people (Silver et al. 2007), there was no difference in the baseline 
levels of oxidised LDL between normal weight and overweight participants (p= 
0.41). These findings might be attributed to the young study population or the small 
sample size of overweight individuals. However, no definite conclusions can be 
made regarding this finding. 
 
This study showed that even with the differences in baseline levels in many 
parameters between the 2 BMI categories, and with the exception of HOMA-IR in 
the placebo group, overweight individuals did not respond differently to PRDC 
hypoinsulinemic and hypotensive properties, as previously suggested by Al Moosawi 
et al. (2012). A finding of this subgroup analysis corresponds to the meta-analysis of 
Ried et al. (2012) on blood pressure, which did not show an impact of BMI on SBP 
and DBP following cocoa/Dc supplementation. In the placebo DC group, the fact 
that the increase in BMI was not different between the normal weight and 
overweight population (p= 0.36) suggests that DC low in polyphenols might increase 
the risk of weight gain in normal weight individuals, and worsen obesity in the 
overweight population. 
The fact that HOMA-IR was only increased in the overweight group (p= 0.017), 
while it was not affected in the normal weight group following placebo DC 
consumption is in line with the study of Al Moosawi et al. (2012), which used a 
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similar placebo DC product, and suggested that overweight individuals are more 
affected by the detrimental effects of fat and energy in the diet (Al Moosawi et al. 
2012). However, the difference in response to HOMA-IR between the 2 BMI 
categories is intriguing since the increase in BMI, glucose and TG levels, and the 
decrease in QUICKI occurred in both groups with no significant impact of BMI. 
Despite the importance of these results, findings based on BMI subgroup analysis are 
limited by several factors such as the uneven number of participants between the 
normal weight and overweight group, and the small sample size when stratifying the 
population according to BMI and type of intervention. In addition, the adoption of 
non parametric tests presents disadvantages over the parametric tests, due to their 
lack of power and their lower accuracy compared to parametric tests (Whitley and 
Ball 2002). Therefore, the results might not help making strong conclusions. Studies 
that assess differences in responses to intervention based on BMI are needed to 
clarify this association. 
 
Qualitative data 
Data regarding acceptability reported adverse effects such as headache, 
gastrointestinal discomfort and unacceptability of chocolate consumption, mainly in 
the PRDC group. Unacceptability of treatment and complaints such as headache and 
constipation were also observed in other studies, mostly in the intervention group 
(5% of participants) compared to the control group (1% of participants) (Ried et al. 
2012). This suggests that polyphenols and particularly flavanols might be 
responsible for most of these adverse effects, along with decreasing chocolate 
palatability due to their bitterness (McShea et al. 2008). The gastrointestinal 
discomfort was reported following the consumption of green tea rich in polyphenols 
(Chow et al. 2003). It was also proposed that doses higher than 500 mg of 
polyphenols were likely to cause side effects such as nausea and stomach upset 
(Mead 2007). In view of the potential role of polyphenols in decreasing carbohydrate 
and lipid absorption in the gut (Gu et al. 2011), the adverse effects noted in this study 
might be attributed to changes in bowel function mainly caused by the fraction of 
undigested substrates in the colon, particularly carbohydrates. The fermentation of 
undigested carbohydrates by intestinal bacteria in the colon leads to the production 
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of SCFA and gases (carbon dioxide, hydrogen and methane) which can cause 
flatulence and abdominal pain (Zopf et al. 2009). This may suggest that the effects of 
PRDC on decreasing fasting insulin levels and countering an increase in body 
weight, triglycerides and glucose levels were mainly due to the inhibitory effect of 
polyphenols on digestive enzymes. 
The headache might be attributed the fact that some people lack sufficient amounts 
of the enzyme responsible for phenylethylamine (amine present in chocolate) 
breakdown (Beckett 2008). Additionally, the fact that chocolate was reported to 
trigger migraine might be due to the release of serotonin following chocolate 
consumption. Serotonin triggers a reaction that constricts blood brain vessels, 
resulting in a headache that is typical of migraine (Emsley and Fell 1999). Although 
headache was also attributed to stress that might precede cravings (Beckett 2008), 
this did not apply to the current study, since chocolate was asked to be consumed 
daily as a part of the intervention. Notably, headache and migraine are caused by 
chocolate consumption regardless of polyphenols. 
 
In conclusion, this study showed a significant increase in insulin sensitivity and a 
decrease in oxidised LDL levels following PRDC consumption, while no effect on 
other parameters was noted. The adverse effects of placebo DC on anthropometric 
markers (increase of BMI) and biochemical markers (increase of TG, insulin, 
HOMA-IR and glucose and decrease of QUICKI) render the analysis of the 
polyphenol content of chocolate in the market necessary before establishing any 
recommendations. 
 
4.2 Study II 
4.2.1 Results  
4.2.1.1 Baseline and population characteristics 
Fourteen volunteers completed the trial, and were mainly recruited from community 
centres in Mussselburgh. Ten participants were European, while the rest was sub-
Saharan African (two participants), Eastern Mediterranean (one participant) and one 
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participant was described as having other ethnicities. Half of this population was 
employed while the others were students. Only 3 participants of this study were 
males. Five participants were obese (BMI between 30-34.9 Kg/m
2
), and the rest were 
overweight. All volunteers had high levels of WC (classification of WC is presented 
in Figure 2.4), and were classified at high risk of metabolic complications, with the 
exception of one male participant who had a WC= 87cm. The baseline 
characteristics of the overall study population and split according to the type of 
intervention are presented in table 4.11. 
Table 4.11: Baseline characteristics of the study population 
  Study population 
N=14 
Placebo group 
N=7 
PRDC group 
N=7 
Difference 
between 
groups 
Significance  
(p=) 
                        Mean ± SD   
Age (years) 40.07 ± 13.3 35.29 ± 14.43 44.86. ± 11.04 0.2 
BMI (Kg/m
2
)  29.3 ± 3.45 29.31 ± 2.73 29.29 ± 4.29 0.1 
WC (cm) 95.18 ±11.64 95.59 ± 11.96 94.76 ± 12.25 0.9 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate, WC: Waist circumference. 
Results are expressed as means ± SD. There were no significant differences between groups. 
Data was analysed using independent t-test. 
 
Regarding supplement intake, only one participant noted having a usual intake of 
dietary supplements in the form of multi-vitamins. Furthermore, 8 volunteers 
reported having a family history of chronic diseases such as diabetes, hypertension 
and/or CVD, and two females mentioned taking daily contraceptives. One woman 
was postmenopausal.  
In relation to physical activity, 50% of the population reported practising more than 
3 hours of exercise per week, and no significant differences in the baseline levels of 
physical activity (expressed by MET/ week) were noted between the placebo DC and 
the PRDC group (placebo DC: 8.8 ± 10.2 MET/ week; PRDC: 15.97 ± 12.46 MET/ 
week, p = 0.26). 
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4.2.1.2 Anthropometric measures 
Weight, BMI, waist circumference, lean body mass and body fat percentage levels 
were normally distributed for all interventions at all time points, as assessed by 
Shapiro-Wilk's test (p > 0.05). In addition, there was homogeneity of variances, as 
assessed by Levene's test of homogeneity of variance (p > 0.05). Moreover, none of 
the 3 above mentioned parameters violated the assumption of sphericity (Mauchly’s 
test > 0.05). 
a. BMI levels 
There was no statistically significant interaction between the intervention and time 
on BMI levels (F (2, 24) = 1.216, p=0.31). However, the main effect of time showed 
a statistically significant difference in BMI levels at the different time points             
(F (2, 24) = 4.925, p= 0.016). Therefore, in order to determine where these 
differences lie, pairwise comparisons using Bonferroni test were carried out. For the 
overall group, changes in BMI levels were not statistically significant between pre 
intervention and mid way point (Mean difference = 0.12 Kg/m
2
 (0.3, 0.12 CI),        
p= 0.58), but BMI levels increased significantly at post intervention compared to pre 
intervention (Mean difference= 0.41 Kg/m
2
 (0.82, 0.007 CI), p= 0.046) (Table 4.12). 
Regarding between-group differences within mixed model ANOVA, the main effect 
of group showed that there was no statistically significant difference in BMI levels 
between intervention groups (F(1, 12) = 0.018, p = 0.9). This increase from baseline 
by 1.26 ± 1.76 Kg (BMI increased by 0.41 ± 0.57 Kg/m
2
) occurred in the whole 
study population after 12 weeks. 
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Table 4.12: Changes in BMI over time in the overall study population and split 
according to the type of intervention 
                Means  ±   SD                      
BMI levels (Kg/m
2
) Study 
population  
(N=14) 
Placebo DC 
(N=7) 
PRDC 
(N=7) 
BMI baseline 29.3 ± 3.45 29.31 ± 2.73 29.29 ± 4.29 
BMI mid intervention 29.42 ± 3.36 29.56 ± 2.53 29.27 ± 4.24 
BMI post intervention 29.71 ± 3.57* 29.94 ± 2.73* 29.49 ± 4.47* 
*Significant difference from baseline, p < 0.05. BMI increased with no significant 
differences between the placebo and the PRDC groups (p=0.9). DC: Dark chocolate, 
PRDC: Polyphenol-rich dark chocolate. Results are expressed as means ± SD. 
  
 
b. Waist circumference 
 Results showed no significant interaction between the intervention and time on WC 
levels (F (2, 24) = 1.955, p= 0.16), suggesting no effect of the type of intervention 
on waist circumference. Levels of WC albeit increased over time in the whole study 
population, did not reach statistical significance ((F (2, 24) = 3.08), p= 0.065). 
Regarding between group differences, there was no statistically significant difference 
in WC levels between intervention groups (F (1, 12) = 0.06, p = 0.81) (Table 4.13). 
 
Table 4.13: Changes in waist circumference over time in the study population 
and split according to the type of intervention 
                   Means ± SD  
WC levels (cm) Study population Placebo DC PRDC 
WC Baseline 95.18 ± 11.64 95.59 ± 11.96 94.76 ± 12.25 
WC mid intervention 95.6 ± 11.65 96.25 ± 12.23 94.94 ± 11.98 
WC Post 96.31 ± 11.68 97.6 ± 12.18 95.01 ± 11.98 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate, WC: waist circumference. 
Results are expressed as means ± SD 
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c. Body fat percentage 
Mixed model ANOVA showed no effect of time and intervention on body fat 
percentage levels (F (1, 12) = 1.33, p=0.27). The main effect of time also showed no 
statistically significant difference in body fat percentage levels at the different time 
points (F (1, 12) = 0.01, p= 0.92), and no significant differences between groups 
were noted (F (1, 12) = 1.12, p =0.31) (Figure 4.8).  
 
 
 
 
Figure 4.8: Changes in body fat percentage in the placebo DC and PRDC 
groups throughout the intervention 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate. Results are expressed as 
mean ± SEM.  Bar charts represent the changes in body fat percentage at the 3 time points 
in both groups. Changes were not significant (p> 0.05). Baseline levels of body fat did not 
significantly differ between PRDC and placebo DC groups (p= 0.29). 
 
d. Lean body mass 
Results documented no significant interaction between intervention and time on 
LBM (F (2, 24) = 0.071, p= 0.93). In addition, there was no significant effect of time 
on LBM levels (F (2, 24) = 1.1, p= 0.93), and no difference in this parameter 
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between the placebo and PRDC groups (F (2, 24) = 0.83, p= 0.38) (Values of pre, 
mid and post LBM are presented in Table 4.16) 
 
As analysis of results showed a significant increase in BMI without inducing 
changes in body fat percentage or LBM, repeated measures analysis for total body 
water were carried out to identify if changes in weight are due to fluctuations of 
body water. Results showed no significant changes in total body water resulting from 
the interaction between time and intervention (F (2, 24) = 0.15, p= 0.86), or from the 
effect of time (F (2, 24) = 3.53, p = 0.54). 
 
4.2.1.3 Basic metabolic rate 
BMR levels were normally distributed for all interventions at all time points, as 
assessed by Shapiro-Wilk's test (p > 0.05). The assumption of sphericity was 
violated, as assessed by Mauchly's test of sphericity (p=0.045). Therefore, a 
Greenhouse-Geisser correction was applied (epsilon (ε) = 0.75).  Results showed no 
statistically significant interaction between the intervention and time on BMR levels 
(F (1.41, 16.9) = 0.21, p= 0.74). In addition, the main effect of time showed no 
significant difference in BMR levels at the different time points (F (1.41, 16.9) = 
0.13, p= 0.8). There was a slight difference in BMR levels between the two groups, 
albeit it did not reach statistical significance (F (1, 12) = 4.31, p =0.06 (Values of 
pre, mid and post BMR are presented in Table 4.16) 
 
4.2.1.4 Urine assessment 
All participants provided urine samples pre, mid and post intervention. Total 
polyphenols, total antioxidant capacity and glucocorticoid levels were then analysed.  
a. Cortisol, cortisone levels and the activity of the enzyme 11-β HSD 
The analysis of glucocorticoids via ELISA method was previously validated for 
accuracy and precision in biological samples (Al Dujaili et al. 2012).  
Cortisol, cortisone levels and 11β HDS1 levels were normally distributed for all 
interventions at all time points, as assessed by Shapiro-Wilk's test (p > 0.05). In 
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addition, there was homogeneity of variances, as assessed by Levene's test for 
homogeneity of variance (p >0 .05). A violation of the assumption of sphericity 
(Mauchly’s test > 0.05) was only noted for cortisone levels. 
 
Cortisol levels were not significantly affected by the intervention and time                     
(F (2, 24) = 0.53, p=0.59), and there was a significant effect of time on these levels         
(F (2, 24) = 2.61, p= 0.094). Differences between groups were also not significant (F 
(1, 12) = 2.55, p = 0.14). 
For cortisone levels, a Greenhouse-Geisser correction was applied (epsilon (ε) = 
0.701). Results showed no statistically significant interaction between the 
intervention and time on cortisone levels (F (1.4, 16.81) = 0.71, p = 0.46). There was 
also no effect of time on cortisone levels (F (1.4, 16.81) = 2.85, p = 0.1), and no 
differences between the 2 groups ((F (1, 12) = 2.11, p = 0.17) regarding this 
parameter. 
As for the activity of the enzyme 11 β-HSD 1, there was no statistically significant 
interaction between the intervention and time on 11 β-HSD 1 levels (F (2, 24) = 
1.076, p=0.32). Similarly, no significant effect of time was noted on 11 β-HSD 1 
activity    (F (2, 24) = 0.55, p= 0.6).  Lastly, differences between the two groups 
were not significant (F (1, 12) = 0.95, p = 0.35) (Table 4.14). 
 
b. Total polyphenols and total antioxidant capacity in the urine 
Total polyphenols and total antioxidant capacity were obtained by comparing the 
absorbance against the generated standard curves prepared with gallic acid / ferrous 
sulphate standards, respectively. The standard curves are presented in Appendix 12. 
 
Total polyphenols and antioxidant capacity were normally distributed for all 
interventions at all time points, as assessed by Shapiro-Wilk's (p>0.05). There was 
homogeneity of variances, as assessed by Levene's test (p > 0.05), and none of the 
above mentioned parameters violated the assumption of sphericity (Mauchly’s test > 
0.05). 
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Results showed no significant interaction between the intervention and time on 
antioxidant capacity (F (2, 24) = 0.97, p=0.4), and no main effect of time on these 
levels at the different time points (F (2, 24) = 0.24, p= 0.79). Regarding between- 
group differences, the main effect of group showed that there was no statistically 
significant difference in urinary antioxidant capacity between intervention groups    
(F (1, 12) = 3.25, p = 0.097). 
As for the levels of polyphenols in the urine, there was no statistically significant 
interaction between the intervention and time on these levels (F (2, 24) = 1.23, 
p=0.093), and no significant effect of time on polyphenol levels was noted (F (2, 24) 
= 0.36, p = 0.7). As for between-group differences, the main effect of group showed 
a statistically significant difference between the two groups (F (1, 12) = 19.77,            
p = 0.01) (Table 4.14). 
 
Table 4.14: Changes in urinary glucocorticoids, antioxidant capacity and total 
polyphenols in the placebo and PRDC groups 
 Intervention Baseline Week 6 Week 12 
Cortisol  
(nmol/day) 
Placebo DC 
PRDC 
67.97 ± 36.9 
99.8 ± 44.75 
80.41 ± 47.97 
137.7 ± 69.74 
97.5 ± 47.37 
109 ± 64.73 
Cortisone  
(nmol/day) 
Placebo DC 
PRDC 
97.52 ± 45.3 
129 ± 56 
113.7 ± 44.6 
190.9 ± 129.7 
136.7 ± 44.6 
178.29 ± 94.64 
11 β-HSD1 
activity 
(cortisol/cortisone) 
Placebo DC 
PRDC 
0.67 ± 0.16 
0.8 ± 0.14 
0.7 ± 0.23 
0.8 ± 0.25 
0.72 ± 0.2 
0.74 ± 0.18 
Total antioxidant 
capacity 
(mM Fe2+/day) 
Placebo DC 
PRDC 
4.88 ± 1.4 
8.32 ± 5.16 
6.62 ± 2.57 
7.6 ± 1.06 
6.09 ± 1.96 
8.22 ± 3.55 
Total polyphenols 
(mg of GAE/day) 
Placebo DC 
PRDC  
69.92 ± 31.42* 
121.85 ± 67.92 
70.88 ± 24.8* 
168.94 ± 124 
99.12 ± 49.8* 
105.03 ± 54.86 
*Significant difference between the placebo DC and the PRDC groups (p= 0.01). DC: Dark 
chocolate, PRDC: Polyphenol-rich dark chocolate, GAE: Gallic acid equivalent, 11 β-
HSD1: 11-beta hydroxysteroid dehydrogenase 1. Results are expressed as means ± SD.      
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4.2.1.5 Assessment of diet diaries and compliance 
None of the macronutrient and energy values violated the assumption of normality 
(Shapiro-Wilk's (p>0.05)), homogeneity (Levene’s test > 0.05) or sphericity 
(Mauchly's test of sphericity (p> 0.05). Reported energy intake did not change 
throughout the intervention in the placebo and PRDC groups (F (2, 24) = 0.79, p = 
0.47). Regarding macronutrients, no significant changes in carbohydrate (F (2, 24) = 
0.62, p= 0.55), or protein intake (F (2, 24) = 1.34, p= 0.28) were noted in both 
groups. However, there was a significant effect of time on fat intake levels (F (2, 24) 
= 4.4, p = 0.024). Yet, pairwise comparisons did not reveal significant differences in 
the levels of fat intake at different time points (p> 0.05). Finally, there were no 
differences between the 2 groups regarding fat intake (p= 0.6) as well as energy       
(p= 0.5), carbohydrate (p= 0.26) and protein (p= 0.76) intakes (Table 4.15). 
 
Table 4.15: Changes in energy and macronutrient intakes throughout the 
intervention in the placebo and PRDC groups 
 Type of 
intervention 
Run-in period Week 6 Week 12 
Energy (Kcal) Placebo DC (N=7) 1826 ± 401 1957 ± 760 1691 ± 439 
 PRDC (N=7) 1764 ± 482 2070 ± 357 2005 ± 406 
Carbohydrate (g) Placebo DC (N=7) 251 ± 59 261 ± 86 233 ± 73.08 
 PRDC (N=7) 188 ± 55 240 ± 98 199 ± 67 
Protein (g) Placebo DC (N=7) 58.06 ± 22.6 76.57 ± 9.99 74.7 ± 13.21 
 PRDC (N=7) 70.76 ± 15.23 76.6 ± 34.22 70.9 ± 23.48 
Fat (g) Placebo DC (N=7) 72.4 ± 19.46 83.76 ± 16.87* 87.93 ± 22.32* 
 PRDC (N=7) 81.04 ± 28.7 77.86 ± 33.04* 66.43 ± 22.89* 
* Significant effect of time on fat intake in the placebo and PRDC groups, p=0.024. DC: 
Dark chocolate, PRDC: Polyphenol-rich dark chocolate. Results are expressed as mean ± 
SD       
 
Reported levels of physical activity (transformed into MET / hour) did not 
significantly change throughout the intervention in both groups (F (2, 24) = 1.2, p= 
0.32) (Values for pre, mid and post MET are presented in table 4.16). 
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4.2.1.6 Food Frequency questionnaire 
Assessing changes in flavonoid intake through FFQ score showed no significant 
change in flavonoid intake in both groups between baseline, week 6 and week 12 (F 
(2, 24) = 2.26, p = 0.13). In addition, no between group differences                                         
(F (1,12)= 4.2, p=0.53) were noted (Baseline, mid and post values for FFQ are 
presented in table 4.16).  
4.2.1.7 Follow up appointment 
Mixed model ANOVA showed no significant difference between the follow-up BMI 
value and the BMI of each of the 3 appointments, resulting from the interaction 
between treatment and time (F (3, 33) = 0.91, p=0.45) or from the effect of time      
(F (3, 33) = 0.36, p=0.086). Results suggest that changes in BMI were not significant 
after four weeks of the end of the study. 
Regarding other parameters, there were no significant differences between the 3 
appointments and the follow-up appointment for waist circumference (p=0.34), body 
fat percentage (p=0.7) and LBM (p=0.32) in both groups. In addition, the reported 
intake of flavonoids did not seem to significantly change after the end of the 
intervention when assessed by FFQ score (p=0.76). Reported levels of physical 
activity assessed by MET/hour did not also change significantly a month after the 
end of the study (p= 0.49). Similar results were noted for energy (p= 0.36) and 
macronutrient intake (carbohydrate (p= 0.39), protein (p= 0.63) and fat (p= 0.07)) in 
both groups at the follow up appointment. Lastly, there was no significant change in 
BMR (p= 0.57) at follow-up (Table 4.16). 
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Table 4.16: Changes in assessed parameters from baseline to follow-up  
 Intervention Baseline Week 6 Week 12  week 16 
(Follow-up) 
BMI (Kg/m
2
) Placebo DC 
PRDC 
29.31 ± 2.73 
29.29 ± 4.29 
29.56 ± 2.53 
29.27 ± 4.24 
29.94 ± 2.73 
29.49 ± 4.47 
29.66 ± 2.9 
29.6 ± 4.52 
WC (cm) Placebo DC 
PRDC 
95.59 ± 11.96 
94.76 ± 12.25 
96.25 ± 12.23 
94.94 ± 11.98 
97.6 ± 12.18 
95.01 ± 11.98 
96.82 ± 13.82 
95.9 ± 12.37 
BMR (Kcal) Placebo DC 
PRDC  
1875± 353  
1581 ± 90* 
1844 ± 358 
1605 ± 95* 
1872 ± 248 
1608 ± 102* 
1882±282 
1586 ± 83* 
Body fat 
percentage (%) 
Placebo DC 
PRDC 
32.79 ± 10.5 
38.1 ± 7.14 
31.8 ± 7.14 
36.79 ± 6.08 
33.7 ± 9.47 
37.3 ± 5.12 
31.52 ± 8.92 
37.07 ± 5.88 
LBM (%) Placebo DC 
PRDC 
64.37 ± 6.34 
61.87 ± 7.11 
63.74 ± 7.31 
60.45 ± 7.44 
62.43 ± 7.98 
58.84 ± 6.85 
68.46 ± 8.97 
62.7 ± 5.75 
Energy intake 
(Kcal) 
Placebo DC 
PRDC 
1826 ± 404 
1764± 482 
1957 ± 760 
2070 ± 357 
1691 ± 439 
2005 ± 406 
1786 ± 453  
1793 ± 302 
Carbohydrate 
intake (g) 
Placebo DC 
PRDC 
262 ± 56 
188 ± 55 
265 ± 94 
240 ± 98 
230 ± 79 
199 ± 67 
213.8 ± 58 
190 ± 58 
Protein intake 
(g) 
Placebo DC 
PRDC 
58.06 ± 22.6 
70.76 ± 15.23 
76.57 ± 9.99 
76.6 ± 34.22 
74.7 ± 13.21 
70.9 ± 23.48 
69 ± 25.97 
70.02 ± 12.32 
Fat intake (g) Placebo DC 
PRDC 
72.4 ± 19.46 
81.04 ± 28.7 
83.76 ± 16.87 
77.86 ± 33.04 
87.93 ± 22.32 
66.43 ± 22.89 
76.53 ± 20.96 
69.23 ± 18.1 
Flavonoid 
intake score 
(FFQ) 
Placebo DC 
PRDC 
361±133 
443 ±292 
 
295 ± 136 
475±268 
408±201 
416±241 
361±239 
402±227 
MET/week Placebo DC 
PRDC 
10.3 ± 10.32 
15.97 ± 12.46 
10.77 ± 9.56 
12.19±10.27 
8.93 ± 7.73 
14.04±12.49 
9.43 ± 6.85 
12.19 ± 8.03 
* Significant difference between the placebo and PRDC groups for BMR (p=0.044). No 
other significant differences between groups were noted. DC: Dark chocolate, PRDC: 
Polyphenol-rich dark chocolate, WC: Waist circumference, BMR: Basic metabolic rate, 
LBM: Lean body mass, FFQ: Food frequency questionnaire, MET: Metabolic equivalent 
task. 
 
In order to identify the accuracy in reporting energy intake via diet dairies in this 
population, energy expenditure for each participant was calculated based on energy 
expenditure, which was estimated via BIA. Levels of physical activity were the ones 
reported by participants. The comparison between mean reported levels of energy 
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intake and calculated energy expenditure is illustrated in Figure 4.9. The ratio of 
calculated energy expenditure to reported energy intake ranged between 1.11 -1.25. 
 
 
 
 
 
Figure 4.9: Differences between mean estimated daily levels of energy 
expenditure and reported levels of energy intake in the study population 
 
4.2.1.8 Pearson’s correlation between selected parameters  
In the current population, BMI levels were significantly correlated to WC levels           
(r =0.85, p<0.001), and to body fat percentage levels, but to a lesser extent (r= 0.68, 
p=0.007). However, changes in BMI at week 12 from baseline were not significantly 
correlated to changes in body fat percentage (r= 0.43, p=0.13), as well as waist 
circumference (r=0.49, p=0.08) between baseline and week 12. 
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4.2.1.9 Eating patterns  
The influence of chocolate consumption on the changes in eating patterns was 
mainly assessed through looking at sugar and saturated fatty acid intakes. Values 
were based on the self-reported diet diaries. For sucrose, results showed no 
significant change in these levels (F (2, 24) = 0.029, p= 0.97) throughout the 
intervention (Pre intervention: 34.37 ± 4.75 g; week 6: 32.01 ± 19.3 g; week 12: 28.5 
± 14.37 g ) in both groups. The analysis of subgroups of fat also showed no 
significant change in saturated fatty acids (SFA) (F (2, 24) = 2.48, p= 0.12) 
following the intervention in the placebo and PRDC groups (Pre intervention:               
23.59 ± 9.7 g; week 6: 26.02 ± 10.56 g ; week 12: 25.71 ± 9.12 g). Also, no 
significant differences between the placebo DC and the PRDC groups were noted for 
sugar (p=0.32) and SFA intakes (p=0.46). 
 
4.2.1.10   Qualitative data: acceptability and side effects of placebo / treatment 
Data regarding acceptability showed that none of the 14 participants found the 
chocolate unacceptable, while  9 participants found it very acceptable, and 5 
participants found it somewhat acceptable. Few side effects were noted. In the PRDC 
group, complaints due to bitterness and headache (one participant), bloating and 
gastrointestinal discomfort (one participant) were reported. In the placebo DC group, 
one participant complained of the high caffeine content in the chocolate. Five 
participants in the placebo DC group and 5 in the PRDC group stated that they will 
continue consuming chocolate frequently. Regarding the change in appetite, 3 
participants noted a change in appetite following DC consumption: One participant 
in the PRDC group and two participants in the placebo DC group noted a decrease in 
the consumption of sweet snacks due to daily chocolate consumption, yet this was 
not supported in the diet diaries of these participants. In addition, two participants 
reported an influence of recording diet diaries on improving healthy eating (eating 
less sweets and snacks) and increasing physical activity, regardless of the type of 
chocolate administered. 
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4.2.1.11 Feasibility outcomes  
a. Drop out rates 
Six participants dropped out throughout the study. Five participants withdrew during 
the first 6 weeks, while one participant dropped at week 8. Reasons for dropout 
included: infection (1 participant), work commitment (1 participant), personal 
problems (2 participants). Two participants dropped out without giving any reasons. 
Therefore, the dropout rate was estimated to be 30 %. 
 
b. Compliance rates 
The compliance was estimated to be 84.82 %. This was calculated by counting the 
returned plastic bags, and asking participants (each 6 weeks) about the number of 
times they missed the daily portion of chocolate. The percentage of compliance was 
calculated for each participant, and the average percentage was considered for the 
fourteen participants. The efficiency of data collection tools and the study design are 
examined in section 5.2.2. 
 
c. Sample size calculation for a large trial 
The outcomes of the small scale study were used to estimate the sample size needed 
for a larger study. This was based on the estimates of means and standards deviations 
of the differences in BMI levels in the two independent groups at different time 
points. Determination of sample size was set at 80% power and a two-sided 
significance level of 0.05, and was based on the sample size tables in clinical studies 
by Machin et al. (1997) (CUHK 2014) (Table 4.17). 
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Table 4.17: Estimation of sample size for a future large scale study 
BMI 
SD 
differences 
Mid – pre  
(Placebo 
DC) 
Mid-pre 
(PRDC)  
Post – pre 
(Placebo 
DC) 
Post –pre 
(PRDC) 
Post – mid 
( Placebo 
DC) 
Post- mid 
PRDC 
  
 
0.117 0.335 0.414 0.57 0.296 0.597 
Sample size 
per group 
(total sample)    
           130  (260)         31  (62)              65  (130) 
DC: Dark chocolate, PRDC: Polyphenol-rich dark chocolate. Calculations were based on 
80% power for an alpha error of 0.05 using standard deviations (SD) of the mean 
differences at different time points in each group based on the tables by Machin et al. 
(1997).  
 
If the highest number is considered, it can be then assumed that a sample size of 260 
participants is required for a power of 80 % and 0.05 level of significance. 
Considering the drop out rate of 30%, 338 participants are then needed to be 
recruited for a large trial. 
 
In summary, the results of this study showed that 12 weeks of the consumption of 
DC low or rich in polyphenols led to an increase in BMI, while no changes in WC or 
body composition were noted. The intervention did not result in significant changes 
in urinary antioxidant capacity and polyphenol levels, as well as in glucocorticoid 
metabolism in both groups. 
 
4.2.2 Discussion 
The discussion part comprises two sections: The first section will discuss the 
outcomes of the study, while the second section will consider the feasibility 
outcomes and sample size calculations for a large trial. 
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4.2.2.1 Section I: Discussion of the outcomes 
 
This study generated preliminary results on the effects of PRDC supplementation on 
body weight and composition in the overweight and obese population. The inclusion 
of participants with an upper range limit for BMI (between 25 - 34.9 Kg/m
2
) was 
considered because of the high complications associated with obesity class II and 
morbidly obese participants (Gibson 2005). In addition, there might be inaccuracy in 
measuring waist circumference for severely obese individuals due to the difficulty in 
finding the waist narrowing; thus, the measurement of WC is commonly taken at the 
umbilical level (Lohman et al. 1988). Also, it appears there is no validation for 
bioelectrical impedance for individuals with BMI over 34 Kg/m
2 
(Kyle et al. 2004b; 
Coppini et al. 2005).    
 
Based on the arguments exposed in section 2.2.1, there was an important rationale 
behind carrying out a human study testing the potential weight-lowering effect of 
PRDC. This is particularly useful for subsequently including this snack in weight 
management programs aiming to reduce or manage lifestyle-related diseases. 
However, rejecting this hypothesis might have a significant implication. In fact, there 
is currently a growing marketing that is promoting the benefits of DC in reducing 
body weight and counteracting obesity. This might be misleading if not supported or 
refuting by human intervention studies.  
 
BMI 
The increase in BMI (0.41 ± 0.57 Kg/m
2
) occurred in the whole population after 12 
weeks, with no significant difference between placebo DC or PRDC consumers      
(p= 0.9). The increase in BMI in the placebo group was previously documented by 
the study of Al Moosawi et al. (2012) following 4 weeks of daily consumption of 
20g of DC (providing 102 Kcal). As for PRDC, an increase in body weight (0.8 Kg) 
previously occurred in 43 human participants following 3 months of daily 
consumption of 25g of flavanol-rich dark chocolate (containing 125 Kcal and 
providing 112 mg of flavanols) (Desch et al. 2010). However, whether this amount 
of flavanols is considered high was not previously discussed, but it is nearly four 
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times lower than the amount of flavanols contained in the PRDC (400mg) in Study 
II. 
The increase in weight in this study population might be primarily explained by the 
fact that participants in both groups did not adhere to the dietary recommendations 
provided, and did not substitute the chocolate by another food. Therefore, DC was 
consumed in addition to the usual diet. Notably, the increase in BMI in the PRDC 
group did not reinforce the findings of “in vitro” studies which suggested a role of 
cocoa polyphenols in decreasing obesity due to their inhibitory actions on 
carbohydrate and fat digestion and absorption (Gu et al. 2011; 2013). Also, results 
did not support the outcomes of animal studies which showed that cocoa polyphenols 
were effective in attenuating weight gain in obesity-induced animals (Matsui et al. 
2005; Yamashita et al. 2012; Gu et al. 2013).  
However, despite the non significant differences between the placebo DC and the 
PRDC in relation to weight gain (p= 0.9), the increase in BMI in the placebo group 
was linear while the increase in the PRDC group mainly occurred after week 6 
(Table 5.11). Also, considering the weight gained in each group, there was a greater 
increase in weight (1.9 ± 1.9 Kg) in the placebo DC group after 12 weeks, compared 
to the PRDC group (0.63 ± 1.45 Kg). This might suggest the probability of an 
adaptation effect to the quantity of polyphenols over time, which might limit their 
efficiency in counteracting weight again over the long term. In fact, it could be 
possible that PRDC was able to offset the increase in weight for the first 6 weeks, 
but not for the next 6 weeks of intervention. The idea of “adaptation effect” was 
previously suggested by Al Moosawi et al. (2012), and could provide an explanation 
for the efficacy of PRDC in counteracting weight again in a 4-week study (Al 
Moosawi et al. 2012). Yet, the small sample size did not help making strong 
conclusions regarding the implication of PRDC in attenuating body weight gain.  
This increase in weight after 12 weeks is not only statistically significant, but can 
also be clinically relevant. It was shown that an increase of 1 Kg of body weight can 
result in an increase of coronary mortality risk by 1 - 1.5 % (Jousilahti et al. 1996). 
Therefore, a careful attention should be provided to the extra calories provided by 
the daily consumption of this snack. 
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An important point to mention is that previous animal studies assessed the 
counteracting effect of cocoa polyphenols on a high-fat induced diet. However, the 
implication of these polyphenols in reducing obesity in the context of a normocaloric 
or a hypocaloric diet remains unclear. For instance, Si et al. (2011) showed that 
administering cocoa-derived epicatechin to obese mice without a high fat diet, 
improved their biochemical markers without influencing body weight. This raises 
questions over the implication of these components in decreasing weight in humans; 
as if they are mainly involved in counteracting induced obesity, their efficacy in 
weight management programs or in reducing weight in individuals following a 
normocaloric diet becomes doubtful. Therefore, based on animal studies, it could be 
suggested that cocoa polyphenols play a positive role only when a high fat diet is 
induced, underlying a possible role of these polyphenols in countering weight gain in 
the population. However, data are inconclusive and further studies targeting animals 
and humans are needed. For instance, animal studies that include control group (no 
cocoa polyphenols and no fat induced diet), intervention group 1(administered cocoa 
polyphenols and high fat induced diet) and intervention group 2 (administered cocoa 
polyphenols along with a normal diet) might be helpful in investigating the 
mechanism of action of cocoa polyphenols on body weight.  
 
Moreover, since the decrease in fat and glucose absorption through the inhibition of 
digestive enzymes was suggested as an important mechanism by which cocoa 
polyphenols might prevent obesity (as suggested by Gu et al. (2011)), the timing of 
intake of cocoa/DC (with meals or with no foods) and meal patterns might affect this 
factor. Nevertheless, in this study, there was no restriction on the timing of chocolate 
intake. While looking at the diet diaries in the PRDC group, four participants 
reported having the chocolate mostly at an afternoon snack with tea or coffee, while 
the others reported having it mainly with lunch and breakfast. Consequently, 
differences arising from the fact that no restriction on the timing of intake was made, 
might have affected the outcomes. Additionally, it was suggested that the 
macronutrient composition of a meal might influence polyphenol absorption, the 
latter being the highest after a carbohydrate-rich meal (Schramm et al. 2003). 
Therefore, a study well controlled for the timing of intake of PRDC is important to 
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surmount this limitation. To explore further, a UK cohort study including 1618 
participants who reported their diet by the means of diet diaries, showed that lunch 
and dinner constitute the largest meals of the day with the highest proportion of 
carbohydrates (39.5 % of lunch and 36.6 % of dinner) (Al Moosawi et al. 2013). 
Consequently, asking participants to consume this snack with lunch or dinner in 
future studies, might help reducing or eliminating the confounding factor of 
consuming this snack with different meals or with no foods. 
Notably, this inhibitory effect of cocoa polyphenols on digestive enzymes was only 
demonstrated in “in vitro studies” which cannot substitute for human studies 
(Etcheverry et al. 2012).  In addition, the doses of polyphenols that exert an 
inhibitory effect in cells might be higher than the physiological levels. Hence, human 
studies investigating the effect of PRDC on macronutrient digestion and absorption, 
while controlling for the timing of chocolate intake are needed. 
 
There is also a question about the dose of flavanols needed and the frequency of DC 
consumption required to induce a weight-lowering effect. PRDC (containing 500 mg 
of polyphenols and providing 102 Kcal) did not result in a weight reduction but in an 
increase in weight in this study. In addition, Gu et al. (2013) stated that the amount 
that reduced body weight in rats was equivalent to 513 mg of flavanols (provides 
221.4 Kcal). Yet, more studies are needed to identify the amount supposed to 
decrease weight in humans. Furthermore, since procyanidins were suggested to 
decrease weight reducing effect compared to the monomeric flavanols (Dorenkott et 
al. 2014), it is important to identify the fraction of polyphenols that is most likely to 
induce a lowering effect on body weight.  
 
Furthermore, although studies showed that the total calorie content of a diet counts 
more than fat intake in weight loss regimens (Harvey-Berino 1999; Djuric et al. 
2002), the difference in fat content between cocoa and DC might have affected the 
ability of polyphenols in DC to reduce weight. It was stated in a review that the 
beneficial effects of cocoa, and particularly its weight-lowering properties might not 
be applicable to dark chocolate (Ali et al. 2014). In addition, cocoa was administered 
to animals in the context of a controlled diet. However, humans exhibit day-to-day 
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fluctuations in their daily food intake (Monsen and Van Horn 2008). This will affect 
the identification of the true effect of DC on weight. This is particularly difficult 
when looking at small changes in body weight in the context of a normo caloric diet. 
Further studies including a large number of participants, controlling for human diets, 
and providing details on the flavonoid and fat contents of chocolate should be 
considered to identify the effect of DC on body weight.  
 
Lastly, it is worth mentioning that the term “anti-obesity” which was used in many 
reviews and studies (Matsui et al. 2005; Min et al. 2012; Ali et al. 2014; Dorenkott et 
al. 2014) might be overstated. In fact, obesity is a multifactorial condition, and it is 
very unlikely that one snack/food could help protecting against it. This term might 
lead to an overestimation of the ability of polyphenols in countering a small 
proportion of fat and energy in the diet. Thus, this designation might need to be 
reconsidered. 
 
Body composition 
The increase in BMI noted in this study was not associated with significant changes 
in body fat percentage, lean body mass or total body water, when the latter 
parameters were assessed by BIA. This was further documented by the non 
significant correlation between changes in body fat percentage and changes in body 
weight from baseline at week 12 (r= 0.43, p= 0.13). The increase in BMI cannot be 
attributed to a change in the amount of clothing since participants were asked to wear 
approximately the same clothes on each occasion. Although participants were asked 
to reduce the intake of caffeine and alcohol prior to the BIA test, the non significant 
changes in body composition might be related to the difference in the level of 
hydration of participants, which my affect the accuracy of BIA (Dehghan and 
Merchant 2008). In addition, even though women were asked about the day of the 
menstrual cycle during each appointment, results were unclear. Females did not 
show an increase in their weight when the appointment was in the last days of their 
cycle. Although a confounding factor, it might be difficult to control for the 
fluctuations in the levels of hydration related to the menstrual cycle of female 
participants, due to the fact that appointments are fixed at a nearly specific time.  
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Waist circumference 
Despite the increase in BMI, no significant changes in waist circumference were 
noted. This also corresponded to the non significant correlation between changes in 
BMI and changes in WC from baseline throughout the study (r= 0.49, p= 0.08). The 
increase in weight cannot therefore be explained by an increase in muscle mass 
(since LBM did not significantly change, p<0.05), and might suggest that changes in 
weight were not sufficient to induce changes in WC. As WC is an important marker 
of diseases (Snijder et al. 2006), further studies are needed to investigate this 
relationship, particularly that PRDC was involved in decreasing WC. This was noted 
in the short-term study of Di Renzo et al. (2013), which showed a decrease in waist 
circumference (–1.24 ± 1.45 cm, p ≤0.05) after one week of PRDC consumption 
(with 2000 mg of polyphenols). However, due to the lack of a control group in the 
latter study, there might be an expectation bias which resulted in a decrease in food 
intake during the week of intervention. Also, because of the short study duration, 
results were inconclusive. Long term placebo-controlled studies are then required to 
identify any potential decrease in WC resulting from PRDC consumption. 
 
Reported energy intake through diet diaries 
The increase in BMI was not associated with an increase in energy intake as reported 
by the diet diaries. One of the most plausible explanations for these findings is 
underreporting. The inaccuracy of self-reporting in estimating the actual intake was 
previously noted, particularly in the obese population (Schoeller 1995; Goris et al. 
2000), and BMI status was considered the major contributing factor to 
underreporting (Bram et al. 1998). It was demonstrated that in obese individuals, the 
amount of nitrogen excreted by the urine is equal to half the amount of nitrogen 
when calculated through the self-reported dietary intake. In another study, the 
reported energy intake constituted 59 ± 24 % of the actual energy expenditure in 
obese individuals when validated through doubly-labelled water. This discrepancy 
was proportional to body fatness. Underreporting was also described by Davison et 
al. (2008), who suggested an underestimation of energy intake and an overestimation 
of physical activity in overweight individuals when assessing the effect of cocoa 
polyphenols on blood pressure and other markers. In addition to BMI, the 
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underestimation was higher in females compared to males (Bandini et al. 1990). 
While the reasons of underreporting are not completely elucidated, inability to 
describe the diet (Schoeller 1995), undereating and underrecording (Goris et al. 
2000) were proposed.  
In this study, the ratio of calculated energy expenditure to reported energy intake 
ranged between 1.11 - 1.25. It was previously suggested that a ratio higher than 1 
indicates underreporting (Garriguet 2008). However, this ratio of 1.11-1.25 
represents the mean level of underreporting in the whole study population. By 
looking at the reported energy intake for each participant, 8 participants constantly 
underreported their energy intake, while 4 participants adequately reported and 2 
participants overestimated their daily energy intake. It might be then more accurate 
to look at the diet diaries of each participant in order to identify underreporting. In 
addition, the application of a correction factor to the self-reported energy intake via 
diet diaries might be helpful in estimating the actual energy intake among the 
population.  
 
ANOVA test showed a significant effect of time on fat intake throughout the 
intervention, as assessed by diet diaries (p= 0.024). However, pairwise comparisons 
did not show a significant change in fat intake at different time points (p>0.05). Fat 
intake seemed to be increased in the placebo DC group, and decreased in the PRDC, 
yet this did not reach statistical significance. Although it appears contradictory, 
getting significant ANOVA results with no significant difference in pairwise 
comparisons has been previously reported in the literature (Westfall 1999), and 
might be explained by the requirements for larger differences to declare significance 
in pairwise comparisons. Other explanations could be the adoption of a univariate 
approach which is considered less powerful than a multivariate output (such as 
Wilk’s lambda and Pillai’s trace) when the sample sizes are small (Stevens 2013).  In 
the case of fat intake, pairwise comparisons seemed to be consistent with the non 
significant results of the multivariate tests (Wilk’s Lambda for the interaction 
between time and intervention = 0.092). This discrepancy between multivariate and 
univariate tests is uncommon and has been attributed to many factors such as the 
presence of outliers (Park et al. 2009). It would then be more recommended to adopt 
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the results of multivariate tests since the latter do not need the sphericity to be 
assumed. Nevertheless, multivariate tests might also be limited by the small sample 
size, which reduces the numbers of degrees of freedom for error, and might therefore 
affect their accuracy (Park et al. 2009).  
As a result, it could be suggested that there were no significant differences in fat 
intake following chocolate consumption in both groups, and that more studies with a 
larger sample size are needed to identify a potential effect of DC intervention on fat 
intake. 
 
Basic metabolic rate 
As for BMR, this study did not show an increase in energy expenditure in both 
groups. Results did not reinforce the findings of an animal study which reported an 
increase in energy expenditure in rats consuming cocoa flavanols (0.2 %) for 2 
weeks (by 42 Kcal/ 22h, p<0.05) through the activation of mitochondrial biogenesis 
(Osakabe 2013). On the other hand, it is known that the increase in weight is 
generally related to an increase in energy expenditure (Schoeller 1998), which is 
responsible for decreasing the pace of weight again over the long term when extra 
calories are consumed. It could be possible that the increase in weight in this study 
was not sufficient to induce an increase in energy expenditure. However, the most 
plausible explanation for this outcome is the fact that energy expenditure was 
estimated via the BIA machine. This estimation is based on lean body mass rather 
than the measurement of actual oxygen consumption and carbon dioxide production, 
which is generally performed via indirect calorimetry (McClave and Snider 1992). 
Consequently, the non significant changes in lean body mass provided an 
explanation for the non significant change in BMR. Further studies well controlled 
for energy intake and physical activity, and using accurate methods for measuring 
energy expenditure (such as indirect calorimetry) are then required. 
 
Follow up appointment 
The follow-up appointment documented no significant changes in BMI levels. As 
shown, participants maintained the gained weight four weeks after the end of the 
intervention. Results seemed to be consistent with the non significant change in 
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energy and macronutrient intake recorded after the end of the study. While taking 
into consideration that the sample size does not help making strong conclusions, it 
might be possible that participants adapted to the extra snack consumed daily, and 
maintained the habit after the study. Notably, although significant differences 
between the placebo DC and PRDC groups were noted for BMR (p=0.044), this 
could be mainly explained by the difference in baseline levels of BMR between the 
groups. This finding is intriguing since there is no significant difference in LBM 
levels between the two groups (p=0.54). Yet, this did not affect the outcomes over 
time.  
 
Eating patterns 
One of the novel suggestions of study II was to assess a potential change in eating 
patterns through the analysis of the intake of sugars and saturated fats following DC 
consumption. Diet diaries did not show a significant difference in sugar intake at 
different time points. In addition to the possibility of a non significant effect of daily 
DC consumption on sugar intake, this result might be due to the difficulty in 
measuring sugar intake through self-reported data. In fact, a study assessing sugar 
intake using a biomarker of sugar in the urine and self-reported techniques (FFQ, 
diet diaries and 24-hour dietary recall) showed an inaccuracy of the self-reported 
techniques in estimating sugar intake (pearson’s correlation between sugar intake 
and self reported techniques ranged between 0.22 and 0.27, p > 0.05), which was 
shown to be underreported. This stresses on the use of a biomarker of total sugar in 
the urine as a way to get a proper estimate of sugar intake (Tasevska et al. 2014). 
This point deserves more investigation, and looking at whether a consumption of a 
sweet snack can decrease the exposition to temptations and promote healthy eating 
(Kroese et al. 2009) need to be considered. 
 
Given all the facts previously exposed, research on DC and its weight lowering 
properties remains novel and many studies targeting the suggested mechanisms of 
action are needed. These mechanisms include the effect of PRDC on the inhibition of 
digestive enzymes (Gu et al. 2013), and the increase in fat oxidation and gene fatty 
acid expression (Matsui et al. 2013); the modulating effect of PRDC on food intake 
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and satiety through the action of polyphenols on neuropeptides via the central 
nervous system (Panickar 2013); and the effect on thermogenesis (Osakabe 2013). 
Also, since the increase in insulin sensitivity due to polyphenols was proposed as one 
of the mechanisms that decrease obesity (Panickar 2013), studies that investigate the 
long term effects of PRDC on body weight while assessing glucose and insulin 
levels, are needed to possibly explain this effect. Nonetheless, it is crucial to mention 
that given future controlled studies might note a significant decrease in body weight 
following PRDC consumption, it is unlikely that these changes will be of clinical 
relevance. However, this will be useful in incorporating PRDC in hypocaloric diets 
aiming to help in weight loss. 
 
Biomarkers of compliance 
As for biomarkers of compliance, this study did not show a significant change in the 
levels of total antioxidant capacity and total polyphenols in the urine. The results 
contradict studies in the literature that showed an increase in urinary polyphenols 
following PRDC consumption (Ito et al. 2005; Al Moosawi et al. 2010; Al Moosawi 
et al. 2012). Even though compliance to DC consumption was reported to be high 
(84.82 %) in this study, levels of polyphenols and antioxidant capacity in the urine 
did not validate the results. These outcomes might be explained by the small sample 
size which did not help to identify the correlation between PRDC consumption and 
polyphenol levels and antioxidant capacity in the urine. Furthermore, outcomes 
might be explained by the fact that, with the exception of other cocoa and chocolate 
products, participants were not asked to limit the intake of foods rich in flavonoids. 
However, this might have masked the increase in phenolic levels in the urine 
following PRDC consumption. In addition, two participants provided huge 
differences in the volume of the collected 24-hour urine between the 3 samples, 
which might be due to their decrease in compliance, rather than a decrease in their 
urine output. This might have influenced the assessment of the change in antioxidant 
and polyphenol levels. Finally, the intra and inter individual variability in the 
metabolism of polyphenols cannot be excluded (Santos-Buelga et al. 2010).  
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However, although studies have discussed the importance of evaluating compliance 
in the urine (Pérez-Jiménez et al. 2010), there are many limitations related to this 
test. In fact, the assessment of polyphenols in the urine is limited by the short half-
life of these components (1-5 days) (Santos-Buelga et al. 2010). Consequently, the 
ability of this test to identify compliance in studies lasting more than a week is 
compromised (Santo-Buelga et al. 2010).  To illustrate, even if participants followed 
the protocol, abstinence from consuming the dose of chocolate for the last few days 
before the appointment might have not clearly identified their compliance. On the 
other hand, this test might provide positive results if participants mainly adhered to 
the protocol for the last few days before the appointment. 
As a result, whether the non significant effect obtained was due to the masking of the 
changes in polyphenols in the urine or to the non compliance of participants remains 
unclear. 
A point worth of note is that despite the significant difference in total polyphenols 
between PRDC and placebo DC within mixed model ANOVA (p=0.01), this did not 
affect the changes in these levels over time, and might be explained by the fact that 
baseline levels of urinary total polyphenols were initially different between the two 
groups. 
 
Cortisol, cortisone levels and the activity of 11 β HSD1 
Although BMI increased, it was not associated with a significant change in cortisol 
and cortisone levels or in the activity of 11-β HSD1. The results are consistent with 
the outcomes of Al Moosawi et al (2010; 2012) which showed no significant 
changes in glucocorticoid metabolism in the PRDC group. As mentioned in section 
5.1.2, factors such as the implication of polyphenols other than flavanols in 
improving cortisol metabolism, and confounding factors such as fat and sodium 
intake, might have led to such outcomes. 
Results do not correspond with the fact that an increase in food intake and body 
weight could lead to an increase in HPA activity and cortisol levels (Drake et al. 
2005). However, the fact that the increase in energy intake and weight were not 
sufficient to induce an increase in HPA cannot be excluded. Lastly, the lack of 
compliance in providing urine samples might have also influenced the results. 
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4.2.2.2 Section II: Discussion of feasibility outcomes for a larger study 
 
The feasibility of a larger study was assessed by the evaluation of the integrity of 
Study II protocol, validity and clarity of questionnaires, acceptability of treatment, as 
well as compliance and drop out rates (Lancaster et al. 2002). Participants self-
completed the forms and questionnaires. Information sheets were clearly stated and 
questions were comprehensible and did not necessitate further modifications. 
For the questionnaires, important information regarding medical history and social 
habits were obtained, and data regarding physical activity were collected before, 
during and after the study. These data mainly aimed to assess eligibility criteria and 
to avoid potential confounders such as diet and exercise. Therefore, these 
questionnaires can be considered valid as they clearly measured what they were 
intended to measure. However, the increase in weight that did not correspond to an 
increase in energy intake in diet diaries, suggests that participants underreported their 
energy intake. Based on this, providing information on how to accurately report food 
intake in the diaries (e.g. mention all food ingredients, use measuring cups) might be 
helpful. In addition, a close monitoring to the diet of participants by a dietitian might 
need to be considered. 
Furthermore, the food frequency questionnaire presented many potential limitations. 
First, as it was solely designed to identify differences in flavonoid intake throughout 
the study, only medium and high flavonoid content foods were considered 
(Appendix 9). Yet, some low flavonoid foods which were not included might have 
been consumed excessively, and have potentially affected the total flavonoid intake. 
In addition, some herbs, peppers and spices that are high in flavonoids (as mentioned 
in the USDA database (USDA 2011b)), were not mentioned due to their common 
low intake. Moreover, other foods also known to contain a high amount of 
flavonoids like lemons, elderberry, tangerines, raw spinach, sweet potatoes (USDA 
2011b) were not included for different reasons such as their low probability of 
consumption while raw, and their intake in small quantities. Consequently, the 
validity of the current FFQ was compromised as it did not entirely assess flavonoid 
intake. In view of the strong correlation between FFQ and total flavonoids in the 
urine according to few studies (Rautiainen et al. 2008; Vian et al. 2013), a properly 
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designed FFQ could help in determining changes in polyphenol intake, can be used 
for  a large study. A detailed FFQ might also be helpful in identifying seasonal 
changes that could affect flavonoid intake, and as a result, influence the study 
outcomes. For instance, Mink et al. (2007) developed a FFQ with 127 food items 
based on USDA data in which foods containing flavonoids were mentioned. 
Analysis of this FFQ was carried out by multiplying the amount of flavonoids (in 
mg) in one serving of food by the frequency of consumption per week. Results were 
then adjusted for energy intake. Designing a similar FFQ might be more precise in 
estimating the total amount of flavonoids in the diet, and could possibly provide 
information on the changes of flavonoid intake throughout the intervention in a 
larger trial. 
 
The dose of dark chocolate (20g which provided 102 Kcal) and the amount of 
polyphenols (500mg of polyphenols) might possibly need to be tested on a large trial 
before considering adopting changes to the quantity of chocolate or to the dose of 
polyphenols. In fact, a lower amount of chocolate with a similar polyphenol dose 
might increase its bitterness and result in a decrease in compliance. Also, choosing a 
higher amount of polyphenols might increase complaints and side effects such as 
gastrointestinal discomfort (Mead 2007). Hence, a study well controlled for 
confounding factors (diet, exercise) might provide suggestions for any future 
changes in the dose of DC or in the amount of polyphenols based on the outcomes. 
Randomization procedure using sealed envelopes and the random allocation of 
chocolate was shown to be appropriate in randomizing participants.  
As for the recruitment rate, one of the main limitations of this study was the 
difficulty in recruiting overweight participants with BMI>25 Kg/m
2
. As stated in 
study I, it is crucial to identify barriers to the participation of the overweight 
population in research studies. In fact, this decrease in participation could lead to a 
reduction in the statistical power and efficiency of trials (IDRE 2014). The difficulty 
remains in the recruitment of participants who were not or had not been on a weight 
management program for two months prior to the study. This was mainly intended to 
identify the effect of DC on BMI in participants who follow their usual diet. 
Excluding participants on a diet program was mainly due to the different pace of 
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weight loss between individuals, which might make it difficult to identify the 
implication of PRDC in weight loss. Based on this, it was not possible to recruit 
volunteers from weight loss centres, as they do not meet the eligibility criteria. In 
addition, as some participants were reluctant to participate attributing the reason to 
geographical distance, offering incentives while involving a wider location should 
probably be considered. 
 
The dropout rate observed in this study was 30 %. This rate matches with the results 
of a weight loss study by Drummond et al. (2004), and with the long term study 
conducted by Curtis et al. (2012) on dark chocolate; yet the latter study lasted for a 
year. This relatively high drop out rate should be taken into consideration in future 
recruitment strategies to avoid an underpowered study.  In addition, only two 
participants reported complaints following PRDC consumption, suggesting few side 
effects of the treatment. Therefore, it would be possible to administer this product for 
a larger number of participants. 
 
In this study, urine collection was intended to analyse compliance to intervention and 
antioxidant capacity resulting from daily PRDC consumption. To minimize burden, 
participants were not asked to provide a 24-hour urine sample before the follow-up 
appointment. However, this might have been important in identifying changes in 
flavonoid intake following the study, and would have provided a better overview of 
the compliance throughout the study (by comparing the levels of 
polyphenols/antioxidant capacity before and after the end of the study). Hence, 
including urine collection before the follow-up appointment should probably be 
included in a future protocol. 
 
For the sample size analysis for a larger trial, the numbers presented should be 
adequate to conduct a future study with significance. The mid-pre intervention 
estimation was 260 participants, which is 419 % higher than the sample size 
estimated at post – pre point (62 participants), and 200 % higher than the post - mid 
point (130 participants). This difference could be explained by the non significant 
results obtained between the post – mid and mid – pre time points in the two groups, 
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which resulted in the need for a larger number of participants to detect an effect. 
Among the sample size options, it would probably be the most significant to go for 
the highest number of participants (338 participants while considering the drop out 
rate), yet the recruitment of such number might be impractical. Therefore, as 
suggested by Delucchi (2004), adopting a particular sample size in studies must be a 
compromise between scientifically suggested numbers and the available time and 
budget. 
 
Lastly, designing a study with more frequent appointments (e.g every 2 weeks) 
might be more helpful in obtaining a better overview of the change in weight 
throughout the study. 
 
In conclusion, results of this small scale study suggest that the daily consumption of 
a dark chocolate snack whether low or high in polyphenols led to an increase in 
weight. The potential underestimation of energy intake by this population rendered it 
difficult to identify changes in energy and macronutrient intakes after dark chocolate 
consumption. Results also suggest the feasibility of the current protocol for a large 
study with few modifications. As a result, snacking on a small amount of chocolate 
should remain in the context of a balanced diet in order to avoid its potential 
unfavourable effects on body weight.    
 
 
 
 
        
 
 
                                   
                          
 
 
             
 227 | P a g e  
 
 CHAPTER 5: GENERAL DISCUSSION AND CONCLUSION 
 
The aim of this research was to assess the preventive effect of PRDC on risk factors 
for type 2 diabetes and CVD including IR, blood pressure, serum cholesterol levels 
and antioxidant and inflammatory markers. For this purpose, participants were 
recruited with no chronic diseases. For the two studies carried out, it was questioned 
whether participants should be identified with the term “healthy”, due to the fact they 
have no history of CVD, type 2 diabetes and hypertension.  However, because of the 
inclusion of normal weight and overweight participants, this identification might 
become inaccurate. In fact, as explained in section 1.1.2, overweight and obesity are 
correlated with more complications than normal weight, such as higher inflammatory 
state and oxidative stress (Silver et al. 2007); and obesity was even qualified as a 
disease (Mechanick et al. 2012). Hence, to avoid any underestimation of the 
overweight and obesity state, the term “healthy participants” was replaced by 
participants with no known hypertension, type 2 diabetes or CVD in both studies. 
 
The difficulty in recruitment did not lead to the required number of participants in 
both studies. Reasons such as the need to perform venepuncture as a study 
requirement (study I), the long term commitment (Study II), the need to restrict 
flavonoid intake for the whole study period (Study I), the burden in reaching the 
research lab location and work commitment were noted by subjects. As an effort to 
improve recruiting, steps such as the increase in advertisement and the coverage of 
the transportation costs were considered. 
 
The use of a relatively low calorie daily dose of chocolate in both trials (20g; 102 
Kcal) resulted in presenting DC as an energy dense food. This has advantages over 
the studies of Di Renzo et al. (2013) and Grassi et al. (2005) which used a high dose 
of DC (100g; contained 561 Kcal and 515 Kcal, respectively); this amount of energy 
provides not less than 20 % and 30% of the daily usual energy intake of men and 
women, respectively (CDC 2011b), and might result in weight gain and other 
complications, particularly over the long term. Therefore, the amount of DC used in 
Studies I and II might have helped in minimizing the detrimental effects mainly 
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noted in the placebo group, and decreased the magnitude of the increase in weight, 
glucose, insulin and TG levels. 
The favourable effects of PRDC on insulin sensitivity and serum oxidised LDL 
underline the importance of PRDC in preventive medicine due to the fact that it is 
cost effective. In fact, it was suggested that 50000$ could be saved per years of life 
when 42 $ per person per year is utilized to buy chocolate (Zomer et al. 2012). Given 
that the favourable effects of PRDC have been established, PRDC could be 
implemented in future recommendations to improve health, in a similar way as olive 
oil or nuts. On the other hand, findings of the placebo group (increase in BMI, 
insulin, IR, glucose and TG levels in study I, and the increase in BMI in study II) 
raise concerns over the different types of DC in the market, as the current methods of 
processing might cause a considerable loss of polyphenols (Cooper et al. 2008). This 
leads to the hypothesis that chocolate in the market might be detrimental to health. 
For marketing purposes, chocolate companies mainly aim to increase food 
palatability by masking the astringent flavour and increasing consumer acceptability. 
This results in the use of processing methods that might cause major polyphenol 
losses. It is then very likely that these companies are more eager to improve taste 
rather than preserving polyphenols. Qualitative data from studies I and II reinforce 
this idea that low polyphenol DC is more preferred than high polyphenol DC. 
Studies that analyse the content of polyphenols in DC in the market are crucial, and 
the need for a legislation regarding the polyphenol amount of chocolate should 
probably be considered, provided that the beneficial effects of PRDC on health have 
been established.    
 
Furthermore, there are some doubts regarding the long term acceptability of the 
regular consumption of chocolate, particularly the one rich in polyphenols (due to its 
bitterness). The study of Ried et al. (2010) showed that 20% of participants found it 
hard to consume chocolate as a long term intervention, and suggested that chocolate 
might not be as practical as capsules. Moreover, with the adverse effects and 
complaints reported in studies I and II, data that support the long term intake of 
polyphenols are needed, and efforts towards improving the bitterness and the taste of 
PRDC should probably be considered. 
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A point worth mentioning is that in study I, the placebo DC resulted in an increase of 
TG (by 0.13 ± 0.23 mmol/l), BMI (by 0.17 ± 0.32 Kg/m
2
), fasting insulin levels (by 
0.77 ± 1.56 µIU/ml), HOMA-IR (by 0.27 ± 0.44) and glucose levels (by 0.44 ± 1.08 
mmol/l). Although results are statistically significant, there is a question about the 
clinical relevance of these outcomes. Levels of TG levels, albeit increased (by 15%) 
remained within normal levels. For glucose, levels slightly increased, and the 
possibility of day-to-day fluctuations in glucose levels cannot be excluded (Sacks 
2011). In addition, after adjusting for baseline imbalances (via ANCOVA), the effect 
of placebo DC on glucose levels was no longer significant (p=0.29). With regards to 
weight, the increase in 1 Kg was reported to be clinically significant (Jousilahti et al. 
1996), thus the increase in body weight might not be considered clinically relevant in 
this study. In view of the small changes from baseline in glucose, triglyceride and 
BMI levels, it cannot be ruled out that few participants in the placebo group did not 
abide by the recommendations to attend the appointments while fasting. As for the 
PRDC group, the reductions in HOMA-IR were small (by 0.2 ± 0.34), compared to 
the studies of Grassi et al. (2005) (HOMA-IR decreased by 0.94 ± 0.42) and Al 
Moosawi et al. (2012) (HOMA-IR decreased by 1.03 ± 0.76). Therefore, results 
obtained constitute a basis for carrying out more studies investigating the long term 
effects of PRDC and low polyphenol DC on anthropometric, biochemical and 
physiological markers.  
Although the aim of both studies was to recruit participants from the whole 
population, there should be a consideration towards including post menopausal 
women, particularly in Study II. As previously discussed, post menopausal women 
undergo losses in lean body mass and have differences in body composition and fat 
distribution, compared to pre-menopausal women. This leads to an increase in the 
ratio of fat mass/ lean mass particularly in the lower part of the body, which affects 
BIA measurement (since BIA electrical current passes through the legs) (Dehghan 
and Merchant 2008). Studies that include exclusively postmenopausal women might 
be helpful in assessing the effect of PRDC consumption in this category. 
 
The reported diet diaries in both studies showed a potential underreporting. This was 
mainly explained by the increase in weight that was not supported by an increase in 
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food intake in the diaries. Thus, it would be important to improve the way of 
estimating the actual daily intake, while considering the practicality of the method, 
and the fact that it does not impose a big effort from participants. In the last few 
years, methods using smart phone devices have been shown to be useful. For 
instance, researchers developed a smart phone application called “Recaller” as a 
nutritional assessment tool (Suzuki et al. 2012). This application constitutes an easy 
method to keep photo records of all consumed foods. Although this method does not 
solve the problem of limiting food intake during an intervention (the fact of 
recording may alter diet (Lee and Nieman 2007)), it reduces the error of assessing 
food portions by individuals and decreasing intake to avoid the burden of reporting. 
This should be helpful in obtaining a better estimate of the actual food and energy 
intake in future studies. 
 
It is important to mention that in view of the increase in TG, glucose, insulin and 
BMI levels in the placebo group after 4 weeks (study I), and the increase in BMI in 
the second study, there is a question about the ethical implication of daily 
administering dark chocolate in long term studies (such as 12 weeks), particularly 
the one deficient in polyphenols. Therefore, an information sheet that mentions the 
potential side effects of DC, particularly for the control group should be considered 
in future trials. Furthermore, the restriction of polyphenol/flavonoid intake as a study 
requirement might need to be considered. This restriction could be problematic 
particularly in studies lasting for a long period (12 weeks), due to the favourable 
effects of polyphenols/flavonoids on health (Stevenson and Hurst 2007). 
 
5.1.1 Limitations 
Given that the aim of the studies was to determine the effect of PRDC consumption 
in the general population, while recruiting normal weight and overweight 
participants, it was not possible to reach the desired number of overweight 
participants in both studies, due to the fact that they were reluctant to participate. As 
this study did not offer incentives apart from the free chocolate, there was no great 
interest for this weight category to take part. A study that looks at the reasons of 
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reluctance of the overweight category to participate in research studies might be 
helpful in increasing compliance among this population. As far as we know, this 
unwillingness was not previously described in the literature. 
 
In addition, women represented the largest part of both studies, which might have 
limited generalization of the results. Other factors such as the considerably young 
population and the predominance of students, were mainly due to the location of the 
studies, and might have also affected study generalization. Furthermore, there was no 
randomization according to age or gender. In study I, there was a significant age 
difference between normal weight and overweight participants in the placebo group 
(p= 0.034). A meta-analysis previously reported a greater effect of cocoa/DC on 
blood pressure when participants were younger (Ried et al. 2012). Hence, 
randomization would have been more reliable in eliminating any possible 
confounding factors. The difficulty arises from the small number of participants, 
which made it impractical to randomize participants according to the above 
mentioned criteria. 
 
Moreover, since there were no restrictions made on the time and frequency of eating 
the daily DC dose in the two studies, inter-individual and intra-individual variations 
in response to intervention arising from consuming DC at fasting or with meals 
cannot be excluded. This is particularly important if the main mechanism by which 
PRDC improves IR and reduces weight, involves its effect on inhibiting digestive 
enzymes (Gu et al. 2011) and increasing GLP-1 in the gut (Dorenkott et al. 2014). 
These differences might have caused a considerable impact on the outcomes.  
 
Similarly to all dietary intervention studies, an inability to control the diet of 
participants resulted from the inclusion of free-living individuals who exhibit a large 
variability in their dietary habits (Monsen and Van Horn 2008). Therefore, it was not 
possible to verify whether participants consumed the dose of chocolate daily as 
required. Also, the day-to day fluctuations in the diet made it difficult to determine 
the true effect of cocoa polyphenols on anthropometric and physiological markers. 
Furthermore, the possibility that participants did not adhere to the dietary protocol, 
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and did not maintain their regular diet throughout the intervention cannot be 
excluded. Therefore, unless studies are controlled for food intake and physical 
activity, many changes in the diet could mask the effects of DC intervention.  
 
Another limitation is the large inter-individual variability in the metabolism of 
polyphenols (Santos-Buelga et al. 2010), which is due to the difference in the colonic 
microflora between individuals (D’arhivio et al. 2007). As it is an oral dose, it is hard 
to determine the absolute availability of polyphenols as it is the case of injected 
doses. The difference in polyphenol metabolism was estimated to be around 15.8 % 
between individuals (Rodriguez-Mateos 2014).  
 
Moreover, both studies consisted of taking baseline and post-intervention data 
(baseline, mid- and post-intervention data in study II), each on one single occasion. 
Therefore, routine measurements were not considered. Although this protocol is 
common in most of the studies (examples: Engler et al 2004; Baba et al 2007a; Al 
Moosawi et al 2012), it is affected by the daily fluctuations in many parameters, and 
particularly body weight and blood glucose levels. Despite the fact that participants 
were asked to maintain their usual diet, it was not possible to control the changes in 
weight resulting from energy fluctuations in the past few days preceding the 
appointments. Measurement of these parameters daily would have been more 
reliable in detecting changes caused by DC supplementation. For instance, Grassi et 
al. (2005) monitored blood pressure daily for the whole study period (15 days). 
However, due to the longer term of the conducted studies (4 weeks and 16 weeks) 
and the burden on participants, it was not practical to assess these parameters 
routinely. 
 
Lastly, the adoption of a parallel study design, despite it advantages, presents few 
limitations in terms of inter participant variation, since the participant does not serve 
as his own control.  This might lead to a decrease in the power of studies (Monsen 
and Van Horn 2007) (Section 3.3.4) 
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5.1.1.1 Study I 
 
Some limitations specific to this study were noted. The compliance to intervention 
was not assessed by analysing total polyphenols in a 24-hour urine sample as a 
biochemical marker for compliance. Despite the limitations related to this test 
(section 3.4.6.2), it might have provided a better idea of adherence. Asking 
participants whether they consumed the chocolate, and counting the empty 
containers were the only means to assess adherence to daily DC consumption. 
Nevertheless, previous studies have also assessed compliance similarly to this study 
(Grassi et al. 2005; Davison et al 2008; Muniyappa et al. 2008). The collection of 
urines samples would have also been useful for the analysis of the urinary F2 
isoprostanes concentration, since the latter parameter represents a direct measure of 
oxidised LDL in the urine (Jialal 1998). 
 
Another limitation is the duration of the study (4 weeks), which might have been 
insufficient to identify the effects of PRDC on some parameters such as blood 
pressure levels. Furthermore, the fact that parameters were assessed at 2 
appointments (baseline and week 4) might have been less reliable than measuring 
these parameters at more frequent appointments (e.g. week 2, week 4 and week 6). 
 
Moreover, the sample size did not provide enough power to explore the effect of 
other factors such as age and gender on the results, as some studies showed their 
impact on the outcomes. While a meta-analysis reported a possible influence of age 
on the effects of cocoa/DC on blood pressure (Ried et al. 2013), a new research 
suggested a minimal implication of age on the metabolism of flavanols (Rodriguez-
Mateos 2014).  Furthermore, a study suggested than males better responded to the 
LDL oxidation lowering properties of cocoa polyphenols than females (Ibero-
Baraibar et al. 2014).  
 
This study did not also help to make strong conclusions regarding the impact of BMI 
on the outcomes. In addition, the findings are limited by the lack of knowledge of the 
physiological mechanisms underlying the improvement of insulin resistance and 
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oxidised LDL, and which polyphenols or polyphenol metabolites were responsible 
for these effects. 
5.1.1.2 Study II 
The main drawback of this study is the small sample size, hence results are mainly 
preliminary. Although expected, the high dropout rate (30 %) probably affected the 
power of the study. In addition, the food frequency questionnaire used was not 
entirely reliable in assessing flavonoid intake of participants during the intervention, 
as it lacks foods with low content of flavonoids. Furthermore, this FFQ did no take 
into consideration the combination foods (such as mixed vegetables and pizza). Also, 
as it was assumed that foods that are not in the USDA table (for foods rich in 
flavonoids) do not contain flavonoids, some other databases need to be checked 
while developing a more accurate FFQ. Moreover, the fact that the intake of 
flavonoids was not restricted during the study might have masked the changes in 
total phenols and antioxidant capacity in the urine resulting from PRDC 
consumption.  
 
Another limitation is the decrease in compliance because of the long term nature of 
the study (12 weeks) which might have led to a decrease in compliance. Low 
compliance was described as the major threat to the validity in trials (Swinscow and 
Campbell 2002). Moreover, there was no blood sample test taken to evaluate the 
long term effect of DC on several biochemical and physiological markers (such as 
insulin, oxidised LDL and lipid levels). This would have been helpful to determine 
any beneficial/detrimental effects on these markers resulting from PRDC/ placebo 
DC consumption, and their correlation with body weight.  
  
Also, the estimation of energy expenditure via BIA machine did not provide an 
accurate measurement of this parameter, and did not help to assess the actual change 
in BMR resulting from a change in oxygen consumption and carbon dioxide 
production throughout the intervention. 
 
Furthermore, there was no measurement of polyphenol and antioxidant capacity in 
the urine before the follow-up appointment. This could have been useful in assessing 
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any differences in polyphenol intake after the study, and in providing additional data 
about compliance. The evaluation of F2 isoprostanes in the urine as a direct 
measurement of LDL oxidation (Jialal 1998) might have also been helpful in 
assessing the antioxidant effects of PRDC.  
 
Moreover, measurement of hip circumference as a part of anthropometric measures 
would have been helpful in assessing the body adiposity index, which can be 
obtained from height and hip circumference, and is highly correlated to fat mass 
(Bergman et al. 2011). This would have provided another measure of adiposity. 
 
Finally, even though efforts towards the estimation of underreporting energy intake 
were considered in this study (by comparing energy intake to energy expenditure), 
underreporting was evaluated through non validated methods such as physical 
activity levels, which were described by participants. In addition, BMR was 
estimated via BIA machine, which presents important drawbacks cannot also be 
excluded (Dehghan and Merchant 2008). This might have affected the estimation of 
the total energy expenditure of participants. 
 
5.1.2 Directions for future research 
The beneficial effects of PRDC on insulin sensitivity and LDL oxidation suggest 
conducting more trials to elucidate these effects, while targeting the general 
population. Determining the optimal dose and duration responsible for decreasing 
risk factors for type 2 diabetes and cardiovascular risk factors, along with identifying 
the types of flavonoids responsible for causing a favourable effect are needed. 
 
It would also be crucial to investigate the mechanisms involved in the effect of cocoa 
polyphenols on insulin responses and oxidative stress. Therefore, studies that assess 
NO levels/NOS enzymatic activity might be helpful. In addition, as AMPK pathway 
was regarded as a principal regulator of lipid and glucose metabolism (Ali et al. 
2014), testing its effects in addition to PI3K/AKT pathway, will help to understand 
the molecular mechanisms underlying the effect of PRDC on obesity and its related 
diseases.  
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In addition, it would be important to identify the receptors to which 
flavonoids/flavanols bind to induce a beneficial effect. In fact, the enhanced 
oxidative capacity in muscles of mice due to epicatechin (Nogueira et al. 2011) 
might suggest the presence of receptors for this monomer in muscles. Another study 
stated that epicatechin works via binding to opioid receptors resulting in cardiac 
protection in mice (Panneerselvam et al. 2010). Knowledge of these receptors will 
constitute an important step towards the identification of the mechanisms of action of 
these flavanols. 
 
Because of the limited number of participants in Study II, larger trials examining the 
link between PRDC and body weight are needed. Research that considers many 
aspects of weight control such as satiety, fatty acid synthesis macronutrient 
absorption and thermogenesis are needed. This includes looking at satiety hormones, 
evaluating visual analogue scales, assessing mitochondrial biogenesis, LBM and 
body fat percentage as well as measuring energy expenditure via indirect 
calorimetry. Moreover, testing the long term effect of PRDC (12 weeks) on glucose 
and insulin levels is crucial, due to the possible link between improving insulin 
resistance and decreasing BMI through improvement of  insulin signaling pathways 
(such as PI3K/Akt).  
 
It is also crucial to ensure that the placebo DC and the intervention DC fairly match 
for all components (methylxanthine, magnesium, cocoa butter), in order to eliminate 
possible confounding factors.  Also, human studies should be well controlled for diet 
and physical activity. This will reduce confounding effects resulting from changes in 
energy intake or physical activity throughout the intervention 
 
Given the potential beneficial effects of PRDC and the detrimental effects of placebo 
DC, a crucial future step would be the analysis of the total polyphenol of DC in the 
UK market. This should constitute a direction towards stating the amount of 
polyphenols as a part of a labelling requirement. In addition, efforts towards uniting 
the processing methods of cocoa might need to be considered. Also, because of the 
lower acceptability of DC rich in polyphenols compared to DC low in polyphenols, 
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and the possible adverse effects of fat and sugar in chocolate, efforts should be made 
to deliver a high-flavonoid chocolate in a low sugar and low fat content, while 
increasing its acceptability and decreasing its bitterness. 
In view of the potential side effects noted, there is a need for data regarding the long-
term safety of chocolate components (flavanols, theobromine etc...) before 
recommending the intake of this snack regularly. It would be also worth taking into 
account the control of the polyphenol content of milk chocolate in view of its wide 
consumption, as the study of Fraga et al. (2005) showed a significant effect of 
flavanol-rich milk chocolate on serum lipids and blood pressure. 
 
Studies should also specify the way polyphenols have been assessed in research, 
because of the potential differences in the estimation based on different methods. 
This will allow a more accurate comparison between studies.  
Moreover, in order to improve the practicality of chocolate as a treatment option, 
testing the frequent but not daily intake of dark chocolate (e.g. 3-4 times a week) 
might be a possible option to monitor the long term intake of DC. In addition, in 
view of the difficulty in recruitment, efforts towards improving recruitment 
strategies should probably be considered. 
 
Lastly, the drawbacks of BMI in identifying some normal weight individuals at high 
risk of CVD (Di Renzo et al. 2013), and overweight individuals with high lean body 
mass (Snijder et al. 2006) underline the need for other anthropometric measures to 
categorize the population at risk. This will be helpful in order to implement 
appropriate prevention strategies.  
 
5.1.3 General Conclusion 
This research aimed to determine the effect of PRDC on anthropometric, 
biochemical, dietary and physiological markers in normal weight and overweight 
adults. Study I is, as far as we know, the fifth human study that analysed the effect of 
PRDC on IR/insulin sensitivity in individuals with no diabetes type 2, hypertension 
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or CVD. Study II provided preliminary human data on the long term effect of PRDC 
on body weight and body composition.  
 
The results showed that consuming 20g of DC rich in polyphenols (500 mg) for a 
period of four weeks exerted lowering properties on insulin resistance and oxidised 
LDL levels, both considered potential risk factors for type 2 diabetes and CVD. Yet, 
because of the complexity of polyphenols, there is a lack of knowledge of the 
mechanisms of action involved in improving IR and oxidative stress. Results 
underline the possible implication of PRDC in preventive medicine due to the fact 
that it is cost effective. Findings suggest that polyphenols, and particularly flavanols, 
might be promising dietary components for the prevention of type 2 diabetes and 
CVD risk factors, and PRDC might be subsequently considered a nutraceutical for 
helping in the prevention or delay of the onset of type 2 diabetes, without causing the 
side effects of medications. This raises the need for further investigations in order to 
make future recommendations.  
 
The non-significant effects of PRDC on blood pressure, serum lipid levels and hs-
CRP noted in study I, and on glucocorticoid metabolism in studies I and II suggest 
that 1) the marketing about the preventive effects on PRDC on blood pressure might 
need to be reconsidered 2) PRDC might not constitute a source of prevention against 
dyslipidemia 3) PRDC might not exert a favourable effect on glucocorticoid 
metabolism 4) PRDC might not decrease inflammation. Results could be attributed 
to the fact that participants did not have diabetes, CVD or hypertension. This made 
them less likely to be affected by the intervention. Further long term studies 
controlling for potential confounding factors are needed to refute the preventive 
effect of PRDC on the above mentioned parameters.  
Daily supplementation of DC (20g) for 12 weeks increased BMI in both placebo DC 
and PRDC groups. This increase in weight was not accompanied with significant 
changes in waist circumference, body composition, urinary glucocorticoid hormones 
and antioxidant capacity. Findings are limited by the small sample size of the study. 
Results suggest the importance of considering the energy and fat content of DC, and 
the introduction of this snack in a controlled calorie diet to avoid its adverse effects. 
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Further studies aiming to determine the effect of PRDC on BMI in humans are 
needed.  
The preliminary results provided by study II suggest the feasibility of carrying out a 
large scale study with a similar protocol that investigates the effect of PRDC on body 
weight. Few modifications such as improving the reliability of FFQ and closely 
monitoring the participant’s diet were proposed. 
The increase in BMI, TG, insulin resistance and glucose in the placebo DC group in 
study I but not in the PRDC group, suggest that polyphenols may counteract the 
negative effects of the high fat and energy in chocolate. However, the increase in 
BMI occurred in the placebo DC and PRDC groups following 12 weeks of 
intervention in Study II. The latter outcome might be attributed to the adaptation to 
the quantity of polyphenols, which could limit the ability of these components 3to 
counteract the adverse effects of fat in the diet over the long term. Further studies 
including a large population might elucidate this effect. 
 
The placebo DC adverse effects on BMI, TG, insulin resistance and glucose levels 
suggest that the analysis of the polyphenol content in the market is necessary. 
Controlling polyphenol intake might start by unifying cocoa processing as a first step 
to include this product in public health recommendations, and ending towards 
regulating and labelling the chocolate with polyphenol or flavonoid content.  
 
The potential underreporting of food intake in the studies did not allow an accurate 
identification of fluctuations in energy intake throughout the study. This suggests 
that reporting of diet diaries should be improved via the instruction of participants on 
how to properly document food intake, and the introduction of photo records as a 
way to improve the estimation of food portions. In addition, the difficulty in 
recruiting overweight participants suggests the need to improve recruitment 
strategies in order to increase the power of future studies. 
 
Lastly, because of the lower acceptability of DC rich in polyphenols compared to DC 
low in polyphenols, efforts should be made to increase the acceptability of PRDC. 
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Testing the frequent but not daily intake of dark chocolate (such as 3-4 times a week) 
might be a better option for the long term intake of DC.  
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 CHAPTER 7: APPENDICES 
 
Appendix 1: Study I Information sheet and consent form for potential 
participants  
 
 
 
                                    Information Sheet for Potential Participants 
  
EFFECTS OF POLYPHENOL-RICH DARK CHOCOLATE ON INSULIN 
SENSITIVITY IN NORMAL WEIGHT AND OVERWEIGHT ADULTS 
 
You are invited to take part in this research study. Please read carefully all the 
information before you decide to participate. 
 
My name is Grace Farhat and I am a PhD student in public health nutrition from the 
school of health sciences at Queen Margaret University in Edinburgh. I am currently 
investigating the effects of dark chocolate rich in polyphenols on different markers 
responsible for the occurrence of several diseases. 
 
Background 
 
Polyphenols are antioxidants widely available in foods. Polyphenol-rich foods -and 
dark chocolate in particular- have been the subject of research of many studies in the 
past few years, focusing on their role in reducing risk factors for type 2 diabetes and 
cardiovascular diseases. Thus, determining the beneficial effect of polyphenols in 
dark chocolate on insulin sensitivity and other health markers might help in 
decreasing the occurrence of chronic diseases. 
 
1/4 
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Procedure 
 
If you agree to participate in the study, you will be advised to follow your usual diet, 
and to substitute dark chocolate for another food usually consumed. The researcher 
may help you with properly replacing dark chocolate instead of other foods. You will 
be also asked to avoid eating high quantities of foods rich in flavonoids like red 
wine, blackberries, blueberries and tea (a list of flavonoid-rich foods will be 
provided to you), one week before the start, and subsequently for the duration of the 
study. You will also be requested to avoid drinking alcohol 24 hours before the visit, 
to avoid heavy physical activity 12 hours before the visit, and to consume the last 
dose of dark chocolate 12 hours prior to the second visit. You will also be requested 
to be on a fasting state when attending the 2 appointments. To evaluate your diet, 
you will be asked to complete a three-day diet diary twice during the intervention.  
  
You will randomly receive 20g of one of the 2 types of dark chocolate (placebo low 
in polyphenols, or dark chocolate rich in polyphenols), daily for a period of 4 weeks. 
Before each appointment, you’ll be asked to collect 2 saliva samples for the 
measurement of cortisol and cortisone levels. A blood test will be performed during 
each of the two visits for the measurement of total cholesterol, HDL, LDL, 
Triglycerides, insulin, glucose, C-reactive protein (a marker of inflammation), and 
oxidised LDL levels.  
Your blood pressure will be measured using a digital sphygmomanometer, and you 
will have your height, weight, waist circumference and BMI measured as well. 
 
Duration of the study 
This study is expected to last for 4 weeks. You will be required to attend 2 
appointments during this period, each appointment will require 25-30 minutes of 
your time.  
 
Risks 
There are no risks related to this research. 
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Benefits 
The dark chocolate consumed may improve your health and biological markers. You 
will receive the dark chocolate free of charge. In addition, you will receive a copy of 
the results of all the tests performed if you wish.  
 
Confidentiality 
 
Your name will be replaced with a participant identification number, and it will not 
be possible for you to be identified in any reporting of the data gathered. All data 
collected will be anonymous. The results may be published in a journal or presented 
at a conference. 
You’ll be free to withdraw from the study at any time without giving any reason. 
If you would like to contact an independent person, who knows about this project but 
is not involved in it, you are welcome to contact Dr Iain Gow. His contact details are 
given below. 
If you have read and understood this information sheet, and all your questions have 
been answered, and you would like to be a participant in the study, please sign the 
consent form. 
 
Contact details of the researcher 
     Name of researcher:   Grace Farhat 
     Address:                    PhD student 
                                         Public Health Nutrition 
                                         Department of Dietetics, Nutrition & Biological Sciences 
                                         Queen Margaret University, Edinburgh 
                                          Musselburgh, East Lothian 
                                          EH21 6UU 
     Email/ Telephone:       gfarhat@qmu.ac.uk / 0131 474 0000 
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Contacts details of the supervisor 
 
     Name of supervisor:   Dr Emad Al-Dujaili 
     Address:       Senior Lecturer in Biochemistry 
                 Department of Dietetics, Nutrition & Biological Sciences 
                                         Queen Margaret University, Edinburgh 
                                         Musselburgh, East Lothian 
                                          EH21 6UU  
     Email/ Telephone:       ealdujaili@qmu.ac.uk / 0131 474 0000 
 
 
Contact details of the independent adviser 
 
     Name of adviser:        Dr Iain Gow 
     Address:                  Lecturer in microbiology 
                   Department of Dietetics, Nutrition & Biological Sciences 
                                         Queen Margaret University, Edinburgh   
                                         Musselburgh, East Lothian 
                                         EH21 6UU  
     Email/ Telephone:       igow@qmu.ac.uk / 0131 474 0000 
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PARTICIPANT CONSENT FORM 
 
Participant Identification number for this study: 
EFFECTS OF POLYPHENOL-RICH DARK CHOCOLATE ON INSULIN 
SENSITIVITY IN NORMAL WEIGHT AND OVERWEIGHT ADULTS 
I confirm that I have read and understood the information sheet and this consent 
form. 
  
I have had the opportunity to ask questions, and have had all my questions answered 
satisfactorily. 
I understand that I am free to withdraw at any time without giving any reason. 
I hereby voluntarily agree to take part in the above study 
 
Name of participant:  ____________________________________ 
Signature of participant: ____________________________________ 
Signature of researcher:   ____________________________________ 
Date:                                     _________________ 
 
Contact details of the researcher: 
Name of researcher           Grace Farhat 
Address:                            PhD student 
                                          Public Health Nutrition 
                                          Department of Dietetics, Nutrition & Biological Sciences 
                                          Queen Margaret University 
                                          Musselburgh 
                                          EH21 6UU 
 Email/Telephone:            gfarhat@qmu.ac.uk / 0131 474 0000 
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Appendix 2: General questionnaire for Study I 
 
 
 
EFFECTS OF POLYPHENOL-RICH DARK CHOCOLATE ON INSULIN 
SENSITIVITY IN NORMAL WEIGHT AND OVERWEIGHT ADULTS 
 
     QUESTIONNAIRE 
 
Participant Identification Number:   Date:    
Date of Birth:     /      /19    Age: 
Sex:   Male                  Female 
Occupation: 
 
Ethnicity:                            European                         South Asian                                              
                                             Chinese                           Ethnic South /Central American
  
                                             Japanese                         Sub-Saharan Africans                                                
                                             Eastern Mediterranean /Middle East Arab 
                                             Other (please specify)…………………………. 
A. Medical and Family History 
 
1. Do you have any of the following diseases:   Yes                 No  
                High Blood Pressure                                                                                                       
           
                Cardiovascular diseases 
                 
                 Diabetes  
                     
                 Stroke  
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2. Do you take any medications for:    Yes                    No      
 
High Cholesterol level                   
If yes, please specify the type and brand name 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
 
High Triglycerides level  
If yes, please specify the type and brand name 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
      
Hypertension  
If yes, please specify the type and brand name 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
            Diabetes  
             If yes, please specify the type and brand name           
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
            Any other conditions                  
             If yes, please specify the condition and brand name of the medication 
                       
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
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3. Do you take any dietary supplements?                     Yes                           No 
 
If yes, please specify the type, brand name and frequency of intake 
…………………………………………………………………………………
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
 
4. For women only 
Are you on a Hormonal Replacement Therapy?                    Yes                No 
 
Do you take contraceptives?                                                    Yes              No 
If yes, Please specify the type 
…………………………………………………………………………………
………………………………………………………………………………… 
 
5. Are there any chronic diseases in your family such as diabetes, hypertension 
and/or heart diseases?        Yes                      No  
 
If yes, please specify: 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
 
B. Personal habits: 
 
6. Do you currently smoke cigarettes, pipe or cigar?   
 
Yes, daily  
 
No   
 
Occasionally 
(Less than one cigarette, pipe or cigar per day) 
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7. Do you consume alcohol? 
Yes, daily                                                    
Please specify what kind(s) of alcoholic beverage(s) you drink and the 
amount daily    consumed                                                                 
…………………………………………………………………………………
………………………………………………………………………………… 
 
No   
 
Occasionally 
 
 
8. Do you exercise?      Yes                     No 
Types of exercise: 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
                                                                                         -------hour(s)      -------day 
                                                                                             ------week 
                                                                                               ------month 
9. Do you usually consume dark chocolate:                      ------pieces       -----day 
                                                    -----week 
                                    -----month 
 
      Do you usually drink cocoa                                            -------cups        -----day 
                               -----week 
                                          -----month  
10. Have you been recently (in the past 2 months) or are you currently on a weight 
management program? 
   Yes                                                No  
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Appendix 3: Physical activity questionnaire for Study I 
 
 
Physical Activity questionnaire (to be filled during the second appointment) 
 
 
Did you exercise during this month?      Yes                       No 
 
 
Types of exercise: 
…………………………………………………………………………………………
………………………………………………………………………………………… 
                                                                                             -------hour(s)  ----------day 
                                                                                            --------week 
                                                                                              -------month 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 312 | P a g e  
 
Appendix 4:  Acceptability of treatment questionnaire for study I 
 
Acceptability of treatment 
1. How did you find consuming dark chocolate for 4 weeks: 
a. Very acceptable 
b. Somewhat acceptable 
c. Unacceptable 
      Reasons for unacceptability: 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
Are you willing to continue having dark chocolate frequently? 
 
   Yes                                     No 
 
Comments: 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
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Appendix 5: Diet diaries form 
 
Participant Identification number: 
 
Please use the forms below to write down all the foods and beverages consumed 
during 3 typical days (preferably 2 weekdays and one weekend) 
 
 
Time Food/Drink Brand name   
(if applicable) 
Amount 
consumed 
    
1/3 
Day 1 
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Time Food/Drink Brand name   
(if applicable) 
Amount 
consumed 
    
Day 2 
2/3 
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Time Food/Drink Brand name  
(if applicable) 
Amount 
consumed 
    Day 3 
3/3 
 316 | P a g e  
 
Appendix 6:  List of foods rich in flavonoids 
Fruits : berries (blueberries, blackberries, strawberries, raspberries, cranberries), 
oranges, apricots, bananas, cherries, plums, blackcurrants, black & red grapes, 
apples, figs, grapefruit, peaches and pears.                                                                                                                     
Fruit juices: Pure apple, pear, grape, grapefruit, pomegranate, lemon, orange, 
raspberry, strawberry, blackberry and cranberry juices 
Vegetables: aubergine, red cabbage, rhubarb, artichoke, asparagus, brocolli, brussel 
sprouts, celery hearts, onions, sweet potatoes,  Soja and soja products                                             
Coffee 
Tea (green tea, black tea) 
Red wine 
Dark chocolate, cocoa powder 
Broadbeans 
Hazelnut, chestnut 
Apple sauce 
List adapted from USDA database of the flavonoid content of selected foods (USDA   
2011a). The list was provided to participants during the run-in phase period 
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Appendix 7: Study II Information sheet and consent form for potential 
participants 
 
                                                                              
 
                                    Information Sheet for Potential Participants 
 
EFFECTS OF POLYPHENOL-RICH DARK CHOCOLATE ON BODY 
WEIGHT IN OVERWEIGHT AND OBESE ADULTS 
 
You are invited to take part in this research study. Please read carefully all the 
information before you decide to participate. 
My name is Grace Farhat and I am a PhD student in public health nutrition from the 
School of health sciences at Queen Margaret University in Edinburgh. I am currently 
investigating the effects of polyphenols (in dark chocolate) on different markers 
responsible for the occurrence of several diseases. 
Background 
Polyphenols are antioxidants widely available in foods. Polyphenol-rich foods -and 
dark chocolate in particular- have been the subject of research of hundreds of studies 
in the past few years, most of these focused on the role of polyphenols in reducing 
risk factors for type 2 diabetes and cardiovascular diseases. Recent studies have 
discussed the possible implication of polyphenol-rich dark chocolate in weight loss 
through different mechanisms, thus determining its effect on body weight might be 
helpful in possibly including dark chocolate in weight loss diets. 
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Procedure: 
If you agree to participate in the study, you will be advised to follow your usual diet, 
while substituting dark chocolate for another food usually consumed. The researcher 
may help you with properly replacing dark chocolate instead of other foods.  
 
You will also be asked to avoid consuming cocoa-rich products or any other type of 
dark chocolate during the whole study period. Additionally, you will be requested to: 
1) Be on a fasting state when attending the four appointments, 2) Avoid heavy 
physical activity 12 hours before each appointemtn, 3) Refrain from consuming 
caffeine-rich beverages (like tea and coffee) 12 hours prior to each appointment, and 
4) Avoid alcohol consumption 24 hours before each visit. To evaluate your diet, you 
will be asked to complete a three-day diet diary and a food frequency questionnaire 
four times throughout the intervention. 
 
You will randomly receive 20g of one of the 2 types of dark chocolate (placebo, or 
dark chocolate rich in polyphenols), daily for a period of 12 weeks. 
Before each appointment, you will be asked to collect a 24-hour urine sample (to 
analyse cortisol, cortisone, total polyphenols and total antioxidant capacity in the 
urine) and you will have your height, weight, waist circumference and body 
composition (body fat percentage and lean body mass) measured during each visit.  
Duration of the study 
This study is expected to last for 12 weeks. You will be asked to attend 3 
appointments during this period, and one follow-up appointment on week 16. Each 
appointment will require no more than 15-20 minutes of your time. 
 
Risks  
There are no risks related to this research. 
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Benefits: 
The dark chocolate consumed may improve your health and biological markers. You 
will receive the dark chocolate free of charge. In addition, you will receive a copy of 
the results of all the tests performed if you wish.  
 
Confidentiality:  
Your name will be replaced with a participant identification number, and it will not 
be possible for you to be identified in any reporting of the data gathered. All data 
collected will be anonymous. The results may be published in a journal or presented 
at a conference. 
 
You’ll be free to withdraw from the study at any time without giving any reason. 
 
If you would like to contact an independent person, who knows about this project but 
is not involved in it, you are welcome to contact Dr Iain Gow. His contact details are 
given below. 
If you have read and understood this information sheet, and any questions you had 
have been answered, and you would like to be a participant in the study, please sign 
the consent form. 
 
Contact details of the researcher:  
Name of researcher:   Grace Farhat 
     Address:               PhD student 
                                    Public Health Nutrition 
                                    Department of Dietetics, Nutrition & Biological Sciences 
                                    Queen Margaret University, Edinburgh 
                                    Musselburgh, East Lothian 
                                    EH21 6UU 
     Email/ Telephone:  gfarhat@qmu.ac.uk / 0131 474 0000 
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Contacts details of the supervisor: 
     Name of supervisor:   Dr Emad Al-Dujaili 
     Address:       Senior Lecturer in Biochemistry 
                                         Department of Dietetics, Nutrition & Biological Sciences 
                                         Queen Margaret University, Edinburgh 
                                         Musselburgh, East Lothian 
                                         EH21 6UU  
     Email/ Telephone:      ealdujaili@qmu.ac.uk / 0131 474 0000 
 
Contact details of the independent adviser 
     Name of adviser:         Dr Iain Gow 
     Address:                   Lecturer in microbiology 
                    Department of Dietetics, Nutrition & Biological Sciences 
                                         Queen Margaret University, Edinburgh 
                                          Musselburgh, East Lothian 
                                          EH21 6UU  
     Email/ Telephone:       igow@qmu.ac.uk / 0131 474 0000 
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PARTICIPANT CONSENT FORM 
 
 
Participant Identification number for this study: 
EFFECTS OF POLYPHENOL-RICH DARK CHOCOLATE ON BODY 
WEIGHT IN OVERWEIGHT AND OBESE ADULTS 
I confirm that I have read and understood the information sheet and this consent 
form. 
  
I have had the opportunity to ask questions, and have had all my questions answered 
satisfactorily 
I understand that I am free to withdraw at any time without giving any reason 
I hereby voluntarily agree to take part in the above study 
 
 
Name of participant:  ____________________________________ 
Signature of participant: ____________________________________ 
Signature of researcher: ____________________________________ 
Date:                                     _________________ 
Contact details of the researcher: 
Name of researcher:        Grace Farhat 
Address:                          PhD student 
                                        Public Health Nutrition 
                                        Department of Dietetics, Nutrition & Biological Sciences 
                                        Queen Margaret University 
                                        Musselburgh 
                                        EH21 6UU 
Email/ Telephone:          gfarhat@qmu.ac.uk / 0131 474 0000 
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Appendix 8: General questionnaire for Study II 
 
 
STUDY II: EFFECTS OF POLYPHENOL-RICH DARK CHOCOLATE ON 
BODY WEIGHT IN OVERWEIGHT AND OBESE ADULTS 
QUESTIONNAIRE 
 
Participant Identification Number:     Date:    
Date of Birth:     /      /19      Age: 
Sex:   Male                  Female 
Occupation: 
Ethnicity:                              European                         South Asian                                              
                                              Chinese                           Ethnic South /Central 
American  
                                              Japanese                          Sub-Saharan Africans                                                
                                              Eastern Mediterranean /Middle East Arab 
                                             Other (please specify)…………………………. 
C. Medical and Family History 
 
1. Do you have any of the following diseases:                                                            
                                                                          Yes                       No  
                High Blood Pressure                                                                                                       
           
                Cardiovascular diseases 
                 
                 Diabetes  
                     
                 Stroke  
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2. Do you take any medications for:                                                     
   Yes              No     
                                          
High Cholesterol level                   
If yes, please specify the type and brand name 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
 
High Triglycerides level  
If yes, please specify the type and brand name 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
      
Hypertension  
If yes, please specify the type and brand name 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
          Diabetes 
          If yes, please specify the type and brand name           
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
           Any other conditions                 
If yes, please specify the condition and brand name of the medication                       
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
                   
 
  
 
 
 
  
 
 
2/5 
 324 | P a g e  
 
3. Do you take any dietary supplements?                      Yes                               No 
 
If yes, please specify the type, brand name and frequency of intake 
…………………………………………………………………………………
…………………………………………………………………………………
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
 
4. For women only 
Are you on a Hormonal Replacement Therapy?                          Yes           No 
 
Do you take contraceptives?                                                         Yes           No 
If yes, Please specify the type 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
 
5. Are there any chronic diseases in your family such as diabetes, hypertension 
and/or heart diseases?           Yes                       No  
 
If yes, please specify: 
…………………………………………………………………………………
…………………………………………………………………………………
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
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6. Personal habits: 
Do you currently smoke cigarettes, pipe or cigar?   
Yes, daily  
 
No   
 
Occasionally 
(Less than one cigarette, pipe or cigar per day) 
 
7. Do you consume alcohol? 
Yes, daily                                                                     
Please specify what kind(s) of alcoholic beverage(s) you drink and the 
amount daily consumed                                                                 
…………………………………………………………………………………
…………………………………………………………………………………
………………………………………………………………………………… 
 
No   
 
Occasionally 
 
 
8. Do you exercise?        Yes                   No 
       Types of exercise:     
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
                                                                                             -------hour(s)   ----------day 
                                                                                             -------week 
                                                                                               ------month 
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9. Do you usually consume dark chocolate:              ……..pieces        ---------day 
                                                                                                                 ---------week 
                               --------month
                                             
       Do you usually drink cocoa                                     …….cups            ----------day 
                             -------week 
                                        ----- month  
10. Have you been recently (in the past 2 months) or are you currently on a weight 
management program? 
 
                     Yes                                                No 
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Appendix 9: Food Frequency questionnaire for Study II 
 
 
 
 
 
 
EFFECTS OF POLYPHENOL-RICH DARK CHOCOLATE ON BODY 
WEIGHT IN OVERWEIGHT AND OBESE ADULTS 
 
 
 
 
 
 
FOOD FREQUENCY QUESTIONNAIRE 
 
 
 
 
 
 
This questionnaire asks you some information about what you eat and is mainly 
designed to assess your polyphenol intake throughout the study. 
Please answer all the questions and try to be the most precise possible. 
If you need any clarification, please ask the researcher 
 
 
 
 
 
 328 | P a g e  
 
YOUR DIET:  
 
Please tick in the appropriate box (One answer per line) 
 
 
 
FOODS AND 
AMOUNTS                            
 AVERAGE    INTAKE       
Fruits Never 
or less than 
once/month 
1-3 per month Once a 
week 
2-4 per 
week 
5-6 per 
week 
Once a 
day 
2-3 
per 
day 
4-5 
per 
day 
>6 per 
day 
Berries (Blueberries, 
blackberries, 
raspberries, 
cranberries, 
strawberries) 
½ cup 
         
Orange (1 medium)          
Apple (1 medium)          
Apricots (3 pieces)          
Cherries (10 pieces)          
Plums (2 pieces)          
Black & Red grapes 
(10 pieces) 
         
Banana (1 medium)          
Figs (2 pieces)          
Grapefruit (half)          
Peach (1 medium)          
Pear (1 medium)          
Blackcurrants (1/4 
cup)  
         
2/4 
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Foods AND 
AMOUNTS                            
 AVERAGE    INTAKE       
Fruits juices (pure) 
 
Never 
or less than 
once/month 
1-3 per 
month 
Once a 
week 
2-4 per 
week 
5-6 per 
week 
Once a 
day 
2-3 
per 
day 
4-5 
per 
day 
>6 per day 
Berry juices 
(Blueberries, 
blackberries, 
raspberries, 
cranberries, 
strawberries) 
(1 cup) 
         
Orange juice (1 cup)          
Apple juice (1 cup)          
Grape juice (1 cup)          
Grapefruit juice (1 
cup) 
         
Pear juice (1 cup)          
Lemon juice (1 cup)          
 
FOODS AND 
AMOUNTS                            
 AVERAGE    INTAKE       
Vegetables Never 
or less than 
once/month 
1-3 per month Once a 
week 
2-4 per 
week 
5-6 per 
week 
Once a 
day 
2-3 
per 
day 
4-5 
per 
day 
>6 per 
day 
Aubergine (raw)  (1 
cup) 
         
Red Cabbage (1 cup)          
Artichoke (1 cup)          
Broccoli (raw) (1 cup)          
Sweet potatoes (1 
medium) 
         
Rhubarb (1/2 cup)          
Asparagus (1/2 cup) 
(cooked) 
         
Brussel sprouts (1/2 
cup) (cooked) 
         
3/4 
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Vegetables 
(continued) 
Never 
or less than 
once/month 
1-3 per month Once a 
week 
2-4 per 
week 
5-6 per 
week 
Once a 
day 
2-3 
per 
day 
4-5 
per 
day 
>6 per 
day 
Celery hearts (1 heart)          
Soybeans (raw) (1/2 
cup) 
         
Soy meat products 
(1/2 cup) 
         
Foods (amount)                            AVERAGE    INTAKE       
Drinks 
 
Never 
or less than 
once/month 
1-3 per 
month 
Once a 
week 
2-4 per 
week 
5-6 per 
week 
Once a 
day 
2-3 
per 
day 
4-5 
per 
day 
>6 per day 
Black tea (1 cup)          
Green tea (1 cup)          
Coffee (instant or 
grounded) (1 cup) 
         
Cocoa hot chocolate 
(1 cup) 
         
Red wine (1 glass)          
Soya milk (1 cup)          
Foods AND 
AMOUNTS                            
 AVERAGE    INTAKE       
Other 
 
Never 
or less than 
once/month 
1-3 per 
month 
Once a 
week 
2-4 per 
week 
5-6 per 
week 
Once a 
day 
2-3 
per 
day 
4-5 
per 
day 
>6 per day 
Dark chocolate (1 
bar=40g) 
         
Milk chocolate (1 
bar=40g) 
         
Hazelnut, Chestnut 
(1/2 cup) 
         
Apple sauce (1Tbsp)          
Broadbeans (1 cup)          
4/4 
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Appendix 10: Physical activity questionnaire for study II 
 
 
PHYSICAL ACTIVITY QUESTIONNAIRE 
 
 
 
Did you exercise during the past 6 weeks?                      Yes                       No 
 
Types of exercise: 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
                                                                                             -------hour(s)    --------day 
                                                                                              -------week 
                                                                                                ------month 
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Appendix 11: Acceptability questionnaire for Study II 
 
 
ACCEPTABILITY QUESTIONNAIRE 
 
1. How did you find consuming dark chocolate for 12 weeks: 
a. Very acceptable 
b. Somewhat acceptable 
c. Unacceptable 
      Reasons for unacceptability: 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
2. Did you notice any change in appetite during this period? Please explain 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
       
3. Are you willing to continue having dark chocolate frequently? 
 
   Yes                                     No 
 
Comments: 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
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Appendix 12: Standard curves for Folin-Ciocalteu and FRAP methods  
 
12.1 Folin-Ciocalteu method 
 
The standard curve for the quantification of total polyphenol content (via Folin-
Ciocalteau method) and total antioxidant capacity (via FRAP method) are presented 
in Figure 12.1 and 12.2, respectively. 
 
12.1: Standard curve for the determination of total phenolics in the urine 
 
 
Y represents the absorbance in nm and X is the concentration of gallic acid 
expressed in mg of GAE/day 
 
 
 
 
 
 
 
 
 
y = 0.0012x + 0.043 
R² = 0.9841 
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12.2: Standard curve for the determination of total antioxidant capacity in the urine 
 
 
Y represents the absorbance in nm and X is the concentration of Fe
2+
 expressed in 
mM of Fe
2+
/day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 0.8313x + 0.133 
R² = 0.971 
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